---
document_datetime: 2024-04-04 12:01:19
document_pages: 150
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0065-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-3820-ii-0065-epar-assessment-report-variation_en.pdf
version: success
processing_time: 402.1450357
conversion_datetime: 2025-12-27 22:46:06.797679
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

17 October 2019 EMA/CHMP/591139/2019/corr. Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Keytruda

International non-proprietary name: pembrolizumab

Procedure No. EMEA/H/C/003820/II/0065

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................6                                                          |
|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ................................................................................................ | 6                                                                                                        |
| 1.2. Steps taken for the assessment of the product .......................................................              | 7                                                                                                        |
| 2. Scientific discussion ................................................................................7              |                                                                                                          |
| 2.1. Introduction                                                                                                       | ...................................................................................................... 7 |
| 2.1.1. Problem statement                                                                                                | .......................................................................................... 7             |
| 2.2. Non-clinical aspects..........................................................................................     | 11                                                                                                       |
| 2.2.1. Ecotoxicity/environmental risk assessment........................................................                | 11                                                                                                       |
| 2.2.2. Discussion and conclusion on non-clinical aspects                                                                | .............................................. 11                                                        |
| 2.3. Clinical aspects ................................................................................................  | 12                                                                                                       |
| 2.3.1. Introduction .................................................................................................   | 12                                                                                                       |
| 2.3.2. Pharmacokinetics ..........................................................................................      | 12                                                                                                       |
| 2.3.3. Discussion on clinical pharmacology                                                                              | ................................................................. 14                                     |
| 2.3.4. Conclusions on clinical pharmacology                                                                             | ............................................................... 14                                       |
| 2.4. Clinical efficacy                                                                                                  | ................................................................................................ 14      |
| 2.4.1. Dose response study(ies) ...............................................................................         | 14                                                                                                       |
| 2.4.2. Main study                                                                                                       | ................................................................................................... 16   |
| 2.4.3. Discussion on clinical efficacy ..........................................................................       | 87                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy...................................................................          | 94                                                                                                       |
| 2.5. Clinical safety .................................................................................................. | 94                                                                                                       |
| 2.5.1. Discussion on clinical safety                                                                                    | ...........................................................................136                           |
| 2.5.2. Conclusions on clinical safety                                                                                   | .........................................................................141                             |
| 2.5.3. PSUR cycle                                                                                                       | ..................................................................................................141    |
| 2.6. Risk management plan.....................................................................................141       |                                                                                                          |
| 2.7. Update of the Product information                                                                                  | .....................................................................144                                 |
| 2.7.1. User consultation..........................................................................................144   |                                                                                                          |
| 3. Benefit-Risk Balance............................................................................144                  |                                                                                                          |
| 3.1. Therapeutic Context                                                                                                | ........................................................................................144              |
| 3.1.1. Disease or condition......................................................................................144    |                                                                                                          |
| 3.1.2. Available therapies and unmet medical need                                                                       | ....................................................145                                                  |
| 3.1.3. Main clinical studies                                                                                            | ......................................................................................145                |
| 3.2. Favourable effects...........................................................................................145   |                                                                                                          |
| 3.3. Uncertainties and limitations about favourable effects                                                             | ..........................................146                                                            |
| 3.4. Unfavourable effects........................................................................................147    |                                                                                                          |
| 3.5. Uncertainties and limitations about unfavourable effects                                                           | .......................................147                                                               |
| 3.6. Effects Table                                                                                                      | ..................................................................................................147    |
| 3.7. Benefit-risk assessment and discussion                                                                             | ..............................................................148                                        |
| 3.7.1. Importance of favourable and unfavourable effects                                                                | ...........................................148                                                           |
| 3.7.2. Balance of benefits and risks..........................................................................149       |                                                                                                          |
| 3.8. Conclusions....................................................................................................149 |                                                                                                          |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations ...............................................................................  149 5. EPAR changes  ......................................................................................  150

<div style=\"page-break-after: always\"></div>

## List of abbreviations

## Abbreviation Definition

1L

First-line therapy (patients/participants who have not received any prior therapy for R/M disease)

2L

Second-line therapy (patients/participants who have received 1 prior therapy for R/M disease)

2L+

Second-line or later therapy (patients/participants who have received 1 or more prior therapies for R/M disease)

5-FU

5 fluorouracil

AE

Adverse event(s)

AEOSI

Adverse event(s) of special interest

ASaT

All Subjects as Treated

BICR

Blinded independent central review

cHL

Classic Hodgkin lymphoma

CHMP

Committee for Medicinal Products for Human Use

CI

Confidence interval

CPS

Combined positive score

CSR

Clinical Study Report

CR

Complete response

DMC

Data monitoring committee

DOR

Duration of response

EC50

Half-maximal effective concentration

ECOG

Eastern Cooperative Oncology Group

EHNS

European Head and Neck Society

EMA

European Medicines Agency

ESMO

European Society for Medical Oncology

ESTRO

European Society for Radiotherapy and Oncology

EU

European Union

FDA

Food and Drug Administration

GCP

Good Clinical Practice

GEJ

Gastroesophageal junction

HNSCC

Head and neck squamous cell carcinoma

HPV

Human papilloma virus

HR

Hazard ratio

IA

Interim analysis

IFN

Interferon

IgG

Immunoglobulin

IL-2

Interleukin-2

ITT

Intention to Treat

KM

Kaplan-Meier

<div style=\"page-break-after: always\"></div>

| mAb    | Monoclonal antibody                           |
|--------|-----------------------------------------------|
| MAH    | Marketing Authorization Holder                |
| MSI-H  | Microsatellite instability high               |
| NCCN   | National Comprehensive Cancer Network         |
| NSCLC  | Non-small cell lung carcinoma                 |
| ORR    | Objective response rate                       |
| OS     | Overall survival                              |
| PD-1   | Programmed cell death 1                       |
| PD-L1  | Programmed cell death ligand 1                |
| PD-L2  | Programmed cell death ligand 2                |
| PFS    | Progression-free survival                     |
| PK     | Pharmacokinetic(s)                            |
| PR     | Partial response                              |
| PRO    | Patient-reported outcomes                     |
| Q3W    | Every 3 weeks                                 |
| RECIST | Response Evaluation Criteria in Solid Tumours |
| R/M    | Recurrent/metastatic                          |
| RSD    | Reference Safety Dataset                      |
| SAE    | Serious adverse event(s)                      |
| SOC    | System organ class                            |
| TNF    | Tumour necrosis factor                        |
| TPS    | Tumour proportion score                       |
| US     | United States                                 |
| USPI   | United states prescribing information         |
| WBC    | White blood cell                              |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 28 November 2018 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) Chemotherapy, first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in adults for Keytruda; based on the results from KEYNOTE-048, a randomized, multi-center, open-label phase 3 study investigating pembrolizumab, or pembrolizumab plus platinum plus 5-FU chemotherapy versus platinum plus 5-FU plus cetuximab in subjects with first-line recurrent or metastatic HNSCC. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. An updated version of the RMP (Version 22.1) is also submitted.

The requested variation proposed amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0043/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0043/2018 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH received Scientific Advice from the CHMP in 2014 on the design elements of the clinical trial KEYNOTE-048 (EMEA/H/SA/2437/5/2014/II).

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Daniela Melchiorri

Co-Rapporteur:

Jan Mueller-Berghaus

| Timetable                                                                                  | Actual dates      |
|--------------------------------------------------------------------------------------------|-------------------|
| Submission date                                                                            | 28 November 2018  |
| Start of procedure:                                                                        | 29 December 2018  |
| CHMP Co-Rapporteur's preliminary assessment report circulated on                           | 22 February 2019  |
| CHMP Rapporteur's preliminary assessment report circulated on                              | 27 February 2019  |
| PRAC Rapporteur's preliminary assessment report circulated on                              | 28 February 2019  |
| PRAC RMP advice and assessment overview adopted by PRAC on                                 | 14 March 2019     |
| CHMP Rapporteurs' updated joint assessment report circulated on                            | 22 March 2019     |
| Request for supplementary information adopted by the CHMP on                               | 28 March 2019     |
| MAH's responses submitted to the CHMP on                                                   | 25 April 2019     |
| CHMP Rapporteurs' preliminary joint assessment report on the MAH's responses circulated on | 3 June 2019       |
| 2 nd Request for supplementary information adopted by the CHMP on                          | 27 June 2019      |
| MAH's responses submitted to the CHMP on                                                   | 18 July 2019      |
| CHMP Rapporteurs' preliminary joint assessment report on the MAH's responses circulated on | 20 August 2019    |
| 3 rd Request for supplementary information adopted by the CHMP on                          | 19 September 2019 |
| MAH's responses submitted to the CHMP on                                                   | 24 September 2019 |
| CHMP Rapporteurs' preliminary joint assessment report on the MAH's responses circulated on | 3 October 2019    |
| CHMP Opinion                                                                               | 17 October 2019   |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Head and neck squamous cell carc inoma (HNSCC) describe an anatomically heterogeneous group of cancers encompassing a variety of tumours originating in the lip, oral cavity, hypopharynx, oropharynx, nasopharynx or larynx, oral cavity and laryngeal cancers being the most common.

<div style=\"page-break-after: always\"></div>

## Epidemiology and risk fac tors, screening tools/prevention

It is the sixth most common malignancy worldwide, accounting for 6% of all cancer cases and responsible for an estimated 1-2% of all cancer deaths 123 . In Europe, approximately 140.000 new cases of HNSCC were diagnosed in 2014, corresponding to an annual incidence of 43/100.000. Median age of diagnosis is in the late 60s and 70s 45 . Tobacco, alcohol, male gender and older age are risk factors for HNSCC, together with HPV infection for cancers located in the oropharynx. Tobacco-related HNSCC disease has declined, whereas HPV-positive disease has increased 6 .

## Biologic features, Aetiology and pathogenesis

More than 90% of head and neck cancers are squamous cell carcinomas, originating from the epithelium of the mucosal lining of the upper aerodigestive tract. These neoplasms are aggressive in their biologic behaviour, resulting in significant destructive disease above the clavicle, with the development of local (cervical) lymph node metastases and distant metastases, even after effective local therapy. Significantly, 10 to 30% of patients with cancer of the lip or oral cavity subsequently develop second primary neoplasms of the upper aerodigestive tract.

HPV-related oropharyngeal cancers represent a distinct entity in terms of biology, where HPV-negative HNSCC disease is driven by stepwise accumulation of mutations whereas HPV-positive disease is driven by the integration of 2 viral oncogenes that target the P53 tumour suppressor gene.

## Clinical presentation, diagnosis and stage/prognosis

Tumours have different clinical behaviour, with HPV-positive disease having better prognosis and better response to treatment compared to HPV-negative cancers. Classical presentation of HNSCC includes pain, dysphagia, odynophagia, dysphonia, otalgia, hoarseness, and citrus intolerance. Human papillomavirus-positive oropharyngeal disease is characterized with early cervical lymph node metastases. A significant number of patients with HNSCC initially present with locoregionally advanced disease (American Joint Committee on Cancer stages I-IVB) and the rate of recurrence is up to 50%. Common sites of metastases include lymph nodes, bone, and lung. The challenges of recurrent or metastatic (R/M) HNSCC include pain, speech, swallowing, breathing, and social function. Survival is predicted primarily by stage, anatomical site and HPV status. Patients with recurrent or metastatic (R/M) HNSCC have a poor prognosis with median overall survival of under 1 year 7 .

## Management

Treatment options for patients with this disease vary according to the disease setting as well as other clinical characteristics. Patients with localized HNSCC (American Joint Committee on Cancer stages I-IVB) are treated with potentially curative therapy using ≥1 treatment modalities (surgery, radiation therapy, chemotherapy, and biologic therapy).  In the first-line treatment of R/M HNSCC, combination therapy with cetuximab plus cisplatin/carboplatin plus 5-fluorouracil followed by maintenance cetuximab (the

1  Siegel RL, Miller KD, Jemal A. Cancer Statistics 2016. Cancer J Clin 2016; 7-30.

2  Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet 2008;371:1695-709.

3  Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000 Mar 18;355(9208):949-55.

4  Gatta G, Botta L, Sanchez MJ, et al. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur J Cancer. 2015;51:2130.

5  Gregoire V, Lefebvre JL, Licitra L, et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment, and follow-up. Annals Oncol 2010; 21 (Suppl 5): v184-v186.

6  Leemans CR, Braakhuis B, Brakenhoff R. Molecular biology of head and neck cancer. Nature Reviews Cancer Vol 11 Jan 2011 7  NCCN guidelines version 2.2018 - Head and Neck Cancers

<div style=\"page-break-after: always\"></div>

'EXTREME' regimen) has shown the best results so far, with median survival of 10-14 months 8 . In clinical practice, other combinations, such as a taxane or cisplatin plus cetuximab, are also sometimes used as first-line treatment for R/M HNSCC when patients are not fit enough for the EXTREME regimen. After disease progression on or after 1L therapy in R/M HNSCC, the treatment options are participation in a clinical trial, systemic therapy or best supportive care. Systemic therapies may include cisplatin/carboplatin, 5-FU, cetuximab, docetaxel, paclitaxel, gemcitabine, vinorelbine, methotrexate, capecitabine nivolumab and pembrolizumab.

The table below summarises the available published data on 1 st  line treatment in patients with R/M HNSCC.

Table 1: Published studies of 1st line treatment in patients with R/M HNSCC

<!-- image -->

| Study/Author                                                     | StudyDesign               | Population                                         | Treatment                                                              | ORR                 | DCR                 | Median DOR                       | Median PFS/TTP                                             | MedianOS                                                                                                                                                                                                  |
|------------------------------------------------------------------|---------------------------|----------------------------------------------------|------------------------------------------------------------------------|---------------------|---------------------|----------------------------------|------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Combination Studies                                              | Combination Studies       | Combination Studies                                | Combination Studies                                                    | Combination Studies | Combination Studies | Combination Studies              | Combination Studies                                        | Combination Studies                                                                                                                                                                                       |
| Liverpool Head and Neck Oncology Group (1990) [Ref.5.4: 03Y XPF] | Phase 3, randomized study | 200 patients with no prior R/M HNSCC treatment for | Cisplatin+5-FU Cisplatin+methotrexate Methotrexate Cisplatin           | 24% 22% 28% 12%     |                     |                                  |                                                            | 388days for patients with CRorPR 165 days for patients with SD (p<0.001) 79 days for patients with PD MedianOSnotstatedbut thefigure within the publicationsshowsthemed survivalwouldbewithin9 monthrange |
| Jacobs 1992 [Ref. 5.4: 03Y [SNX                                  | Phase 3, randomized study | 249 patients with no prior RMHNSCC treatmentfor    | Cisplatin+5-FU Cisplatin 5-FU                                          | 32% 17% 13%         |                     |                                  | 2.4 months 2.0 months 1.7 months                           | 5.5 months 5.0 months 6.1 months                                                                                                                                                                          |
| Forastiere 1992 [Ref. 5.4: 03W N8M]                              | Phase 3, randomized study | 277 patients with no prior treatment for RMHNSCC   | Cisplatin+5-FU Carboplatin+5-FU Methotrexate                           | 32% 21% 10%         |                     | 4.2 months 5.1 months 4.1 months |                                                            | 6.6 months 5.0months 5.6months                                                                                                                                                                            |
| Clavel1994 [Ref. 5.4: 052T LG]                                   | Phase 3, randomized study | 382 patients                                       | Cisplatin+methotrexate+bleomycin+ vincristine Cisplatin+5-FU Cisplatin | 34% 31% 15%         |                     |                                  | Overallnodifferencebetweenthetreatment groups inPFS and OS | Overallnodifferencebetweenthetreatment groups inPFS and OS                                                                                                                                                |
| Schrijver 1998 [Ref. 5.4: 03Y XNC]                               | Phase 3, randomized study | 244 patients with no prior treatment for R/M HNSCC | Cisplatin+5-FU+IFN2b Cisplatin+5-FU                                    | 38.4% 47.1%         |                     |                                  |                                                            | 6.02 months 6.28 months                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Forastiere 2001 [Ref. 5.4: 03Y XNJ]         | Phase 3, randomized study                     | 210 patients with no prior treatment for RMHNSCC                | Cisplatin+paclitaxel(lowdose) Cisplatin+paclitaxel (high dose)         | 36% 35%                                           |                                 |                                | 4.0months* 4.1 months* *EFS    | 6.8 months 7.6 months                    |
|---------------------------------------------|-----------------------------------------------|-----------------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------|---------------------------------|--------------------------------|--------------------------------|------------------------------------------|
| Gibson 2005 (ECOG) [Ref. 5.4: 03Y XQS]      | Phase 3, randomized study                     | 218patients with noprior treatment for RMHNSCC                  | Cisplatin+5-FU Cisplatin+paclitaxel                                    | 29.8% 26%                                         |                                 |                                |                                | 8.7months 8.1 months                     |
| EXTREME. Vermorken 2008 [Ref. 5.4: 03W NBF] | Phase 3, randomized study                     | 442 patients with no prior treatment for RMHNSCC                | Cisplatin or carboplatin+5-FU Cisplatin or carboplatin+5-FU+ cetuximab | 20% 36% (p<0.001)                                 | 60% 81% (p<0.001)               | 4.7 months 5.6 months (p=0.21) | 3.3months 5.6 months (p<0.001) | 7.4 months 10.1 months (p=0.04)          |
| ECOG (Burtness 2005) [Ref. 5.4: 0425 Y6]    | Phase 3, randomized, placebo- controlledstudy | 123 patients with no prior treatment for RMHNSCC                | Cisplatin+placebo Cisplatin+cetuximab                                  | 10% 26% (p=0.03)                                  |                                 |                                | 2.7 months 4.2 months          | 8.0months 9.2months                      |
| Monotherapy studies                         | Monotherapy studies                           | Monotherapy studies                                             | Monotherapy studies                                                    | Monotherapy studies                               | Monotherapy studies             | Monotherapy studies            | Monotherapy studies            | Monotherapy studies                      |
| Catimel1994a [Ref. 5.4: 052T KT]            |                                               | 43 patients with noprior treatmentfor RMHNSCC                   | Docetaxel                                                              | 32%                                               |                                 |                                |                                |                                          |
| Dreyfuss 1996 [Ref. 5.4: 052T LT]           | Phase 2                                       | 31 patients with noprior treatmentfor RMHNSCC                   | Docetaxel                                                              | 42%                                               |                                 | 5.0 months (2 to 14)           |                                | 7patients alivewith a medianFUof12months |
| Forastiere 1998 [Ref. 5.4: 052T NR]         | Phase 2                                       | 34 patients with noprior treatmentfor RM HNSCC                  | Paclitaxel                                                             | 40%                                               |                                 | 4.5 months (2 to 20)           |                                | 9.2 months                               |
| Martin 1993 [Ref. 5.4: 052T                 |                                               | 37male patients with noprior treatmentfor RMHNSCC               | Ifosfamide                                                             | 26%                                               |                                 | 3.0 months (3 to 5)            |                                |                                          |
| Study/Author                                | Study Design                                  | Population                                                      | Treatment                                                              | ORR                                               | DCR                             | Median DOR                     | Medlian PFS/TTP                | Merdian OS                               |
| Gilbert 2007 [Ref. 5.4: 052 YW8]            | Phase 2                                       | 22 evaluable patients with no priortreatment for R/M HNSCC      | Irinotecan                                                             | 20.0% at125 mg/m² dose and 12.5% at 75 mg/m² dose |                                 |                                |                                | 6.7 months                               |
| Sandler1998 [Ref. 5.4: 052T PX]             | Phase 2                                       | 24 patients with no prior treatment for R/M HNSCC               | Ifosfamide                                                             | 4.3%                                              |                                 |                                |                                |                                          |
| Degardin 1998 [Ref. 5.4: 04W 7H2]           | Phase 2                                       | 71 patients with no prior treatmentfor R/M HNSCC (56 evaluable) | Vinorelbine                                                            | 16%                                               | 32% (SD for a minimum of8weeks) | 19 weeks                       | 12 weeks                       | 32 weeks                                 |
| Samlowski 2001 [Ref. 5.4: 04W 7HK]          | Phase 2                                       | 29 patients with no prior treatment for RMHNSCC (26 evaluable)  | Gemcitabine                                                            | 0%                                                |                                 |                                | 2 months                       | 6 months                                 |

Abbreviations:5-FU=5-fluorouracil;CR=Completeresponse;DCR=Disease controlrate;DOR=Duration ofresponse;EFS=Event-free survival;FU=follow-up:HNSCC=Head and neck squamous cell carcinoma;IFN=Interferon;ORR=Objective response rate;OS=Overall survival;PD=Progressive disease;PFS=Progression-free survival;PR=Partial response; R/M=Recurrent/metastatic; SD=Stable disease; TTP=Time to progression.

## About the product

Keytruda (pembrolizumab) is a humanized monoclonal anti-PD-1 antibody that blocks the interaction between programmed cell death 1 (PD-1) receptor and its ligands, programmed cell death 1 ligand 1 (PD-L1)  and  programmed  cell  death  1  ligand  2  (PD-L2).  The  PD-1  pathway,  especially  the  PD-1 receptor-ligand interaction, represents a major immune-control switch that may be engaged by ligands expressed  in  the  tumour  microenvironment  to  overcome  active  antitumour-specific  T  cell  immune surveillance. A variety of cancers, unlike healthy organs, express abundant levels of PD-1 ligands, PD-L1 and PD-L2. Binding of either PD-1 ligand to PD-1 inhibits T cell activation triggered through the T cell receptor. The high expression of PD-L1 on tumour cells has been found to correlate with poor prognosis and survival in various cancers and suggests that the PD-1/PD-L1 pathway plays a critical role in tumour evasion and is, thus, an attractive target for therapeutic intervention.

Keytruda was recently approved as monotherapy of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in adults whose tumours express PDL1 TSP ≥ 50% and progressing on or after

<div style=\"page-break-after: always\"></div>

platinum-containing chemotherapy (EMEA/H/C/003820/II/0042).

The scope of this variation is to include a new indication for Keytruda for the first-line treatment of R/M HNSCC in adults, as monotherapy or in combination with chemotherapy. The proposed indication is based on the results from KEYNOTE-048, a randomized, multi-center, open-label phase 3 study investigating pembrolizumab, or pembrolizumab plus platinum plus 5-FU chemotherapy versus platinum plus 5-FU plus cetuximab  in  subjects  with  first-line  recurrent  or  metastatic  HNSCC.  A  total  of  882  patients  were randomized to one of the 3 treatment arms.

The MAH applied for the following indications:

KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in adults.

The CHMP agreed to the following indications:

KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PDL1 with a CPS ≥ 1 (see section 5.1).

## Type of Application and aspects on development

The MAH received Scientific Advice from the CHMP in 2014 on the design elements of the clinical trial KEYNOTE-048 (EMEA/H/SA/2437/5/2014/II). The MAH did follow some of the advice given (e.g. OS as most convincing proof of benefit (later upgraded from secondary to dual primary endpoint), pre-planned subgroup analyses by PD-L1 status).

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Pembrolizumab is a protein, which is expected to biodegrade in the environment and not be a significant risk to the environment. As an unaltered protein, being extensively degraded in the patient's body by regular proteolytic mechanisms before excretion, pembrolizumab is unlikely to result in a significant environmental exposure. Thus, according to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), pembrolizumab is exempt from submission of Environmental Risk Assessment studies as the product and excipients do not pose a significant risk to the environment.

## 2.2.2. Discussion and conclusion on non-clinical aspects

No new nonclinical data has been provided to support this application. The applicant did not submit studies for the ERA. According to the relevant guideline, in the case of products containing proteins as active pharmaceutical ingredient(s), this is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Trial ID              |   Phase | Country / Region                       | Trial Title                                                                                                                                | Trial design                                       | Dosing regimen                                                                                                                                                                                                                                             | Trial population                                                                                              | Subject exposure                                                                                                               |
|-----------------------|---------|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| 3475-048 KEYNOTE- 048 |       3 | Worldwide, US, EU, Rest of World (ROW) | A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metasta tic Head and Neck Squamous Cell Carcinoma | Randomized active-controlled multi-site open-label | Pembrolizumab 200 mg IV, Q3W Cisplatin 100 mg/m 2 IV, Q3W Carboplatin AUC 5 IV, Q3W 5-FU 1000 mg/m 2 /day IV continuous from Day 1-4 of each cycle, Q3W Cetuximab: initial dose 400 mg/m 2 IV over 2 hours on Day 1, followed by 250 mg/m 2 IV over 1 hour | Males/females Age : ≥18 of age on the day of consent Subjects with recurrent or metastic head and neck cancer | Received at least 1 dose: Pembrolizumab monotherapy: 300 Pembrolizumab plus chemotherapy: 276 Cetuximab plus chemotherapy: 287 |

## 2.3.2. Pharmacokinetics

Pharmacokinetic data from KEYNOTE-048 suggest that pembrolizumab exposures in 1L HNSCC participants administered with 200 mg Q3W pembrolizumab as monotherapy or in combination with platinum and 5-FU are consistent with the historical reference PK dataset from melanoma and NSCLC participants (KEYNOTE-001, KEYNOTE-002, KEYNOTE-006, KEYNOTE-010, and KEYNOTE-024) in Cycle 1 and at steady state (Figure 1). This supports the use of the recommended pembrolizumab dose of 200 mg Q3W. Additional justifications for the use of the newly proposed dosing regimen of 400 mg Q6W in 1L HNSCC participants are provided below.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Postdose cycle 1, predose before cycle 2 dosing and predose at steady state (at and after Cycle 8) on log scale. Red and blue symbols are individual observed data (nominal time) from subjects with Head and Neck Cancer in KEYNOTE-048; black line is median predicted concentrations from the model for a regimen of 200 mg Q3W and the grey shaded area represents the 90% prediction interval.

Figure  1:  Observed  concentration  data  with  a  cut-off  of  22  days  after  last  dosing  of  KEYNOTE-048 subjects receiving 200 mg Q3W pembrolizumab with reference model-predicted pharmacokinetic profile for 200 mg Q3W dose regimen

Moreover, observed pembrolizumab serum concentration values in KEYNOTE-048 are found to be consistent with other approved studies in different tumour types (KEYNOTE-024 in NSCLC, KEYNOTE-045 and KEYNOTE-052 in UC, KEYNOTE-055 in HNSCC, KEYNOTE-087 in HL, KEYNOTE-158 and KEYNOTE-164 in MSI-H) following the fixed dose administration of 200 mg Q3W as shown in (Table 2).

Table  2:  Summary  statistics  of  pembrolizumab  observed  serum  concentration  values  following administration  of  multiple  I.V.  doses  of  200  mg  Q3W  in  studies  KEYNOTE-024,  KEYNOTE-045, KEYNOTE-048, KEYNOTE-052, KEYNOTE-055, KEYNOTE-087, KEYNOTE-158 and KEYNOTE-164

| Time point       | Study/Indication   |   N | GM (%CV) (µg/mL)   | AM (SD) (µg/mL)   |    Min |   Median |   Max |
|------------------|--------------------|-----|--------------------|-------------------|--------|----------|-------|
| Cycle 1 Postdose | KN024 NSCLC        | 147 | 67.5 (23)          | 69.27 (16)        | 36.6   |     66.8 | 132   |
| Cycle 1 Postdose | KN045 UC           | 247 | 65.7 (26)          | 67.93 (18)        | 33.9   |     65.9 | 144   |
| Cycle 1 Postdose | KN048 1L HNSCC     | 495 | 61.8 (29)          | 64.15 (18)        |  9.48  |     61.7 | 165   |
| Cycle 1 Postdose | KN052 UC           | 298 | 58 (28)            | 60.18 (17)        | 22.8   |     57.4 | 148   |
| Cycle 1 Postdose | KN055 HNSCC        |  43 | 56.5 (28)          | 58.94 (21)        | 33.1   |     54.9 | 162   |
| Cycle 1 Postdose | KN087 HL           | 195 | 60.7 (28)          | 63.06 (18)        | 31.2   |     61.3 | 183   |
| Cycle 1 Postdose | KN158 MSIH         |  90 | 64.4 (27)          | 66.65 (18)        | 31.2   |     65.2 | 133   |
| Cycle 1 Postdose | KN164 MSIH         |  56 | 62.2 (28)          | 64.59 (19)        | 34.9   |     61.2 | 150   |
| Cycle 2 Predose  | KN024 NSCLC        | 132 | 11.1 (54)          | 12.26 (5)         |  0.535 |     12.2 |  28.5 |
| Cycle 2 Predose  | KN045 UC           | 233 | 13.1 (47)          | 14.18 (5)         |  0.475 |     13.9 |  29.3 |
| Cycle 2 Predose  | KN048 1L HNSCC     | 458 | N.A.               | 13.37 (5)         |  0     |     13.2 |  29.6 |
| Cycle 2 Predose  | KN052 UC           | 286 | 11.1 (42)          | 11.91 (4)         |  2.07  |     11.5 |  26.2 |
| Cycle 2 Predose  | KN055 HNSCC        |  40 | 10.7 (47)          | 11.76 (5)         |  3.45  |     11.6 |  33.1 |
| Cycle 2 Predose  | KN087 HL           | 200 | 14.4 (40)          | 15.36 (5)         |  3.06  |     15.3 |  30   |
| Cycle 2 Predose  | KN164 MSIH         |  56 | 12.5 (35)          | 13.23 (5)         |  5.44  |     12.4 |  25.6 |
| Cycle 8 Predose  | KN024 NSCLC        |  82 | 30.6 (50)          | 33.61 (13)        |  5.26  |     32.7 |  64.1 |
| Cycle 8 Predose  | KN045 UC           | 104 | 33.4 (64)          | 37.83 (17)        |  1.13  |     37.5 |  95.6 |
| Cycle 8 Predose  | KN048 1L HNSCC     | 235 | 34.2 (50)          | 37.51 (15)        |  1.77  |     34.8 | 127   |
| Cycle 8 Predose  | KN052 UC           |  59 | 28 (38)            | 29.86 (10)        |  8.15  |     27.9 |  59.8 |
| Cycle 8 Predose  | KN055 HNSCC        |   7 | 27.8 (41)          | 29.64 (11)        | 16.8   |     24.5 |  43.3 |
| Cycle 8 Predose  | KN087 HL           |  68 | 43.9 (43)          | 47.37 (17)        | 13.9   |     47.5 |  92.4 |
| Cycle 8 Predose  | KN164 MSIH         |  34 | 33.6 (43)          | 36.23 (14)        |  8.4   |     33.7 |  78.8 |

GM = Geometric Mean; %CV = Geometric Coefficient of Variation; SD = Standard Deviation; AM = Arithmetic Mean; Results for time points with N ≥ 3.

<div style=\"page-break-after: always\"></div>

An additional dosing regimen of 400 mg Q6W has been approved in the EU on 28 March 2019 for all monotherapy  indications  approved  at  the  time  based  on  PK  and  exposure-response  bridging  using modeling and simulations analyses (procedure number EMEA/H/C/003820/II/0062). The inferences from these analyses support the dosing regimen of 400 mg Q6W across indications, including 1L HNSCC, given the similarity in PK (as outlined above) and based on the following additional rationale:

- Pembrolizumab  acts  via  binding  to  PD-1  on  immune  cells,  not  tumour  cells;  hence  meaningful differences in exposure/dose-response are not expected across cancer types.
- Consistent, flat exposure-response relationships are seen for pembrolizumab in multiple tumour types
- o Efficacy  is  seen  at  the  same  dosing  regimen  across  multiple  indications  (melanoma,  NSCLC, HNSCC, UC, cHL, GC, MSI-H cancers, PMBCL, HCC and cervical cancer).
- Clearance is similar across tumour types, suggesting saturation of the target on immune cells in circulation  is  achieved  at  the  clinical  dose,  which  is  the  same  across  tumour  types;  this  further supports that PK/exposures and exposure-response are consistent across indications.

## 2.3.3. Discussion on clinical pharmacology

A dosing regimen of 200 mg Q3W is recommended for pembrolizumab treatment in patients with R/M HNSCC, as pharmacokinetic and clinical pharmacology properties remain similar across indications.

A robust characterization of the PK and immunogenicity of pembrolizumab has been provided in previous submissions in other monotherapy indications in the non-adjuvant settings. A description of the clinical pharmacology  of  pembrolizumab  in  subjects  with  previously  treated  HNSCC  was  included  in  the KEYNOTE-040 submission to support 200 mg Q3W as the recommended dose of pembrolizumab in this patient population (see EPAR for EMEA/H/C/003820/II/0042).

A description of the pharmacology of pembrolizumab in combination with chemotherapy was included in the KEYNOTE-021-G/KEYNOTE-189 submission (see EPAR for EMEA/H/C/003820/II/0043). This analysis demonstrated  that  the  PK  and  immunogenicity  of  pembrolizumab  are  not  impacted  by  concomitant chemotherapy.

Considering  the  consistency  in  exposure  between  subjects  with  1L  HNSCC  tumour  treated  with pembrolizumab 200 mg Q3W in monotherapy and subjects with other tumour type treated with the same regimen, the use of 400 mg Q6W as additional dosing option for pembrolizumab as monotherapy in the 1L HNSCC is supported by the already proposed modelling and simulation approach.

## 2.3.4. Conclusions on clinical pharmacology

The clinical pharmacology data and rationale submitted support the use of the currently authorised dosing regimens for the first-line treatment of metastatic or unresectable recurrent HNSCC as monotherapy or in combination with platinum and 5 FU chemotherapy.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No specific dose-response study was conducted. The planned dose of pembrolizumab for this trial is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W dose is justified by:

<div style=\"page-break-after: always\"></div>

-  Clinical  data  from  eight  randomized  studies  demonstrating  flat  dose-  and  exposure-  efficacy relationships from 2 mg/kg Q3W to 10 mg/kg every two weeks (Q2W)

· Clinical data showing meaningful improvement in benefit-risk including overall survival at 200 mg Q3W across multiple indications

·  Pharmacology  data  showing  full  target  saturation  in  both  systemic  circulation  (inferred  from pharmacokinetic [PK] data) and tumour (inferred from physiologically based pharmacokinetic [PBPK] analysis) at 200 mg Q3W

Among the eight  randomized  dose-comparison  studies,  a  total  of  2262  subjects  were  enrolled  with melanoma and NSCLC. All of these studies demonstrated flat dose- and exposure-response relationships across the doses studied representing an approximate 5 to 7.5 fold difference in exposure. Subsequently, flat dose-/exposure-response relationships were also observed in other tumour types including head and neck cancer, bladder cancer, gastric cancer and classical Hodgkin Lymphoma, confirming 200 mg Q3W as the appropriate dose independent of the tumour type.

Additionally, pharmacology data show target saturation at 200 mg Q3W.

Finally, population PK analysis of pembrolizumab, which characterized the influence of body weight and other subject covariates on exposure, has shown that the fixed-dosing provides similar control of PK variability as weight based dosing, with considerable overlap in the distribution of exposures from the 200 mg Q3W fixed dose and 2 mg/kg Q3W dose.

Supported by these PK characteristics, and given that fixed-dose has advantages of reduced dosing complexity  and  reduced  potential  of  dosing  errors,  the  200  mg  Q3W  fixed-dose  was  selected  for evaluation across all pembrolizumab protocols.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

## A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-048)

<!-- image -->

## Methods

## Study participants

Key inclusion criteria included:

1. Histologically or cytologically-confirmed R/M HNSCC that was considered incurable by local therapies.
- No prior systemic therapy in the recurrent or metastatic setting. Systemic therapy which was completed more than 6 months prior to signing consent if given as part of combination therapy for locally advanced disease was allowed.
- The eligible primary tumour locations were oropharynx, oral cavity, hypopharynx, and larynx.
- Participants may not have had a primary tumour site of nasopharynx (any histology).
2. Written informed consent
3. ≥18 years of age
4. Measurable disease based on RECIST 1.1 as determined by the site. Tumour lesions situated in a previously irradiated area were considered measurable if progression had been demonstrated in such lesions.
5. ECOG performance status of 0 or 1.

<div style=\"page-break-after: always\"></div>

6. Adequate organ function
7. Had results from testing of HPV status for oropharyngeal cancer defined as p16 IHC testing using CINtec® p16 Histology assay and a 70% cutoff point. If HPV status was previously tested using this method, no additional testing was required.
8. Had provided tissue for PD-L1 biomarker analysis from a core or excisional biopsy. Repeat samples may be required if adequate tissue was not provided. A newly obtained biopsy (within 90 days prior to start of study treatment) was strongly preferred, but an archival sample was acceptable.
9. Female participants of childbearing potential had a negative blood pregnancy test within 72 hours prior to receiving the first dose of study medication.

## Key exclusion criteria included:

1. Had disease that was suitable for local therapy administered with curative intent.
2. Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
3. Had radiation therapy (or other non-systemic therapy) within 2 weeks prior to randomization or participant  had  not  fully  recovered  (ie,  ≤Grade  1  or  at  baseline)  from  AEs  due  to  a  previously administered treatment.
4. Had a life expectancy of less than 3 months and/or had rapidly progressing disease (e.g. tumor bleeding, uncontrolled tumour pain) in the opinion of the treating investigator.
5. Had a diagnosis of immunodeficiency or was receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention. Corticosteroid use as pre-medication for allergic reactions (e.g. IV contrast), or as a prophylactic management of AEs related to the chemotherapies specified in the protocol was allowed.
6. Had a diagnosed and/or treated additional malignancy within 5 years prior to randomization with the exception of: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, curatively resected in situ cervical cancer, and curatively resected in situ breast cancer.
7. Had known active CNS metastases and/or carcinomatous meningitis.
8. Active  autoimmune  disease  that  had  required  systemic  treatment  in  past  2  year.  Replacement therapy was not considered a form of systemic treatment.
9. Had had an allogeneic tissue/solid organ transplant.
10. Had a history of (noninfectious) pneumonitis that required steroids or current pneumonitis; active infection requiring systemic therapy; known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study; known history of HIV; known active Hepatitis B or C.
11. Was pregnant or breastfeeding
12. Had received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
13. Had received a live vaccine within 30 days of planned start of study therapy.

## Treatments

Pembrolizumab plus chemotherapy group (pembro combo): pembrolizumab + cisplatin/carboplatin + 5-FU

<div style=\"page-break-after: always\"></div>

## Pembrolizumab monotherapy group (pembro mono): pembrolizumab

Standard treatment group (control): cetuximab + cisplatin/carboplatin + 5-FU (EXTREME regimen)

| Intervention   | Dose/ Potency                                                              | Dose Frequency   | Route of Administration   | Regimen                                            | Use                                      |
|----------------|----------------------------------------------------------------------------|------------------|---------------------------|----------------------------------------------------|------------------------------------------|
| Pembrolizumab  | 200 mg                                                                     | Every 3 weeks    | Intravenous               | Day 1 of each cycle (3 week cycles)                | Experimental                             |
| Cisplatin      | 100 mg/m 2                                                                 | Every 3 weeks    | Intravenous               | Day 1 of each cycle (3 week cycles) for 6 cycles   | Comparator regimen and combination agent |
| Carboplatin    | AUC 5 mg/mL/min                                                            | Every 3 weeks    | Intravenous               | Day 1 of each cycle (3 week cycles) for 6 cycles   | Comparator regimen and combination agent |
| 5-FU           | 1000 mg/m 2 /day 1-4 of each cycle                                         | Every 3 weeks    | Intravenous               | Day 1-4 of each cycle (3 week cycles) for 6 cycles | Comparator regimen and combination agent |
| Cetuximab      | Initial dose on day 1 is 400 mg/m 2 followed by weekly doses of 250 mg/m 2 | Every week       | Intravenous               | Days 1, 8, and 15 of each cycle (3 week cycles)    | Comparator regimen                       |

Subjects  may  receive  a  maximum  of  6  cycles  (infusions)  of  the  chemotherapy  agents  (carboplatin, cisplatin, and 5-FU).

After  platinum  and  5-FU  are  discontinued,  for  subjects  with  at  least  stable  disease,  cetuximab monotherapy may continue until disease progression or unacceptable toxicity occurs.

Treatment  on  trial  continued  until  disease  progression  is  verified  by  the  central  imaging  vendor, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision, noncompliance, subject receives 24 months of study medication (pembrolizumab arms only), pregnancy, or administrative reasons. Subjects on either pembrolizumab arm who attain a complete response (CR) may consider stopping trial treatment if they meet criteria for holding therapy. Subjects receiving pembrolizumab who stop trial treatment after receiving 24 months of study medication for reasons  other  than  disease  progression  or  intolerability,  or  subjects  who  attain  a  CR  and  stop  trial treatment may be eligible for up to one year of retreatment upon experiencing centrally-verified disease progression at investigator's discretion.

Investigators may switch subjects from cisplatin to carboplatin during the course of the study if toxicities occur. If the cisplatin dose was modified prior to switching, the subject may start at a carboplatin dose of AUC 5 and will be eligible to receive an additional 2 dose modifications of carboplatin.

If subjects on the cetuximab + platinum + 5-FU arm are required to have the platinum and/or 5-FU discontinued  for  toxicity,  the  subject  and  may  continue  to  receive  cetuximab  alone.  In  the  case  of cetuximab toxicity, subjects may continue on chemotherapy alone.

The first on-study imaging was performed at 9 weeks after the date of randomization and then every 6 weeks thereafter or more frequently if clinically indicated. After 1 year, imaging time point will occur every 9 weeks. Progressive disease should be verified by the central imaging vendor prior to subject discontinuation from treatment. Local reading (investigator assessment with site radiology reading) were used to determine eligibility and for subject management.

<div style=\"page-break-after: always\"></div>

## Objectives

## Primary objectives:

- To compare PFS per RECIST 1.1 as assessed by BICR in first line R/M HNSCC subjects, treated with pembrolizumab monotherapy versus standard treatment.
- To compare PFS per RECIST 1.1 as assessed by BICR in first line R/M HNSCC subjects, treated with pembrolizumab in combination with chemotherapy versus standard treatment.
- To  evaluate  OS  in  first  line  R/M  HNSCC  subjects,  treated  with  pembrolizumab  monotherapy versus standard treatment.
- To evaluate OS in first line R/M HNSCC subjects, treated with pembrolizumab in combination with chemotherapy versus standard treatment.

## Secondary objectives:

- To evaluate the safety and tolerability profile of pembrolizumab monotherapy or a combination of pembrolizumab with chemotherapy in all first line R/M HNSCC subjects.

The following secondary objectives were evaluated in (1) PDL1 ≥20 CPS, (2) PD -L1 ≥1 CPS and (3) all participants for both pembrolizumab in combination with chemotherapy and pembrolizumab monotherapy compared to standard treatment:

- To evaluate proportion progression-free at 6 months and 12 months per RECIST 1.1 by BICR of first line R/M HNSCC subjects.
- To evaluate ORR per RECIST 1.1 by BICR in first line R/M HNSCC subjects.
- To evaluate mean change from baseline in global health status/quality of life in 1L R/M HNSCC subjects.
- To evaluate time to deterioration (TTD) in global health status/quality of life, pain and swallowing in first line R/M HNSCC subjects.

## Exploratory Objectives:

- To evaluate DOR per RECIST 1.1 by BICR in 1L R/M HNSCC participants.
- To evaluate ORR, DOR, and PFS using irRECIST as assessed by BICR in 1L R/M HNSCC participants.
- To evaluate changes in health-related quality-of-life assessments from baseline in participants with R/M HNSCC using the EORTC QLQ-C30 and EORTC QLQ-H&amp;N35.
- To characterize utilities in participants with R/M HNSCC cancer using the EuroQol EQ-5D.
- To evaluate changes in opioid analgesic use from baseline in participants with R/M HNSCC, based on reported concomitant medications, supplemented with a daily Pain Medication Log.
- To investigate the relationship between pembrolizumab treatment and biomarkers predicting response (eg, PD-L1, genetic variation, serum soluble PD-L1) utilizing archival tumour tissue, and blood sampling.
- To explore the relationship between genetic variation and response to the treatment(s) administered. Variation across the human genome will be analyzed for association with clinical data collected in this study.

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

Table 3: KEYNOTE-048 Efficacy Endpoints

| Endpoints   |                                                       | Populations                                                                                                    | Definitions                                                                                                                   |
|-------------|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| Primary     | OS                                                    | ITT (Combo) PD- L1 ≥1 CPS (Combo) PD- L1 ≥20 CPS (Combo) ITT (Mono) PD- L1 ≥1 CPS (Mono) PD- L1 ≥20 CPS (Mono) | Time from randomization to death due to any cause                                                                             |
| Primary     | PFS                                                   | ITT (Combo) PD- L1 ≥1 CPS (Combo) PD- L1 ≥20 CPS (Combo) ITT (Mono) PD- L1 ≥1 CPS (Mono) PD- L1 ≥20 CPS (Mono) | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause                                  |
| Secondary   | ORR                                                   | ITT (Combo) PD- L1 ≥1 CPS (Combo) PD- L1 ≥20 CPS (Combo) ITT (Mono) PD- L1 ≥1 CPS (Mono) PD- L1 ≥20 CPS (Mono) | Proportion of participants who had CR or PR (per RECIST 1.1 based on BICR)                                                    |
| Secondary   | PFS at 6 months and 12 months                         | ITT (Combo) PD- L1 ≥1 CPS (Combo) PD- L1 ≥20 CPS (Combo) ITT (Mono) PD- L1 ≥1 CPS (Mono) PD- L1 ≥20 CPS (Mono) | Proportion of participants who have duration of PFS ≥6 months and 12 months, respectively.                                    |
| Secondary   | Mean change from baseline in QLQ-C30 global QOL score | FAS (Combo) PD- L1 ≥1 CPS (Combo) PD- L1 ≥20 CPS (Combo) FAS (Mono) PD- L1 ≥1 CPS (Mono) PD- L1 ≥20 CPS (Mono) | EORTC QLQ-C30 global health status/quality of life scores at baseline and week 15                                             |
| Secondary   | TTD in global QOL, pain, and swallowing               | FAS (Combo) PD- L1 ≥1 CPS (Combo) PD- L1 ≥20 CPS (Combo) FAS (Mono) PD- L1 ≥1 CPS (Mono) PD -L1 ≥20 CPS (Mono) | Time from baseline to first onset of patient reported outcomes (PRO) deterioration with confirmation (true deterioration * ). |
| Exploratory | DOR                                                   | ITT (Combo) PD- L1 ≥1 CPS (Combo) PD- L1 ≥20 CPS (Combo) ITT (Mono) PD- L1 ≥1 CPS (Mono) PD- L1 ≥20 CPS (Mono) | Time from first documented evidence of CR or PR until PD (per RECIST 1.1 based on BICR) or death                              |

CPS=Combined Positive Score; CR=complete response; DOR=Duration of response; HRQoL=Health related quality of life;

Mono=pembrolizumab monotherapy; ORR=Objective response rate; OS=Overall survival; PD=Progressive disease; PD

L1=Programmed cell death ligand-1; PFS=Progression-free survival; PR=Partial response; QLQ-C30=Quality of Life Core

Questionnaire, Version 3.0;QOL=Quality of life; RECIST 1.1=Response Evaluation Criteria in Solid Tumours, version 1.1; TTD=Time to deterioration.

*defined in the global health status/quality of life, pain, and swallowing endpoints as a 10 points or greater worsening from baseline for each multi-item scale and confirmed by a second adjacent 10 or more deterioration from baseline under a right-censoring rule.

## Sample size

A total of 825 participants with a 1:1:1 ratio were planned to be randomized into 3 treatment groups: pembrolizumab monotherapy, pembrolizumab plus chemotherapy, and standard treatment.

KEYNOTE-048 is an event and time driven trial. The sample size was chosen to achieve the required number of PFS and OS events at the time of the 1 st  planned analysis, followed by time driven analysis at a 2 nd  interim and final timepoints, as summarized in the following table:

<div style=\"page-break-after: always\"></div>

Table 4: Summary of PFS and OS Analysis Strategies

| PFS and OS Analyses   | Key Endpoints   | Timing of Analysis          | Expected Number of Events at the Time of Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Primary Purpose of Analysis                                    |
|-----------------------|-----------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| Interim analysis 1    | PFS OS          | ~30 months from study start | ~423 PFS events between pembrolizumab plus chemotherapy and standard treatment in all participants                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Demonstrate PFS and OS superiority                             |
| Interim analysis 2    | OS              | ~38 months from study start | ~421 deaths between pembrolizumab plus chemotherapy and standard treatment in all participants                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Demonstrate PFS (if not significant at IA1) and OS superiority |
| Final analysis        | OS              | ~44 months from study start |  ≥222 deaths between one experimental treatment and standard treatment in PD-L1 CPS ≥20  ≥359 deaths between one experimental treatment and standard treatment in PD-L1 CPS ≥1  ≥455 deaths between one experimental treatment and standard treatment in all participants Note: if the expected number of deaths for a hypothesis is not observed by the time that the trial is open for 44 months, the timing of the final analysis may be delayed for up to 2 months or when the target death event numbers are observed, whichever occurs first. | Demonstrate OS superiority                                     |

For the interim analyses, the actual timing is determined by the minimum follow-up; and for the final analysis, the actual timing is determined by both the expected event numbers and minimum follow-up.  However, to prevent the trial form continuing to an unreasonable duration, if the the expected number of deaths for a hypothesis is not observed by the time that the trial is open for 44 months, the timing of the final analysis may be delayed for up to 2 months or when the target death event numbers are observed, whichever occurs first.

The table only lists the timing and the required event numbers of the hypotheses that drive the analysis.

In particular, at the time of the final PFS analysis (interim analysis 2 for OS):

- for  subjects  with  PDL1  CPS≥20 ,  it  was  expected  to  observe  approximately  237  PFS  events between one experimental treatment and standard treatment. The study had 90% power with each experimental treatment (pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy) to detect a hazard ratio of 0.58 vs. standard treatment at alpha = 0.19% (one-sided).
- for  subjects  with  PDL1  CPS≥1 ,  it  was  expected  to  observe  approximately  378  PFS  events between one experimental treatment and standard treatment. The study had 98.6% power with each experimental treatment (pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy) to detect a hazard ratio of 0.59 vs. standard treatment at alpha = 0.19% (one-sided).
- for all subjects, it  was  expected  to  observe  approximately  474  PFS  events  between pembrolizumab  monotherapy  and  standard  treatment.  The  study  had  99.6%  power  with pembrolizumab monotherapy to detect a hazard ratio of 0.6 vs. standard treatment at alpha = 0.19% (one-sided).
- for all subjects, it  was  expected  to  observe  approximately  474  PFS  events  between pembrolizumab  in  combination  with  chemotherapy  and  standard  treatment.  The  study  had 97.7% power with pembrolizumab in combination with chemotherapy to detect a hazard ratio of 0.6 vs. standard treatment at alpha = 0.02% (one-sided).

<div style=\"page-break-after: always\"></div>

The PFS sample size calculation was based on the following assumptions: 1) progression-free survival following an exponential distribution with a median of 6 months in the standard treatment arm; 2) hazard ratios equal to 0.58 for subjects with PD-L1 CPS ≥ 20, 0.59 for subjects with PD-L1 CPS ≥ 1 and 0.6 for all subjects; 3) an enrolment period of 21 months; 4) at least 9 months follow-up at interim analysis 1, and 17 months follow-up at interim analysis 2; and 5) a yearly dropout rate of 5%.

At the time of the final OS analysis:

- for subjects with PD-L1 CPS ≥ 20, it is expected that approximately 222 deaths will have been observed between one experimental treatment and standard treatment. The study has 90.5% power with each experimental treatment (pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy) to detect a hazard ratio of 0.6 vs. standard treatment at alpha = 0.7% (one-sided).
- for subjects with PD-L1 CPS ≥ 1, it is expected that approximately 359 deaths will have been observed between one experimental treatment and standard treatment. The study has 94.3% power with each experimental treatment (pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy) to detect a hazard ratio of 0.65 vs. standard treatment at alpha = 0.7% (one-sided).
- for all subjects, it is expected that approximately 455 deaths will have been observed between one experimental treatment and standard treatment. The study has 87.85% power with a hazard ratio  of  0.85  to  establish  non-inferiority  (NI  margin  =  1.2)  for  each  experimental  treatment (pembrolizumab  monotherapy  or  pembrolizumab  in  combination  with  chemotherapy)  vs. standard treatment at alpha = 0.7% (one-sided) (that is, the treatment could be considered as non-inferior to the standard treatment arm in terms of OS if the upper bound of the CI, based on the alpha level allocated to the analysis for the HR is &lt;1.2).
- for all subjects, it is expected that approximately 455 deaths will have been observed between one experimental treatment and standard treatment. The study has 90.4% power with each experimental treatment (pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy)  to  detect  a  hazard  ratio  of  0.7  vs.  standard  treatment  at  alpha  =  0.7% (one-sided).

The OS sample size calculation was based on the following assumptions: 1) overall survival following an exponential distribution with a median of 10 months in the standard treatment arm; 2) the hazard ratios equal to 0.6 for subjects with PD-L1 CPS ≥ 20, 0.65 for subjects with PD-L1 CPS ≥ 1, 0.7 for all subjects for the superiority hypotheses, and 0.85 for all subjects for the non-inferiority hypotheses; 3) an enrollment period of 21 months; 4) at least 23 months follow-up at the final analysis; and 5) a yearly dropout rate of 2%.

The assumptions for median PFS of 6 months and median OS of 10 months in the standard treatment arm were based on the median PFS and median OS estimates from the EXTREME trial. The assumptions do not take  into  account  potential  prognostic  implications  in  a  biomarker  selected  population.  As  such,  the median of the standard treatment arm for the PD-L1 positive subgroups may be more or less than 6 months for PFS and more or less than 10 months for OS.

## Randomisation

Randomization occurred centrally using an interactive voice response system / integrated web response system (IVRS/IWRS). Subjects were assigned randomly in a 1:1:1 ratio to one of the 3 treatment arms.

Randomization was stratified according to the following factors:

1. PD-L1 tumou r expression by TPS (≥50% vs not ≥50%)

<div style=\"page-break-after: always\"></div>

2. HPV status (positive vs. negative); HPV status for oropharynx cancer was determined by p16 IHC. HPV status for subjects without oropharynx cancer (e.g. cancers of the oral cavity, hypopharynx and larynx) was considered HPV negative.
3. ECOG Performance Scale (0 vs. 1)

## Blinding (masking)

Study was open-label.

PD-L1 status of all participants was blinded to both Investigators and the Sponsor.

## Statistical methods

## Efficacy population

The analysis of primary efficacy endpoints were based on the intention-to-treat (ITT) population, i.e., subjects were included in the treatment group to which they were randomized.

## Statistical methods

Table 5: Efficacy analysis methods

| Endpoint/Variable (Description, Time Point)                                                     | Statistical Method                                                                                                                     | AnalysisPopulation                                                                              | Missing Data Approach                                                                           |
|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Primary Analyses:                                                                               | Primary Analyses:                                                                                                                      | Primary Analyses:                                                                               | Primary Analyses:                                                                               |
| PFS (RECIST 1.1) by BICR                                                                        | Testing: Stratified Log- rank test Estimation: Stratified Cox model with Efron's tie handling method                                   | ITT All subjects Subjects with PD-L1 CPS 20 and CPS 1                                           | Censored according torulesinTable18                                                             |
| OS                                                                                              | Testing: Stratified Log- rank test (for superiority hypotheses only) Estimation: Stratified Cox model with Efron's tie handling method | ITT  All subjects Subjects with PD-L1 CPS 20 and CPS 1                                          | Censored at last known alive date                                                               |
| SecondaryAnalyses:                                                                              | SecondaryAnalyses:                                                                                                                     | SecondaryAnalyses:                                                                              | SecondaryAnalyses:                                                                              |
| PFS at 6 months/12 months (RECIST 1.1) by BICR                                                  | Kaplan-Meier estimation with CI                                                                                                        | ITT All subjects Subjects with PD-L1 CPS 20 and CPS 1                                           | Censored according to primary censoring rule in Table 18                                        |
| ORR (RECIST 1.1) by BICR                                                                        | Stratified Miettinen and Nurminen method                                                                                               | ITT  All subjects Subjects with PD-L1 CPS 20 and CPS 1                                          | Subjects with missing data are considered non- responders                                       |
| ExploratoryAnalyses:                                                                            | ExploratoryAnalyses:                                                                                                                   | ExploratoryAnalyses:                                                                            | ExploratoryAnalyses:                                                                            |
| DOR (RECIST 1.1) by BICR                                                                        | Summary statistics using Kaplan-Meier method                                                                                           | All responders in ITT                                                                           | Non-responders are excluded in analysis                                                         |
| Sensitivity analyses will be performed for PFS, ORR and DOR based on investigator's assessment. | Sensitivity analyses will be performed for PFS, ORR and DOR based on investigator's assessment.                                        | Sensitivity analyses will be performed for PFS, ORR and DOR based on investigator's assessment. | Sensitivity analyses will be performed for PFS, ORR and DOR based on investigator's assessment. |

The non-parametric Kaplan-Meier method was used to estimate the PFS/OS curve in each treatment group. The treatment difference in PFS/OS was assessed by the stratified log-rank test. A stratified Cox proportional hazard model with Efron's method of tie handling was used to assess the magnitude of the treatment difference (i.e., hazard ratio) between the treatment arms. The hazard ratio and its 95% CI from the stratified Cox model with a single treatment covariate was reported.

<div style=\"page-break-after: always\"></div>

The same stratification factors used for randomization were used as the stratification factors in both the stratified log-rank test and the stratified Cox model (as well as in the stratified Miettinen and Nurminen method) for the analyses in all subjects and in subjects with PD-L1 CPS ≥ 1. For analyses in the PD-L1 CPS ≥ 20 subgroup, HPV status and ECOG status were used as the stratification factors. In case the event count in any stratum is &lt;5, for the analysis purpose, stratification factors would be combined in the order of ECOG-&gt;HPV status-&gt;PDL1 status (defined by TPS) until event count in every stratum is ≥5.

## Sensitivity analyses

To  account  for  the  possible  non-proportional  hazards  effect  associated  with  immunotherapies,  two sensitivity analyses were conducted, the first based on the weighted log-rank test with parameter (0,1), the other using the restricted mean survival time (RMST) method.

Adjustment for the effect on OS of crossover (of subjects in the standard therapy arm that may switch to another anti PD-1 treatment following confirmation of progressive disease) is planned based on methods such as Rank Preserving Structural Failure Time (RPSFT) model, two stage model, etc., based on an examination of the appropriateness of the data to the assumptions required by the methods.

Sensitivity analyses were performed for PFS, ORR and DOR based on investigator's assessment.

In order to evaluate the robustness of the PFS endpoint per RECIST 1.1 by central imaging vendor, two sensitivity analyses with a different set of censoring rules were performed. The censoring rules for PFS primary endpoint and sensitivity analyses are summarized in the following table:

Table 6: Censoring rules for Primary and Sensitivity Analyses of PFS

| Situation                                                               | Primary Analysis                                                    | Sensitivity Analysis 1                                                         | Sensitivity Analysis 2                                                                                           |
|-------------------------------------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| No PD and no death; new anticancer treatment is not initiated           | Censored at last disease assessment                                 | Censored at last disease assessment                                            | Censored at last disease assessment if still on study therapy; progressed at treatment discontinuation otherwise |
| No PD and no death; new anticancer treatment is initiated               | Censored at last disease assessment before new anticancer treatment | Censored at last disease assessment before new anticancer treatment            | Progressed at date of new anticancer treatment                                                                   |
| No PD and no death; ≥ 2 consecutive missed disease assessments          | Censored at last disease assessment                                 | Censored at last disease assessment prior to ≥2 consecutive missed visits      | Censored at last disease assessment                                                                              |
| PD or death documented after ≤ 1 missed disease assessment              | Progressed at date of documentedPD or death                         | Progressed at date of documentedPD or death                                    | Progressed at date of documentedPD or death                                                                      |
| PD or death documented at any time after ≥ 2 missed disease assessments | Progressed at date of documentedPD or death                         | Censored at last disease assessment prior to the ≥ 2 missed disease assessment | Progressed at date of documentedPD or death                                                                      |

## Interim analyses

Two interim efficacy analyses and a final analysis are planned in this study. A summary table of PFS and OS analysis strategy is shown in section 'sample size'.

At first interim analysis (IA1), PFS/OS analyses took place when all subjects have been followed up for at least  9  months.  Assuming  21  months  enrolment  period  for  825  all  subjects,  interim  analysis  1  was

<div style=\"page-break-after: always\"></div>

projected  to  occur  ~30  months  after  study  start,  with  the  primary  objective  to  demonstrate  PFS superiority of pembrolizumab (monotherapy or in combination with chemotherapy).

The second interim analysis (IA2), which is the final PFS analysis, took place when all subjects have been followed up for at least 17 months.  Assuming 21 months enrolment period for 825 all subjects, interim analysis  2  was  projected  to  occur  ~38  months  after  study  start,  with  the  primary  objective  to demonstrate OS superiority of pembrolizumab (monotherapy or in combination with chemotherapy). A PFS hypothesis was to be tested only if superior PFS was not declared for that hypothesis at interim analysis 1 (IA1).

## Subgroup analyses

To determine whether the treatment effect is consistent across various subgroups, the estimate of the between-group treatment effect (with a nominal 95% CI) for the primary endpoint was estimated and plotted by treatment group within each category of the following classification variables:

- Stratification factors
- PDL1 expression level defined by CPS (≥20 vs. not ≥20; and ≥1 vs. not ≥1)
- Age category (&lt;65 vs. ≥65 years)
- Sex (female vs. male)
- Race (white vs. all others)
- Region (North America [NA] vs European Union [EU] vs Rest of the World [ROW])
- Smoking status (never vs. former vs. current)
- Disease status (recurrent vs. metastatic)

Subgroup analyses did not use stratified analyses. The consistency of the treatment effect was assessed descriptively.

## Multiplicity

The overall type I error rate was strongly controlled at 2.5% (one-sided) with:

- 0.19% allocated to each PFS hypothesis of pembrolizumab monotherapy vs. standard treatment (H1)  and  pembrolizumab  in  combination  with  chemotherapy  vs.  standard  treatment  (H4)  in subjects with PD-L1 CPS ≥ 20;
- 0.02% allocated to PFS hypothesis of pembrolizumab in combination with chemotherapy vs. standard treatment in all subjects (H6);
- 0.7% allocated to each OS hypothesis of pembrolizumab monotherapy vs. standard treatment (H7) and pembrolizumab in combination with chemotherapy vs. standard treatment (H11) in subjects with PD-L1 CPS ≥ 20;
- 0.7%  allocated  to  OS  non-inferiority  hypothesis  of  pembrolizumab  in  combination  with chemotherapy vs. standard treatment in all subjects (H13).

The alpha reallocation strategy followed the graphical approach of Maurer and Bretz, as reported in the following figure:

<div style=\"page-break-after: always\"></div>

Figure 2: multiplicity strategy

<!-- image -->

Figure 3: Alpha Re-allocation Schema at IA2 and FA for KEYNOTE-048

<!-- image -->

The stratified Miettinen and Nurminen's method was used for comparison of the objective response rates between the treatment groups.

For subjects who demonstrate CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. DOR was assessed using RECIST 1.1 separately by BICR and by investigator's assessment.

<div style=\"page-break-after: always\"></div>

The PRO analyses are based on the PRO FAS population, defined as all randomized participants who have at least 1 PRO assessment available and have received at least 1 dose of the study medication. PROs were evaluated using the EORTC QLQ-30, EORTC QLQ-H&amp;N35 and the EQ-5D questionnaires.

## Results

## Participant flow

<!-- image -->

Note: 'Completed' in  the  Follow-up phase indicates the  participant completed 24  months (initial treatment phase) of treatment with pembrolizumab.

## Recruitment

This study was conducted at 228 centres in 37 countries. First participant first visit was on 01-APR-2015, last patient was randomized on 17-JAN-2017.

Enrolment in the pembrolizumab plus chemotherapy group was paused on 13 August 2015 and reopened on 2 October 2015, based on the external DMC recommendation after 20 participants were randomized to that group, following the review of the first 3 death events in 14 participants enrolled in that group as of 24-JUL-2015. After the DMC completed their safety assessment of those 20 subjects who had completed 2 cycles of study treatment, the DMC recommended lifting the enrolment pause.

Interim Analysis 2 (IA2): data cut-off is 13-JUN-2018, data-base lock is 29-JUN-2018.

At the IA2, the median duration of follow-up was 13.0 months (range: 0.1, 36.6) in the pembrolizumab plus chemotherapy group and 10.7 months (range: 0.1, 35.3) in the standard treatment group. The

<div style=\"page-break-after: always\"></div>

median follow-up duration for all subjects was 11.7 months (range: 0.2, 37.3) in the pembrolizumab monotherapy group and 10.7 months (range: 0.1, 35.3) in the standard treatment group.

Final Analysis (FA): data cut-off is 25-FEB-2019, data-base lock is 25-MAR-2019. The median duration of follow-up was 13.0 months (range: 0.1, 43.4) in the pembrolizumab plus chemotherapy group and 10.7 months  (range:  0.1,  40.7)  in  the  standard  treatment  group.  The  median  follow-up  duration  for  all subjects was 11.5 months (range: 0.2, 45.7) in the pembrolizumab monotherapy group and 10.7 months (range: 0.1, 41.8) in the standard treatment group.

## Conduct of the study

## Protocol amendments

The main protocol changes are summarized below:

Table 7: Summary of MK-3475 KEYNOTE-048 Protocol Amendments

| Protocol or Amendment                             | Rationale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Protocol (05-DEC-2014)                            | Original protocol.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Amendment 01 (26-JUN-2015) Global (all countries) | Increased sample size from 750 to 780 subjects, including the first 600 subjects with any level of PD-L1 expression and the remaining 180 subjects with strongly positive PD-L1 expression                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Amendment 05 (05-AUG-2016) Global (all countries) | Enrollment target was updated from 780 to 825 subjects, OS was added to the primary objectives and hypotheses, and the description of the biomarker selected population was updated. In addition, the SAP was updated to: 1. Move OS from a secondary efficacy endpoint to primary, 2. For PD-L1 positive sub-populations, updated strongly positive and positive as defined by tumour proportion score (TPS) to PD-L1 ≥20% CPS, PD-L1 ≥10% CPS, and P D-L1 ≥ 1% CPS. 3. Updated analysis populations, statistical methods, power and sample size calculation, multiplicity strategy, interim analysis plan, and subgroup analyses, accordingly.                                                                                                                                                                                                                    |
| Amendment 07 (17-MAR-2017) Global (all countries) | CPS 10% was removed from the analyses plan. Only the 20% and 1% CPS cutpoints will be analyzed. Therefore, references to PD-L1 10% CPS were removed. Hypothesis numbering was modified accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Amendment 08 (24-AUG-2017) Global (all countries) | Increased follow-up time at the interim and final analyses by 3 months, and updated timing of each analysis. Power calculations and analysis plan (expected timing, required number of events and boundary properties) were updated accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Amendment 09 (09-NOV-2017) Global (all countries) | Updated the dose modifications table for pembrolizumab including the addition of guidelines for the management of myocarditis based upon health authority feedback; added hypotheses for PFS and OS superiority in the biomarker positive subpopulation for comparison of pembrolizumab in combination with chemotherapy versus standard treatment; increased the follow-up period by 3 months for the second interim analysis and final analysis with power calculations and analysis plan updated accordingly, moved DOR to an exploratory endpoint; added OS and PFS hypotheses in the biomarker-positive subpopulation for pembrolizumab combination therapy, and updated the multiplicity strategy accordingly; and added language to allow for collection of survival status for subjects in all phases of the study at time points specified by the Sponsor. |
| Amendment 10 (11-JAN-2019) Global (all countries) | Modified to indicate the number of expected events, rather than required events; references to 'event-driven' were removed and text was modified to describe the timing of the final analysis to account for the scenario if the number of deaths for 1 hypothesis accumulates slower than expected to prevent the trial continuing for an unreasonable period for the final analysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

## Change from TPS to CPS score

TPS is defined by the percentage of neoplastic cells expressing PD-L1 at any intensity (weak, moderate, or strong), and only takes into account the expression of PD-L1 on neoplastic cells.

CPS is defined by the number of tumour cells and mononuclear inflammatory cells within the tumourtumour nests and the adjacent supporting stroma expressing PD-L1 at any intensity divided by number of tumourtumour cells, then multiplied by 100.

In  KEYNOTE-048,  with  protocol  amendment  05  (dated  05-AUG-2016),  the  pre-specified  biomarker scoring method for the analysis of efficacy was updated from TPS to CPS, and the biomarker cut point for efficacy analyses was changed from strongly positive PDL1 (TPS ≥50%) to CPS ≥20, CPS ≥10, and CPS ≥1 (and subsequently limited to CPS ≥20 and CPS ≥1 in protocol amendment 07, dated 17-MAR-2017).

Similarly, the PD-L1 biomarker analysis population and cutoff in KEYNOTE-040 (2L HNSCC study) was changed from TPS ≥50% to CPS ≥1 during the study (protocol amendment 10, dated 10 -MAR-2016).

Based on data from KEYNOTE-012 for BOR, PFS, and OS, the MAH considered that PD-L1 expression in both  tumour  and  infiltrating  immune  cells  (CPS  scoring)  showed  improved  association  with  clinical outcome under pembrolizumab treatment when compared with PD-L1 expression in tumour cells alone (TPS scoring). In KEYNOTE-012, patients whose tumour s were CPS ≥1 showed increased response rates relative to patients whose tumours were CPS&lt;1. In contrast, the 1% and 50% TPS cutoffs showed fairly similar response rates above and below the cutoff and there seemed to be poor sensitivity in general when scoring tumour alone.

In  addition,  based  on  clinical  utility,  sensitivity,  specificity,  as  well  as  the  prevalence  of  patients associated with various PDL1 cut points evaluated in this analysis, the MAH selected CPS ≥1 and CPS ≥20 as the biomarker cutoffs for PD -L1 assessment in KEYNOTE-048. The CPS assay was analytically validated and the testing site personnel appropriately trained on CPS ≥20 and ≥1 before implementation to determine PD-L1 status in the KEYNOTE-048 study. Furthermore, the MAH considered that the survival benefit in CPS ≥1 and CPS ≥20 populations at the IA2 of KEYNOTE -048 demonstrated clinical validation for the scoring method. Additionally, the MAH reported that the method has been extensively analytically validated  in  HNSCC  by  the  MAH's  IHC  partner,  Agilent,  to  demonstrate  sensitivity,  robustness  and reproducibility.

PD-L1 expression was based on the PD-L1 IHC 22C3 pharmDxTM Kit.

## Protocol deviations

A total of 308 (34.9%) of the 882 randomized participants had one or more important protocol deviations (ie, those that may significantly impact the quality or integrity of key study data or that may significantly affect a participant's rights, safety, or wellbeing): 85 patients (28.2%) in the pembro mono, 116 (41.3%) in the pembro combo, and 107 (35.7%) in the control arm.

Important protocol deviations were reported across the following categories:

- Had no documented initial consent to enter the trial, or did not have their consent form updated per the  Informed  Consent  implementation  plan  following  a  significant  safety  change  to  the  Risk Language/Informed Consent (following site/regional approval of the ICF),
- Entered into the study (ie, progressed beyond screening) and did not meet key inclusion/exclusion criteria,
- Received incorrect study intervention and/or were administered improperly stored study intervention,
- Received prohibited concomitant intervention,

<div style=\"page-break-after: always\"></div>

- Experienced an SAE/ECI/pregnancy and information was not reported as required per the protocol,
- Missed key safety or efficacy procedures which may impact participant safety or data integrity.

No important protocol deviations were classified as GCP compliance issues.

## Changes Following Study Unblinding

Following the DMC review on 23-JUL-2018 and the unblinding of the study team and program statisticians on  26-JUL-2018,  it  was  identified  that  one  participant  randomized  to  the  pembrolizumab  plus chemotherapy  group  was  erroneously  excluded  from  the analyses comparing  the efficacy of pembrolizumab plus chemotherapy to standard treatment. After the discovery and following confirmation of the error, the analysis dataset was updated to subsequently include this participant. No data points were altered in the clinical database or the SDTM source data to fix this error, and that the change was implemented only in the analysis dataset.

On 11-OCT-2018, several cases of measurement discrepancy were reported by independent reviewers and  PAREXEL  Medical  Imaging  (PXL)  staff,  where  the  value  presented  in  ALICE  (Medical  Imaging proprietary viewing software) differed from the value captured in the ANALYSIS eCRF. A decision was made to remediate measurement discrepancies through a modified re-review in a consistent manner for all MSD studies where PXL was utilized as the central imaging vendor. In KEYNOTE-048, 16 participants were identified by PXL's assurance tool with measurement discrepancies in scope for the remediation process.  Following  remediation,  a  change  in  assessment  occurred  with  4  participants.  A  sensitivity analysis performed with these 4 new assessments showed minimal impact to IA2 PFS assessment for KEYNOTE-048. The findings do not impact the OS outcomes.

## Baseline data

## Pembrolizumab plus chemotherapy (platinum+5-FU) vs chemotherapy (EXTREME regimen)

Table 8: Subject Characteristics (Pembro Combo vs Control) (ITT Population)

|                                  | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   | Total    | Total   |
|----------------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|----------|---------|
|                                  | n                              | (%)                            | n                          | (%)                        | n        | (%)     |
| Subjects in population           | 281                            |                                | 278                        |                            | 559      |         |
| Gender                           |                                |                                |                            |                            |          |         |
| Male                             | 224                            | (79.7)                         | 242                        | (87.1)                     | 466      | (83.4)  |
| Female                           | 57                             | (20.3)                         | 36                         | (12.9)                     | 93       | (16.6)  |
| Age (Years)                      |                                |                                |                            |                            |          |         |
| <65                              | 180                            | (64.1)                         | 181                        | (65.1)                     | 361      | (64.6)  |
| >=65                             | 101                            | (35.9)                         | 97                         | (34.9)                     | 198      | (35.4)  |
| Mean                             | 60.7                           |                                | 60.9                       |                            | 60.8     |         |
| SD                               | 9.8                            |                                | 10.0                       |                            | 9.9      |         |
| Median                           | 61.0                           |                                | 61.0                       |                            | 61.0     |         |
| Range                            | 20 to 85                       |                                | 24 to 84                   |                            | 20 to 85 |         |
| Race                             |                                |                                |                            |                            |          |         |
| American Indian Or Alaska Native | 3                              | (1.1)                          | 6                          | (2.2)                      | 9        | (1.6)   |
| Asian                            | 60                             | (21.4)                         | 49                         | (17.6)                     | 109      | (19.5)  |
| Black Or African American        | 11                             | (3.9)                          | 6                          | (2.2)                      | 17       | (3.0)   |
| Multi-Racial                     | 4                              | (1.4)                          | 9                          | (3.2)                      | 13       | (2.3)   |
| White                            | 203                            | (72.2)                         | 207                        | (74.5)                     | 410      | (73.3)  |
| Missing                          | 0                              | (0.0)                          | 1                          | (0.4)                      | 1        | (0.2)   |

<div style=\"page-break-after: always\"></div>

| Ethnicity                                  |           |        |           |        |           |        |
|--------------------------------------------|-----------|--------|-----------|--------|-----------|--------|
| Hispanic Or Latino                         | 45        | (16.0) | 44        | (15.8) | 89        | (15.9) |
| Not Hispanic Or Latino                     | 213       | (75.8) | 211       | (75.9) | 424       | (75.8) |
| Not Reported                               | 18        | (6.4)  | 14        | (5.0)  | 32        | (5.7)  |
| Unknown                                    | 5         | (1.8)  | 9         | (3.2)  | 14        | (2.5)  |
| Region Group                               |           |        |           |        |           |        |
| NA                                         | 60        | (21.4) | 59        | (21.2) | 119       | (21.3) |
| EU                                         | 88        | (31.3) | 94        | (33.8) | 182       | (32.6) |
| ROW                                        | 133       | (47.3) | 125       | (45.0) | 258       | (46.2) |
| Smoking Status                             |           |        |           |        |           |        |
| Never Smoker                               | 57        | (20.3) | 61        | (21.9) | 118       | (21.1) |
| Ex Smoker                                  | 168       | (59.8) | 179       | (64.4) | 347       | (62.1) |
| Current Smoker                             | 56        | (19.9) | 36        | (12.9) | 92        | (16.5) |
| Missing                                    | 0         | (0.0)  | 2         | (0.7)  | 2         | (0.4)  |
| ECOG                                       |           |        |           |        |           |        |
| 0                                          | 110       | (39.1) | 108       | (38.8) | 218       | (39.0) |
| 1                                          | 171       | (60.9) | 170       | (61.2) | 341       | (61.0) |
| HPV Status                                 |           |        |           |        |           |        |
| Positive                                   | 60        | (21.4) | 61        | (21.9) | 121       | (21.6) |
| Negative                                   | 221       | (78.6) | 217       | (78.1) | 438       | (78.4) |
| PD-L1 TPS Status                           |           |        |           |        |           |        |
| Strongly Positive                          | 66        | (23.5) | 62        | (22.3) | 128       | (22.9) |
| Not Strongly Positive                      | 215       | (76.5) | 216       | (77.7) | 431       | (77.1) |
| PD-L1 CPS Status (CPS>=1)                  |           |        |           |        |           |        |
| CPS >=1                                    | 242       | (86.1) | 235       | (84.5) | 477       | (85.3) |
| CPS <1                                     | 39        | (13.9) | 43        | (15.5) | 82        | (14.7) |
| PD-L1 CPS Status (CPS>=20)                 |           |        |           |        |           |        |
| CPS >=20                                   | 126       | (44.8) | 110       | (39.6) | 236       | (42.2) |
| CPS <20                                    | 154       | (54.8) | 165       | (59.4) | 319       | (57.1) |
| Missing                                    | 1         | (0.4)  | 3         | (1.1)  | 4         | (0.7)  |
| PD-L1 CPS Status                           |           |        |           |        |           |        |
| CPS<1                                      | 39        | (13.9) | 43        | (15.5) | 82        | (14.7) |
| 1<=CPS<20                                  | 116       | (41.3) | 125       | (45.0) | 241       | (43.1) |
| CPS>=20                                    | 126       | (44.8) | 110       | (39.6) | 236       | (42.2) |
| Baseline Tumour Size (mm) (Grouping by ITT | Median)   |        |           |        |           |        |
| >=Median                                   | 146       | (52.0) | 124       | (44.6) | 270       | (48.3) |
| <Median                                    | 114       | (40.6) | 135       | (48.6) | 249       | (44.5) |
| Missing                                    | 21        | (7.5)  | 19        | (6.8)  | 40        | (7.2)  |
| Subjects with data                         | 260       |        | 259       |        | 519       |        |
| Mean                                       | 82.3      |        | 78.7      |        | 80.5      |        |
| SD                                         | 61.6      |        | 67.7      |        | 64.7      |        |
| Median                                     | 67.3      |        | 58.7      |        | 63.6      |        |
| Range                                      | 12 to 385 |        | 10 to 419 |        | 10 to 419 |        |
| Disease Status                             |           |        |           |        |           |        |
| Metastatic                                 | 201       | (71.5) | 187       | (67.3) | 388       | (69.4) |
| Recurrent                                  | 76        | (27.0) | 88        | (31.7) | 164       | (29.3) |
| Neither                                    | 4         | (1.4)  | 3         | (1.1)  | 7         | (1.3)  |
| Primary Tumour Staging                     |           |        |           |        |           |        |

<div style=\"page-break-after: always\"></div>

| T0                                       | 42     | (14.9)   | 34          | (12.2)   | 76          | (13.6)   |
|------------------------------------------|--------|----------|-------------|----------|-------------|----------|
| T1                                       | 22     | (7.8)    | 12          | (4.3)    | 34          | (6.1)    |
| T1A                                      | 1      | (0.4)    | 0           | (0.0)    | 1           | (0.2)    |
| T2                                       | 40     | (14.2)   | 48          | (17.3)   | 88          | (15.7)   |
| T3                                       | 37     | (13.2)   | 36          | (12.9)   | 73          | (13.1)   |
| T3B                                      | 0      | (0.0)    | 1           | (0.4)    | 1           | (0.2)    |
| T4                                       | 38     | (13.5)   | 52          | (18.7)   | 90          | (16.1)   |
| T4A                                      | 54     | (19.2)   | 47          | (16.9)   | 101         | (18.1)   |
| T4B                                      | 13     | (4.6)    | 22          | (7.9)    | 35          | (6.3)    |
| TX                                       | 34     | (12.1)   | 26          | (9.4)    | 60          | (10.7)   |
| Regional Lymph Nodes Staging             |        |          |             |          |             |          |
| N0                                       | 76     | (27.0)   | 77          | (27.7)   | 153         | (27.4)   |
| N1                                       | 37     | (13.2)   | 47          | (16.9)   | 84          | (15.0)   |
| N2                                       | 134    | (47.7)   | 118         | (42.4)   | 252         | (45.1)   |
| N3                                       | 22     | (7.8)    | 29          | (10.4)   | 51          | (9.1)    |
| NX                                       | 12     | (4.3)    | 7           | (2.5)    | 19          | (3.4)    |
| Metastatic Staging                       |        |          |             |          |             |          |
| M0                                       | 80     | (28.5)   | 91          | (32.7)   | 171         | (30.6)   |
| M1                                       | 201    | (71.5)   | 187         | (67.3)   | 388         | (69.4)   |
| Overall Cancer Staging                   |        |          |             |          |             |          |
| III                                      | 15     | (5.3)    | 13          | (4.7)    | 28          | (5.0)    |
| IVA                                      | 50     | (17.8)   | 58          | (20.9)   | 108         | (19.3)   |
| IVB                                      | 15     | (5.3)    | 20          | (7.2)    | 35          | (6.3)    |
| IVC                                      | 201    | (71.5)   | 187         | (67.3)   | 388         | (69.4)   |
| Primary Tumour Location-Oral Cavity      |        |          |             |          |             |          |
| Yes                                      | 82     | (29.2)   | 84          | (30.2)   | 166         | (29.7)   |
| No                                       | 199    | (70.8)   | 194         | (69.8)   | 393         | (70.3)   |
| Primary Tumour Location-Larynx           |        |          |             |          |             |          |
| Yes                                      | 46     | (16.4)   | 56          | (20.1)   | 102         | (18.2)   |
| No                                       | 235    | (83.6)   | 222         | (79.9)   | 457         | (81.8)   |
| Primary Tumour Location-Hypopharynx      |        |          |             |          |             |          |
| Yes                                      | 44     | (15.7)   | 36          | (12.9)   | 80          | (14.3)   |
| No                                       | 237    | (84.3)   | 242         | (87.1)   | 479         | (85.7)   |
| Primary Tumour Location-Oropharynx       |        |          |             |          |             |          |
| Yes                                      | 113    | (40.2)   | 107         | (38.5)   | 220         | (39.4)   |
| No                                       | 168    | (59.8)   | 171         | (61.5)   | 339         | (60.6)   |
| Time from Latest Platinum Therapy (days) |        |          |             |          |             |          |
| Subjects with data                       | 130    |          | 130         |          | 260         |          |
| Mean                                     | 795.0  |          | 893.5       |          | 844.3       |          |
| SD                                       | 954.8  |          | 920.1       |          | 937.1       |          |
| Median                                   | 457.5  |          | 585.5       |          | 513.5       |          |
| Range                                    | 146 to | 6278     | 119 to      | 6817     | 119 to 6817 |          |
| Time from Prior Systemic Therapy (days)  |        |          |             |          |             |          |
| Subjects with data                       | 141    |          | 138         |          | 279         |          |
| Mean                                     | 760.0  |          | 871.3       |          | 815.0       |          |
| SD                                       | 922.1  |          | 894.8       |          | 908.8       |          |
| Median                                   | 449.0  |          | 571.5       |          | 502.0       |          |
| Range                                    | 146 to | 6278     | 119 to 6817 |          | 119 to 6817 |          |
| Database Cutoff Date: 13JUN2018.         |        |          |             |          |             |          |

<div style=\"page-break-after: always\"></div>

Table 9: Summary of Prior Line of Systemic Therapy (Pembro Combo vs Control) (ITT Population)

|                                               | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   | Total   | Total   |
|-----------------------------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|---------|---------|
|                                               | n                              | (%)                            | n                          | (%)                        | n       | (%)     |
| Subjects in population                        | 281                            |                                | 278                        |                            | 559     |         |
| Subjects with no prior systemic therapy       | 140                            | (49.8)                         | 140                        | (50.4)                     | 280     | (50.1)  |
| Primary/Locally Advanced/With Curative Intent | 136                            | (48.4)                         | 136                        | (48.9)                     | 272     | (48.7)  |
| Cetuximab                                     | 19                             | (6.8)                          | 16                         | (5.8)                      | 35      | (6.3)   |
| Platinum                                      | 125                            | (44.5)                         | 128                        | (46.0)                     | 253     | (45.3)  |
| Recurrent/With Curative Intent                | 10                             | (3.6)                          | 4                          | (1.4)                      | 14      | (2.5)   |
| Cetuximab                                     | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |
| Platinum                                      | 9                              | (3.2)                          | 3                          | (1.1)                      | 12      | (2.1)   |

A subject can have multiple prior systemic therapies and be counted in different rows that are applicable.  But every subject is counted a single time for each applicable row and column.

Database Cutoff Date: 13JUN2018.

Table 10 : Subject Characteristics (Pembro Combo vs Control) (ITT population) (CPS≥1 and CPS≥20)

|                                  | CPS>=1                       | CPS>=1                       | CPS>=1                   | CPS>=1                   | CPS>=20                      | CPS>=20                      | CPS>=20                  | CPS>=20                  |
|----------------------------------|------------------------------|------------------------------|--------------------------|--------------------------|------------------------------|------------------------------|--------------------------|--------------------------|
|                                  | Pembrolizumab + Chemotherapy | Pembrolizumab + Chemotherapy | Cetuximab + Chemotherapy | Cetuximab + Chemotherapy | Pembrolizumab + Chemotherapy | Pembrolizumab + Chemotherapy | Cetuximab + Chemotherapy | Cetuximab + Chemotherapy |
|                                  | n                            | (%)                          | n                        | (%)                      | n                            | (%)                          | n                        | (%)                      |
| Subjects in population           | 242                          |                              | 235                      |                          | 126                          |                              | 110                      |                          |
| Gender                           |                              |                              |                          |                          |                              |                              |                          |                          |
| Male                             | 188                          | (77.7)                       | 203                      | (86.4)                   | 90                           | (71.4)                       | 96                       | (87.3)                   |
| Female                           | 54                           | (22.3)                       | 32                       | (13.6)                   | 36                           | (28.6)                       | 14                       | (12.7)                   |
| Age (Years)                      |                              |                              |                          |                          |                              |                              |                          |                          |
| <65                              | 153                          | (63.2)                       | 152                      | (64.7)                   | 77                           | (61.1)                       | 77                       | (70.0)                   |
| >=65                             | 89                           | (36.8)                       | 83                       | (35.3)                   | 49                           | (38.9)                       | 33                       | (30.0)                   |
| Mean                             | 60.6                         |                              | 60.8                     |                          | 61.1                         |                              | 59.8                     |                          |
| SD                               | 9.9                          |                              | 10.3                     |                          | 9.6                          |                              | 10.2                     |                          |
| Median                           | 61.0                         |                              | 61.0                     |                          | 62.0                         |                              | 60.0                     |                          |
| Range                            | 20 to 85                     |                              | 24 to 84                 |                          | 28 to 85                     |                              | 24 to 80                 |                          |
| Race                             |                              |                              |                          |                          |                              |                              |                          |                          |
| American Indian Or Alaska Native | 2                            | (0.8)                        | 6                        | (2.6)                    | 1                            | (0.8)                        | 3                        | (2.7)                    |
| Asian                            | 48                           | (19.8)                       | 43                       | (18.3)                   | 24                           | (19.0)                       | 20                       | (18.2)                   |
| Black Or African American        | 10                           | (4.1)                        | 3                        | (1.3)                    | 3                            | (2.4)                        | 1                        | (0.9)                    |
| Multi-Racial                     | 4                            | (1.7)                        | 9                        | (3.8)                    | 3                            | (2.4)                        | 4                        | (3.6)                    |
| White                            | 178                          | (73.6)                       | 173                      | (73.6)                   | 95                           | (75.4)                       | 82                       | 82                       |
| Missing                          | 0                            | (0.0)                        | 1                        | (0.4)                    |                              | -                            | (74.5)                   | (74.5)                   |
| Ethnicity                        |                              |                              |                          |                          |                              |                              |                          |                          |
| Hispanic Or Latino               | 39                           | (16.1)                       | 34                       | (14.5)                   | 24                           | (19.0)                       | 15                       | (13.6)                   |
| Not Hispanic Or Latino           | 185                          | (76.4)                       | 181                      | (77.0)                   | 96                           | (76.2)                       | 82                       | (74.5)                   |
| Not Reported                     | 14                           | (5.8)                        | 13                       | (5.5)                    | 4                            | (3.2)                        | 8                        | (7.3)                    |
| Unknown                          | 4                            | (1.7)                        | 7                        | (3.0)                    | 2                            | (1.6)                        | 5                        | (4.5)                    |
| Region Group                     |                              |                              |                          |                          |                              |                              |                          |                          |
| NA                               | 53                           | (21.9)                       | 51                       | (21.7)                   | 30                           | (23.8)                       | 30                       | (27.3)                   |
| EU                               | 76                           | (31.4)                       | 82                       | (34.9)                   | 39                           | (31.0)                       | 35                       | (31.8)                   |
| ROW                              | 113                          | (46.7)                       | 102                      | (43.4)                   | 57                           | (45.2)                       | 45                       | (40.9)                   |
| Smoking Status                   |                              |                              |                          |                          |                              |                              |                          |                          |

<div style=\"page-break-after: always\"></div>

| Never Smoker                        | 50        | (20.7)   | 58        | (24.7)   | 30        | (23.8)   | 28        | (25.5)   |
|-------------------------------------|-----------|----------|-----------|----------|-----------|----------|-----------|----------|
| Ex Smoker                           | 143       | (59.1)   | 142       | (60.4)   | 75        | (59.5)   | 63        | (57.3)   |
| Current Smoker                      | 49        | (20.2)   | 33        | (14.0)   | 21        | (16.7)   | 18        | (16.4)   |
| Missing                             | 0         | (0.0)    | 2         | (0.9)    | 0         | (0.0)    | 1         | (0.9)    |
| ECOG                                |           |          |           |          |           |          |           |          |
| 0                                   | 92        | (38.0)   | 94        | (40.0)   | 47        | (37.3)   | 47        | (42.7)   |
| 1                                   | 150       | (62.0)   | 141       | (60.0)   | 79        | (62.7)   | 63        | (57.3)   |
| HPV Status                          |           |          |           |          |           |          |           |          |
| Positive                            | 53        | (21.9)   | 50        | (21.3)   | 27        | (21.4)   | 25        | (22.7)   |
| Negative                            | 189       | (78.1)   | 185       | (78.7)   | 99        | (78.6)   | 85        | (77.3)   |
| PD-L1 TPS Status                    |           |          |           |          |           |          |           |          |
| Strongly Positive                   | 66        | (27.3)   | 62        | (26.4)   | 65        | (51.6)   | 58        | (52.7)   |
| Not Strongly Positive               | 176       | (72.7)   | 173       | (73.6)   | 61        | (48.4)   | 52        | (47.3)   |
| PD-L1 CPS Status (CPS>=20)          |           |          |           |          |           |          |           |          |
| CPS >=20                            | 126       | (52.1)   | 110       | (46.8)   |           | -        |           | -        |
| CPS <20                             | 115       | (47.5)   | 123       | (52.3)   |           |          |           |          |
| Missing                             |           |          |           | (0.9)    |           |          |           |          |
|                                     | 1         | (0.4)    | 2         |          |           |          |           |          |
| Baseline Tumour Size (mm) (Grouping | by ITT    | Median)  |           |          |           |          |           |          |
| >=Median                            | 128       | (52.9)   | 102       | (43.4)   | 63        | (50.0)   | 42        | (38.2)   |
| <Median                             | 95        | (39.3)   | 116       | (49.4)   | 54        | (42.9)   | 59        | (53.6)   |
| Missing                             | 19        | (7.9)    | 17        | (7.2)    | 9         | (7.1)    | 9         | (8.2)    |
| Subjects with data                  | 223       |          | 218       |          | 117       |          | 101       |          |
| Mean                                | 82.7      |          | 73.0      |          | 74.7      |          | 65.8      |          |
| SD                                  | 59.8      |          | 58.6      |          | 47.6      |          | 55.0      |          |
|                                     | 68.1      |          | 56.0      |          | 64.7      |          |           |          |
| Median                              |           |          |           |          |           |          | 51.2      |          |
| Range                               | 12 to 385 |          | 10 to 419 |          | 13 to 206 |          | 10 to 320 |          |
| Disease Status                      |           |          |           |          |           |          |           |          |
| Metastatic                          | 173       | (71.5)   | 154       | (65.5)   | 87        | (69.0)   | 69        | (62.7)   |
| Recurrent                           | 65        | (26.9)   | 78        | (33.2)   | 38        | (30.2)   | 40        | (36.4)   |
| Neither                             | 4         | (1.7)    | 3         | (1.3)    | 1         | (0.8)    | 1         | (0.9)    |
| Primary Tumour Staging              |           |          |           |          |           |          |           |          |
| T0                                  | 33        | (13.6)   | 33        | (14.0)   | 16        | (12.7)   | 20        | (18.2)   |
| T1                                  | 18        | (7.4)    | 9         | (3.8)    | 11        | (8.7)    | 4         | (3.6)    |
| T1A                                 | 1         | (0.4)    | 0         | (0.0)    | -         |          | -         |          |
| T2                                  | 38        | (15.7)   | 42        | (17.9)   | 15        | (11.9)   | 20        | (18.2)   |
| T3                                  | 33        | (13.6)   | 31        | (13.2)   | 20        | (15.9)   | 11        | (10.0)   |
| T3B                                 | 0         | (0.0)    | 1         | (0.4)    | -         |          | -         |          |
| T4                                  | 31        | (12.8)   | 43        | (18.3)   | 14        | (11.1)   | 18        | (16.4)   |
| T4A                                 | 48        | (19.8)   | 39        | (16.6)   | 30        | (23.8)   | 21        | (19.1)   |
| T4B                                 | 11        | (4.5)    | 20        | (8.5)    | 7         | (5.6)    | 7         | (6.4)    |
| TX                                  | 29        | (12.0)   | 17        | (7.2)    | 13        | (10.3)   | 9         | (8.2)    |
| Regional Lymph Nodes Staging        |           |          |           |          |           |          |           |          |
| N0                                  | 64        | (26.4)   | 63        | (26.8)   | 38        | (30.2)   | 34        | (30.9)   |
| N1                                  | 33        | (13.6)   | 41        | (17.4)   | 11        | (8.7)    | 27        | (24.5)   |
| N2                                  | 114       | (47.1)   | 102       | (43.4)   | 61        | (48.4)   | 36        | (32.7)   |
| N3                                  | 20        | (8.3)    | 23        | (9.8)    | 10        | (7.9)    | 11        | (10.0)   |
| NX                                  | 11        | (4.5)    | 6         | (2.6)    | 6         | (4.8)    | 2         | (1.8)    |
| Metastatic Staging                  |           |          |           |          |           |          |           |          |
| M0                                  | 69        | (28.5)   | 81        | (34.5)   | 39        | (31.0)   | 41        | (37.3)   |
| M1                                  | 173       | (71.5)   | 154       | (65.5)   | 87        | (69.0)   | 69        | (62.7)   |

<div style=\"page-break-after: always\"></div>

| Overall Cancer Staging                   | Overall Cancer Staging                   | Overall Cancer Staging                   | Overall Cancer Staging                   | Overall Cancer Staging                   | Overall Cancer Staging                   | Overall Cancer Staging                   | Overall Cancer Staging                   | Overall Cancer Staging                   |
|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| III IVA IVB IVC                          | 14 42 13 173                             | (5.8) (17.4) (5.4) (71.5)                | 10 54 17 154                             | (4.3) (23.0) (7.2) (65.5)                | 11 22 6 87                               | (8.7) (17.5) (4.8) (69.0)                | 6 26 9 69                                | (5.5) (23.6) (8.2) (62.7)                |
| Primary Tumour Location-Oral Cavity      | Primary Tumour Location-Oral Cavity      | Primary Tumour Location-Oral Cavity      | Primary Tumour Location-Oral Cavity      | Primary Tumour Location-Oral Cavity      | Primary Tumour Location-Oral Cavity      | Primary Tumour Location-Oral Cavity      | Primary Tumour Location-Oral Cavity      | Primary Tumour Location-Oral Cavity      |
| Yes No                                   | 77 165                                   | (31.8) (68.2)                            | 73 162                                   | (31.1) (68.9)                            | 51 75                                    | (40.5) (59.5)                            | 44 66                                    | (40.0) (60.0)                            |
| Primary Tumour Location-Larynx           | Primary Tumour Location-Larynx           | Primary Tumour Location-Larynx           | Primary Tumour Location-Larynx           | Primary Tumour Location-Larynx           | Primary Tumour Location-Larynx           | Primary Tumour Location-Larynx           | Primary Tumour Location-Larynx           | Primary Tumour Location-Larynx           |
| Yes No                                   | 37 205                                   | (15.3) (84.7)                            | 48 187                                   | (20.4) (79.6)                            | 14 112                                   | (11.1) (88.9)                            | 16 94                                    | (14.5) (85.5)                            |
| Primary Tumour Location-Hypopharynx      | Primary Tumour Location-Hypopharynx      | Primary Tumour Location-Hypopharynx      | Primary Tumour Location-Hypopharynx      | Primary Tumour Location-Hypopharynx      | Primary Tumour Location-Hypopharynx      | Primary Tumour Location-Hypopharynx      | Primary Tumour Location-Hypopharynx      | Primary Tumour Location-Hypopharynx      |
| Yes                                      | 33 209                                   | (13.6) (86.4)                            | 30 205                                   | (12.8)                                   | 17                                       | (13.5)                                   | 7                                        | (6.4)                                    |
| No                                       |                                          | (40.5)                                   |                                          | (87.2)                                   | 109                                      | (86.5)                                   | 103                                      | (93.6)                                   |
| Primary Tumour Location-Oropharynx       | Primary Tumour Location-Oropharynx       | Primary Tumour Location-Oropharynx       | Primary Tumour Location-Oropharynx       | Primary Tumour Location-Oropharynx       | Primary Tumour Location-Oropharynx       | Primary Tumour Location-Oropharynx       | Primary Tumour Location-Oropharynx       | Primary Tumour Location-Oropharynx       |
| Yes No                                   | 98 144                                   | (59.5)                                   | 88 147                                   | (37.4) (62.6)                            | 45 81                                    | (35.7) (64.3)                            | 43 67                                    | (39.1) (60.9)                            |
| Time from Latest Platinum Therapy (days) | Time from Latest Platinum Therapy (days) | Time from Latest Platinum Therapy (days) | Time from Latest Platinum Therapy (days) | Time from Latest Platinum Therapy (days) | Time from Latest Platinum Therapy (days) | Time from Latest Platinum Therapy (days) | Time from Latest Platinum Therapy (days) | Time from Latest Platinum Therapy (days) |
| Subjects with data Mean SD Median Range  | 109 734.4 939.9 441.0 146 to             | 6278                                     | 113 866.8 883.0 575.0 201 to             | 6817                                     | 53 813.7 1137.9 430.0 146 to             | 6278                                     | 50 951.0 1157.3 502.0 224 to             | 6817                                     |
| Time from Prior Systemic Therapy (days)  | Time from Prior Systemic Therapy (days)  | Time from Prior Systemic Therapy (days)  | Time from Prior Systemic Therapy (days)  | Time from Prior Systemic Therapy (days)  | Time from Prior Systemic Therapy (days)  | Time from Prior Systemic Therapy (days)  | Time from Prior Systemic Therapy (days)  | Time from Prior Systemic Therapy (days)  |
| Subjects with data Mean SD Median Range  | 118 705.3 905.8 440.0 146 to 6278        | 118 705.3 905.8 440.0 146 to 6278        | 118 851.8 863.8 601.0 201 to 6817        | 118 851.8 863.8 601.0 201 to 6817        | 57 764.6 1100.4 421.0 146 to 6278        | 57 764.6 1100.4 421.0 146 to 6278        | 52 933.9 1135.7 521.5 224 to 6817        | 52 933.9 1135.7 521.5 224 to 6817        |
| Database Cutoff Date: 13JUN2018.         | Database Cutoff Date: 13JUN2018.         | Database Cutoff Date: 13JUN2018.         | Database Cutoff Date: 13JUN2018.         | Database Cutoff Date: 13JUN2018.         | Database Cutoff Date: 13JUN2018.         | Database Cutoff Date: 13JUN2018.         | Database Cutoff Date: 13JUN2018.         | Database Cutoff Date: 13JUN2018.         |

The choice of platinum compound in KEYNOTE-048 was made by the investigator before randomization, which was documented in IVRS. Overall, approximately 60% received carboplatin and 40% received cisplatin  at  first  dose  in  the  pembrolizumab  +  chemo  group  and  standard  treatment  group.  In  the pembrolizumab plus chemotherapy group and standard treatment group, 119 (43.1%) and 119 (41.5%) participants  were  assigned  to  receive  cisplatin,  respectively.  During  the  study,  33.6%  (40  of  119 participants)  and  30.3%  (36  of  119  participants)  switched  from  cisplatin  to  carboplatin  in  the pembrolizumab plus chemotherapy and standard treatment groups, respectively. For participants who switched from cisplatin to carboplatin, the median number of cycles of cisplatin and carboplatin received in  the  pembrolizumab  plus  chemotherapy group was 2 cycles  and 2 cycles, respectively, and in the standard treatment group was 2 cycles and 3 cycles, respectively.

<div style=\"page-break-after: always\"></div>

## Pembrolizumab vs chemotherapy (EXTREME regimen)

Table 11: Subject Characteristics (Pembro Mono vs Control) (ITT Population)

|                                  | Pembrolizumab   | Pembrolizumab   | Cetuximab +   | Cetuximab +   | Total    | Total   |
|----------------------------------|-----------------|-----------------|---------------|---------------|----------|---------|
|                                  | n               | (%)             | n             | (%)           | n        | (%)     |
| Subjects in population           | 301             |                 | 300           |               | 601      |         |
| Gender                           |                 |                 |               |               |          |         |
| Male                             | 250             | (83.1)          | 261           | (87.0)        | 511      | (85.0)  |
| Female                           | 51              | (16.9)          | 39            | (13.0)        | 90       | (15.0)  |
| Age (Years)                      |                 |                 |               |               |          |         |
| <65                              | 190             | (63.1)          | 195           | (65.0)        | 385      | (64.1)  |
| >=65                             | 111             | (36.9)          | 105           | (35.0)        | 216      | (35.9)  |
| Mean                             | 61.2            |                 | 61.0          |               | 61.1     |         |
| SD                               | 9.4             |                 | 10.0          |               | 9.7      |         |
| Median                           | 62.0            |                 | 61.0          |               | 61.0     |         |
| Range                            | 22 to 94        |                 | 24 to 84      |               | 22 to 94 |         |
| Race                             |                 |                 |               |               |          |         |
| American Indian Or Alaska Native | 5               | (1.7)           | 6             | (2.0)         | 11       | (1.8)   |
| Asian                            | 58              | (19.3)          | 54            | (18.0)        | 112      | (18.6)  |
| Black Or African American        | 4               | (1.3)           | 6             | (2.0)         | 10       | (1.7)   |
| Multi-Racial                     | 12              | (4.0)           | 9             | (3.0)         | 21       | (3.5)   |
| White                            | 219             | (72.8)          | 224           | (74.7)        | 443      | (73.7)  |
| Missing                          | 3               | (1.0)           | 1             | (0.3)         | 4        | (0.7)   |
| Ethnicity                        |                 |                 |               |               |          |         |
| Hispanic Or Latino               | 46              | (15.3)          | 44            | (14.7)        | 90       | (15.0)  |
| Not Hispanic Or Latino           | 233             | (77.4)          | 231           | (77.0)        | 464      | (77.2)  |
| Not Reported                     | 19              | (6.3)           | 16            | (5.3)         | 35       | (5.8)   |
| Unknown                          | 3               | (1.0)           | 9             | (3.0)         | 12       | (2.0)   |
| Region Group                     |                 |                 |               |               |          |         |
| NA                               | 75              | (24.9)          | 62            | (20.7)        | 137      | (22.8)  |
| EU                               | 87              | (28.9)          | 105           | (35.0)        | 192      | (31.9)  |
| ROW                              | 139             | (46.2)          | 133           | (44.3)        | 272      | (45.3)  |
| Smoking Status                   |                 |                 |               |               |          |         |
| Never Smoker                     | 62              | (20.6)          | 64            | (21.3)        | 126      | (21.0)  |
| Ex Smoker                        | 186             | (61.8)          | 193           | (64.3)        | 379      | (63.1)  |
| Current Smoker                   | 53              | (17.6)          | 41            | (13.7)        | 94       | (15.6)  |
| Missing                          | 0               | (0.0)           | 2             | (0.7)         | 2        | (0.3)   |
| ECOG                             |                 |                 |               |               |          |         |
| 0                                | 118             | (39.2)          | 117           | (39.0)        | 235      | (39.1)  |
| 1                                | 183             | (60.8)          | 183           | (61.0)        | 366      | (60.9)  |
| HPV Status                       |                 |                 |               |               |          |         |
| Positive                         | 63              | (20.9)          | 67            | (22.3)        | 130      | (21.6)  |
| Negative                         | 238             | (79.1)          | 233           | (77.7)        | 471      | (78.4)  |
| PD-L1 TPS Status                 |                 |                 |               |               |          |         |
| Strongly Positive                | 67              | (22.3)          | 66            | (22.0)        | 133      | (22.1)  |
| Not Strongly Positive            | 234             | (77.7)          | 234           | (78.0)        | 468      | (77.9)  |

<div style=\"page-break-after: always\"></div>

| PD-L1 CPS Status (CPS>=1)                  | PD-L1 CPS Status (CPS>=1)   | PD-L1 CPS Status (CPS>=1)   | PD-L1 CPS Status (CPS>=1)   | PD-L1 CPS Status (CPS>=1)   | PD-L1 CPS Status (CPS>=1)   | PD-L1 CPS Status (CPS>=1)   |
|--------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| CPS >=1                                    | 257                         | (85.4)                      | 255                         | (85.0)                      | 512                         | (85.2)                      |
| CPS <1                                     | 44                          | (14.6)                      | 45                          | (15.0)                      | 89                          | (14.8)                      |
| PD-L1 CPS Status (CPS>=20)                 |                             |                             |                             |                             |                             |                             |
| CPS >=20                                   | 133                         | (44.2)                      | 122                         | (40.7)                      | 255                         | (42.4)                      |
| CPS <20                                    | 167                         | (55.5)                      | 175                         | (58.3)                      | 342                         | (56.9)                      |
| Missing                                    | 1                           | (0.3)                       | 3                           | (1.0)                       | 4                           | (0.7)                       |
| PD-L1 CPS Status                           |                             |                             |                             |                             |                             |                             |
| CPS<1                                      | 44                          | (14.6)                      | 45                          | (15.0)                      | 89                          | (14.8)                      |
| 1<=CPS<20                                  | 124                         | (41.2)                      | 133                         | (44.3)                      | 257                         | (42.8)                      |
| CPS>=20                                    | 133                         | (44.2)                      | 122                         | (40.7)                      | 255                         | (42.4)                      |
| Baseline Tumour Size (mm) (Grouping by ITT | Median)                     |                             |                             |                             |                             |                             |
| >=Median                                   | 128                         | (42.5)                      | 134                         | (44.7)                      | 262                         | (43.6)                      |
| <Median                                    | 148                         | (49.2)                      | 145                         | (48.3)                      | 293                         | (48.8)                      |
| Missing                                    | 25                          | (8.3)                       | 21                          | (7.0)                       | 46                          | (7.7)                       |
| Subjects with data                         | 276                         |                             | 279                         |                             | 555                         |                             |
| Mean                                       | 75.9                        |                             | 78.2                        |                             | 77.1                        |                             |
| SD                                         | 62.1                        |                             | 66.7                        |                             | 64.4                        |                             |
| Median                                     | 54.1                        |                             | 58.7                        |                             | 57.1                        |                             |
| Range                                      | 10 to 430                   |                             | 10 to 419                   |                             | 10 to 430                   |                             |
| Disease Status                             |                             |                             |                             |                             |                             |                             |
| Metastatic                                 | 216                         | (71.8)                      | 203                         | (67.7)                      | 419                         | (69.7)                      |
| Recurrent                                  | 82                          | (27.2)                      | 94                          | (31.3)                      | 176                         | (29.3)                      |
| Neither                                    | 3                           | (1.0)                       | 3                           | (1.0)                       | 6                           | (1.0)                       |
| Primary Tumour Staging                     |                             |                             |                             |                             |                             |                             |
| T0                                         | 26                          | (8.6)                       | 38                          | (12.7)                      | 64                          | (10.6)                      |
| T1                                         | 14                          | (4.7)                       | 15                          | (5.0)                       | 29                          | (4.8)                       |
| T1A                                        | 1                           | (0.3)                       | 0                           | (0.0)                       | 1                           | (0.2)                       |
| T2                                         | 40                          | (13.3)                      | 53                          | (17.7)                      | 93                          | (15.5)                      |
| T3                                         | 47                          | (15.6)                      | 37                          | (12.3)                      | 84                          | (14.0)                      |
| T3A                                        | 1                           | (0.3)                       | 0                           | (0.0)                       | 1                           | (0.2)                       |
| T3B                                        | 0                           | (0.0)                       | 1                           | (0.3)                       | 1                           | (0.2)                       |
| T4                                         | 58                          | (19.3)                      | 52                          | (17.3)                      | 110                         | (18.3)                      |
| T4A                                        | 63                          | (20.9)                      | 48                          | (16.0)                      | 111                         | (18.5)                      |
| T4B                                        | 17                          | (5.6)                       | 25                          | (8.3)                       | 42                          | (7.0)                       |
| TX                                         | 34                          | (11.3)                      | 31                          | (10.3)                      | 65                          | (10.8)                      |
| Regional Lymph Nodes Staging               |                             |                             |                             |                             |                             |                             |
| N0                                         | 88                          | (29.2)                      | 81                          | (27.0)                      | 169                         | (28.1)                      |
| N1                                         | 44                          | (14.6)                      | 48                          | (16.0)                      | 92                          | (15.3)                      |
| N2                                         | 133                         | (44.2)                      | 131                         | (43.7)                      | 264                         | (43.9)                      |
| N3                                         | 23                          | (7.6)                       | 31                          | (10.3)                      | 54                          | (9.0)                       |
| NX                                         | 13                          | (4.3)                       | 9                           | (3.0)                       | 22                          | (3.7)                       |
| Metastatic Staging                         |                             |                             |                             |                             |                             |                             |
| M0                                         | 85                          | (28.2)                      | 97                          | (32.3)                      | 182                         | (30.3)                      |
| M1                                         | 216                         | (71.8)                      | 203                         | (67.7)                      | 419                         | (69.7)                      |

<div style=\"page-break-after: always\"></div>

| Overall Cancer Staging                   |                                  |                                  |                                  |                                  |                                  |                                  |
|------------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| II                                       | 1                                | (0.3)                            | 1                                | (0.3)                            | 2                                | (0.3)                            |
| III                                      | 11                               | (3.7)                            | 14                               | (4.7)                            | 25                               | (4.2)                            |
| IVA                                      | 60                               | (19.9)                           | 61                               | (20.3)                           | 121                              | (20.1)                           |
| IVB                                      | 13                               | (4.3)                            | 21                               | (7.0)                            | 34                               | (5.7)                            |
| IVC                                      | 216                              | (71.8)                           | 203                              | (67.7)                           | 419                              | (69.7)                           |
| Primary Tumour Location-Oral Cavity      |                                  |                                  |                                  |                                  |                                  |                                  |
| Yes                                      | 82                               | (27.2)                           | 91                               | (30.3)                           | 173                              | (28.8)                           |
| No                                       | 219                              | (72.8)                           | 209                              | (69.7)                           | 428                              | (71.2)                           |
| Primary Tumour Location-Larynx           |                                  |                                  |                                  |                                  |                                  |                                  |
| Yes                                      | 74                               | (24.6)                           | 61                               | (20.3)                           | 135                              | (22.5)                           |
| No                                       | 227                              | (75.4)                           | 239                              | (79.7)                           | 466                              | (77.5)                           |
| Primary Tumour Location-Hypopharynx      |                                  |                                  |                                  |                                  |                                  |                                  |
| Yes                                      | 38                               | (12.6)                           | 39                               | (13.0)                           | 77                               | (12.8)                           |
| No                                       | 263                              | (87.4)                           | 261                              | (87.0)                           | 524                              | (87.2)                           |
| Primary Tumour Location-Oropharynx       |                                  |                                  |                                  |                                  |                                  |                                  |
| Yes                                      | 113                              | (37.5)                           | 114                              | (38.0)                           | 227                              | (37.8)                           |
| No                                       | 188                              | (62.5)                           | 186                              | (62.0)                           | 374                              | (62.2)                           |
| Time from Latest Platinum Therapy (days) |                                  |                                  |                                  |                                  |                                  |                                  |
| Subjects with data                       | 132                              |                                  | 137                              |                                  | 269                              |                                  |
| Mean                                     | 766.3                            |                                  | 887.0                            |                                  | 827.8                            |                                  |
| SD Median                                | 666.0 518.5                      |                                  | 902.7 596.0                      |                                  | 796.2 553.0                      |                                  |
| Range                                    | 193 to                           | 4620                             | 119 to                           | 6817                             | 119 to 6817                      |                                  |
| Time from Prior Systemic Therapy (days)  |                                  |                                  |                                  |                                  |                                  |                                  |
| Subjects with data                       | 151                              |                                  | 146                              |                                  | 297                              |                                  |
| Mean                                     | 809.8                            |                                  | 862.7                            |                                  | 835.8                            |                                  |
| SD                                       | 980.9                            |                                  | 877.0                            |                                  | 930.1                            |                                  |
| Median                                   | 511.0                            |                                  | 571.5                            |                                  | 530.0                            |                                  |
| Range                                    | 35 to                            | 9264                             | 119 to 6817                      |                                  | 35 to 9264                       |                                  |
| Database Cutoff Date: 13JUN2018.         | Database Cutoff Date: 13JUN2018. | Database Cutoff Date: 13JUN2018. | Database Cutoff Date: 13JUN2018. | Database Cutoff Date: 13JUN2018. | Database Cutoff Date: 13JUN2018. | Database Cutoff Date: 13JUN2018. |

Table 12: Summary of Prior Line of Systemic Therapy (Pembro Mono vs Control) (ITT Population)

|                                               | Pembrolizumab   | Pembrolizumab   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   | Total   | Total   |
|-----------------------------------------------|-----------------|-----------------|----------------------------|----------------------------|---------|---------|
|                                               | n               | (%)             | n                          | (%)                        | n       | (%)     |
| Subjects in population                        | 301             |                 | 300                        |                            | 601     |         |
| Subjects with no prior systemic therapy       | 150             | (49.8)          | 154                        | (51.3)                     | 304     | (50.6)  |
| Primary/Locally Advanced/With Curative Intent | 143             | (47.5)          | 143                        | (47.7)                     | 286     | (47.6)  |
| Cetuximab                                     | 20              | (6.6)           | 18                         | (6.0)                      | 38      | (6.3)   |
| Platinum                                      | 125             | (41.5)          | 134                        | (44.7)                     | 259     | (43.1)  |
| Recurrent/With Curative Intent                | 11              | (3.7)           | 5                          | (1.7)                      | 16      | (2.7)   |
| Cetuximab                                     | 3               | (1.0)           | 0                          | (0.0)                      | 3       | (0.5)   |
| Platinum                                      | 9               | (3.0)           | 4                          | (1.3)                      | 13      | (2.2)   |

A subject can have multiple prior systemic therapies and be counted in different rows that are applicable.  But every subject is counted a single time for each applicable row and column.

Database Cutoff Date: 13JUN2018.

<div style=\"page-break-after: always\"></div>

Table 13 : Subject Characteristics (Pembro Mono vs Control) (ITT population) (CPS≥1 and CPS≥20)

|                                                                                     | CPS>=1        | CPS>=1                          | CPS>=1                   | CPS>=1                          | CPS>=20       | CPS>=20                         | CPS>=20                  | CPS>=20                  |
|-------------------------------------------------------------------------------------|---------------|---------------------------------|--------------------------|---------------------------------|---------------|---------------------------------|--------------------------|--------------------------|
|                                                                                     | Pembrolizumab | Pembrolizumab                   | Cetuximab + Chemotherapy | Cetuximab + Chemotherapy        | Pembrolizumab | Pembrolizumab                   | Cetuximab + Chemotherapy | Cetuximab + Chemotherapy |
|                                                                                     | n             | (%)                             | n                        | (%)                             | n             | (%)                             | n                        | (%)                      |
| Subjects in population                                                              | 257           |                                 | 255                      |                                 | 133           |                                 | 122                      |                          |
| Gender                                                                              |               |                                 |                          |                                 |               |                                 |                          |                          |
| Male                                                                                | 209           | (81.3)                          | 220                      | (86.3)                          | 104           | (78.2)                          | 108                      | (88.5)                   |
| Female                                                                              | 48            | (18.7)                          | 35                       | (13.7)                          | 29            | (21.8)                          | 14                       | (11.5)                   |
| Age (Years)                                                                         |               |                                 |                          |                                 |               |                                 |                          |                          |
| <65 >=65 Mean                                                                       | 163 94 60.8   | (63.4) (36.6)                   | 166 89 60.8              | (65.1) (34.9)                   | 80 53 60.5    | (60.2) (39.8)                   | 85 37 59.8               | (69.7) (30.3)            |
| Race                                                                                |               |                                 |                          |                                 |               |                                 |                          |                          |
| American Indian Or Alaska Native Asian Black Or African American Multi-Racial White | 4 50 3 10 188 | (1.6) (19.5) (1.2) (3.9) (73.2) | 6 47 3 9 189 1           | (2.4) (18.4) (1.2) (3.5) (74.1) | 2 24 2 7 98   | (1.5) (18.0) (1.5) (5.3) (73.7) | 3 22 1 4                 | (2.5) (18.0) (0.8) (3.3) |
|                                                                                     |               |                                 |                          |                                 |               |                                 |                          | -                        |
| Missing                                                                             | 2 35 204 16   | (0.8) (13.6) (79.4)             | 34 199 15                | (0.4) (13.3) (78.0)             | 22 101        | - (16.5) (75.9)                 | 92                       | (75.4) (12.3)            |
| Ethnicity                                                                           |               |                                 |                          |                                 |               |                                 |                          |                          |
| Hispanic Or Latino Not Hispanic Or Latino Not Reported Unknown                      | 2             | (6.2) (0.8)                     | 7                        | (5.9) (2.7)                     | 10 0          | (7.5) (0.0)                     | 15 93 9 5                | (76.2) (7.4) (4.1)       |
| Region Group                                                                        |               |                                 |                          |                                 |               |                                 |                          |                          |
| NA                                                                                  | 68 74 115     | (26.5) (28.8) (44.7)            | 54 92 109                | (21.2) (36.1) (42.7)            | 32 44 57      | (24.1) (33.1) (42.9)            | 31 42                    | (25.4) (34.4)            |
| ROW                                                                                 |               |                                 |                          |                                 |               |                                 |                          |                          |
| EU                                                                                  |               |                                 |                          |                                 |               |                                 | 49                       |                          |
| Smoking                                                                             |               |                                 |                          |                                 |               |                                 |                          |                          |
|                                                                                     |               |                                 |                          |                                 | 34            |                                 |                          | (40.2)                   |
| Never Ex Smoker                                                                     | 154           | (59.9)                          | 156                      | (61.2)                          | 82            | (61.7)                          | 71                       | (58.2)                   |
| Current Smoker                                                                      | 44            | (17.1)                          | 36                       | (14.1)                          | 17            | (12.8) (0.0)                    |                          | (16.4)                   |
| Status                                                                              |               |                                 |                          |                                 |               |                                 |                          |                          |
| Smoker                                                                              | 59            | (23.0)                          | 61                       | (23.9)                          |               | (25.6)                          | 30                       | (24.6)                   |
| Missing                                                                             | 0             | (0.0) (40.5)                    | 2 101                    | (0.8) (39.6)                    | 0             |                                 | 20 1                     | (0.8)                    |
| 1                                                                                   | 153           | (59.5)                          |                          | (60.4)                          |               |                                 |                          |                          |
| ECOG                                                                                |               |                                 |                          |                                 |               |                                 |                          |                          |
| 0                                                                                   | 104           |                                 |                          |                                 | 58            | (43.6)                          | 52                       | (42.6)                   |
|                                                                                     |               |                                 |                          |                                 |               |                                 | 70                       |                          |
|                                                                                     |               |                                 | 154                      |                                 |               |                                 |                          |                          |
|                                                                                     |               |                                 |                          |                                 | 75            |                                 |                          |                          |
|                                                                                     |               |                                 |                          |                                 |               | (56.4)                          |                          | (57.4)                   |
| HPV Status                                                                          |               |                                 |                          |                                 |               |                                 |                          |                          |
| Positive                                                                            | 54            | (21.0)                          | 55                       | (21.6)                          | 24            | (18.0)                          | 28                       | (23.0)                   |
| Negative                                                                            | 203           | (79.0)                          | 200                      | (78.4)                          | 109           | (82.0)                          | 94                       | (77.0)                   |
| PD-L1 TPS Status                                                                    |               |                                 |                          |                                 |               |                                 |                          | (50.8)                   |
| Not Strongly                                                                        |               | (73.9)                          |                          | (74.1)                          | 67            |                                 | 60                       | (49.2)                   |
| Strongly                                                                            |               | (26.1)                          | 66                       | (25.9)                          | 66            | (49.6)                          | 62                       |                          |
| Positive                                                                            | 190           |                                 | 189                      |                                 |               | (50.4)                          |                          |                          |
| Positive                                                                            | 67            |                                 |                          |                                 |               |                                 |                          |                          |

<div style=\"page-break-after: always\"></div>

| PD-L1 CPS Status (CPS>=20)                         | PD-L1 CPS Status (CPS>=20)                         | PD-L1 CPS Status (CPS>=20)                         | PD-L1 CPS Status (CPS>=20)                         | PD-L1 CPS Status (CPS>=20)                         | PD-L1 CPS Status (CPS>=20)                         | PD-L1 CPS Status (CPS>=20)                         | PD-L1 CPS Status (CPS>=20)                         |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| CPS >=20                                           | 133                                                | (51.8)                                             | 122                                                | (47.8)                                             |                                                    |                                                    |                                                    |
| CPS <20                                            | 123                                                | (47.9)                                             | 131                                                | (51.4)                                             |                                                    |                                                    | -                                                  |
| Missing                                            | 1                                                  | (0.4)                                              | 2                                                  | (0.8)                                              | -                                                  |                                                    |                                                    |
| Baseline Tumour Size (mm) (Grouping by ITT Median) | Baseline Tumour Size (mm) (Grouping by ITT Median) | Baseline Tumour Size (mm) (Grouping by ITT Median) | Baseline Tumour Size (mm) (Grouping by ITT Median) | Baseline Tumour Size (mm) (Grouping by ITT Median) | Baseline Tumour Size (mm) (Grouping by ITT Median) | Baseline Tumour Size (mm) (Grouping by ITT Median) | Baseline Tumour Size (mm) (Grouping by ITT Median) |
| >=Median                                           | 102                                                | (39.7)                                             | 111                                                | (43.5)                                             | 54                                                 | (40.6) 48                                          | (39.3)                                             |
| <Median                                            | 133                                                | (51.8)                                             | 125                                                | (49.0)                                             | 67                                                 | (50.4) 64                                          | (52.5)                                             |
| Missing                                            | 22                                                 | (8.6)                                              | 19                                                 | (7.5)                                              | 12                                                 | (9.0) 10                                           | (8.2)                                              |
| Subjects with data                                 | 235                                                |                                                    | 236                                                |                                                    | 121                                                | 112                                                |                                                    |
| Mean                                               | 74.3                                               |                                                    | 73.2                                               |                                                    | 74.3                                               |                                                    | 67.2                                               |
| SD                                                 | 60.4                                               |                                                    | 58.2                                               |                                                    | 61.2                                               |                                                    | 55.8                                               |
| Median                                             | 52.7                                               |                                                    | 56.0                                               |                                                    | 52.5                                               |                                                    | 51.4                                               |
| Range                                              | 10 to 338                                          |                                                    | 10 to 419                                          |                                                    | 11 to 338                                          | 10                                                 | to 320                                             |
| Disease Status                                     |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |
| Metastatic                                         | 179                                                | (69.6)                                             | 168                                                | (65.9)                                             | 88                                                 | (66.2)                                             | 79 (64.8)                                          |
| Recurrent                                          | 75                                                 | (29.2)                                             | 84                                                 | (32.9)                                             | 42                                                 | (31.6) 42                                          | (34.4)                                             |
| Neither                                            | 3                                                  | (1.2)                                              | 3                                                  | (1.2)                                              | 3                                                  | (2.3) 1                                            | (0.8)                                              |
| Primary Tumour Staging                             |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |
| T0                                                 | 23                                                 | (8.9)                                              | 37                                                 | (14.5)                                             | 14                                                 | (10.5) 23                                          | (18.9)                                             |
| T1                                                 | 11                                                 | (4.3)                                              | 11                                                 | (4.3)                                              | 6                                                  | (4.5) 4                                            | (3.3)                                              |
| T2                                                 | 33                                                 | (12.8)                                             | 47                                                 | (18.4)                                             | 19                                                 | (14.3) 22                                          | (18.0)                                             |
| T3                                                 | 41                                                 | (16.0)                                             | 32                                                 | (12.5)                                             | 17                                                 | (12.8) 12                                          | (9.8)                                              |
| T3A                                                | 1                                                  | (0.4)                                              | 0                                                  | (0.0)                                              | -                                                  | -                                                  |                                                    |
| T3B                                                | 0                                                  | (0.0)                                              | 1                                                  | (0.4)                                              | -                                                  | -                                                  |                                                    |
| T4                                                 | 51                                                 | (19.8)                                             | 43                                                 | (16.9)                                             | 26                                                 | (19.5) 18                                          | (14.8)                                             |
| T4A                                                | 55                                                 | (21.4)                                             | 40                                                 | (15.7)                                             | 31                                                 | (23.3) 22                                          | (18.0)                                             |
| T4B                                                | 13                                                 | (5.1)                                              | 23                                                 | (9.0)                                              | 3                                                  | (2.3) 9                                            | (7.4)                                              |
| TX                                                 | 29                                                 | (11.3)                                             | 21                                                 | (8.2)                                              | 17                                                 | (12.8) 12                                          | (9.8)                                              |
| Regional Lymph Nodes Staging                       |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |
| N0                                                 | 71                                                 | (27.6)                                             | 67                                                 | (26.3)                                             | 34                                                 | (25.6) 37                                          | (30.3)                                             |
| N1                                                 | 37                                                 | (14.4)                                             | 42                                                 | (16.5)                                             | 20                                                 | (15.0) 27                                          | (22.1)                                             |
| N2                                                 | 119                                                | (46.3)                                             | 113                                                | (44.3)                                             | 61                                                 | (45.9) 44                                          | (36.1)                                             |
| N3                                                 | 18                                                 | (7.0)                                              | 25                                                 | (9.8)                                              | 9                                                  | (6.8) 11                                           | (9.0)                                              |
| NX                                                 | 12                                                 | (4.7)                                              | 8                                                  | (3.1)                                              | 9                                                  | (6.8) 3                                            | (2.5)                                              |
| Metastatic Staging                                 |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |
| M0                                                 | 78                                                 | (30.4)                                             | 87                                                 | (34.1)                                             | 45                                                 | (33.8) 43                                          | (35.2)                                             |
| M1                                                 | 179                                                | (69.6)                                             | 168                                                | (65.9)                                             | 88                                                 | (66.2) 79                                          | (64.8)                                             |
| Overall Cancer Staging                             |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |
| II                                                 | 1                                                  | (0.4)                                              | 1                                                  | (0.4)                                              | -                                                  | -                                                  |                                                    |
| III                                                | 10                                                 | (3.9)                                              | 11                                                 | (4.3)                                              | 8 (6.0)                                            | 6                                                  | (4.9)                                              |
| IVA                                                | 56 11                                              | (21.8) (4.3)                                       | 57 18                                              | (22.4) (7.1)                                       | 33 4 (3.0)                                         | (24.8) 28 9                                        | (23.0) (7.4)                                       |
| IVB IVC                                            | 179                                                | (69.6)                                             | 168                                                | (65.9)                                             | 88                                                 | (66.2) 79                                          | (64.8)                                             |
| Primary Tumour Location-Oral Cavity                | Primary Tumour Location-Oral Cavity                |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |
| Yes                                                | 75                                                 | (29.2)                                             | 80                                                 | (31.4)                                             | 49                                                 | (36.8) 49                                          | (40.2)                                             |
| No                                                 | 182                                                | (70.8)                                             | 175                                                | (68.6)                                             | 84                                                 | (63.2) 73                                          | (59.8)                                             |
| Primary Tumour Location-Larynx                     | Primary Tumour Location-Larynx                     |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |
| Yes                                                | 57                                                 | (22.2)                                             | 53                                                 | (20.8)                                             | 25                                                 | (18.8) 19                                          | (15.6)                                             |
| No                                                 | 200                                                | (77.8)                                             | 202                                                | (79.2)                                             | 108                                                | (81.2) 103                                         | (84.4)                                             |

<div style=\"page-break-after: always\"></div>

| Primary Tumour Location-Hypopharynx       | Primary Tumour Location-Hypopharynx       | Primary Tumour Location-Hypopharynx       | Primary Tumour Location-Hypopharynx       | Primary Tumour Location-Hypopharynx       | Primary Tumour Location-Hypopharynx       | Primary Tumour Location-Hypopharynx       | Primary Tumour Location-Hypopharynx       |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Yes No                                    | 34 223                                    | (13.2) (86.8)                             | 32 223                                    | (12.5) (87.5)                             | 16 117                                    | (12.0) (88.0)                             | (6.6) 114                                 |
| (93 4) Primary Tumour Location-Oropharynx | (93 4) Primary Tumour Location-Oropharynx | (93 4) Primary Tumour Location-Oropharynx | (93 4) Primary Tumour Location-Oropharynx | (93 4) Primary Tumour Location-Oropharynx | (93 4) Primary Tumour Location-Oropharynx | (93 4) Primary Tumour Location-Oropharynx | (93 4) Primary Tumour Location-Oropharynx |
| Yes No                                    | 97 160                                    | (37.7) (62.3)                             | 94 161                                    | (36.9) (63.1)                             | 46 87                                     | (34.6) (65.4)                             | (37.7) (62.3)                             |
| Time from Latest Platinum Therapy (days)  | Time from Latest Platinum Therapy (days)  | Time from Latest Platinum Therapy (days)  | Time from Latest Platinum Therapy (days)  | Time from Latest Platinum Therapy (days)  | Time from Latest Platinum Therapy (days)  | Time from Latest Platinum Therapy (days)  | Time from Latest Platinum Therapy (days)  |
| Subjects with data Mean SD Median Range   | 112 754.6 676.3 510.0 193 to              | 4620                                      | 120 860.9 864.3 585.5 201 to              | 6817                                      | 56 840.1 803.3 512.5 193 to 4620          | 56 940.4 1102.8 529.5 224 to 6817         | 56 940.4 1102.8 529.5 224 to 6817         |
| Time from Prior Systemic Therapy (days)   | Time from Prior Systemic Therapy (days)   | Time from Prior Systemic Therapy (days)   | Time from Prior Systemic Therapy (days)   | Time from Prior Systemic Therapy (days)   | Time from Prior Systemic Therapy (days)   | Time from Prior Systemic Therapy (days)   | Time from Prior Systemic Therapy (days)   |
| Subjects with data Mean SD Median Range   | 130 810.8 1029.7 507.5 35 to              | 9264                                      | 125 847.0 846.5 627.0 201 to 6817         | 35                                        | 63 971.1 1373.3 509.0 to 9264             | 58 925.4 1084.3 582.5 224 to 6817         | 58 925.4 1084.3 582.5 224 to 6817         |
| Database Cutoff Date: 13JUN2018.          | Database Cutoff Date: 13JUN2018.          | Database Cutoff Date: 13JUN2018.          | Database Cutoff Date: 13JUN2018.          | Database Cutoff Date: 13JUN2018.          | Database Cutoff Date: 13JUN2018.          | Database Cutoff Date: 13JUN2018.          | Database Cutoff Date: 13JUN2018.          |

## Numbers analysed

Two comparisons were made in the study:

- pembrolizumab plus chemotherapy versus standard treatment
- pembrolizumab monotherapy versus standard treatment.

No comparisons were conducted between the pembrolizumab monotherapy and pembrolizumab plus chemotherapy group.

A total of 882 participants were randomized to either pembro mono (301) or pembro combo (281) or to the control arm (300).

Due to an enrolment pause in the pembro combo arm recommended by the external DMC that occurred between 13-AUG-2015 and 02-OCT-2015, 22 subjects enrolled in the control arm during the pause were excluded for the comparison between the pembro combo vs control, according to ITT principle. As a result, the primary efficacy analyses were based on the ITT population which included:

- 559 participants in the pembro combo (n=281) versus control (n=278) analysis;
- 601 participants in the pembro mono (n=301) versus control (n=300)

Efficacy endpoints have been analyzed for three populations:

- ITT (all participants regardless of PD-L1 status),
- PDL1 CPS ≥1 population,
- PDL1 CPS ≥20 population.

Quality-of-life endpoints in the treatment group comparisons have been analyzed for three populations:

- patient  reported  outcomes  FAS  population  (referred  to  as  the  'PRO  FAS'  population  and consisting of all participants regardless of PD-L1 status who were randomized and treated and had at least one PRO assessment)

<div style=\"page-break-after: always\"></div>

- PDL1 CPS ≥1 population,
- PDL1 CPS ≥20 population.

Table 14 : Study Population (Pembro Combo vs Control)

|                                     | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   | Total   | Total   |
|-------------------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|---------|---------|
|                                     | n                              | (%)                            | n                          | (%)                        | n       | (%)     |
| Subjects Randomized                 | 281                            |                                | 300                        |                            | 581     |         |
| Intention-to-Treat (ITT)            | 281                            | (100.0)                        | 278                        | (92.7)                     | 559     | (96.2)  |
| Intention-to-Treat (ITT) (CPS >=1)  | 242                            | (86.1)                         | 235                        | (78.3)                     | 477     | (82.1)  |
| Intention-to-Treat (ITT) (CPS >=20) | 126                            | (44.8)                         | 110                        | (36.7)                     | 236     | (40.6)  |
| All-Subjects-as-Treated (ASaT)      | 276                            | (98.2)                         | 287                        | (95.7)                     | 563     | (96.9)  |
| Database Cutoff Date: 13JUN2018.    |                                |                                |                            |                            |         |         |

Table 15 : Study Population (Pembro Mono vs Control)

|                                     | Pembrolizumab                    | Pembrolizumab                    | Cetuximab + Chemotherapy         | Cetuximab + Chemotherapy         | Total                            | Total                            |
|-------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                     | n                                | (%)                              | n                                | (%)                              | n                                | (%)                              |
| Subjects Randomized                 | 301                              |                                  | 300                              |                                  | 601                              |                                  |
| Intention-to-Treat (ITT)            | 301                              | (100.0)                          | 300                              | (100.0)                          | 601                              | (100.0)                          |
| Intention-to-Treat (ITT) (CPS >=1)  | 257                              | (85.4)                           | 255                              | (85.0)                           | 512                              | (85.2)                           |
| Intention-to-Treat (ITT) (CPS >=20) | 133                              | (44.2)                           | 122                              | (40.7)                           | 255                              | (42.4)                           |
| All-Subjects-as-Treated (ASaT)      | 300                              | (99.7)                           | 287                              | (95.7)                           | 587                              | (97.7)                           |
| Database Cutoff Date: 13JUN2018.    | Database Cutoff Date: 13JUN2018. | Database Cutoff Date: 13JUN2018. | Database Cutoff Date: 13JUN2018. | Database Cutoff Date: 13JUN2018. | Database Cutoff Date: 13JUN2018. | Database Cutoff Date: 13JUN2018. |

## Outcomes and estimation

The  MAH  provided  the  results  of  the second  interim  analysis (IA2)  of  this  study,  which  was  a time-driven analysis, occurring approximately 38 months from study start ( data cut-off 13-Jun-2018 , all participants were followed for at least 17 months) (results are from IA2 unless differently indicated).

During the procedure, the MAH provided the final analysis (FA) data ( data cut-off 25-Feb-2019 ). At FA, only Hypotheses 11, 12, and 10 were tested for statistical significance and the corresponding p-values were  used  for  statistical  inference.  For  the  other  tables  in  this  section,  p-values  were  provided  for descriptive purpose only.

<div style=\"page-break-after: always\"></div>

Table 16: Overall alpha level, nominal p-value and p-value at boundary for each hypothesis at IA2

| Hypothe sis       | Popul ation      | Test             | Overall alpha   |   Nomin al p- value | p-value boundary   | Outcome                                       |
|-------------------|------------------|------------------|-----------------|---------------------|--------------------|-----------------------------------------------|
| H1: PFS (M vs. S) | CPS ≥20          | Superiority      | 0.0019          |           0.45625   | 0.0016             | Not yet successful                            |
| H2: PFS (M vs. S) | CPS ≥1           | Superiority      | NA              |           0.93303   | NA                 | Not tested                                    |
| H3: PFS (M vs. S) | All participants | Superiority      | NA              |           0.99951   | NA                 | Not te ste d                                  |
| H4: PFS (C vs. S) | CPS ≥20          | Superiority      | 0.0019          |           0.01622   | 0.0017             | Not yet successful                            |
| H5: PFS (C vs. S) | CPS ≥1           | Superiority      | NA              |           0.02286   | NA                 | Not te sted                                   |
| H6: PFS (C vs. S) | All participants | Superiority      | 0.0002          |           0.16971   | 0.0002             | Not tested                                    |
| H7: OS (M vs. S)  | CPS ≥20          | Superiority      | 0.007           |           0.00074   | 0.0024             | Successfulwithinitial alpha allocation        |
| H8: OS (M vs. S)  | CPS ≥1           | Superiority      | 0.013993        |           0.00855   | 0.0109             | Successful with alpha shifted from H7 and H14 |
| H9: OS (M vs. S)  | All participants | Non- inferiority | 0.013993        |           0.0001399 | 0.0117             | Successful with alpha shifted fromH8          |
| H10: OS (M vs. S) | All participants | Superiority      | 0.013993        |           0.04563   | 0.0117             | Not yet successful                            |
| H11: OS (C vs. S) | CPS ≥20          | Superiority      | 0.007           |           0.00984   | 0.0018             | Not yet successful                            |
| H12: OS (C vs. S) | CPS ≥1           | Superiority      | NA              |           0.00072   | NA                 | Not te ste d                                  |
| H13: OS (C vs. S) | All participants | Non- inferiority | 0.007           |           4e-06     | 0.0041             | Successful withinitial alpha allocation       |
| H14: OS (C vs. S) | All participants | Superiority      | 0.007t          |           0.00335   | 0.0041             | Successful with alpha shifted from H13        |

Table 17 : Overall Alpha Level and p-value at Boundary for Hypotheses Tested at FA - KEYNOTE-048

| Hypothesis        | Population       | Test        |   Overall alpha |   p-value boundary § |   Observed p-value |
|-------------------|------------------|-------------|-----------------|----------------------|--------------------|
| H11: OS (C vs. S) | CPS≥20           | Superiority |        0.007    |               0.0023 |            0.00044 |
| H12: OS (C vs. S) | CPS≥1            | Superiority |        0.007    |               0.0026 |            2e-05   |
| H10: OS (M vs. S) | All participants | Superiority |        0.020986 |               0.0059 |            0.01985 |

Note : results of KEYNOTE-048 study are presented below separately for the two comparisons:

- Pembro combo vs control
- Pembro mono vs control

## Pembrolizumab plus chemotherapy (platinum+5-FU) vs chemotherapy (EXTREME regimen)

## Final analysis (cut-off date 25 Feb 2019, DBL 25-MAR-2019)

During the procedure, the MAH provided the results of the Final analysis for KEYNOTE-048 study.

<div style=\"page-break-after: always\"></div>

Table 18: Key Efficacy Results Pembrolizumab Plus Chemotherapy vs Standard Treatment ITT, CPS ≥1 and CPS ≥20 Population Findings KEYNOTE -048 (FA)

|                                                                      | ITT (All Participants)                | ITT (All Participants)   | PD-L1 CPS ≥1                          | PD-L1 CPS ≥1        | PD-L1 CPS ≥20                         | PD-L1 CPS ≥20       |
|----------------------------------------------------------------------|---------------------------------------|--------------------------|---------------------------------------|---------------------|---------------------------------------|---------------------|
|                                                                      | Pembrolizumab Plus Chemotherapy N=281 | Std Treatment N=278      | Pembrolizumab Plus Chemotherapy N=242 | Std Treatment N=235 | Pembrolizumab Plus Chemotherapy N=126 | Std Treatment N=110 |
| OS                                                                   |                                       |                          |                                       |                     |                                       |                     |
| Number of events (%)                                                 | 213 (75.8)                            | 247 (88.8)               | 177 (73.1)                            | 213 (90.6)          | 84 (66.7)                             | 98 (89.1)           |
| Median in months(95% CI)                                             | 13.0 (10.9, 14.7)                     | 10.7 (9.3, 11.7)         | 13.6 (10.7, 15.5)                     | 10.4 (9.1, 11.7)    | 14.7 (10.3, 19.3)                     | 11.0 (9.2, 13.0)    |
| HR (95% CI)                                                          | 0.72 (0.60, 0.87)                     | 0.72 (0.60, 0.87)        | 0.65 (0.53, 0.80)                     | 0.65 (0.53, 0.80)   | 0.60 (0.45, 0.82)                     | 0.60 (0.45, 0.82)   |
| P-value (superiority statistic)                                      | 0.00025                               | 0.00025                  | 0.00002                               | 0.00002             | 0.00044                               | 0.00044             |
| OS rate at 12 months (95% CI)                                        | 53.0 (47.0, 58.7)                     | 43.9 (38.0, 49.7)        | 55.0 (48.5, 61.0)                     | 43.5 (37.0, 49.7)   | 57.1 (48.0, 65.2)                     | 46.1 (36.6, 55.1)   |
| OS rate at 18 months (95% CI)                                        | 37.6 (32.0, 43.3)                     | 27.2 (22.1, 32.6)        | 39.1 (33.0, 45.2)                     | 26.7 (21.2, 32.5)   | 43.5 (34.7, 51.9)                     | 27.7 (19.6, 36.3)   |
| OS rate at 24 months (95% CI)                                        | 29.4 (24.2, 34.8)                     | 18.2 (13.9, 22.9)        | 30.8 (25.1, 36.7)                     | 16.8 (12.3, 21.9)   | 35.4 (27.2, 43.8)                     | 19.4 (12.6, 27.3)   |
| PFS (BICR per RECIST 1.1)                                            |                                       |                          |                                       |                     |                                       |                     |
| Number of events (%)                                                 | 250 (89.0)                            | 260 (93.5)               | 212 (87.6)                            | 221 (94.0)          | 106 (84.1)                            | 104 (94.5)          |
| Median in months (95% CI)                                            | 4.9 (4.7, 6.1)                        | 5.1 (4.9, 6.1)           | 5.1 (4.7, 6.2)                        | 5.0 (4.8, 6.0)      | 5.8 (4.7, 7.6)                        | 5.3 (4.9, 6.3)      |
| HR (95% CI) b                                                        | 0.93 (0.78, 1.11)                     | 0.93 (0.78, 1.11)        | 0.84 (0.69, 1.02)                     | 0.84 (0.69, 1.02)   | 0.76 (0.58, 1.01)                     | 0.76 (0.58, 1.01)   |
| P-value                                                              | 0.21211                               | 0.21211                  | 0.03697                               | 0.03697             | 0.02951                               | 0.02951             |
| PFS rate at 6 months (95% CI)                                        | 44.7 (38.8, 50.5)                     | 44.9 (38.9, 50.8)        | 44.9 (38.5, 51.1)                     | 43.3 (36.9, 49.6)   | 49.4 (40.3, 57.9)                     | 47.2 (37.5, 56.2)   |
| PFS rate at 9 months (95% CI)                                        | 26.9 (21.8, 32.3)                     | 20.5 (15.9, 25.6)        | 28.0 (22.4, 33.9)                     | 19.4 (14.5, 24.8)   | 35.4 (27.0, 43.8)                     | 21.7 (14.4, 29.9)   |
| PFS rate at 12 months (95% CI)                                       | 17.2 (13.0, 21.9)                     | 13.6 (9.8, 18.1)         | 19.7 (14.8, 25.0)                     | 12.5 (8.6, 17.3)    | 23.9 (16.7, 31.7)                     | 14.0 (8.2, 21.3)    |
| ORR (BICR per RECIST 1.1, with confirmation)                         |                                       |                          |                                       |                     |                                       |                     |
| %(95% CI)                                                            | 35.6 (30.0, 41.5)                     | 36.3 (30.7, 42.3)        | 36.4 (30.3, 42.8)                     | 35.7 (29.6, 42.2)   | 42.9 (34.1, 52.0)                     | 38.2 (29.1, 47.9)   |
| Complete Responses (CR)                                              | 17 (6.0%)                             | 8 (2.9%)                 | 16 (6.6%)                             | 7 (3.0%)            | 12 (9.5%)                             | 4 (3.6%)            |
| Partial Responses (PR)                                               | 83 (29.5%)                            | 93 (33.5%)               | 72 (29.8%)                            | 77 (32.8%)          | 42 (33.3%)                            | 38 (34.5%)          |
| Stable Disease (SD)                                                  | 78 (27.8%)                            | 95 (34.2%)               | 64 (26.4%)                            | 77 (32.8%)          | 29 (23.0%)                            | 38 (34.5%)          |
| Progressive Disease (PD)                                             | 48 (17.1%)                            | 33 (11.9%)               | 42 (17.4%)                            | 29 (12.3%)          | 19 (15.1%)                            | 9 (8.2%)            |
| DOR (Confirmed CR or PR, BICR per RECIST 1.1)                        |                                       |                          |                                       |                     |                                       |                     |
| Number of responders                                                 | 100                                   | 101                      | 88                                    | 84                  | 54                                    | 42                  |
| Median in months (range)                                             | 6.7 (1.6+ - 39.0+)                    | 4.3 (1.2+ - 31.5+)       | 6.7 (1.6+ - 39.0+)                    | 4.3 (1.2+ - 31.5+)  | 7.1 (2.1+ - 39.0+)                    | 4.2 (1.2+ - 31.5+)  |
| Median time to response (range)                                      | 2.1 (1.4 - 13.7)                      | 2.1 (1.3 - 10.4)         | 2.1 (1.4 - 13.7)                      | 2.1 (1.3 - 10.4)    | 2.1 (1.4 - 13.7)                      | 2.1 (1.9 - 6.0)     |
| Number (Kaplan-Meier %) With Extended Response Duration ( ≥6 months) | 49 (53.5)                             | 28 (36.8)                | 44 (54.3)                             | 21 (34.3)           | 31 (60.2)                             | 11 (34.0)           |

Abbreviations: BICR=Blinded independent central review; CI=Confidence interval; CPS=Combined positive score; CR=Complete response; DOR=Duration of response; HR=Hazard ratio; ITT=Intention to treat; ORR=Objective response rate; OS=Overall survival; PD-L1=Programmed cell death ligand 1; PFS=Progression-free survival; PR=Partial response; RECIST 1.1=Response Evaluation Criteria in Solid Tumours Version 1.1; Std=Standard.  Database cutoff date: 25-FEB-2019

<div style=\"page-break-after: always\"></div>

## Primary endpoints

## OS - pembro combo vs control

At IA2 in the ITT population, treatment with pembrolizumab plus chemotherapy resulted in a statistically significant and clinically meaningful benefit in OS over standard treatment (HR 0.77 [0.63, 0.93], p = 0.00335). The OS results at the FA confirmed the results at IA2 (HR 0.72 [0.60, 0.87]). In the population of participants whose tumors express PD-L1 CPS ≥ 1 or PD-L1 CPS ≥ 20, at the final analysis, statistically significant superiority in OS was demonstrated for pembrolizumab plus chemotherapy over standard treatment. Overall, OS HR point estimates improved compared to the IA2 in the ITT population and all CPS subgroups, with the exception of CPS&lt;1 population (from 1.07 to 1.21).

Figure 4: Kaplan-Meier estimates of Overall survival (ITT, CPS≥1, CPS≥20) - Pembro Combo vs Control (FA)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 19: Summary of Timing of Overall Survival Events (Pembro Combo vs Control) - ITT Population

|                                 | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Cetuximab+Chemotherapy   | Cetuximab+Chemotherapy   |
|---------------------------------|------------------------------|------------------------------|--------------------------|--------------------------|
|                                 | 11                           | (%)                          | 11                       | (%)                      |
| NumberofSubjectsinPopulation    | 281                          |                              | 278                      |                          |
| SubjectsWith OSEvent            | 213                          | (75.8)                       | 247                      | (88.8)                   |
| <30DaysFollowingRandomization   | 16                           | (5.7)                        | 13                       | (4.7)                    |
| 30-60DaysFollowingRandomization | 10                           | (3.6)                        | 7                        | (2.5)                    |
| >60DaysFollowingRandomization   | 187                          | (66.5)                       | 227                      | (81.7)                   |
| SubjectsWithoutOSEvent          | 68                           | (24.2)                       | 31                       | (11.2)                   |
| (DatabaseCutoffDate:25FEB2019). |                              |                              |                          |                          |

## PFS - pembro combo vs control

PFS was not tested at FA, as prespecified in the protocol. PFS did not show improvement; however, PFS rates at 9 and 12 months were higher in pembrolizumab combination compared to control.

Figure  5:  KaplanMeier  estimates  of  PFS,  based  on  BICR  assessment  per  RECIST  1.1  (ITT,  CPS≥1, CPS≥20), Pembro Combo vs Control (IA2)

<!-- image -->

PFS sensitivity analysis 1 and PFS sensitivity analysis 2, yielded results similar to the primary analysis for the overall population. A comparison of PFS based on investigator's assessment for the overall population performed as sensitivity analyses yielded similar results as the analyses based on BICR.

Secondary endpoints - Interim analysis 2 (data cut-off 13-JUN-2018, DBL 29-JUN-2018)

<div style=\"page-break-after: always\"></div>

## ORR - pembro combo vs control

ORR results based on BICR assessment per RECIST 1.1 for the ITT, CPS≥1 and CPS≥20 are reported in tables below. Objective responses are confirmed.

Table 20: Analysis of objective response (confirmed) based on BICR assessment per RECIST 1.1 (Pembro Combo vs Control) - ITT population (IA2)

|                            |     |                                |                                       | Difference in %6 vs.Control   | Difference in %6 vs.Control   |
|----------------------------|-----|--------------------------------|---------------------------------------|-------------------------------|-------------------------------|
| Treahment                  | N   | Nuumber of Objective Responses | Objective Response Rate (96) (95% C1) | Estimate (95% CI)             | p-Value                       |
| Pembrolizumab+Chemotherapy | 281 | 100                            | 35.6 (30.0,41.5)                      | -0.8 (-8.7,7.2)               | 0.5740                        |
| Cetuximab+Chemotherapy     | 278 | 101                            | 36.3 (30.7,42.3)                      |                               |                               |

ResponsesarebasedonBICRassessmentsperRECIST1.1withconfinmation.

Based on Mietinen&amp; Nuuminen method stratified by ECOG (0 vs.1),HPV status(Positive Vs.Negative)and PD-L1 status (Stongly Positive,Not Strongly Positive);in case the event coumtin on stratum is &lt;5,stratification factors willbe eliminated in the order of ECOG-&gt;HpV status-&gt;PD-L1status umtil event Coumtin every strahum is=5:if no subjecis are in one of the treatmentgroupsinvolved ina comparison for aparticular strahum,then that strahum is excluded fromthetreatmentcomparison.

Database Cutoff Date:13JUN2018.

Source:[P048V01MK3475:adam-adsl; adrs]

Table 21: Summary of best objective response with confirmation based on BICR assessment per RECIST 1.1 (Pembro Combo vs Control) - ITT population

|                                      | Pembrolizumab+Chemotherapy           | Pembrolizumab+Chemotherapy           | Cetuximab +Chemotherapy              | Cetuximab +Chemotherapy              |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
|                                      |                                      | (96)                                 | n                                    | (%6)                                 |
| Number of Subjects in Population     | 281                                  |                                      | 278                                  |                                      |
| Complete Response (CR)               | 17                                   | (6.0)                                | 8                                    | (2.9)                                |
| Partial Response (PR)                | 83                                   | (29.5)                               | 93                                   | (33.5)                               |
| Objective Response(CR+PR)            | 100                                  | (35.0)                               | 101                                  | (36.3)                               |
| Stable Disease (SD)                  | 78                                   | (27.8)                               | t6                                   | (33.8)                               |
| Progressive Disease (PD)             | 48                                   | (17.1)                               | 34                                   | (12.2)                               |
| Non-CR/Non-PD (NN)                   | 13                                   | (4.6)                                | 9                                    | (3.2)                                |
| Not Evaluable (NE)                   | 5                                    | (1.8)                                | 2                                    | (0.7)                                |
| No Assessment                        | 37                                   | (13.2)                               | 38                                   | (13.7)                               |
| BICR=BlindedIndependentCentralReview | BICR=BlindedIndependentCentralReview | BICR=BlindedIndependentCentralReview | BICR=BlindedIndependentCentralReview | BICR=BlindedIndependentCentralReview |

Source:IP048V01MK3475:adam-adsl: adrsl

Table 22: Summary of best objective response with confirmation based on BICR assessment per RECIST 1.1 (Pembro Combo vs Control) CPS≥1

|                                                                                                                                            | Pembrolizumab+Chemotherapy                                                                                                                 | Pembrolizumab+Chemotherapy                                                                                                                 | Cetuximab+Chemotherapy                                                                                                                     | Cetuximab+Chemotherapy                                                                                                                     |
|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                            |                                                                                                                                            | (%)                                                                                                                                        | n                                                                                                                                          | (96)                                                                                                                                       |
| Number of SubjectsinPopulation                                                                                                             | 242                                                                                                                                        |                                                                                                                                            | 235                                                                                                                                        |                                                                                                                                            |
| Complete Response (CR)                                                                                                                     | 16                                                                                                                                         | (6.6)                                                                                                                                      | 7                                                                                                                                          | (3.0)                                                                                                                                      |
| Partial Response (PR)                                                                                                                      | 72                                                                                                                                         | (29.8)                                                                                                                                     | 77                                                                                                                                         | (32.8)                                                                                                                                     |
| Objective Response (CR+PR)                                                                                                                 | 88                                                                                                                                         | (36.4)                                                                                                                                     | 84                                                                                                                                         | (35.7)                                                                                                                                     |
| Stable Disease (SD)                                                                                                                        | 64                                                                                                                                         | (26.4)                                                                                                                                     | 76                                                                                                                                         | (32.3)                                                                                                                                     |
| Progressive Disease (PD)                                                                                                                   | 42                                                                                                                                         | (17.4)                                                                                                                                     | 30                                                                                                                                         | (12.8)                                                                                                                                     |
| Non-CR/Non-PD (NN)                                                                                                                         | 11                                                                                                                                         | (4.5)                                                                                                                                      | 9                                                                                                                                          | (3.8)                                                                                                                                      |
| Not Evaluable (NE)                                                                                                                         | 4                                                                                                                                          | (1.7)                                                                                                                                      | 2                                                                                                                                          | (0.9)                                                                                                                                      |
| No Assessment                                                                                                                              | 33                                                                                                                                         | (13.6)                                                                                                                                     | 34                                                                                                                                         | (14.5)                                                                                                                                     |
| BICR=BlindedIndependentCentralReview Responses are based on BICR assessments per RECIST 1.1with confirmation. DatabaseCutoffDate:13JUN2018 | BICR=BlindedIndependentCentralReview Responses are based on BICR assessments per RECIST 1.1with confirmation. DatabaseCutoffDate:13JUN2018 | BICR=BlindedIndependentCentralReview Responses are based on BICR assessments per RECIST 1.1with confirmation. DatabaseCutoffDate:13JUN2018 | BICR=BlindedIndependentCentralReview Responses are based on BICR assessments per RECIST 1.1with confirmation. DatabaseCutoffDate:13JUN2018 | BICR=BlindedIndependentCentralReview Responses are based on BICR assessments per RECIST 1.1with confirmation. DatabaseCutoffDate:13JUN2018 |

Source:[P048V01MK3475:adam-adsl; adrs]

<div style=\"page-break-after: always\"></div>

Table  23:  Summary  of  Best  Objective  Response  with  Confirmation  Based  on  BICR  per  RECIST  1.1 (Pembro Combo vs Control) (ITT Population) (CPS ≥ 20)

|                                                                                                                 | Pembrolizumab+Chemotherapy                                                                                      | Pembrolizumab+Chemotherapy                                                                                      | Cetuximab+ Chemotherapy                                                                                         | Cetuximab+ Chemotherapy                                                                                         |
|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
|                                                                                                                 |                                                                                                                 | (96)                                                                                                            |                                                                                                                 | (%6)                                                                                                            |
| Numberof Subjects inPopulation                                                                                  | 126                                                                                                             |                                                                                                                 | 110                                                                                                             |                                                                                                                 |
| Complete Response (CR)                                                                                          | 12                                                                                                              | (9.5)                                                                                                           | 4                                                                                                               | (3.6)                                                                                                           |
| Partial Response (PR)                                                                                           | 42                                                                                                              | (33.3)                                                                                                          | 38                                                                                                              | (34.5)                                                                                                          |
| Objective Response (CR+PR)                                                                                      | 54                                                                                                              | (42.9)                                                                                                          | 42                                                                                                              | (38.2)                                                                                                          |
| Stable Disease (SD)                                                                                             | 29                                                                                                              | (23.0)                                                                                                          | 37                                                                                                              | (33.6)                                                                                                          |
| Progressive Disease (PD)                                                                                        | 19                                                                                                              | (15.1)                                                                                                          | 10                                                                                                              | (9.1)                                                                                                           |
| Non-CR/Non-PD (NN)                                                                                              | +                                                                                                               | (3.2)                                                                                                           | 5                                                                                                               | (4.5)                                                                                                           |
| Not Evaluable (NE)                                                                                              | 2                                                                                                               | (1.6)                                                                                                           | 0                                                                                                               | (0.0)                                                                                                           |
| No Assessment                                                                                                   | 18                                                                                                              | (14.3)                                                                                                          | 16                                                                                                              | (14.5)                                                                                                          |
| BICR=BlindedIndependent CentralReview Responses are based on BICR assessments per RECIST 1.l with confinmation. | BICR=BlindedIndependent CentralReview Responses are based on BICR assessments per RECIST 1.l with confinmation. | BICR=BlindedIndependent CentralReview Responses are based on BICR assessments per RECIST 1.l with confinmation. | BICR=BlindedIndependent CentralReview Responses are based on BICR assessments per RECIST 1.l with confinmation. | BICR=BlindedIndependent CentralReview Responses are based on BICR assessments per RECIST 1.l with confinmation. |

Snnrre-[pn48u01MK3475·adam-adel·adre]

Analysis of objective response with both confirmed and unconfirmed responses yielded similar results as analysis with confirmed responses, in all three populations analysed.

Overall, no relevant changes in ORR are observed at the updated cut-off date for the final analysis compared to the results at the IA2.

## Patients Reported Outcomes - pembro combo vs control

The PRO FAS population (i.e. all participants regardless of PD-L1 status who were randomized and treated and  had  at  least  one  PRO  assessment)  included  270  participants  in  the  pembrolizumab  plus chemotherapy group and 260 participants in the standard treatment group who completed the EORTC QLQ-C30 questionnaire. The compliance rates for the EORTC QLQ-30 were similar in both pembro combo and  control  arm  at  baseline  (94.4%  vs  93.8%)  and  remained  high  at  Week  15  (82%  vs  78.9%). Compliance rates at baseline through Week 15 were similar for the EORTC QLQ H&amp;N35 and EQ-5D.

Mean Change from Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life Score (secondary endpoint)

Table 24: Analysis of change from baseline of EORTC QLQ-C30 Global health status/Qol scales at Week 15 (Pembro combo vs Control) - FAS population

|                                                     | Baseline                                            | Baseline                                            | Week15   | Week15         | ChangefromBaseline atWeek15   | ChangefromBaseline atWeek15     | ChangefromBaseline atWeek15   |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|----------|----------------|-------------------------------|---------------------------------|-------------------------------|
| Treatment                                           | N                                                   | Mean (SD)                                           | N        | Mean (SD)      | N                             | LS Mean (95% CI)                |                               |
| Pembrolizumab + Chemotherapy                        | 255                                                 | 62.19 (21.184)                                      | 173      | 64.60 (21.096) | 268                           | 1.17 (-1.79, 4.12)              |                               |
| Cetuximab+Chemotherapy                              | 244                                                 | 59.97 (21.863)                                      | 167      | 63.27 (18.727) | 259                           | 0.77(-2.22,3.76)                | 0.77(-2.22,3.76)              |
| PairwiseComparison                                  |                                                     |                                                     |          |                |                               | Difference inLS Means ( 95% CI) | p-Value                       |
| Pembrolizumab+Chemotherapyvs.Cetuximab+Chemotherapy | Pembrolizumab+Chemotherapyvs.Cetuximab+Chemotherapy | Pembrolizumab+Chemotherapyvs.Cetuximab+Chemotherapy |          |                |                               | 0.40 (-3.46,4.26)               | 0.839                         |

DatabaseCutoff:13JUN2018

<div style=\"page-break-after: always\"></div>

<!-- image -->

Time to Deterioration in EORTC QLQ-C30 Global Health Status/Quality of Life (secondary endpoint)

In the PRO FAS population, TTD in the EORTC QLQ-C30 global health status/QoL score for pembrolizumab plus chemotherapy was HR = 1.37 (95% CI: 0.94, 2.00) (see figure below):

Figure 6: Kaplan-Meier plot of time to true deterioration for EORTC QLQ-C30 global health status/QoL (Pembro combo vs control) - FAS population (Cutoff date 13JUN2018)

<!-- image -->

Time to Deterioration EORTC QLQ-H&amp;N35 Pain and Swallowing Scores (secondary endpoints)

In the PRO FAS population, TTD in the EORTC QLQ-H&amp;N35 pain score was HR = 1.37 (95% CI: 0.93, 2.02) and swallowing score was HR = 1.05 (95% CI: 0.69, 1.59) for pembrolizumab plus chemotherapy when compared with standard treatment (see figures below):

<div style=\"page-break-after: always\"></div>

<!-- image -->

FAS population - Cutoff date: 13 Jun 2018

Figure 7: Kaplan-Meier plot of time to deterioration for EORTC QLQ-H&amp;N35 Pain (Pembro combo vs control)

## Exploratory endpoints

- Time to response and duration of response

Table  25:  Summary  of  time  to  response  and  duration  of  response  based  on  BICR  per  RECIST  1.1  in subjects with confirmed response (Pembro combo vs control) - ITT

|                                                                                                                                                                                                                                                        | Pembrolizmab+ Chemotherapy (N=281)                                                                                                                                                                                                                     | Cetuximab+ Chemotherapy (N=278)                                                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number of subjects with response                                                                                                                                                                                                                       | 100                                                                                                                                                                                                                                                    | 101                                                                                                                                                                                                                                                    |
| Time toResponse(months)                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                        |
| Mean (SD) Median (Range)                                                                                                                                                                                                                               | 2.6 (1.6) 2.1 (1.4-13.7)                                                                                                                                                                                                                               | 2.5 (0.8) 2.1 (1.3-6.2)                                                                                                                                                                                                                                |
| Response Duration*(months)                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                        |
| Median (Range)                                                                                                                                                                                                                                         | 6.7 (1.6+ - 30.4+)                                                                                                                                                                                                                                     | 4.3 (1.2+ - 27.9+)                                                                                                                                                                                                                                     |
| Number(%+) of Subjects with Extended Response Duration:                                                                                                                                                                                                |                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                        |
| ≥6months                                                                                                                                                                                                                                               | 49 (53.5)                                                                                                                                                                                                                                              | 28 (36.8)                                                                                                                                                                                                                                              |
| Includes subjects with confinmedcomplete response or partial response. From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. DatabaseCutoffDate:13JUN2018. | Includes subjects with confinmedcomplete response or partial response. From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. DatabaseCutoffDate:13JUN2018. | Includes subjects with confinmedcomplete response or partial response. From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. DatabaseCutoffDate:13JUN2018. |

Source:[P048V01MK3475:adam-adsl:adrs:adtte]

85

Figure 8: Kaplan-Meier plot of time to deterioration for EORTC QLQ-H&amp;N35 Swallowing (Pembro combo vs control)

<div style=\"page-break-after: always\"></div>

Table 26: Summary of response outcome in subjects with confirmed response based on BICR per RECIST 1.1 (Pembro combo vs control) - ITT population

|                                                                               | Pembrolizumab+ Chemotherapy (N=281)   | Cetuximab+ Chemotherapy (N=278)   |
|-------------------------------------------------------------------------------|---------------------------------------|-----------------------------------|
| NumberofSubjectswithResponse                                                  | 100                                   | 101                               |
| Subjects WhoProgressed orDied+(%)                                             | 71 (71.0)                             | 74 (73.3)                         |
| Range of DOR (months)                                                         | 2.4 to 21.8                           | 2.0 to 15.5                       |
| Censored Subjects(9)                                                          | 29 (29.0)                             | 27 (26.7)                         |
| Subjectswhomissed2ormoreconsecutivedisease assessments                        | 4 (4.0)                               | 11 (10.9)                         |
| Subjectswhostartednewanti-cancertreatment                                     | 4 (4.0)                               | 5 (5.0)                           |
| Subjects who were lost to follow-up                                           | 0 (0.0)                               | 0 (0.0)                           |
| Subjects whose last adequate assessment was ≥ 5 months prior todatacutoffdate | 1 (1.0)                               | 2 (2.0)                           |
| Ongoing responsef                                                             | 20 (20.0)                             | 9 (8.9)                           |
| ≥6months                                                                      | 20 (20.0)                             | 9 (8.9)                           |
| RangeofDOR(months)                                                            | 14.1+ to 30.4+                        | 16.0+ to27.9+                     |

- I Includes subjects who progressed or died without previously missing 2 or more consecutive disease assessments.

Includes subjects with a confinmed complete response or partial response.

- Includes subjects who are alive, have not progressed, have not initiated new anti-cancer treatment, are notlosttofollow-up,andwhoselastdiseaseassessmentwas&lt;5monthspriortodatacutoffdate.

'+' indicates there was no progressive disease by the time of last disease assessment. DatabaseCutoffDate:13JUN2018

- For censored subjects who met multiple criteria for censoring and do not have ongoing response, subjects are included in the censoring criterion that occuured earliest.

Source:[P048V01MK3475:adam-adsl;adtte]

Figure 9: Kaplan-Meier estimates of duration of response in subjects with confirmed response based on BICR per Recist 1.1 (Pembro combo vs control) - ITT population

<!-- image -->

Figure 10: Kaplan-Meier estimates of duration of response in subjects with confirmed response based on BICR per Recist 1.1 (Pembro combo vs control) CPS≥1

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 11: Kaplan-Meier estimates of duration of response in subjects with confirmed response based on BICR per Recist 1.1 (Pembro combo vs control) CPS≥20

<!-- image -->

DOR and TTR results at the FA were consistent with prior data at IA2. Median time to response was similar,  median  DOR  was  longer,  and  more  participants  had  a  response  duration ≥ 6  months  (KM estimation) in pembrolizumab combination.

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## -Subgroup analyses - Pembro combo vs Control

Forest Plots of OS, PFS and ORR by subgroup factors are reported in the figures below:

<!-- image -->

(database cut-off 25 Feb 2019)

Figure 12: Forest plots of OS Hazard Ratio in the ITT, CPS≥1 and CPS≥20 populations - pembro combo vs control

<div style=\"page-break-after: always\"></div>

<!-- image -->

(database cut-off 25 Feb 2019)

Figure 13 : Forest plots of PFS Hazard Ratio based on BICR per RECIST 1.1 in the ITT, CPS≥1 and CPS≥20 populations - pembro combo vs control

<div style=\"page-break-after: always\"></div>

<!-- image -->

(database cut-off 25 Feb 2019)

Figure 14: Forest plots of Best objective response (confirmed) rate based on BICR per RECIST 1.1 in the ITT, CPS≥1 and CPS≥20 populations - pembro combo vs control

Analyses in the CPS &lt;1, CPS &lt;20, and CPS ≥1 to &lt;20 Populations - pembro combo vs control

The subset analyses described in the three populations CPS &lt;1, CPS &lt;20, and CPS ≥1 to &lt;20 were requested  by  the  CHMP.  These  analyses  are  exploratory  analyses,  not  adequately  powered  to  test statistical significance, and should be interpreted with caution and considered hypothesis generating.

<div style=\"page-break-after: always\"></div>

Table 27 : Key Efficacy Results Pembrolizumab Plus Chemotherapy vs Standard Treatment CPS &lt;1, CPS &lt;20, and CPS ≥1 to CPS &lt;20 Po pulation Findings KEYNOTE-048 (FA)

|                                                                      | PD-L1 CPS <1                         | PD-L1 CPS <1       | PD-L1 CPS <20                         | PD-L1 CPS <20       | PD-L1 CPS ≥1 to CPS <20               | PD-L1 CPS ≥1 to CPS <20   |
|----------------------------------------------------------------------|--------------------------------------|--------------------|---------------------------------------|---------------------|---------------------------------------|---------------------------|
|                                                                      | Pembrolizumab Plus Chemotherapy N=39 | Std Treatment N=43 | Pembrolizumab Plus Chemotherapy N=154 | Std Treatment N=165 | Pembrolizumab Plus Chemotherapy N=116 | Std Treatment N=125       |
| OS                                                                   |                                      |                    |                                       |                     |                                       |                           |
| Number of events (%)                                                 | 36 (92.3)                            | 34 (79.1)          | 128 (83.1)                            | 146 (88.5)          | 93 (80.2)                             | 115 (92.0)                |
| Median in months(95% CI)                                             | 11.3 (9.5, 14.0)                     | 10.7 (8.5, 15.9)   | 11.8 (10.4, 14.0)                     | 10.2 (8.9, 12.1)    | 12.7 (9.4, 15.3)                      | 9.9 (8.6, 11.5)           |
| HR (95% CI)                                                          | 1.21 (0.76, 1.94)                    | 1.21 (0.76, 1.94)  | 0.83 (0.65, 1.05)                     | 0.83 (0.65, 1.05)   | 0.71 (0.54, 0.94)                     | 0.71 (0.54, 0.94)         |
| P-value (superiority statistic)                                      | 0.78932                              | 0.78932            | 0.05693                               | 0.05693             | 0.00726                               | 0.00726                   |
| OS rate at 12 months (95% CI)                                        | 41.0 (25.7, 55.8)                    | 46.5 (31.2, 60.4)  | 49.4 (41.2, 56.9)                     | 43.3 (35.6, 50.7)   | 52.6 (43.1, 61.2)                     | 41.1 (32.4, 49.6)         |
| OS rate at 18 months (95% CI)                                        | 28.2 (15.3, 42.7)                    | 30.2 (17.4, 44.1)  | 33.1 (25.8, 40.6)                     | 27.4 (20.9, 34.4)   | 34.5 (26.0, 43.1)                     | 25.8 (18.5, 33.7)         |
| OS rate at 24 months (95% CI)                                        | 20.5 (9.6, 34.2)                     | 25.6 (13.8, 39.1)  | 24.7 (18.2, 31.7)                     | 17.7 (12.3, 23.9)   | 25.9 (18.3, 34.1)                     | 14.5 (9.0, 21.3)          |
| PFS (BICR per RECIST 1.1)                                            |                                      |                    |                                       |                     |                                       |                           |
| Number of events (%)                                                 | 38 (97.4)                            | 39 (90.7)          | 143 (92.9)                            | 153 (92.7)          | 106 (91.4)                            | 117 (93.6)                |
| Median in months (95% CI)                                            | 4.7 (3.4, 6.2)                       | 6.2 (5.0, 7.3)     | 4.9 (4.3, 5.3)                        | 5.2 (4.8, 6.2)      | 4.9 (4.2, 5.3)                        | 4.9 (3.7, 6.0)            |
| HR (95% CI)b                                                         | 1.46 (0.93, 2.30)                    | 1.46 (0.93, 2.30)  | 1.05 (0.84, 1.32)                     | 1.05 (0.84, 1.32)   | 0.93 (0.71, 1.21)                     | 0.93 (0.71, 1.21)         |
| P-value                                                              | 0.94898                              | 0.94898            | 0.66834                               | 0.66834             | 0.29189                               | 0.29189                   |
| PFS rate at 6 months (95% CI)                                        | 43.6 (27.9, 58.3)                    | 53.8 (37.6, 67.6)  | 41.3 (33.4, 49.0)                     | 44.3 (36.5, 51.8)   | 40.1 (31.0, 49.0)                     | 40.0 (31.2, 48.5)         |
| ORR (BICR per RECIST 1.1)                                            |                                      |                    |                                       |                     |                                       |                           |
| %(95% CI)                                                            | 30.8 (17.0, 47.6)                    | 39.5 (25.0, 55.6)  | 29.9 (22.8, 37.8)                     | 35.8 (28.5, 43.6)   | 29.3 (21.2, 38.5)                     | 33.6 (25.4, 42.6)         |
| DOR (Confirmed CR or PR, BICR per RECIST 1.1)                        |                                      |                    |                                       |                     |                                       |                           |
| Number of responders                                                 | 12                                   | 17                 | 46                                    | 59                  | 34                                    | 42                        |
| Median in months (range)                                             | 5.7 (2.6 - 20.6+)                    | 4.3 (2.0 - 31.2+)  | 5.7 (1.6+ - 25.6+)                    | 4.6 (1.4+ - 31.4+)  | 5.6 (1.6+ - 25.6+)                    | 4.6 (1.4+ - 31.4+)        |
| Median time to response (range)                                      | 2.2 (2.1-3.4)                        | 2.1 (1.9-4.9)      | 2.1 (1.9-6.1)                         | 2.1 (1.3-10.4)      | 2.1 (1.9-6.1)                         | 2.1 (1.3-10.4)            |
| Number (Kaplan-Meier %) With Extended Response Duration ( ≥6 months) | 5 (46.9)                             | 7 (49.0)           | 18 (45.1)                             | 17 (38.5)           | 13 (44.3)                             | 10 (34.0)                 |

Abbreviations: BICR=Blinded independent central review; CI=Confidence interval; CPS=Combined positive score; CR=Complete response; DOR=Duration of response; HR=Hazard ratio; ITT=Intention to treat; NR=Not reached; ORR=Objective response rate; OS=Overall survival; PD-L1=Programmed cell death ligand 1; PFS=Progression-free survival; PR=Partial response; RECIST 1.1=Response Evaluation Criteria in Solid Tumours Version 1.1; Std=Standard. Database cutoff date: 25-FEB-2019

<div style=\"page-break-after: always\"></div>

## Overall survival

<!-- image -->

1≤CPS&lt;20

15

20

25

Time in Monhs

49

100-

06

8

70-

09

OS

40

30-

20-

10

O

0

AtRisk

Penbro+Chemo

116

5

95

10

67

34

26

Panbra+Chama

ICensored

Contirol

35

16

125

100

62

43.

28.

16

6

1

Figure 15: Kaplan-Meier of OS - Pembro combo vs control (Final analysis)

| Overall     | N#Events 559/420   | HR 0.76   | ID 9696 (0.63, 0.92)   |                         |
|-------------|--------------------|-----------|------------------------|-------------------------|
| PD-L1 CPS1  |                    |           |                        |                         |
| CPS >=1     | 477/354            | 0.72      | (0.58, 0.89)           |                         |
| CPS ≤1      | 82/66              | 1.07      | (0.66, 1.74)           |                         |
| PD-L1 CPS20 |                    |           |                        |                         |
| CPS >=20    | 236/164            | 0.7       | (0.52, 0.96)           |                         |
| CPS≤20      | 319/252            | 0.84      | (0.65, 1.07)           |                         |
| PD-L1 CPS   |                    |           |                        |                         |
| CPS≤1       | 82/66              | 1.07      | (0.66, 1.74)           |                         |
| CPS=20      | 236/164            | 0.7       | (0.52, 0.96)           |                         |
| 1<=CPS≤20   | 241/190            | 0.75      | (0.57, 1.01)           |                         |
|             |                    |           |                        | 0.1 0.5                 |
|             |                    |           |                        | Combo <-Favor-> Control |

(DatabaseCutoffDate:13JUN2018)

Figure 16: Forest plot of OS Hazard Ratio by PD-L1 subgroup (Pembro combo vs control) - ITT population (IA2)

8.

BAAirNS

拍

40

<div style=\"page-break-after: always\"></div>

Figure 17: Kaplan-Meier estimates of PFS based on BICR assessment per RECIST 1.1 (primary analysis) Pembro combo vs control

<!-- image -->

Analyses in the TPS&lt;50% and TPS≥50% Populations - pembro combo vs control

Table 28: Key Efficacy Results OS/PFS/ORR/DOR Findings for Pembrolizumab Plus Chemotherapy versus Standard Treatment for TPS &lt;50%, TPS ≥50% Populations - KEYNOTE-048 IA2 Analysis

45 (72.6)

12.2 (8.9, 15.9)

0.28508§

56 (90.3)

|                                 | PD-L1 TPS <50%                        | PD-L1 TPS <50%      | PD- L1 TPS ≥50%                      | PD- L1 TPS ≥50%    |
|---------------------------------|---------------------------------------|---------------------|--------------------------------------|--------------------|
|                                 | Pembrolizumab Plus Chemotherapy N=215 | Std Treatment N=216 | Pembrolizumab Plus Chemotherapy N=66 | Std Treatment N=62 |
| OS                              |                                       |                     |                                      |                    |
| Number of events (%)            | 153 (71.2)                            | 178 (82.4)          | 44 (66.7)                            | 45 (72.6)          |
| Median in months(95% CI)        | 12.8 (10.6, 15.0)                     | 10.3 (9.0, 11.4)    | 13.5 (9.3, 16.6)                     | 12.2 (8.9, 15.9)   |
| HR (95% CI)                     | 0.74 (0.59, 0.92)                     | 0.74 (0.59, 0.92)   | 0.88 (0.58, 1.35)                    | 0.88 (0.58, 1.35)  |
| P-value (superiority statistic) | 0.00291§                              | 0.00291§            | 0.28508§                             | 0.28508§           |
| OS rate at 12 months (95% CI)   | 52.1 (45.2, 58.5)                     | 41.9 (35.2, 48.3)   | 56.1 (43.3, 67.0)                    | 51.3 (38.2, 62.9)  |
| PFS (BICR per RECIST 1.1)       |                                       |                     |                                      |                    |
| Number of events (%)            | 192 (89.3)                            | 197 (91.2)          | 52 (78.8)                            | 56 (90.3)          |

<div style=\"page-break-after: always\"></div>

4.9 (3.6, 6.2)

0.02785§

2.2 (2.0-6.0)

6 (31.6)

|                                                                     | PD-L1 TPS <50%                        | PD-L1 TPS <50%      | PD- L1 TPS ≥50%                      | PD- L1 TPS ≥50%    |
|---------------------------------------------------------------------|---------------------------------------|---------------------|--------------------------------------|--------------------|
|                                                                     | Pembrolizumab Plus Chemotherapy N=215 | Std Treatment N=216 | Pembrolizumab Plus Chemotherapy N=66 | Std Treatment N=62 |
| Median in months (95% CI)                                           | 4.9 (4.6, 5.8)                        | 5.2 (4.9, 6.1)      | 5.7 (3.4, 9.7)                       | 4.9 (3.6, 6.2)     |
| HR (95% CI)                                                         | 0.99 (0.81, 1.21)                     | 0.99 (0.81, 1.21)   | 0.67 (0.45, 1.01)                    | 0.67 (0.45, 1.01)  |
| P-value                                                             | 0.45725§                              | 0.45725§            | 0.02785§                             | 0.02785§           |
| PFS rate at 6 months (95% CI)                                       | 13.8 (9.5, 18.8)                      | 12.8 (8.6, 17.8)    | 49.7 (36.9, 61.2)                    | 42.6 (29.9, 54.7)  |
| ORR (BICR per RECIST 1.1)                                           |                                       |                     |                                      |                    |
| (%) (95% CI)                                                        | 34.9 (28.5,41.7)                      | 37.5 (31.0,44.3)    | 37.9 (26.2,50.7)                     | 32.3 (20.9,45.3)   |
| DOR (Confirmed CR or PR, BICR per RECIST 1.1)                       |                                       |                     |                                      |                    |
| Number of responders                                                | 75                                    | 81                  | 25                                   | 20                 |
| Median in months (range)                                            | 6.0 (1.6+ - 30.4+)                    | 4.3 (1.4+ - 27.9+)  | 8.3 (2.1+ - 25.5+)                   | 4.5 (1.2+ - 22.3+) |
| Median time to response (range)                                     | 2.1 (1.8-13.7)                        | 2.1 (1.3-6.2)       | 2.1 (1.4-10.6)                       | 2.2 (2.0-6.0)      |
| Number (Kaplan-Meier %) With Extended Response Duration (≥6 months) | 35 (50.6)                             | 22 (38.3)           | 14 (62.5)                            | 6 (31.6)           |

Abbreviations: BICR=Blinded independent central review; CI=Confidence interval; CR=Complete response; DOR=Duration of response; HR=Hazard ratio; ORR=Objective response rate; OS=Overall survival; PD-L1=Programmed cell death ligand 1; PFS=Progression-free survival; PR=Partial response; RECIST 1.1=Response Evaluation Criteria in Solid Tumours Version 1.1; Std=Standard.

§ One-sided p-value based on log-rank test stratified by ECOG (0 vs. 1) and HPV status (Positive vs. Negative).

Database Cutoff Date: 13JUN2018

## Proportional Hazards (PH) assumption for OS

The PH assumption for OS was examined using both graphical and analytical methods. From both the plots  and  p-value  from  the  test,  there  is  evidence  of  departure  from  the  PH  assumption  in  the  ITT population of pembro combo vs control.

Plot  of  log(-log(survival))  against  log(time)  was  generated  for  pembro  combo  vs  control  in  the  ITT population. If the PH assumption was satisfied then the curves should be approximately parallel to each other. Plot of Schoenfeld residuals versus survival time was generated for pembro combo vs control in the ITT population. If the PH assumption was satisfied then the plot of scaled residuals over time should be randomly distributed at either side of the 'zero' line.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Database cutoff date: 13 Jun 2018

The PH assumption was also tested at the 0.1 significance level by including treatment*time as a factor in the model (see table below). Nonsignificance (p-value &gt;0.1) of this factor would suggest proportionality.

Table  29:  Assessment  of  proportional  hazard  assumption  for  overall  survival  Cox  PH  Model  with treatment-by-time interaction

| Comparison                                                                                                                                                                                                    | Population                                                                                                                                                                                                    | p-value!                                                                                                                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrocombovs.Standardtreatment                                                                                                                                                                               | ITT                                                                                                                                                                                                           | 0.03941                                                                                                                                                                                                       |
| Pembromonovs.Standardtreatment                                                                                                                                                                                | ITT CPS>=1 CPS>=20                                                                                                                                                                                            | 0.02066 0.04742 0.04289                                                                                                                                                                                       |
| Two-sided p-value of Wald Chi-square test based on Cox regression model with Efron's method of tie handlingwithtreatmentandtreatment-by-timeinteractionascovariates,stratifiedbyfactorsusedfor randomization. | Two-sided p-value of Wald Chi-square test based on Cox regression model with Efron's method of tie handlingwithtreatmentandtreatment-by-timeinteractionascovariates,stratifiedbyfactorsusedfor randomization. | Two-sided p-value of Wald Chi-square test based on Cox regression model with Efron's method of tie handlingwithtreatmentandtreatment-by-timeinteractionascovariates,stratifiedbyfactorsusedfor randomization. |

To account for the non-proportional hazards effect associated with immunotherapies, two sensitivity analyses were conducted:

- 1) Weighted log-rank test with parameter (0,1) (which puts more weight on the late differences between the survival curves, commonly seen with immunotherapy, rather than early differences)

Table 30: Analysis of overall survival using Log-Rank and weighted Log-Rank tests

| Comparison                       | Population   | Test              | p-valuet        |
|----------------------------------|--------------|-------------------|-----------------|
| Pembrocombovs.Standard treatment | ITT          | Log-Rank FH (0,1) | 0.00335 0.00130 |
| Pembromonovs.Standardtreatment   | ITT          | Log-Rank FH (0,1) | 0.04563 0.00080 |
|                                  | CPS>=1       | Log-Rank FH (0,1) | 0.00855 0.00015 |
|                                  | CPS>=20      | Log-Rank FH (0,1) | 0.00074 <.00001 |

FH (O,1): Fleming and Harrington weighted log-rank test weighting towards late difference. Database Cutoff Date: 13JUN2018.

- 2) Restricted mean survival time (RMST) method

Table 31: Summary of RMST of overall survival (Pembro combo vs control) - ITT population

|                                                                    | Pembrolizumab + Chemotherapy (N=281)                               | Pembrolizumab + Chemotherapy (N=281)                               | Cetuximab + Chemotherapy (N=278)                                   | Cetuximab + Chemotherapy (N=278)                                   | Difference (95% CI) vs. Control                                    |
|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                                                    | Number of Events                                                   | RMST                                                               | Number of Events                                                   | RMST                                                               |                                                                    |
| RMST based on 3 months of follow up                                | 37                                                                 | 2.78                                                               | 29                                                                 | 2.83                                                               | -0.04 (-0.15 , 0.06)                                               |
| RMST based on 6 months of follow up                                | 68                                                                 | 5.26                                                               | 58                                                                 | 5.35                                                               | -0.09 (-0.35 , 0.17)                                               |
| RMST based on 9 months of follow up                                | 99                                                                 | 7.37                                                               | 114                                                                | 7.42                                                               | -0.05 (-0.49 , 0.39)                                               |
| RMST based on 12 months of follow up                               | 132                                                                | 9.12                                                               | 155                                                                | 8.94                                                               | 0.18 (-0.45 , 0.81)                                                |
| RMST based on 15 months of follow up                               | 158                                                                | 10.6                                                               | 176                                                                | 10.1                                                               | 0.47 (-0.35 , 1.28)                                                |
| RMST based on 18 months of follow up                               | 175                                                                | 11.8                                                               | 201                                                                | 11.0                                                               | 0.73 (-0.27 , 1.73)                                                |
| RMST based on 24 months of follow up                               | 193                                                                | 13.8                                                               | 217                                                                | 12.4                                                               | 1.38 (0.05 ,2.72)                                                  |
| RMST:Restrictedmeansurvivaltime (Database Cutoff Date: 13JUN2018). | RMST:Restrictedmeansurvivaltime (Database Cutoff Date: 13JUN2018). | RMST:Restrictedmeansurvivaltime (Database Cutoff Date: 13JUN2018). | RMST:Restrictedmeansurvivaltime (Database Cutoff Date: 13JUN2018). | RMST:Restrictedmeansurvivaltime (Database Cutoff Date: 13JUN2018). | RMST:Restrictedmeansurvivaltime (Database Cutoff Date: 13JUN2018). |

<div style=\"page-break-after: always\"></div>

Table 32: Summary of RMST of PFS based on BICR per RECIST 1.1 (Pembro combo vs control) - ITT population

|                                      | Pembrolizumab+Chemotherapy (N=281)   | Pembrolizumab+Chemotherapy (N=281)   | Cetuximab+Chemotherapy (N=278)   | Cetuximab+Chemotherapy (N=278)   | Difference (95% CI) vs.Control   |
|--------------------------------------|--------------------------------------|--------------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                      | NumberofEvents                       | RMST                                 | Number ofEvents                  | RMST                             |                                  |
| RMSTbased on3months of follow up     | 80                                   | 2.61                                 | 61                               | 2.70                             | -0.09 (-0.21,0.03)               |
| RMST based on 6 months of follow up  | 152                                  | 4.30                                 | 150                              | 4.48                             | -0.18 (-0.49 , 0.13)             |
| RMSTbasedon9months offollowup        | 200                                  | 5.31                                 | 215                              | 5.31                             | -0.00 (-0.48 ,0.47)              |
| RMST based on 12 months of follow up | 226                                  | 5.94                                 | 233                              | 5.77                             | 0.17 (-0.45 , 0.78)              |
| RMSTbasedon15monthsoffollowup        | 232                                  | 6.41                                 | 240                              | 6.09                             | 0.31 (-0.42,1.05)                |

(DatabaseCutoffDate:13JUN2018).

Subsequent anticancer therapies

Table 33 : Subjects Who Received Subsequent Anti-Cancer Therapy (pembro combo vs control) - ITT population

|                                                      | Pembrolizumab + Chemotherapy (N=281)   | Cetuximab + Chemotherapy (N=278)   |
|------------------------------------------------------|----------------------------------------|------------------------------------|
| Subjects Who Received New Anti-Cancer Therapy        | 107 (38.1)                             | 143 (51.4)                         |
| Subjects Who Did Not Receive New Anti-Cancer Therapy | 163 (58.0)                             | 122 (43.9)                         |
| Unknown (Withdrew Consent)                           | 11 (3.9)                               | 13 (4.7)                           |
| (Database Cutoff Date: 13JUN2018).                   | (Database Cutoff Date: 13JUN2018).     | (Database Cutoff Date: 13JUN2018). |

A third or higher lines of therapy was administered to 39 (13.9%) subjects in the pembro combo arm vs 51 (18.3%) in the control arm.

The most frequently used 2L therapy was paclitaxel (or paclitaxel albumin) in 14.2% of pembrolizumab plus chemotherapy participants and in 11.9% of standard treatment participants, and the most frequently used 3L therapy also being paclitaxel in 4.6% of pembrolizumab plus chemotherapy participants, and 5.0% of standard treatment participants.

At the database cut-off of 25-FEB-2019, overall 115 (40.9%) and 145 (52.2%) patients have received a subsequent anticancer therapy in pembro combo and control arm, respectively.

Table 34: Subjects who received subsequent checkpoint immunotherapy (pembro combo vs control) ITT population

|                                                           | Pembrolizumab + Chemotherapy (N=281)   | Cetuximab + Chemotherapy (N=278)   |
|-----------------------------------------------------------|----------------------------------------|------------------------------------|
| Subjects Who Received Subsequent Checkpoint Immunotherapy | 15 (5.3)                               | 69 (24.8)                          |
| Subjects Who Did Not Receive Subsequent Checkpoint        | 255 (90.7)                             | 195 (70.1)                         |
| Immunotherapy                                             |                                        |                                    |
| Unknown (Withdrew Consent)                                | 11 (3.9)                               | 14 (5.0)                           |
| Database Cutoff Date: 13JUN2018                           | Database Cutoff Date: 13JUN2018        | Database Cutoff Date: 13JUN2018    |

PFS2 (IA2: cutoff date 13 -JUN- 2018)

PFS2 was defined as the time from randomization to subsequent disease progression after initiation of an anti-cancer  therapy  subsequent  to  discontinuation  of  study-specified  treatments,  or  death  from  any cause, whichever occurs first. If progression after next-line therapy cannot be measured, a PFS event is defined as end or discontinuation of next-line treatment or death from any cause, whichever occurs first. Subjects alive and for whom a PFS event has not been observed should be censored at the last time known to be alive and without second disease progression.

<div style=\"page-break-after: always\"></div>

Figure 18: Kaplan-Meier estimates of PFS2 based on investigator assessment (pembro combo vs control) - ITT population

<!-- image -->

Table 35: Analysis of PFS2 based on investigator assessment (Pembro combo vs control) - ITT population

| Treatment                                                        | N                                                                | Number of Events (%)                                             | Person- Months   | Event Rate/ 100 Person- Months (%)   | Median PFS2 t (Months) (95% CI)   | PFS2Rate at Months 6 in % t (95% CI)   |
|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------|--------------------------------------|-----------------------------------|----------------------------------------|
| Pembrolizumab+Chemotherapy                                       | 281                                                              | 217 (77.2)                                                       | 3484.7           | 6.2                                  | 10.4 (9.3, 12.3)                  | 73.7 (68.1, 78.4)                      |
| Cetuximab+Chemotherapy                                           | 278                                                              | 245 (88.1)                                                       | 2902.5           | 8.4                                  | 9.0 (8.4, 10.0)                   | 72.6 (66.9, 77.4)                      |
| Pairwise Comparisons                                             |                                                                  |                                                                  |                  |                                      | Hazard Ratio+(95% CI+             | p-Value                                |
| Primary Pembrolizumab + Chemotherapy vs.Cetuximab + Chemotherapy | Primary Pembrolizumab + Chemotherapy vs.Cetuximab + Chemotherapy | Primary Pembrolizumab + Chemotherapy vs.Cetuximab + Chemotherapy |                  |                                      | 0.74 (0.62, 0.89)                 | 0.00081$                               |

$ One-sided p-value based on log-rank test stratified by ECOG, HPV status and PD-L1 status. In case the event count in on stratum is &lt;5, stratification factors will be eliminated in the order ofECOG-&gt;HPV status-&gt;PD-L1 status until event count in every stratum is ≥5. DatabaseCutoffDate:13JUN2018.

<div style=\"page-break-after: always\"></div>

## Pembrolizumab vs chemotherapy (EXTREME regimen)

## Interim analysis 2 (data cut-off 13-Jun-2018, DBL 29 June 2018)

A total of 13 (4.3%) of 300 participants randomized to standard treatment decided not to receive any study medication, versus 1 (0.3%) of 301 participants randomized to pembrolizumab monotherapy.

During the procedure, the MAH provided the results of the Final analysis for KEYNOTE-048 study (cut-off date 25-FEB-2019, DBL 25-MAR-2019).

A summary of all efficacy results for the comparison pembro mono vs chemotherapy at the Final analysis is presented in the table below:

<div style=\"page-break-after: always\"></div>

Table 36: Key Efficacy Results Pembrolizumab Monotherapy vs Standard Treatment ITT, CPS ≥1 and CPS ≥20 Population Findings KEYNOTE -048 (FA)

|                                                                      | ITT (All Participants)          | ITT (All Participants)   | PD-L1 CPS ≥1                    | PD-L1 CPS ≥1        | PD-L1 CPS ≥20                   | PD-L1 CPS ≥20       |
|----------------------------------------------------------------------|---------------------------------|--------------------------|---------------------------------|---------------------|---------------------------------|---------------------|
|                                                                      | Pembrolizumab Monotherapy N=301 | Std Treatment N=300      | Pembrolizumab Monotherapy N=257 | Std Treatment N=255 | Pembrolizumab Monotherapy N=133 | Std Treatment N=122 |
| OS                                                                   |                                 |                          |                                 |                     |                                 |                     |
| Number of events (%)                                                 | 237 (78.7)                      | 264 (88.0)               | 197 (76.7)                      | 229 (89.8)          | 94 (70.7)                       | 108 (88.5)          |
| Median in months(95% CI)                                             | 11.5 (10.3, 13.4)               | 10.7 (9.3, 11.7)         | 12.3 (10.8, 14.3)               | 10.3 (9.0, 11.5)    | 14.8 (11.5, 20.6)               | 10.7 (8.8, 12.8)    |
| HR (95% CI)                                                          | 0.83 (0.70, 0.99)               | 0.83 (0.70, 0.99)        | 0.74 (0.61, 0.90)               | 0.74 (0.61, 0.90)   | 0.58 (0.44, 0.78)               | 0.58 (0.44, 0.78)   |
| P-value (superiority statistic)                                      | 0.01985                         | 0.01985                  | 0.00133                         | 0.00133             | 0.00010                         | 0.00010             |
| OS rate at 12 months (95% CI)                                        | 48.7 (42.9, 54.2)               | 44.4 (38.7, 49.9)        | 50.4 (44.1, 56.4)               | 43.6 (37.4, 49.6)   | 56.4 (47.5, 64.3)               | 44.9 (35.9, 53.4)   |
| OS rate at 18 months (95% CI)                                        | 35.7 (30.3, 41.1)               | 27.2 (22.3, 32.4)        | 38.7 (32.7, 44.6)               | 26.6 (21.3, 32.1)   | 45.1 (36.5, 53.3)               | 26.6 (19.1, 34.7)   |
| OS rate at 24 months (95% CI)                                        | 27.0 (22.1, 32.1)               | 18.8 (14.6, 23.5)        | 28.9 (23.5, 34.5)               | 17.4 (13.0, 22.4)   | 35.3 (27.3, 43.4)               | 19.1 (12.7, 26.6)   |
| PFS (BICR per RECIST 1.1)                                            |                                 |                          |                                 |                     |                                 |                     |
| Number of events (%)                                                 | 272 (90.4)                      | 277 (92.3)               | 228 (88.7)                      | 237 (92.9)          | 115 (86.5)                      | 114 (93.4)          |
| Median in months (95% CI)                                            | 2.3 (2.2, 3.3)                  | 5.2 (4.9, 6.1)           | 3.2 (2.2, 3.4)                  | 5.0 (4.8, 6.0)      | 3.4 (3.2, 3.8)                  | 5.3 (4.8, 6.3)      |
| HR (95% CI) b                                                        | 1.29 (1.09, 1.53)               | 1.29 (1.09, 1.53)        | 1.13 (0.94, 1.36)               | 1.13 (0.94, 1.36)   | 0.99 (0.76, 1.29)               | 0.99 (0.76, 1.29)   |
| P-value                                                              | 0.99830                         | 0.99830                  | 0.89580                         | 0.89580             | 0.46791                         | 0.46791             |
| PFS rate at 6 months (95% CI)                                        | 26.2 (21.4, 31.3)               | 45.7 (39.9, 51.3)        | 28.7 (23.3, 34.4)               | 43.9 (37.6, 49.9)   | 33.0 (25.2, 41.0)               | 46.6 (37.5, 55.2)   |
| PFS rate at 9 months (95% CI)                                        | 20.0 (15.7, 24.7)               | 21.4 (16.9, 26.3)        | 23.5 (18.5, 28.9)               | 19.8 (15.1, 25.0)   | 26.8 (19.5, 34.5)               | 22.0 (15.1, 29.8)   |
| PFS rate at 12 months (95% CI)                                       | 17.6 (13.5, 22.1)               | 15.0 (11.2, 19.4)        | 20.6 (15.9, 25.8)               | 13.6 (9.6, 18.2)    | 23.5 (16.6, 31.1)               | 15.1 (9.3, 22.2)    |
| ORR (BICR per RECIST 1.1, with confirmation)                         |                                 |                          |                                 |                     |                                 |                     |
| %(95% CI)                                                            | 16.9 (12.9, 21.7)               | 36.0 (30.6, 41.7)        | 19.1 (14.5, 24.4)               | 34.9 (29.1, 41.1)   | 23.3 (16.4, 31.4)               | 36.1 (27.6, 45.3)   |
| Complete Responses (CR)                                              | 14 (4.7%)                       | 8 (2.7%)                 | 14 (5.4%)                       | 7 (2.7%)            | 10 (7.5%)                       | 4 (3.3%)            |
| Partial Responses (PR)                                               | 37 (12.3%)                      | 100 (33.3%)              | 35 (13.6%)                      | 82 (32.2%)          | 21 (15.8%)                      | 40 (32.8%)          |
| Stable Disease (SD)                                                  | 82 (27.2%)                      | 102 (34.0%)              | 72 (28.0%)                      | 84 (32.9%)          | 40 (30.1%)                      | 43 (35.2%)          |
| Progressive Disease (PD)                                             | 122 (40.5%)                     | 37 (12.3%)               | 100 (38.9%)                     | 33 (12.9%)          | 42 (31.6%)                      | 12 (9.8%)           |
| DOR (Confirmed CR or PR, BICR per RECIST 1.1)                        |                                 |                          |                                 |                     |                                 |                     |
| Number of responders                                                 | 51                              | 108                      | 49                              | 89                  | 31                              | 44                  |
| Median in months (range)                                             | 22.6 (1.5+ - 43.0+)             | 4.5 (1.2+ - 38.7+)       | 23.4 (1.5+ - 43.0+)             | 4.5 (1.2+ - 38.7+)  | 22.6 (2.7+ - 43.0+)             | 4.2 (1.2+ - 31.5+)  |
| Median time to response (range)                                      | 2.1 (1.5 - 9.1)                 | 2.1 (1.3 - 10.4)         | 2.1 (1.5 - 9.1)                 | 2.1 (1.3 - 10.4)    | 2.1 (1.5 -9.1)                  | 2.1 (1.9 - 6.0)     |
| Number (Kaplan-Meier %) With Extended Response Duration ( ≥6 months) | 37 (77.8)                       | 32 (38.8)                | 37 (81.1)                       | 24 (36.0)           | 24 (83.5)                       | 12 (34.8)           |

Abbreviations: BICR=Blinded independent central review; CI=Confidence interval; CPS=Combined positive score; CR=Complete response; DOR=Duration of response; HR=Hazard ratio; ITT=Intention to treat; ORR=Objective response rate; OS=Overall survival; PD-L1=Programmed cell death ligand 1; PFS=Progression-free survival; PR=Partial response; RECIST 1.1=Response Evaluation Criteria in Solid Tumours Version 1.1; Std=Standard.  Database cutoff date: 25-FEB-2019

<div style=\"page-break-after: always\"></div>

## Primary endpoints

## OS - pembro mono vs control

OS benefit in the ITT population did not reach statistically significant superiority at FA (HR 0.83 [0.70, 0.99], p=0.01985).

In the population of participants whose tumours express PD-L1 CPS ≥ 1 or PD-L1 CPS ≥ 20, comparing pembrolizumab monotherapy to standard treatment, FA OS results confirmed the statistically significant OS benefit observed at IA2.

Overall,  OS  HR  point  estimates  improved  compared  to  the  IA2  in  the  ITT  population  and  all  CPS subgroups, with the exception of CPS&lt;1 population (from 1.37 to 1.51).

<!-- image -->

Control

122

100

64

42

28

21

13

B

3

0

0

Figure  19:  Kaplan-Meier  Estimates  of  Overall  Survival  (Pembro  Mono  vs  Control)  -  (Final  Analysis  cut-off date 25 Feb 2019)

Table 37: Summary of Timing of Overall Survival Events (Pembro Mono vs Control) - ITT Population

|                                 | Pembrolizumab   | Pembrolizumab   | Cetuximab+Chemotherapy   | Cetuximab+Chemotherapy   |
|---------------------------------|-----------------|-----------------|--------------------------|--------------------------|
|                                 | 11              | (%)             | 11                       | (%)                      |
| NumberofSubjectsinPopulation    | 301             |                 | 300                      |                          |
| SubjectsWithOSEvent             | 237             | (78.7)          | 264                      | (88.0)                   |
| <30DaysFollowingRandomization   | 13              | (4.3)           | 13                       | (4.3)                    |
| 30-60DaysFollowingRandomization | 19              | (6.3)           | 7                        | (2.3)                    |
| >60DaysFollowingRandomization   | 205             | (68.1)          | 244                      | (81.3)                   |
| SubjectsWithoutOSEvent          | 64              | (21.3)          | 36                       | (12.0)                   |
| (DatabaseCutoffDate:25FEB2019). |                 |                 |                          |                          |

## PFS - pembro mono vs control

<div style=\"page-break-after: always\"></div>

There was no statistically significant improvement in PFS in the CPS ≥20 population, therefore, PFS in the CPS ≥1 and ITT populations were not tested as per the multiplicity strategy.

Figure 20: KaplanMeier plots of Progression Free Survival, based on BICR per RECIST 1.1 (ITT, CPS≥1, CPS≥20), Pembro Mono vs Control (IA2 - cut-off date 13-Jun-2018, DBL 29 June 2018)

<!-- image -->

PFS was not tested at FA, as prespecified in the protocol. PFS did not show improvement; however, PFS rates at 9 and 12 months were higher for pembro in the CPS ≥ 1 and CPS ≥20 populations.

<div style=\"page-break-after: always\"></div>

Figure 21: KaplanMeier estimates of PFS, based on BICR assessment per RECIST 1.1 (ITT, CPS≥1, CPS≥20), Pembro mono vs Control - (Final Analysis - cut-off date 25 Feb 2019)

<!-- image -->

## Secondary endpoints

## ORR - pembro mono vs control

ORR results based on BICR assessment per RECIST 1.1 for the ITT, CPS ≥ 1 and CPS ≥ 20 are reported in tables below. Objective responses are confirmed.

Table  38:  Analysis  of  Objective  Response  (Confirmed)  Based  on  BICR  Assessment  per  RECIST  1.1 (Pembro mono vs Control) - ITT Population)

|                        |     |                                |                                    | Differencein%6vs.Control   | Differencein%6vs.Control   |
|------------------------|-----|--------------------------------|------------------------------------|----------------------------|----------------------------|
| Treabment              | N   | Nuumber of Objective Responses | Objective Response Rate (6）(95%CI) | Estimate (95% C1)          | p-Value                    |
| Pembrolizumab          | 301 | 51                             | 16.9 (12.9,21.7)                   | -19.0 (-25.8,-12.1)        | 1.0000                     |
| Cetuximab+Chemotherapy | 300 | 108                            | 36.0 (30.6,41.7)                   |                            |                            |

<div style=\"page-break-after: always\"></div>

Table  39:  Summary  of  Best  Objective  Response  with  Confirmation  Based  on  BICR  per  RECIST  1.1 (Pembro mono vs Control) - ITT Population

|                              | Pembrolizumab   | Pembrolizumab   | Cetuximab+Chemotherapy   | Cetuximab+Chemotherapy   |
|------------------------------|-----------------|-----------------|--------------------------|--------------------------|
|                              |                 | (%)             | n                        | (%)                      |
| NumberofSubjectsinPopulation | 301             |                 | 300                      |                          |
| Complete Response (CR)       | 14              | (4.7)           | 8                        | (2.7)                    |
| Partial Response (PR)        | 37              | (12.3)          | 100                      | (33.3)                   |
| Objective Response(CR+PR)    | 51              | (16.9)          | 108                      | (36.0)                   |
| Stable Disease (SD)          | 82              | (27.2)          | 101                      | (33.7)                   |
| Progressive Disease (PD)     | 122             | (40.5)          | 38                       | (12.7)                   |
| Non-CR/Non-PD (NN)           | 14              | (4.7)           | 11                       | (3.7)                    |
| Not Evaluable (NE)           | 6               | (2.0)           | 2                        | (0.7)                    |
| No Assessment                | 26              | (8.6)           | 40                       | (13.3)                   |

BICR=BlindedIndependent CentralReview

Responses are based on BICR assessments per RECIST 1.1 with coufimmation

DatabaseCutoffDate:13JUN2018

Table  40:  Summary  of  Best  Objective  Response  with  Confirmation  Based  on  BICR  per  RECIST  1.1 (Pembro mono vs Control) CPS≥1

|                                 | Pembrolizumab   | Pembrolizumab   | Cetuximab+Chemotherapy   | Cetuximab+Chemotherapy   |
|---------------------------------|-----------------|-----------------|--------------------------|--------------------------|
|                                 | n               | (96)            |                          | (%6)                     |
| Number of Subjects inPopulation | 257             |                 | 255                      |                          |
| Complete Response (CR)          | 14              | (5.4)           | 7                        | (2.7)                    |
| Partial Response (PR.)          | 35              | (13.6)          | 82                       | (32.2)                   |
| Objective Response (CR+PR)      | 49              | (19.1)          | 89                       | (34.9)                   |
| Stable Disease (SD)             | 72              | (28.0)          | 83                       | (32.5)                   |
| Progressive Disease (PD)        | 100             | (38.9)          | 34                       | (13.3)                   |
| Non-CR/Non-PD (NN)              | 11              | (4.3)           | 11                       | (4.3)                    |
| Not Evaluable (NE)              | 5               | (1.9)           | 2                        | (0.8)                    |
| No Assessment                   | 20              | (7.8)           | 36                       | (14.1)                   |

BICR=Blinded Independent Central Review

Responses are based on BICR assessments per RECIST 1.1 with coufinmation.

Database CutoffDate:13JUN2018

Table  41:  Summary  of  Best  Objective  Response  with  Confirmation  Based  on  BICR  per  RECIST  1.1 (Pembro mono vs Control) CPS≥20

|                                                                       | Pembrolizumab                                                         | Pembrolizumab                                                         | Cetuximab+Chemotherapy                                                | Cetuximab+Chemotherapy                                                |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                       |                                                                       | (96)                                                                  |                                                                       | (96)                                                                  |
| Number of Subjects inPopulation                                       | 133                                                                   |                                                                       | 122                                                                   |                                                                       |
| Complete Response (CR)                                                | 10                                                                    | (7.5)                                                                 | 4                                                                     | (3.3)                                                                 |
| Partial Response (PR)                                                 | 21                                                                    | (15.8)                                                                | 40                                                                    | (32.8)                                                                |
| Objective Response (CR+PR)                                            | 31                                                                    | (23.3)                                                                | 44                                                                    | (36.1)                                                                |
| Stable Disease (SD)                                                   | 40                                                                    | (30.1)                                                                | 42                                                                    | (34.4)                                                                |
| Progressive Disease (PD)                                              | 42                                                                    | (31.6)                                                                | 13                                                                    | (10.7)                                                                |
| Non-CR/Non-PD (NN)                                                    | 8                                                                     | (6.0)                                                                 | 6                                                                     | (4.9)                                                                 |
| Not Evaluable (NE)                                                    |                                                                       | (0.8)                                                                 | 0                                                                     | (0.0)                                                                 |
| No Assessment                                                         | 11                                                                    | (8.3)                                                                 | 17                                                                    | (13.9)                                                                |
| BICR=BlindedIndependent Central Review                                | BICR=BlindedIndependent Central Review                                | BICR=BlindedIndependent Central Review                                | BICR=BlindedIndependent Central Review                                | BICR=BlindedIndependent Central Review                                |
| Responses arebased onBICR assessments per RECIST 1.1with confinmation | Responses arebased onBICR assessments per RECIST 1.1with confinmation | Responses arebased onBICR assessments per RECIST 1.1with confinmation | Responses arebased onBICR assessments per RECIST 1.1with confinmation | Responses arebased onBICR assessments per RECIST 1.1with confinmation |

BICR=BlindedIndependent Central Review

Responses arebased onBICR assessments per RECIST 1.1with confinmation

Database Cutoff Date:13JUN2018

Analysis of objective response with both confirmed and unconfirmed responses yielded similar results as analysis with confirmed responses.

ORR results at the updated FA cut-off date were consistent with the results at the IA2. ORR was lower in pembrolizumab monotherapy responders; however, more responders achieved a complete response.

## Patient Reported Outcome - pembro mono vs control

The PRO FAS population (i.e. all participants regardless of PD-L1 status who were randomized and treated and had at least one PRO assessment) included 294 and 280 participants in the pembrolizumab and in the control group, respectively. The compliance rates for the EORTC QLQ-30 were similar in both pembro

<div style=\"page-break-after: always\"></div>

mono and control arm at baseline (94.9% versus 92%) and remained high at Week 15 (94.2% versus 83%). Compliance rates at baseline through Week 15 were similar for the EORTC QLQ H&amp;N35 and EQ-5D.

Mean Change from Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life Score (secondary endpoint)

Table 42: Analysis of change from baseline of EORTC QLQ-C30 Global health status/Qol scales at Week 15 (Pembro mono vs Control) - FAS population

|                                           | Baseline                                  | Baseline       | Week 15   | Week 15        | Changefrom Baseline at Week 15   | Changefrom Baseline at Week 15   | Changefrom Baseline at Week 15   |
|-------------------------------------------|-------------------------------------------|----------------|-----------|----------------|----------------------------------|----------------------------------|----------------------------------|
| Treatment                                 | N                                         | Mean (SD)      | N         | Mean (SD)      | N                                | LS Mean ( 95% CI)                |                                  |
| Pembrolizumab                             | 280                                       | 61.31 (21.599) | 191       | 64.66 (20.546) | 294                              | 0.85 (-1.90, 3.59)               |                                  |
| Cetuximab + Chemotherapy                  | 262                                       | 59.70 (21.479) | 182       | 62.59 (18.803) | 279                              | 0.60 (-2.19,3.40)                | 0.60 (-2.19,3.40)                |
| Pairwise Comparison                       |                                           |                |           |                |                                  | Difference in LS Means ( 95% CI) | p-Value                          |
| Pembrolizumab vs.Cetuximab + Chemotherapy | Pembrolizumab vs.Cetuximab + Chemotherapy |                |           |                |                                  | 0.24 (-3.34, 3.82)               | 0.893                            |

Time to Deterioration in EORTC QLQ-C30 Global Health Status/Quality of Life (secondary endpoint)

<!-- image -->

In the PRO FAS population, TTD in the EORTC QLQ-C30 global health status/QoL score for pembrolizumab plus monotherapy compared to standard treatment resulted HR = 1.38 (95% CI: 0.95, 2.00) (see figure below):

<div style=\"page-break-after: always\"></div>

Figure 22: Kaplan-Meier plot of time to true deterioration for EORTC QLQ-C30 global health status/QoL (Pembro mono vs control) - FAS population (Cutoff date 13JUN2018)

<!-- image -->

Time to Deterioration EORTC QLQ-H&amp;N35 Pain and Swallowing Scores (secondary endpoints)

In the PRO FAS population, TTD in the EORTC QLQ-H&amp;N35 pain score was HR = 0.80 (95% CI: 0.53, 1.21) and  swallowing  score  was  HR  =  1.26  (95%  CI:  0.85,  1.88)  for  pembrolizumab  monotherapy  when compared with standard treatment (see figures below):

<!-- image -->

(Database Cutoff Date: 13JUN2018)

Figure 23: Kaplan-Meier plot of time to true deterioration  for  EORTC  QLQ-H&amp;N35  Pain  (Pembro mono vs control)

<!-- image -->

(Database Cutoff Date:13JUN2018)

Figure 24: Kaplan-Meier plot of time to deterioration for EORTC  QLQ-H&amp;N35  Swallowing  (Pembro combo  vs control)

<div style=\"page-break-after: always\"></div>

## Exploratory endpoints

## Duration of Response (and Time to Response) - pembro mono vs control

Table 43: Summary of TTR and DOR based on BICR per RECIST 1.1 in subjects with CR in ITT population pembro mono vs control

|                                                                                                                                                                                                                                                           | Pembrolizumab (N=301)                                                                                                                                                                                                                                     | Cetuximab + Chemotherapy (N=300)                                                                                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number of subjects with responsel                                                                                                                                                                                                                         | 51                                                                                                                                                                                                                                                        | 108                                                                                                                                                                                                                                                       |
| Time to Response (months)                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                           |
| Mean (SD)                                                                                                                                                                                                                                                 | 3.0 (1.8)                                                                                                                                                                                                                                                 | 2.5 (0.8)                                                                                                                                                                                                                                                 |
| Median (Range)                                                                                                                                                                                                                                            | 2.1 (1.5-9.1)                                                                                                                                                                                                                                             | 2.1 (1.3-6.2)                                                                                                                                                                                                                                             |
| Response Duration (months)                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                           |
| Median (Range)                                                                                                                                                                                                                                            | 20.9 (1.5+ -34.8+)                                                                                                                                                                                                                                        | 4.5 (1.2+ -30.6+)                                                                                                                                                                                                                                         |
| Number (%) of Subjects with Extended Response Duration:                                                                                                                                                                                                   |                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                           |
| ≥6 months                                                                                                                                                                                                                                                 | 36 (75.7)                                                                                                                                                                                                                                                 | 32 (38.8)                                                                                                                                                                                                                                                 |
| Includes subjects with confinmed complete response or partial response. From product-limit (Kaplan-Meier) method for censored data. +\" indicates there is no progressive disease by the time of last disease assessment. Database Cutoff Date: 13JUN2018. | Includes subjects with confinmed complete response or partial response. From product-limit (Kaplan-Meier) method for censored data. +\" indicates there is no progressive disease by the time of last disease assessment. Database Cutoff Date: 13JUN2018. | Includes subjects with confinmed complete response or partial response. From product-limit (Kaplan-Meier) method for censored data. +\" indicates there is no progressive disease by the time of last disease assessment. Database Cutoff Date: 13JUN2018. |

Source: [P048V01MK3475: adam-adsl; adrs; adtte]

Table 44: Summary of response outcome in subjects with CR based on BICR per RECIST 1.1 (ITT population) -

## pembro mono vs control

|                                                                                  | Pembrolizumab (N=301)   | Cetuximab + Chemotherapy (N=300)   |
|----------------------------------------------------------------------------------|-------------------------|------------------------------------|
| Number of Subjects with Response                                                 | 51                      | 108                                |
| Subjects Who Progressed or Died (%)                                              | 25 (49.0)               | 77 (71.3)                          |
| Range of DOR (months)                                                            | 2.2 to 23.4             | 2.0 to 15.5                        |
| Censored Subjects (%)                                                            | 26 (51.0)               | 31 (28.7)                          |
| Subjects who missed 2 or more consecutive disease assessments                    | 1(2.0)                  | 12 (11.1)                          |
| Subjects who started new anti-cancer treatment                                   | 2 (3.9)                 | 6(5.6)                             |
| Subjects who were lost to follow-up                                              | 0 (0.0)                 | 0 (0.0)                            |
| Subjects whose last adequate assessment was ≥ 5 months prior to data cutoff date | 0 (0.0)                 | 2 (1.9)                            |
| Ongoing responses                                                                | 23 (45.1)               | 11 (10.2)                          |
| ≥6 months                                                                        | 23 (45.1)               | 11 (10.2)                          |
| Range ofDOR (months)                                                             | 13.6+ to 34.8+          | 16.0+ to 30.6+                     |

Souce:[P048V01MK3475:adam-adsl; adtte]

Kaplan-Meier Estimates of Duration of Response in Subjects With Confirmed Response Based on BICR per RECIST 1.1 (Pembro Mono vs Control) (ITT Population)

<!-- image -->

Figure 25: Kaplan-Meier estimates of DoR in subjects with CR based on BICR per RECIST 1.1 (ITT population) - pembro mono vs control

<div style=\"page-break-after: always\"></div>

Figure 26: Kaplan-Meier estimates of DOR in subjects with confirmed response based on BICR per RECIST 1.1 in CPS≥1 and CPS≥20 - pembro mono vs control

<!-- image -->

DOR and TTR results at the FA were consistent with prior data at IA2. Median TTR was similar, median DOR was longer and more participants had a response duration ≥ 6 months in the pembro mono arm compared to control.

<div style=\"page-break-after: always\"></div>

## Ancillary analyses - pembro mono vs control

## Subgroup analyses - Pembro mono vs Control

Forest Plots of OS, PFS and ORR by subgroup factors are reported in the figures below:

| CPS≥1   | CPS≥1   | CPS≥1   |
|---------|---------|---------|

<!-- image -->

(database cut-off 25 Feb 201 9)

Figure 27 : Forest plots of OS Hazard Ratio in the ITT, CPS≥1 and CPS≥20 populations - pembro mono vs control

<div style=\"page-break-after: always\"></div>

## PFS

<!-- image -->

(database cut-off 25 Feb 2019)

Figure 28 : Forest plots of PFS Hazard Ratio based on BICR per RECIST 1.1 in the ITT, CPS≥1 and CPS≥20 populations - pembro mono vs control

<div style=\"page-break-after: always\"></div>

## ORR

|                       | N/#Events      | ORR Diff          | 95% CI                     |           |                              | N/#Events     | ORR Dif     | 95% CI                    |                        |    |
|-----------------------|----------------|-------------------|----------------------------|-----------|------------------------------|---------------|-------------|---------------------------|------------------------|----|
| Overall               | 512/138        | -15.8             | (-23.4,-8.2)               |           |                              | 255/75        | -12.8       | (-23.8,-1.5)              |                        |    |
| Age                   | 329/96         | -18.9             | (-28.4,-9.2)               |           | <65yeers                     | 165/52        | -12.6       | (-26.4,1.6)               |                        |    |
| <65yeers >=65yeers    | 183/42         | -10.0             | (-22.2,2.2)                |           | >=65years                    | 90/23         | -11.7       | (-30.6,6.6)               |                        |    |
| Sex Femae             | 83/16 429/122  | -16.1 -15.3       | (-34.5,1.2) (-23.6,-6.9)   |           | Female Male                  |               |             |                           |                        |    |
| Mae                   |                |                   |                            |           |                              | 43/7 212/68   | -18.2 -10.1 | (-46.3,5.3) (-22.4,2.5)   |                        |    |
| Raoe White All Others | 377/102 132/36 | -12.6 -25.1       | (-21.4,-3.6) (-39.4,-10.1) |           | White All Others             | 190/57 65/18  | -11.4 -16.7 | (-24.2,1.7) (-38.1,5.3)   |                        |    |
| ECOG 0 1              | 205/64         | -20.4             | (-32.6,-7.8)               |           | 0 1                          |               |             | (-24.4,4.3)               |                        |    |
| Region                | 307/74         | -12.9             | (-22.3,3.3)                |           |                              | 110/37 145/38 | -16.4 -10.1 | (-33.5,1.3)               |                        |    |
| NA EU                 | 166/48 122/23  | -16.0 -16.8 -13.2 | (-30.7,-2.0) (-26.3,0.8)   |           | NA EU ROW                    | 63/16 86/27   | -19.9 -17.7 | (-40.5,1.9) (-36.5,2.0)   |                        |    |
| Smoking status        |                | -30.8             |                            |           | Never                        |               | -28.2       |                           |                        |    |
| ROW Never             | 224/67         |                   | (-28.5, -4.8)              |           |                              | 106/32        | -4.6        | (-22.2,12.9)              |                        |    |
| Former                | 310/81 120/31  | -10.6 -16.7       | (-45.0,-15.8) (-20.3,-0.8) |           | Smoking status               | 153/45 64/16  | -2.9        | (-17.5,11.5) (-48.3,-7.1) |                        |    |
| Current HPV status    | 80/26          |                   | (-36.7,4.1)                |           | Current Former               |               | -26.5       |                           |                        |    |
|                       |                | -4.9              |                            |           |                              | 37/14         |             | (-53.1,5.4)               |                        |    |
| Positive Negative     |                | -18.8             | (-22.0,12.4)               |           | HPV status Negative Positive | 52/17         | -16.1 1.2   |                           |                        |    |
|                       | 403/105 109/33 |                   | (-27.1,-10.3)              |           | Disese status                | 203/58        |             | (-23.9,26.7) (-28.5,-3.6) |                        |    |
| Disease status        |                | -15.7             | (-25.0,-6.2)               |           |                              | 167/55 84/19  | -16.8       |                           |                        |    |
|                       | 347/100        |                   |                            |           | Maastatic                    |               |             |                           |                        |    |
| Metastatic            |                |                   |                            |           |                              |               |             | (-30.6,-2.5)              |                        |    |
| Reaurrent             |                | -13.9             |                            |           | Recurrent                    |               | -2.4        |                           |                        |    |
|                       | 159/35         |                   | (-26.4,-1.0)               |           |                              |               |             | (-20.5,15.8)              |                        |    |
|                       |                |                   |                            | -40 -20 0 |                              |               |             |                           | -20 0                  | 20 |
|                       |                |                   |                            |           |                              |               |             |                           | -40                    |    |
|                       |                |                   |                            |           |                              |               |             |                           | Control <-Favor→> Mono |    |

<!-- image -->

(database cut-off 25 Feb 2019)

Figure 29: Forest plots of Best objective response (confirmed) rate based on BICR per RECIST 1.1 in the ITT, CPS≥1 and CPS≥20 populations - pembro mono vs control

## Analyses in CPS &lt;1, CPS &lt;20, and CPS ≥1 to &lt;20 Populations - pembro mono vs control

The subset analyses described in the three populations CPS &lt;1, CPS &lt;20, and CPS ≥1 to &lt;20 were requested by the CHMP, are exploratory analyses, not adequately powered to test statistical significance, and should be interpreted with caution and considered hypothesis generating.

<div style=\"page-break-after: always\"></div>

Table  45:  Key  Efficacy  Results  Pembrolizumab  Monotherapy versus  Standard  Treatment  CPS  &lt;1,  CPS  &lt;20,  and  CPS  ≥1  to  CPS  &lt;20  Population  Findings KEYNOTE-048 (FA)

|                                                                      | PD-L1 CPS <1                   | PD-L1 CPS <1       | PD-L1 CPS <20                   | PD-L1 CPS <20       | PD-L1 CPS ≥1 to CPS <20         | PD-L1 CPS ≥1 to CPS <20   |
|----------------------------------------------------------------------|--------------------------------|--------------------|---------------------------------|---------------------|---------------------------------|---------------------------|
|                                                                      | Pembrolizumab Monotherapy N=44 | Std Treatment N=45 | Pembrolizumab Monotherapy N=167 | Std Treatment N=175 | Pembrolizumab Monotherapy N=124 | Std Treatment N=133       |
| OS                                                                   |                                |                    |                                 |                     |                                 |                           |
| Number of events (%)                                                 | 40 (90.9)                      | 35 (77.8)          | 142 (85.0)                      | 153 (87.4)          | 103 (83.1)                      | 121 (91.0)                |
| Median in months(95% CI)                                             | 7.9 (4.7, 13.6)                | 11.3 (9.1, 15.9)   | 10.3 (8.4, 12.1)                | 10.3 (9.1, 12.2)    | 10.8 (9.0, 12.6)                | 10.1 (8.7, 12.1)          |
| HR (95% CI)                                                          | 1.51 (0.96, 2.37)              | 1.51 (0.96, 2.37)  | 1.01 (0.81, 1.27)               | 1.01 (0.81, 1.27)   | 0.86 (0.66, 1.12)               | 0.86 (0.66, 1.12)         |
| P-value (superiority statistic)                                      | 0.96241                        | 0.96241            | 0.54273                         | 0.54273             | 0.12827                         | 0.12827                   |
| OS rate at 12 months (95% CI)                                        | 38.6 (24.5, 52.6)              | 48.9 (33.7, 62.4)  | 42.8 (35.2, 50.2)               | 44.8 (37.3, 52.0)   | 44.0 (35.1, 52.5)               | 42.4 (33.9, 50.7)         |
| OS rate at 18 months (95% CI)                                        | 18.2 (8.5, 30.7)               | 31.1 (18.4, 44.7)  | 28.3 (21.7, 35.3)               | 28.2 (21.7, 35.0)   | 31.8 (23.7, 40.0)               | 26.5 (19.3, 34.2)         |
| OS rate at 24 months (95% CI)                                        | 15.9 (7.0, 28.1)               | 26.7 (14.9, 40.0)  | 20.5 (14.7, 26.9)               | 19.0 (13.5, 25.1)   | 22.0 (15.1, 29.6)               | 15.9 (10.3, 22.6)         |
| PFS (BICR per RECIST 1.1)                                            |                                |                    |                                 |                     |                                 |                           |
| Number of events (%)                                                 | 44 (100.0)                     | 40 (88.9)          | 156 (93.4)                      | 160 (91.4)          | 113 (91.1)                      | 123 (92.5)                |
| Median in months (95% CI)                                            | 2.1 (1.9, 2.3)                 | 6.2 (5.1, 7.6)     | 2.2 (2.1, 2.3)                  | 5.3 (4.8, 6.2)      | 2.2 (2.1, 2.9)                  | 4.9 (3.8, 6.0)            |
| HR (95% CI)b                                                         | 4.31 (2.63, 7.08)              | 4.31 (2.63, 7.08)  | 1.56 (1.25, 1.95)               | 1.56 (1.25, 1.95)   | 1.25 (0.96, 1.61)               | 1.25 (0.96, 1.61)         |
| P-value                                                              | 1.00000                        | 1.00000            | 0.99996                         | 0.99996             | 0.95093                         | 0.95093                   |
| PFS rate at 6 months (95% CI)                                        | 11.4 (4.2, 22.6)               | 56.0 (40.0, 69.2)  | 21.0 (15.2, 27.4)               | 45.8 (38.2, 53.1)   | 24.2 (17.1, 32.0)               | 41.4 (32.8, 49.7)         |
| ORR (BICR per RECIST 1.1)                                            |                                |                    |                                 |                     |                                 |                           |
| %(95% CI)                                                            | 4.5 (0.6, 15.5)                | 42.2 (27.7, 57.8)  | 12.0 (7.5, 17.9)                | 36.6 (29.4, 44.2)   | 14.5 (8.8, 22.0)                | 33.8 (25.9,42.5)          |
| DOR (Confirmed CR or PR, BICR per RECIST 1.1)                        |                                |                    |                                 |                     |                                 |                           |
| Number of responders                                                 | 2                              | 19                 | 20                              | 64                  | 18                              | 45                        |
| Median in months (range)                                             | 2.6 (2.2 - 3.0)                | 7.8 (2.0 - 38.6+)  | 15.2 (1.5+ - 38.9+)             | 5.0 (1.4+ - 38.7+)  | NR (1.5+ - 38.9+)               | 5.0 (1.4+ - 38.7+)        |
| Median time to response (range)                                      | 1.9 (1.7-2.1)                  | 2.1 (1.9-4.9)      | 2.1 (1.7-7.6)                   | 2.1 (1.3-10.4)      | 2.2 (2.0-7.6)                   | 2.1 (1.3-10.4)            |
| Number (Kaplan-Meier %) With Extended Response Duration ( ≥6 months) | 0 (NR)                         | 8 (52.7)           | 13 (68.4)                       | 20 (41.2)           | 13 (76.5)                       | 12 (36.6)                 |

Abbreviations: BICR=Blinded independent central review; CI=Confidence interval; CPS=Combined positive score; CR=Complete response; DOR=Duration of response; HR=Hazard ratio; ITT=Intention to treat; NR=Not reached; ORR=Objective response rate; OS=Overall survival; PD-L1=Programmed cell death ligand 1; PFS=Progression-free survival; PR=Partial response; RECIST 1.1=Response Evaluation Criteria in Solid Tumors Version 1.1; Std=Standard. Database cutoff date: 25-FEB-2019

<div style=\"page-break-after: always\"></div>

## Overall survival

<!-- image -->

Figure 30: Kaplan-Meier of OS - Pembro mono vs control (Final analysis)

| Overall     | N/# Events 601/453   | HR 0.83   | 95%CI (0.69, 1)   |                      |
|-------------|----------------------|-----------|-------------------|----------------------|
| PD-L.1 CPS1 |                      |           |                   |                      |
| CPS >=1     | 512/383              | 0.76      | (0.62, 0.93)      |                      |
| CPS <1      | 89/70                | 1.37      | (0.86, 2.2)       |                      |
| PD-L1 CPS20 |                      |           |                   |                      |
| CPS >=20    | 255/177              | 0.67      | (0.5, 0.9)        |                      |
| CPS<20      | 342/272              | 1.02      | (0.8, 1.29)       |                      |
| PD-L1 CPS   |                      |           |                   |                      |
| CPS<1       | 89/70                | 1.37      | (0.86, 2.2)       |                      |
| CPS>=20     | 255/177              | 0.67      | (0.5, 0.9)        |                      |
| 1<=CPS <20  | 257/206              | 0.9       | (0.68, 1.18)      |                      |
|             |                      |           |                   | S 10                 |
|             |                      |           |                   | Mono<_Favor=>Control |

(DatabaseCutoffDate:13JUN2018).

Figure 31: Forest plot of OS Hazard Ratio by PD-L1 subgroup (Pembro combo vs control) - ITT population (IA2)

<div style=\"page-break-after: always\"></div>

## Progression free survival

Figure 32: Kaplan-Meier estimates of PFS based on BICR assessment per RECIST 1.1 (primary analysis) Pembro mono vs control

<!-- image -->

Analyses in TPS &lt;50% and TPS ≥50% Populations - pembro mono vs control

Table 46: Key Efficacy Results Pembrolizumab Monotherapy versus Standard Treatment TPS &lt;50%, TPS ≥50% Population Findings - KEYNOTE-048 IA2 Analysis

49 (74.2)

11.4 (8.6, 15.8)

0.32407§

59.6)

60 (90.9)

|                                 | PD-L1 TPS <50%                  | PD-L1 TPS <50%      | PD- L1 TPS ≥50%                | PD- L1 TPS ≥50%    |
|---------------------------------|---------------------------------|---------------------|--------------------------------|--------------------|
|                                 | Pembrolizumab Monotherapy N=234 | Std Treatment N=234 | Pembrolizumab Monotherapy N=67 | Std Treatment N=66 |
| OS                              |                                 |                     |                                |                    |
| Number of events (%)            | 168 (71.8)                      | 191 (81.6)          | 45 (67.2)                      | 49 (74.2)          |
| Median in months † (95% CI)     | 11.6 (10.3, 13.8)               | 10.3 (9.1, 11.7)    | 11.7 (7.0, 17.1)               | 11.4 (8.6, 15.8)   |
| HR (95% CI) ‡                   | 0.84 (0.68, 1.03)               | 0.84 (0.68, 1.03)   | 0.91 (0.60, 1.37)              | 0.91 (0.60, 1.37)  |
| P-value (superiority statistic) | 0.04863§                        | 0.04863§            | 0.32407§                       | 0.32407§           |
| OS rate at 12 months (95% CI)   | 49.8 (43.2, 56.0)               | 43.3 (36.9, 49.6)   | 47.2 (34.8, 58.6)              | 48.2 (35.7, 59.6)  |
| PFS (BICR per RECIST 1.1)       |                                 |                     |                                |                    |
| Number of events (%)            | 213 (91.0)                      | 210 (89.7)          | 56 (83.6)                      | 60 (90.9)          |
| Median in months † (95% CI)     | 2.3 (2.2, 3.3)                  | 5.3 (4.9, 6.2)      | 3.3 (2.1, 4.7)                 | 4.9 (3.6, 6.2)     |
| HR (95% CI) ‡                   | 1.45 (1.19, 1.76)               | 1.45 (1.19, 1.76)   | 0.95 (0.65, 1.38)              | 0.95 (0.65, 1.38)  |

<div style=\"page-break-after: always\"></div>

0.39271§

53.2)

2.2 (2.0-6.0)

6 (30.0)

|                                                                       | PD-L1 TPS <50%                  | PD-L1 TPS <50%      | PD- L1 TPS ≥50%                | PD- L1 TPS ≥50%    |
|-----------------------------------------------------------------------|---------------------------------|---------------------|--------------------------------|--------------------|
|                                                                       | Pembrolizumab Monotherapy N=234 | Std Treatment N=234 | Pembrolizumab Monotherapy N=67 | Std Treatment N=66 |
| P-value                                                               | 0.99990§                        | 0.99990§            | 0.39271§                       | 0.39271§           |
| PFS rate at 12 months † (95% CI)                                      | 15.0 (10.8, 20.0)               | 14.9 (10.6, 20.0)   | 31.3 (20.7, 42.5)              | 41.5 (29.3, 53.2)  |
| ORR(BICR per RECIST 1.1)                                              |                                 |                     |                                |                    |
| (%) (95% CI)                                                          | 14.1 (9.9,19.2)                 | 37.2 (31.0,43.7)    | 26.9 (16.8,39.1)               | 31.8 (20.9,44.4)   |
| DOR (Confirmed CR or PR BICR per RECIST 1.1)                          |                                 |                     |                                |                    |
| Number of responders                                                  | 33                              | 87                  | 18                             | 21                 |
| Median in months (range)                                              | 15.2 (1.5+ - 30.6+)             | 4.5 (1.4+ - 30.6+)  | 23.4 (2.7 - 34.8+)             | 4.4 (1.2+ - 22.3+) |
| Median time to response (range)                                       | 2.1 (1.7-9.1)                   | 2.1 (1.3-6.2)       | 2.1 (1.5-8.9)                  | 2.2 (2.0-6.0)      |
| Number (Kaplan-Meier% † ) With Extended Response Duration (≥6 months) | 22 (71.7)                       | 26 (41.1)           | 14 (83.0)                      | 6 (30.0)           |

## Analysis of the first part of the OS curves

## Table  47:  Piecewise  Hazard  Rate  for  Overall  Survival  (Pembro  Mono  vs  Control)  (ITT  Population) (CPS&gt;=1)

| Month                           | Pembrolizumab (N=257)           | Pembrolizumab (N=257)           | Cetuximab + Chemotherapy(N=255)   | Cetuximab + Chemotherapy(N=255)   | HR                              |
|---------------------------------|---------------------------------|---------------------------------|-----------------------------------|-----------------------------------|---------------------------------|
|                                 | Event                           | Rate                            | Event                             | Rate                              |                                 |
| 2                               | 27                              | 0.055                           | 19                                | 0.039                             | 1.42                            |
| 4                               | 23                              | 0.053                           | 18                                | 0.040                             | 1.32                            |
| 6                               | 23                              | 0.059                           | 17                                | 0.041                             | 1.44                            |
| 7                               | 5                               | 0.028                           | 20                                | 0.105                             | 0.27                            |
| 8                               | 11                              | 0.064                           | 14                                | 0.081                             | 0.79                            |
| 9                               | 7                               | 0.043                           | 22                                | 0.141                             | 0.31                            |
| 10                              | 7                               | 0.045                           | 12                                | 0.089                             | 0.51                            |
| 12+                             | 74                              | 0.048                           | 84                                | 0.076                             | 0.63                            |
| Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018   | Database Cutoff Date: 13JUN2018   | Database Cutoff Date: 13JUN2018 |

## Table 48: Summary of Death Reasons (ITT Population-Patients Who Died Within 6 Months) (CPS&gt;=1)

54 (100.0)

16 (29.6)

8 (14.8)

1 (1.9)

2 (3.7)

|                                 | Pembrolizumab (N=73) n(%)       | Cetuximab + Chemotherapy (N=54) n(%)   |
|---------------------------------|---------------------------------|----------------------------------------|
| Subjects who died               | 73 (100.0)                      | 54 (100.0)                             |
| Progressive Disease             | 52 (71.2)                       | 27 (50.0)                              |
| Adverse Event                   | 18 (24.7)                       | 24 (44.4)                              |
| Not Related                     | 14 (19.2)                       | 16 (29.6)                              |
| Related                         | 4 (5.5)                         | 8 (14.8)                               |
| Unknown                         | 3 (4.1)                         | 3 (5.6)                                |
| Withdrawal By Subject           | 1 (1.4)                         | 1 (1.9)                                |
| Other                           | 2 (2.7)                         | 2 (3.7)                                |
| Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018        |

<div style=\"page-break-after: always\"></div>

Table  49:  Piecewise  Hazard  Rate  for  Overall  Survival  (Pembro  Mono  vs  Control)  (ITT  Population) (CPS&gt;=20)

| Month                           | Pembrolizumab(N=133)            | Pembrolizumab(N=133)            | Cetuximab + Chemotherapy(N=122)   | Cetuximab + Chemotherapy(N=122)   | HR                              |
|---------------------------------|---------------------------------|---------------------------------|-----------------------------------|-----------------------------------|---------------------------------|
|                                 | Event                           | Rate                            | Event                             | Rate                              |                                 |
| 2                               | 14                              | 0.056                           | 9                                 | 0.038                             | 1.45                            |
| 4                               | 8                               | 0.035                           | 8                                 | 0.037                             | 0.95                            |
| 6                               | 11                              | 0.052                           | 8                                 | 0.040                             | 1.31                            |
| 7                               | 4                               | 0.041                           | 10                                | 0.107                             | 0.38                            |
| 8                               | 5                               | 0.054                           | 7                                 | 0.085                             | 0.64                            |
| 9                               | 3                               | 0.034                           | 9                                 | 0.119                             | 0.28                            |
| 10                              | 2                               | 0.023                           | 6                                 | 0.089                             | 0.26                            |
| 12+                             | 35                              | 0.037                           | 38                                | 0.070                             | 0.53                            |
| Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018   | Database Cutoff Date: 13JUN2018   | Database Cutoff Date: 13JUN2018 |

## Table 50: Summary of Death Reasons (ITT Population-Patients Who Died Within 6 Months) (CPS&gt;=20)

25 (100.0)

5 (20.0)

4 (16.0)

1 (4.0)

1 (4.0)

|                                 | Pembrolizumab (N=33) n(%)       | Cetuximab + Chemotherapy (N=25) n(%)   |
|---------------------------------|---------------------------------|----------------------------------------|
| Subjects who died               | 33 (100.0)                      | 25 (100.0)                             |
| Progressive Disease             | 23 (69.7)                       | 14 (56.0)                              |
| Adverse Event                   | 9 (27.3)                        | 9 (36.0)                               |
| Not Related                     | 6 (18.2)                        | 5 (20.0)                               |
| Related                         | 3 (9.1)                         | 4 (16.0)                               |
| Unknown                         | 1 (3.0)                         | 2 (8.0)                                |
| Withdrawal By Subject           | 1 (3.0)                         | 1 (4.0)                                |
| Other                           | 0 (0.0)                         | 1 (4.0)                                |
| Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018        |

<div style=\"page-break-after: always\"></div>

| Variable Overall                    | Subgroup                                | #Events/N 128/512    |
|-------------------------------------|-----------------------------------------|----------------------|
| Age                                 | <65 -66                                 | 81/329 47/183        |
| Sex                                 | Female Male                             | 35/83 93/429         |
| Race                                | All Others Whlte                        | 31/132 96/377        |
| ECOG                                | 0 1                                     | 37/205 91/307        |
| Region                              | EU NA ROW                               | 37/166 26/122 65/224 |
| Smoking Status                      | Current Smoker Ex Smoker Never Smoker   | 16/80 72/310 38/120  |
| HPV Status                          | Negative Positive                       | 111/403 17/109       |
| PD-L1 Status (TPS50%) at Baseline   | Not Strongly Positive Strongly Positive | 94/379 34/133        |
| Disease Presentation                | Metastatic Recurrent                    | 84/347 44/159        |
| Primary Tumor Locotion Oral Cavity  | No Yes                                  | 80/357 48/155        |
| Primary Tumor Location-Larynx       | No Yes                                  | 101/402 27/110       |
| PritaryTurmur Lueutiur-Hypupharyrix | Nu Yes                                  | 113/446 15/66        |
| PrimaryTumor Location-Oropharynx    | No Yes                                  | 88/321 40/191        |
| Hemoglobin                          | Hemoglobin<median Hemoglobin>=median    | 89/249 33/252        |
|                                     | <Median >=Median                        |                      |
| Baseline Tumor Burden               |                                         | 54/258 66/213        |
|                                     | No                                      | 27/140               |
| Prior Radiation                     | Yes                                     | 101/372              |

<!-- image -->

Figure 33: Forest plot of OS Hazard ratio by subgroup factors CPS≥1 population - up to month 6

<!-- image -->

0.5

1.0

2.0

4.0

8.0

Figure 34 : Forest plot of OS Hazard ratio by subgroup factors 1≤CPS &lt;20 population - up to month 6

## Proportional Hazards (PH) assumption for OS

The PH assumption for OS was examined using both graphical (not shown) and analytical methods (see above 'ancillary analyses' in pembro combo comparison section). From both the plots and p-value from the test, there is evidence of departure from the PH assumption in all the three population (ITT, CPS≥1, CPS≥20) of pembro mono vs control.

<div style=\"page-break-after: always\"></div>

To account for the non-proportional hazards effect associated with immunotherapies, two sensitivity analyses were conducted:

- 1) Weighted  log-rank  test  with  parameter  (0,1)  (see  above  'ancillary  analyses'  in  pembro  combo comparison section)
- 2) Restricted mean survival time (RMST) method

Sensitivity analyses: Restricted mean survival times (RMST) - pembro mono vs control

Table 51: Summary of RMST of overall survival (Pembro mono vs control) - ITT population

|                                                                       | Pembrolizumab (N=301)                                                 | Pembrolizumab (N=301)                                                 | Cetuximab + Chemotherapy (N=300)                                      | Cetuximab + Chemotherapy (N=300)                                      | Difference (95% CI) vs. Control                                       |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                       | Number of Events                                                      | RMST                                                                  | Number of Events                                                      | RMST                                                                  |                                                                       |
| RMST based on 3 months of follow up                                   | 45                                                                    | 2.76                                                                  | 30                                                                    | 2.84                                                                  | -0.07 (-0.17,0.02)                                                    |
| RMST based on 6 months of follow up                                   | 90                                                                    | 5.08                                                                  | 62                                                                    | 5.37                                                                  | -0.29 (-0.54 , -.03)                                                  |
| RMST based on 9 months of follow up                                   | 120                                                                   | 7.03                                                                  | 125                                                                   | 7.43                                                                  | -0.40 (-0.83 , 0.04)                                                  |
| RMST based on 12 months of follow up                                  | 152                                                                   | 8.69                                                                  | 166                                                                   | 8.94                                                                  | -0.25 (-0.88 , 0.37)                                                  |
| RMST based on 15 months of follow up                                  | 172                                                                   | 10.0                                                                  | 191                                                                   | 10.1                                                                  | -0.07 (-0.88 , 0.73)                                                  |
| RMST based on 18 months of follow up                                  | 189                                                                   | 11.2                                                                  | 217                                                                   | 11.1                                                                  | 0.17 (-0.81 , 1.15)                                                   |
| RMST based on 24 months of follow up                                  | 206                                                                   | 13.2                                                                  | 233                                                                   | 12.4                                                                  | 0.76 (-0.56,2.08)                                                     |
| RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). | RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). | RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). | RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). | RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). | RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). |

Table 52: Summary of RMST of overall survival (Pembro mono vs control) CPS≥1

|                                                                       | Pembrolizumab (N=257)                                                 | Pembrolizumab (N=257)                                                 | Cetuximab + Chemotherapy (N=255)                                      | Cetuximab + Chemotherapy (N=255)                                      | Difference (95% CI) vs. Control                                       |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                       | Number of Events                                                      | RMST                                                                  | Number of Events                                                      | RMST                                                                  |                                                                       |
| RMST based on 3 months of follow up                                   | 36                                                                    | 2.77                                                                  | 29                                                                    | 2.82                                                                  | -0.05 (-0.16 , 0.05)                                                  |
| RMST based on 6 months of follow up                                   | 73                                                                    | 5.13                                                                  | 54                                                                    | 5.33                                                                  | -0.20 (-0.48 , 0.08)                                                  |
| RMST based on 9 months of follow up                                   | 96                                                                    | 7.14                                                                  | 110                                                                   | 7.37                                                                  | -0.23 (-0.71 , 0.24)                                                  |
| RMST based on 12 months of follow up                                  | 125                                                                   | 8.86                                                                  | 143                                                                   | 8.86                                                                  | 0.00 (-0.67,0.68)                                                     |
| RMST based on 15 months of follow up                                  | 143                                                                   | 10.3                                                                  | 164                                                                   | 10.0                                                                  | 0.26 (-0.61 ,1.14)                                                    |
| RMST based on 18 months of follow up                                  | 154                                                                   | 11.5                                                                  | 186                                                                   | 10.9                                                                  | 0.58 (-0.49 ,1.65)                                                    |
| RMST based on 24 months of follow up                                  | 171                                                                   | 13.6                                                                  | 200                                                                   | 12.2                                                                  | 1.35 (-0.08 , 2.78)                                                   |
| RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). | RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). | RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). | RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). | RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). | RMST:Restricted mean survival time. (Database Cutoff Date:13JUN2018). |

Table 53: Summary of RMST of overall survival (Pembro mono vs control) CPS≥20

|                                                                    | Pembrolizumab (N=133)                                              | Pembrolizumab (N=133)                                              | Cetuximab + Chemotherapy (N=122)                                   | Cetuximab + Chemotherapy (N=122)                                   | Difference (95% CI)                                                |
|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                                                    | Number of Events                                                   | RMST                                                               | Number of Events                                                   | RMST                                                               |                                                                    |
| RMST based on 3 months of follow up                                | 16                                                                 | 2.78                                                               | 13                                                                 | 2.83                                                               | -0.05 (-0.20 ,0.10)                                                |
| RMST based on 6 months of follow up                                | 33                                                                 | 5.22                                                               | 25                                                                 | 5.35                                                               | -0.13 (-0.52 ,0.26)                                                |
| RMST based on 9 months of follow up                                | 45                                                                 | 7.33                                                               | 51                                                                 | 7.41                                                               | -0.09 (-0.75 ,0.58)                                                |
| RMST based on 12 months of follow up                               | 57                                                                 | 9.22                                                               | 67                                                                 | 8.95                                                               | 0.27 (-0.68 ,1.22)                                                 |
| RMST based on 15 months of follow up                               | 66                                                                 | 10.8                                                               | 79                                                                 | 10.1                                                               | 0.70 (-0.53,1.93)                                                  |
| RMST based on 18 months of follow up                               | 71                                                                 | 12.2                                                               | 89                                                                 | 11.1                                                               | 1.20 (-0.31 ,2.71)                                                 |
| RMST based on 24 months of follow up                               | 79                                                                 | 14.8                                                               | 93                                                                 | 12.4                                                               | 2.34 (0.29 ,4.39)                                                  |
| RMST:Restrictedmeansurvivaltime. (Database Cutoff Date:13JUN2018). | RMST:Restrictedmeansurvivaltime. (Database Cutoff Date:13JUN2018). | RMST:Restrictedmeansurvivaltime. (Database Cutoff Date:13JUN2018). | RMST:Restrictedmeansurvivaltime. (Database Cutoff Date:13JUN2018). | RMST:Restrictedmeansurvivaltime. (Database Cutoff Date:13JUN2018). | RMST:Restrictedmeansurvivaltime. (Database Cutoff Date:13JUN2018). |

Subsequent anticancer therapies

Table  54:  Subjects  Who  Received  Subsequent  Anti-Cancer  Therapy  (Pembro  Mono  vs  Control)  (ITT Population)

|                                                      | Pembrolizumab (N=301)   | Cetuximab + Chemotherapy (N=300)   |
|------------------------------------------------------|-------------------------|------------------------------------|
| Subjects Who Received New Anti-Cancer Therapy        | 140 (46.5)              | 156 (52.0)                         |
| Subjects Who Did Not Receive New Anti-Cancer Therapy | 150 (49.8)              | 129 (43.0)                         |
| Unknown (Withdrew Consent)                           | 11 (3.7)                | 15 (5.0)                           |

<div style=\"page-break-after: always\"></div>

## (Database Cutoff Date: 13JUN2018).

A third or higher lines of therapy was administered to a similar rate of subjects in both arms: 56 (18.6%) vs 54 (18%) in pembro mono vs control.

The  most  frequently  used  2L  therapy  was  carboplatin  in  21.3%  of  pembrolizumab  monotherapy participants, and paclitaxel in 13.0% of standard treatment participants, and the most frequently used 3L therapy being paclitaxel in 8.0% of pembrolizumab monotherapy participants, and nivolumab in 5.7% of standard treatment participants.

Table 55: subjects who received subsequent checkpoint immunotherapy (pembro mono vs control) ITT population

|                                             | Pembrolizumab (N=301)   | Cetuximab + Chemotherapy (N=300)   |
|---------------------------------------------|-------------------------|------------------------------------|
| Subjects Who Received Subsequent Checkpoint | 13 (4.3)                | 73 (24.3)                          |
| Immunotherapy SubjectsWho Did Not Receive   | 276 (91.7)              | 211 (70.3)                         |
| Subsequent Checkpoint Immunotherapy         |                         | 16 (5.3)                           |
| Unknown (Withdrew Consent)                  | 12 (4.0)                |                                    |
| Database Cutoff Date: 13JUN2018             |                         |                                    |

Updated data: At the database cut-off of 25-FEB-2019, overall 148 (49.2%) and 159 (53%) patients have received a subsequent anticancer therapy in pembro mono and control arm, respectively.

Figure 35: Kaplan-Meier estimates of PFS2 based on investigator assessment (pembro mono vs control) CPS ≥ 1

<!-- image -->

Table 56: Analysis of PFS2 based on investigator assessment (Pembro mono vs control) - CPS ≥ 1

| Treatment                                      | N                                              | Number of Events (%)   | Person- Months   | EventRate/ 100 Person- Months (%)   | Median PFS2 ↑ (Months) (95% CI)   | PFS2 Rate at Months 6 in % I (95% CI)   |
|------------------------------------------------|------------------------------------------------|------------------------|------------------|-------------------------------------|-----------------------------------|-----------------------------------------|
| Pembrolizumab                                  | 257                                            | 197 (76.7)             | 2965.0           | 6.6                                 | 9.4 (8.3, 10.3)                   | 66.4 (60.2, 71.8)                       |
| Cetuximab + Chemotherapy                       | 255                                            | 226 (88.6)             | 2665.6           | 8.5                                 | 8.9 (8.3, 9.8)                    | 71.3 (65.3, 76.4)                       |
| Pairwi se Comparisons                          |                                                |                        |                  |                                     | Hazard Ratio+(95% CI)             | p-Value                                 |
| Primary Pembrolizumabvs.Cetuximab+Chemotherapy | Primary Pembrolizumabvs.Cetuximab+Chemotherapy |                        |                  |                                     | 0.81 (0.67, 0.98)                 | 0.01702                                 |

<div style=\"page-break-after: always\"></div>

## Summary of main study

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 57: Summary of Efficacy for trial KEYNOTE-048

<!-- image -->

| Title: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma   | Title: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma   | Title: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma   | Title: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma                                                                                         | Title: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma                                                                                         | Title: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                   | P048V02MK3475 (IND: 122,325 EudraCT: 2014-003698-41)                                                                                               | P048V02MK3475 (IND: 122,325 EudraCT: 2014-003698-41)                                                                                               | P048V02MK3475 (IND: 122,325 EudraCT: 2014-003698-41)                                                                                                                                                                                     | P048V02MK3475 (IND: 122,325 EudraCT: 2014-003698-41)                                                                                                                                                                                     | P048V02MK3475 (IND: 122,325 EudraCT: 2014-003698-41)                                                                                                                                                                                     |
| Design                                                                                                                                             | Phase 3, randomized, multi-center, open-label, 3 arms                                                                                              | Phase 3, randomized, multi-center, open-label, 3 arms                                                                                              | Phase 3, randomized, multi-center, open-label, 3 arms                                                                                                                                                                                    | Phase 3, randomized, multi-center, open-label, 3 arms                                                                                                                                                                                    | Phase 3, randomized, multi-center, open-label, 3 arms                                                                                                                                                                                    |
| Design                                                                                                                                             | Duration of main phase:                                                                                                                            | Duration of main phase:                                                                                                                            | enrollment started on 1 Apr 2015; study ongoing                                                                                                                                                                                          | enrollment started on 1 Apr 2015; study ongoing                                                                                                                                                                                          | enrollment started on 1 Apr 2015; study ongoing                                                                                                                                                                                          |
| Design                                                                                                                                             | Duration of Run-in phase:                                                                                                                          | Duration of Run-in phase:                                                                                                                          | not applicable                                                                                                                                                                                                                           | not applicable                                                                                                                                                                                                                           | not applicable                                                                                                                                                                                                                           |
| Design                                                                                                                                             | Duration of Extension phase:                                                                                                                       | Duration of Extension phase:                                                                                                                       | not applicable                                                                                                                                                                                                                           | not applicable                                                                                                                                                                                                                           | not applicable                                                                                                                                                                                                                           |
| Hypothesis                                                                                                                                         | Superiority and Non-inferiority                                                                                                                    | Superiority and Non-inferiority                                                                                                                    | Superiority and Non-inferiority                                                                                                                                                                                                          | Superiority and Non-inferiority                                                                                                                                                                                                          | Superiority and Non-inferiority                                                                                                                                                                                                          |
| Treatments groups                                                                                                                                  | Pembro combo                                                                                                                                       | Pembro combo                                                                                                                                       | Cisplatin 100 mg/m2 Q3W OR carboplatin AUC 5 Q3W for 6 cycles + 5-FU 1000 mg/m2/day D1-4 Q3W for 6 cycles + Pembrolizumab 200 mg Q3W until progression 301 pts randomized                                                                | Cisplatin 100 mg/m2 Q3W OR carboplatin AUC 5 Q3W for 6 cycles + 5-FU 1000 mg/m2/day D1-4 Q3W for 6 cycles + Pembrolizumab 200 mg Q3W until progression 301 pts randomized                                                                | Cisplatin 100 mg/m2 Q3W OR carboplatin AUC 5 Q3W for 6 cycles + 5-FU 1000 mg/m2/day D1-4 Q3W for 6 cycles + Pembrolizumab 200 mg Q3W until progression 301 pts randomized                                                                |
| Treatments groups                                                                                                                                  | Pembro mono                                                                                                                                        | Pembro mono                                                                                                                                        | Pembrolizumab 200 mg Q3W until progression 281 pts randomized                                                                                                                                                                            | Pembrolizumab 200 mg Q3W until progression 281 pts randomized                                                                                                                                                                            | Pembrolizumab 200 mg Q3W until progression 281 pts randomized                                                                                                                                                                            |
| Treatments groups                                                                                                                                  | Control                                                                                                                                            | Control                                                                                                                                            | Cisplatin 100 mg/m2 Q3W OR carboplatin AUC 5 Q3W for 6 cycles + 5-FU 1000 mg/m2/day D1-4 Q3W for 6 cycles + Cetuximab 400 mg/m2 on D1 (loading dose) followed by 250 mg/m2 weekly until progression (EXTREME regimen) 300 pts randomized | Cisplatin 100 mg/m2 Q3W OR carboplatin AUC 5 Q3W for 6 cycles + 5-FU 1000 mg/m2/day D1-4 Q3W for 6 cycles + Cetuximab 400 mg/m2 on D1 (loading dose) followed by 250 mg/m2 weekly until progression (EXTREME regimen) 300 pts randomized | Cisplatin 100 mg/m2 Q3W OR carboplatin AUC 5 Q3W for 6 cycles + 5-FU 1000 mg/m2/day D1-4 Q3W for 6 cycles + Cetuximab 400 mg/m2 on D1 (loading dose) followed by 250 mg/m2 weekly until progression (EXTREME regimen) 300 pts randomized |
| Endpoints and definitions                                                                                                                          | Dual Primary                                                                                                                                       | OS (CPS≥20, CPS≥1,ITT)                                                                                                                             | Time from randomization to death due to any cause                                                                                                                                                                                        | Time from randomization to death due to any cause                                                                                                                                                                                        | Time from randomization to death due to any cause                                                                                                                                                                                        |
| Endpoints and definitions                                                                                                                          | Dual Primary                                                                                                                                       | PFS (CPS≥20, CPS≥1,ITT)                                                                                                                            | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause                                                                                                                                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause                                                                                                                                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause                                                                                                                                             |
| Endpoints and definitions                                                                                                                          | Secondary                                                                                                                                          | ORR (CPS≥20, CPS≥1,ITT)                                                                                                                            | Proportion of participants who had confirmed CR or PR (per RECIST 1.1 based on BICR)                                                                                                                                                     | Proportion of participants who had confirmed CR or PR (per RECIST 1.1 based on BICR)                                                                                                                                                     | Proportion of participants who had confirmed CR or PR (per RECIST 1.1 based on BICR)                                                                                                                                                     |
| Endpoints and definitions                                                                                                                          | Secondary                                                                                                                                          | QoL, PRO                                                                                                                                           | EORTC QLQ-C30 global health status/quality of life scores at baseline and week 15. Time from baseline to first onset of patient reported outcomes (PRO) deterioration with confirmation (true deterioration).                            | EORTC QLQ-C30 global health status/quality of life scores at baseline and week 15. Time from baseline to first onset of patient reported outcomes (PRO) deterioration with confirmation (true deterioration).                            | EORTC QLQ-C30 global health status/quality of life scores at baseline and week 15. Time from baseline to first onset of patient reported outcomes (PRO) deterioration with confirmation (true deterioration).                            |
| Endpoints and definitions                                                                                                                          | Exploratory                                                                                                                                        | DOR (CPS≥20, CPS≥1,ITT)                                                                                                                            | Time from first documented evidence of CR or PR until PD (per RECIST 1.1 based on BICR) or death                                                                                                                                         | Time from first documented evidence of CR or PR until PD (per RECIST 1.1 based on BICR) or death                                                                                                                                         | Time from first documented evidence of CR or PR until PD (per RECIST 1.1 based on BICR) or death                                                                                                                                         |
| Data cut-off Database lock                                                                                                                         | 25 Feb 2019 (FA) 25 Mar 2019 (FA)                                                                                                                  | 25 Feb 2019 (FA) 25 Mar 2019 (FA)                                                                                                                  | 25 Feb 2019 (FA) 25 Mar 2019 (FA)                                                                                                                                                                                                        | 25 Feb 2019 (FA) 25 Mar 2019 (FA)                                                                                                                                                                                                        | 25 Feb 2019 (FA) 25 Mar 2019 (FA)                                                                                                                                                                                                        |
| Results and Analysis                                                                                                                               | Results and Analysis                                                                                                                               | Results and Analysis                                                                                                                               | Results and Analysis                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                     |
| Analysis description                                                                                                                               | Primary Analysis                                                                                                                                   | Primary Analysis                                                                                                                                   | Primary Analysis                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                         |
| Analysis population and time point description                                                                                                     | Intent to treat                                                                                                                                    | Intent to treat                                                                                                                                    | Intent to treat                                                                                                                                                                                                                          | Intent to treat                                                                                                                                                                                                                          | Intent to treat                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability                                                                                                    | Treatment group Pembrolizumab                                                                                                                      | Treatment group Pembrolizumab                                                                                                                      | Treatment group Pembrolizumab                                                                                                                                                                                                            | Pembrolizumab + Chemo                                                                                                                                                                                                                    | SOC (vs. Mono) (vs. Combo)                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                    | ITT - Number of subject 301                                                                                                                        | ITT - Number of subject 301                                                                                                                        | ITT - Number of subject 301                                                                                                                                                                                                              | 281                                                                                                                                                                                                                                      | 300 (vs. Mono) 287 (vs. Combo)                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability                                                                                                    | OS number of events (%) 237 (78.7%)                                                                                                                | OS number of events (%) 237 (78.7%)                                                                                                                | OS number of events (%) 237 (78.7%)                                                                                                                                                                                                      | 213 (75.8%)                                                                                                                                                                                                                              | 264 (88%) 247 (88.8%)                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability                                                                                                    | OS (Median (months)) 11.5                                                                                                                          | OS (Median (months)) 11.5                                                                                                                          | OS (Median (months)) 11.5                                                                                                                                                                                                                | 13                                                                                                                                                                                                                                       | 10.7                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                    | 95%-CI (10.3, 13.4)                                                                                                                                | 95%-CI (10.3, 13.4)                                                                                                                                | 95%-CI (10.3, 13.4)                                                                                                                                                                                                                      | (10.9, 14.7)                                                                                                                                                                                                                             | (9.3, 11.7)                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability                                                                                                    | PFS (Median (months)) 2.3                                                                                                                          | PFS (Median (months)) 2.3                                                                                                                          | PFS (Median (months)) 2.3                                                                                                                                                                                                                | 4.9                                                                                                                                                                                                                                      | 5.1                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability                                                                                                    | 95%-CI (2.2, 3.3)                                                                                                                                  | 95%-CI (2.2, 3.3)                                                                                                                                  | 95%-CI (2.2, 3.3)                                                                                                                                                                                                                        | (4.7, 6.1)                                                                                                                                                                                                                               | (4.9, 6.1)                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                    | PD- L1 CPS ≥ 1 257                                                                                                                                 | PD- L1 CPS ≥ 1 257                                                                                                                                 | PD- L1 CPS ≥ 1 257                                                                                                                                                                                                                       | 242                                                                                                                                                                                                                                      | 255 (vs. Mono) 235 (vs. Combo)                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                                                                                            | OS number of                                 | OS number of                                 | 197 (76.7%)                            | 197 (76.7%)                                | 177 (73.1%) 229 (89.8%)                  |
|--------------------------------------------------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------|--------------------------------------------|------------------------------------------|
|                                                                                            | events (%) OS (Median 12.3                   | events (%) OS (Median 12.3                   | 13.6                                   | 13.6                                       | 213 (90.6%) 10.3 10.4                    |
|                                                                                            | (months)) 95%-CI (10.8,                      | (months)) 95%-CI (10.8,                      | 14.3) (10.7, 15.5)                     | 14.3) (10.7, 15.5)                         | (9.0, 11.5) (9.1, 11.7)                  |
|                                                                                            | PFS (Median 3.2                              | PFS (Median 3.2                              | 5.1                                    | 5.1                                        | 5.0                                      |
|                                                                                            | (months)) 95%-CI (2.2,                       | (months)) 95%-CI (2.2,                       | (4.7, 6.2)                             | (4.7, 6.2)                                 | (4.8, 6.0)                               |
|                                                                                            | 3.4) PD- L1 CPS ≥ 20 133                     | 3.4) PD- L1 CPS ≥ 20 133                     | 126                                    | 126                                        | 122 (vs. Mono) 110 (vs. Combo)           |
|                                                                                            | OS number of events (%) 94 (70.7%)           | OS number of events (%) 94 (70.7%)           | 84 (66.7%)                             | 84 (66.7%)                                 | 108 (88.5%) 98 (89.1%)                   |
|                                                                                            | OS (Median 14.8                              | OS (Median 14.8                              | 14.7                                   | 14.7                                       | 10.7 11.0                                |
|                                                                                            | (months)) 95%-CI (11.5,                      | (months)) 95%-CI (11.5,                      | (10.3, 19.3)                           | (10.3, 19.3)                               | (8.8, 12.8) (9.2, 13.0)                  |
|                                                                                            | PFS (Median (months)) 3.4                    | PFS (Median (months)) 3.4                    | 5.8                                    | 5.8                                        | 5.3                                      |
| Effect estimate per comparison                                                             | 95%-CI (3.2, 3.8) OS all subjects Comparison | 95%-CI (3.2, 3.8) OS all subjects Comparison | (4.7, 7.6) groups Pembrolizumab        | vs. SOC                                    | (4.8, 6.3) Pembrolizumab + Chemo vs. SOC |
|                                                                                            |                                              |                                              |                                        |                                            | 0.72                                     |
|                                                                                            | HR                                           | HR                                           | 0.83                                   | 0.83                                       |                                          |
|                                                                                            |                                              |                                              | (0.70, 0.99)                           | (0.70, 0.99)                               | (0.60, 0.87)                             |
|                                                                                            | (superiority) OS PD -L1 CPS ≥ 1 HR           | (superiority) OS PD -L1 CPS ≥ 1 HR           |                                        | (one-sided, 0.74 (0.61, 0.90) 0.00133 (H8) | H10) 0.65 (0.53, 0.80) 0.00002 (H2)      |
|                                                                                            | P-value OS PD -L1 CPS ≥ 20 HR                | P-value OS PD -L1 CPS ≥ 20 HR                |                                        | 0.58                                       | 0.60 (0.45, 0.82) 0.00044 (H11)          |
|                                                                                            | PFS all subjects HR                          | PFS all subjects HR                          | (0.44, 0.78) 0.00010 (H7) 1.29         | (0.44, 0.78) 0.00010 (H7) 1.29             | 0.93 (0.78, 1.11) 0.21211                |
|                                                                                            | 95%-CI P-value PFS PD-L1 CPS ≥ 1 HR 95%-CI   | 95%-CI P-value PFS PD-L1 CPS ≥ 1 HR 95%-CI   | (1.09, 1.53) 0.99830 1.13 (0.94, 1.36) | (1.09, 1.53) 0.99830 1.13 (0.94, 1.36)     | 0.84 (0.69, 1.02)                        |
|                                                                                            | P-value                                      | P-value                                      | 0.89580                                | 0.89580                                    | 0.03697                                  |
|                                                                                            | PFS PD-L1 CPS ≥ 20 HR 95%-CI P-value         | PFS PD-L1 CPS ≥ 20 HR 95%-CI P-value         | 0.99 (0.76, 1.29) 0.46791              | 0.99 (0.76, 1.29) 0.46791                  | 0.76                                     |
|                                                                                            |                                              |                                              |                                        |                                            | (0.58, 1.01) 0.02951                     |
| Notes                                                                                      | * Hypothesis rejected                        | * Hypothesis rejected                        | * Hypothesis rejected                  | * Hypothesis rejected                      | * Hypothesis rejected                    |
| Analysis description Analysis population and time point description Descriptive statistics | Secondary Analyses Intent to treat           | Secondary Analyses Intent to treat           | Secondary Analyses Intent to treat     | Secondary Analyses Intent to treat         | Secondary Analyses Intent to treat       |
| and estimate variability                                                                   | Treatment group Pembrolizumab                | Treatment group Pembrolizumab                | Pembrolizumab + Chemo                  | Pembrolizumab + Chemo                      | SOC (vs. Mono) (vs. Combo)               |
|                                                                                            | Number of subject 301                        | Number of subject 301                        | 281                                    | 281                                        | 300 (vs. Mono) 278 (vs. Combo)           |
|                                                                                            | ORR 16.9                                     | ORR 16.9                                     | 35.6                                   | 35.6                                       | 36.3                                     |
|                                                                                            | 95%-CI (12.9, 21.7)                          | 95%-CI (12.9, 21.7)                          | (30.0, 41.5)                           | (30.0, 41.5)                               | (30.7, 41.7)                             |
|                                                                                            | PD- L1 CPS ≥ 1 257                           | PD- L1 CPS ≥ 1 257                           | 242                                    | 242                                        | 255 (vs. Mono) 235 (vs. Combo)           |
|                                                                                            | ORR 19.1                                     | ORR 19.1                                     | 36.4                                   | 36.4                                       | 34.9 35.7                                |
|                                                                                            | 95%-CI (14.5, 24.4)                          | 95%-CI (14.5, 24.4)                          | (30.3, 42.8)                           | (30.3, 42.8)                               | (29.1, 41.1) (29.6, 42.2)                |
|                                                                                            |                                              |                                              | 126                                    | 126                                        | 122 (vs. Mono) 110 (vs.                  |
|                                                                                            | PD- L1 CPS ≥ 20 133                          | PD- L1 CPS ≥ 20 133                          |                                        |                                            | Combo)                                   |
|                                                                                            | ORR 23.3                                     | ORR 23.3                                     | 42.9                                   | 42.9                                       | 36.1 38.2                                |
|                                                                                            | 95%-CI                                       | 95%-CI                                       |                                        | (34.1, 52.0)                               | (27.6, 45.3) (29.1, 47.9)                |
| Effect estimate per comparison                                                             | ORR                                          | Comparison groups                            | Comparison groups                      | Pembrolizumab vs. SOC                      | Pembrolizumab + Chemo vs. SOC            |
|                                                                                            |                                              |                                              |                                        | -19.0                                      | -0.8                                     |
|                                                                                            |                                              | Difference 95%-CI                            | Difference 95%-CI                      | (-25.8, -12.1)                             | (-8.7, 7.2)                              |

<div style=\"page-break-after: always\"></div>

|       |                                                                                                                                                                                                                                                                                                  | P-value                                                                                                                                                                                                                                                                                          | 1.0000                                                                                                                                                                                                                                                                                           | 0.5740                                                                                                                                                                                                                                                                                           |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       | ORR, PD-L1 CPS ≥ 1                                                                                                                                                                                                                                                                               | Difference                                                                                                                                                                                                                                                                                       | -15.9                                                                                                                                                                                                                                                                                            | 0.5                                                                                                                                                                                                                                                                                              |
|       |                                                                                                                                                                                                                                                                                                  | 95%-CI                                                                                                                                                                                                                                                                                           | (-23.4, -8.3)                                                                                                                                                                                                                                                                                    | (-8.2, 9.1)                                                                                                                                                                                                                                                                                      |
|       |                                                                                                                                                                                                                                                                                                  | P-value                                                                                                                                                                                                                                                                                          | 1.0000                                                                                                                                                                                                                                                                                           | 0.4586                                                                                                                                                                                                                                                                                           |
|       | ORR, PD-L1                                                                                                                                                                                                                                                                                       | Difference                                                                                                                                                                                                                                                                                       | -12.8                                                                                                                                                                                                                                                                                            | 5.0                                                                                                                                                                                                                                                                                              |
|       | CPS ≥ 20                                                                                                                                                                                                                                                                                         | 95%-CI                                                                                                                                                                                                                                                                                           | (23.8, -1.5)                                                                                                                                                                                                                                                                                     | (-7.5, 17.4)                                                                                                                                                                                                                                                                                     |
|       |                                                                                                                                                                                                                                                                                                  | P-value                                                                                                                                                                                                                                                                                          | 0.9869                                                                                                                                                                                                                                                                                           | 0.2161                                                                                                                                                                                                                                                                                           |
| Notes | The study was designed to compare pembro combo to standard treatment, and to compare pembro mono to standard treatment. No comparison was conducted between pembro mono and pembro combo groups. 22 subjects enrolled in the control arm during an enrollment pause in the pembro combo arm were | The study was designed to compare pembro combo to standard treatment, and to compare pembro mono to standard treatment. No comparison was conducted between pembro mono and pembro combo groups. 22 subjects enrolled in the control arm during an enrollment pause in the pembro combo arm were | The study was designed to compare pembro combo to standard treatment, and to compare pembro mono to standard treatment. No comparison was conducted between pembro mono and pembro combo groups. 22 subjects enrolled in the control arm during an enrollment pause in the pembro combo arm were | The study was designed to compare pembro combo to standard treatment, and to compare pembro mono to standard treatment. No comparison was conducted between pembro mono and pembro combo groups. 22 subjects enrolled in the control arm during an enrollment pause in the pembro combo arm were |

## Clinical studies in special populations

## Age

## Table 58: efficacy results according to age (ITT population) KN-048 - Final analysis (data cut-off 25-FEB-2019)

| Age                     | <65 y                   | 65-74 y                 | 75-84 y               |
|-------------------------|-------------------------|-------------------------|-----------------------|
| Pembro combo vs control | Pembro combo vs control | Pembro combo vs control |                       |
| Nb patients (inv,cont)  | 180, 181                | 86, 71                  | 14, 26                |
| OS (HR) (months)        | 0.84 mOS 11.7 vs 10.7   | 0.53 mOS 14.6 vs 9.3    | 0.52 mOS 14.3 vs 10.7 |
| PFS (HR)                | 1.00                    | 0.65                    | 1.03                  |
| ORR                     | 34.4% vs 39.2%          | 40.7% vs 32.4%          | 21.4% vs 26.9%        |
| Pembro mono vs control  | Pembro mono vs control  | Pembro mono vs control  |                       |
| Nb patients (inv,cont)  | 190, 195                | 95, 77                  | 15, 28                |
| OS (HR) (months)        | 0.81 mOS 11.8 vs 10.7   | 0.76 mOS 11.3 vs 10.1   | 1.30 mOS 10.8 vs 12.1 |
| PFS (HR)                | 1.19                    | 1.34                    | 2.45                  |
| ORR                     | 16.8% vs 38.5%          | 17.9% vs 32.5%          | 13.3% vs 28.6%        |

Inv = investigational arm. Cont = control arm.  (table made by assessor)

## Gender

Table 59: Key Efficacy Results Males Versus Females OS Findings for Pembrolizumab - Pembrolizumab Monotherapy Versus Standard Treatment ITT, CPS ≥1, and CPS ≥20 Population Findings - KEYNOTE-048 IA2 Analysis

0.80 (0.38, 1.70)

0.35 (0.13, 0.94)

0.63 (0.46, 0.88)

0.55 (0.39, 0.79)

|                                                                                                                | ITT (All Participants)                                                                                         | ITT (All Participants)                                                                                         | PD- L1 CPS ≥1                                                                                                  | PD- L1 CPS ≥1                                                                                                  | PD- L1 CPS ≥20                                                                                                 | PD- L1 CPS ≥20                                                                                                 |
|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
|                                                                                                                | Pembrolizumab Plus Chemotherapy N=281                                                                          | Std Treatment N=278                                                                                            | Pembrolizumab Plus Chemotherapy N=242                                                                          | Std Treatment N=235                                                                                            | Pembrolizumab Plus Chemotherapy N=126                                                                          | Std Treatment N=110                                                                                            |
| OS Results in Females Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses | OS Results in Females Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses | OS Results in Females Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses | OS Results in Females Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses | OS Results in Females Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses | OS Results in Females Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses | OS Results in Females Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses |
| HR (95% CI) Primary analysis                                                                                   | 0.93 (0.58, 1.49)                                                                                              | 0.93 (0.58, 1.49)                                                                                              | 0.89 (0.54, 1.46)                                                                                              | 0.89 (0.54, 1.46)                                                                                              | 0.80 (0.38, 1.70)                                                                                              | 0.80 (0.38, 1.70)                                                                                              |
| HR (95% CI) Multivariable analysis                                                                             | 0.71 (0.41, 1.22)                                                                                              | 0.71 (0.41, 1.22)                                                                                              | 0.66 (0.37, 1.17)                                                                                              | 0.66 (0.37, 1.17)                                                                                              | 0.35 (0.13, 0.94)                                                                                              | 0.35 (0.13, 0.94)                                                                                              |
| OS Results in Males Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses   | OS Results in Males Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses   | OS Results in Males Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses   | OS Results in Males Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses   | OS Results in Males Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses   | OS Results in Males Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses   | OS Results in Males Pembrolizumab Monotherapy versus Standard Treatment Primary Analysis Versus MVA Analyses   |
| HR (95% CI) Primary analysis                                                                                   | 0.81 (0.67, 1.00)                                                                                              | 0.81 (0.67, 1.00)                                                                                              | 0.74 (0.59, 0.92)                                                                                              | 0.74 (0.59, 0.92)                                                                                              | 0.63 (0.46, 0.88)                                                                                              | 0.63 (0.46, 0.88)                                                                                              |
| HR (95% CI) Multivariable analysis                                                                             | 0.82 (0.67, 1.01)                                                                                              | 0.82 (0.67, 1.01)                                                                                              | 0.73 (0.58, 0.92)                                                                                              | 0.73 (0.58, 0.92)                                                                                              | 0.55 (0.39, 0.79)                                                                                              | 0.55 (0.39, 0.79)                                                                                              |

Abbreviations: CI=Confidence interval; CPS=Combined positive score; HR=Hazard ratio; IA2=Interim analysis 2; ITT=Intention to treat; MVA=Multivariate analyses; OS=Overall survival; PD-L1=Programmed cell death ligand 1; Std=Standard. Database cutoff date: 13-JUN-2018

## Recurrent disease

<div style=\"page-break-after: always\"></div>

Table  60:  Key  Efficacy  Results  OS  Findings  for  Pembrolizumab  Plus  Chemotherapy  versus  Standard Treatment in Recurrent Disease in ITT, CPS ≥1, and CPS ≥20 Populations - KEYNOTE-048 Final Analysis

| Popul ation   | N (Combo/ SOC)   | Number of Events   | Number of Events   | Median in months (95% CI)   | Median in months (95% CI)   | HR (95% CI)       | P-value   | OS rate at 12 months (95% CI)   | OS rate at 12 months (95% CI)   | OS rate at 24 months (95% CI)   | OS rate at 24 months (95% CI)   |
|---------------|------------------|--------------------|--------------------|-----------------------------|-----------------------------|-------------------|-----------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|               | N (Combo/ SOC)   | Pembro Plus Chemo  | Std Treatment      | Pembro Plus Chemo           | Std Treatment               |                   |           | Pembro Plus Chemo               | Std Treatment                   | Pembro Plus Chemo               | Std Treatment                   |
| ITT           | 76/88            | 64 (84.2)          | 78 (88.6)          | 13.0 (8.5, 14.4)            | 11.1 (9.2, 13.4)            | 0.90 (0.65, 1.25) | 0.26311   | 51.3 (39.6, 61.8)               | 48.9 (38.1, 58.8)               | 21.1 (12.7, 30.8)               | 17.0 (10.1, 25.6)               |
| CPS≥1         | 65/78            | 54 (83.1)          | 71 (91.0)          | 13.4 (8.5, 15.3)            | 11.0 (8.8, 13.0)            | 0.80 (0.56, 1.14) | 0.10913   | 53.8 (41.0, 65.0)               | 47.4 (36.1, 58.0)               | 21.5 (12.5, 32.1                | 15.4 (8.4, 24.2)                |
| CPS ≥20       | 38/40            | 28 (73.7)          | 36 (90.0)          | 14.5 (7.9, 21.0)            | 11.1 (8.8, 13.6)            | 0.66 (0.40, 1.09) | 0.05168   | 60.5 (43.3, 74.0)               | 47.5 (31.6, 61.8)               | 28.9 (15.7, 43.6)               | 15.0 (6.1, 27.6)                |

Abbreviations: CI=Confidence interval; COMBO=combination therapy; CPS=Combined positive score; HR=Hazard ratio; ITT=Intention to treat; N=number of participants; OS=Overall survival; SOC=standard of care.  Database cutoff date: 25-FEB-2019

Table 61: Key Efficacy Results OS Findings for Pembrolizumab Monotherapy versus Standard Treatment for Recurrent Disease in ITT, CPS≥1, CPS≥20 Populations - KEYNOTE-048 Final Analysis

| Popu lation   | N (Mono/ SOC)   | Number of Events   | Number of Events   | Median in months (95% CI)   | Median in months (95% CI)   | HR (95% CI)       | P-value   | OS rate at 12 months (95% CI)   | OS rate at 12 months (95% CI)   | OS rate at 24 months (95% CI)   | OS rate at 24 months (95% CI)   |
|---------------|-----------------|--------------------|--------------------|-----------------------------|-----------------------------|-------------------|-----------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Popu lation   | N (Mono/ SOC)   | Pembro Mono        | Std Treatment      | Pembro Mono                 | Std Treatment               | HR (95% CI)       | P-value   | Pembro Mono                     | Std Treatment                   | Pembro Mono                     | Std Treatment                   |
| ITT           | 82/94           | 70 (85.4)          | 81 (86.2)          | 11.5 (7.8, 13.3)            | 12.1 (9.8, 14.1)            | 1.09 (0.79, 1.50) | 0.69191   | 46.3 (35.3, 56.7)               | 52.1 (41.6, 61.6)               | 18.3 (10.8, 27.3)               | 20.2 (12.8, 28.8)               |
| CPS≥1         | 75/84           | 64 (85.3)          | 74 (88.1)          | 11.5 (7.8, 13.0)            | 12.1 (9.2, 13.9)            | 1.03 (0.74, 1.44) | 0.57175   | 45.3 (33.9, 56.1)               | 51.2 (40.1, 61.2)               | 18.7 (10.8, 28.2)               | 19.0 (11.5, 28.1)               |
| CPS ≥20       | 42/42           | 33 (78.6)          | 37 (88.1)          | 12.6 (8.8, 16.0)            | 11.7 (8.8, 14.1)            | 0.78 (0.49, 1.25) | 0.14718   | 52.4 (36.4, 66.1)               | 50.0 (34.2, 63.9)               | 26.2 (14.1, 40.0)               | 16.7 (7.3, 29.3)                |

Abbreviations: CI=Confidence interval; MONO= monotherapy; CPS=Combined positive score; HR=Hazard ratio; ITT=Intention to treat; N=number of participants; OS=Overall survival; SOC=standard of care.  Database cutoff date: 25-FEB-2019

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

KEYNOTE-048 is an ongoing, Phase 3, randomized, multicenter, active-controlled, 3 arms, open-label clinical study in first line patients with R/M HNSCC considered incurable by local therapies.

The eligibility criteria of the study are considered acceptable, and the enrolled population appears overall representative of real life, although data are restricted to patients with good performance status (ECOG 0-1).

Patients were randomized 1:1:1 to three arms: pembro combo (pembrolizumab + cisplatin/carboplatin + 5FU), pembro mono (pembrolizumab) or standard treatment (cetuximab + cisplatin/carboplatin + 5FU, known  as  EXTREME  regimen).  The  EXTREME  regimen  is  considered  an  appropriate  comparator  in accordance with current treatment guidelines, and overall, the control arm performed as expected based on the EXTREME pivotal study (Vermorken, 2008).

The  use  of  cisplatin  or  carboplatin  based  on  investigator's  decision  (taken  before  randomization)  is considered  clinically  appropriate.  The  use  of  platinum  compounds  appeared  balanced  in  the  ASaT population (approximately 40% received cisplatin and 60% carboplatin in both chemo-containing arms). While the use of platinum compound was quite balanced in the two arms of CPS≥1 population, in CPS&lt;1 ~10% more subjects started with cisplatin in the control group, on the contrary more patients (~8%) received cisplatin at first dose in the pembro combo arm of CPS≥20 population. During the study, 33.6% (40 of 119 participants) and 30.3% (36 of 119 participants) switched from cisplatin to carboplatin in the pembrolizumab  plus  chemotherapy  and  standard  treatment  groups,  respectively,  with  no  overall imbalances in exposure to each platinum compound in those subjects.

<div style=\"page-break-after: always\"></div>

The study was designed to compare pembro combo to standard treatment, and to compare pembro mono to standard treatment. No comparison was conducted between the pembrolizumab monotherapy and pembrolizumab plus chemotherapy groups.

Participants were stratified according to PDL1 (TPS≥50% vs not ≥50%), HPV (positive vs negative) and ECOG (0 vs 1). Stratification factors appear appropriate.

OS and PFS (by BICR per RECIST 1.1) were the primary efficacy endpoints in KEYNOTE-048. They were tested  for  superiority  of  pembrolizumab  monotherapy  and  pembrolizumab  plus  chemotherapy  over standard treatment, respectively, in 3 populations: 1) PDL1 CPS ≥20, 2) PD -L1 CPS≥1, and 3) ITT. The choice of OS and PFS as primary endpoints are considered of relevance for the evaluation of clinical efficacy.

KEYNOTE-048 is an event and time driven trial. The sample size was chosen to achieve the required number of PFS and OS events at the time of the 1 st  planned analysis, followed by time driven analysis at a 2 nd  interim and final timepoints.

Most common reason for non-eligibility was ECOG ≥ 2 (20.8%). A total of 882 patients were recruited and randomized in 228 centers worldwide from 1-APR-2015 to 17-JAN-2017.

Overall, the important protocol deviations occurred in a similar rate in each of the 3 treatment arms, thus not raising concern on relevant impact on study results.

Several changes to the sample size and to the follow-up have been made with respect to the original protocol. Likely due to these changes regarding the extension of the sample size and of the follow-up time, more PFS/OS events than planned have been observed in all populations (except for the CPS ≥ 20 population), inflating the power and affecting minimal detectable HRs that slightly shift toward the null hypothesis.  Expected  timing  of  the  analyses  was  updated  to  reflect  changes  in  follow-up  time,  and efficacy boundaries used to control the type I error were adjusted according to the alpha level spent at the actual time of IA2 (following the predefined spending function) and to the number of PFS/OS events actually observed at the cut-off date.

As occurred in study KEYNOTE-040, leading to the approval of pembrolizumab in the 2LR/M HNSCC (see Keytruda EPAR var II/42), the PD-L1 scoring method was changed from TPS (tumor proportion score, i.e. PD-L1 expression on tumor cells only), used as stratification factor, to CPS (combined positive score, considering PD-L1 expression on tumour and immune cells infiltrating the tumour stroma), applied for the analysis of efficacy. In both KEYNOTE-040 and KEYNOTE-048, the choice of the new scoring system was based on external data from the single arm study KEYNOTE-012, showing that CPS with cut-off 1 was able to discriminate patients with worse and better outcome compared to TPS. The biomarker cut point for efficacy analyses was also changed from strongly positive (TPS≥50%) to CPS≥20, CPS≥10, and CPS ≥1, although  subsequently  the  cut-point  of  10  was  removed  with  protocol  amendment  n.7  (dated 17/03/2017). The final analyses were therefore conducted according to the new CPS score with cut-offs ≥20 and ≥1.

The evaluation of the proportional hazards assumption indicates that there is evidence of departure from the PH assumption, commonly seen with immunotherapy.

Overall, approximately half of the subjects in the control arm received a subsequent anticancer therapy after being treated within the trial (18% at least 2 further lines). Subsequent checkpoint inhibitors were used by participants in the KEYNOTE-048 study (no crossover was pre-specified). In the ITT population, a much larger number of participants crossed over to checkpoint inhibitors in the standard treatment group (about 25%) compared with the number of participants who crossed over to checkpoint inhibitors in the pembrolizumab plus chemotherapy group (5.3%) or in the pembrolizumab monotherapy group (4.3%). Sensitivity analyses performed to analyse the phenomenon of switching showed OS results in the

<div style=\"page-break-after: always\"></div>

ITT as well as in subgroups according to PD-L1 score for both comparisons similar to the respective primary analyses (with the exception of the method that censors patients crossing over, suggesting a different timing of switching occurring in the two treatment arms).

## Efficacy data and additional analyses

The results originally submitted by the MAH were based on the pre-planned IA2 (i.e. final for PFS and interim for OS) with a data cut-off date 13-JUN-2018. During the procedure, the MAH provided the results relative to the Final Analysis with a data cut-off date 25-FEB-2019.

The two comparisons are reported separately below.

## 1) PEMBRO COMBO vs CONTROL

Baseline characteristics in the ITT population appeared overall well balanced. Median age was 61, with about 35% of patients over 65 in both arms. About 40% of subjects had ECOG 0 and 60% ECOG 1. A higher proportion of female (20.3% vs 12.9%) and current smoker (19.9% vs 12.9%) was however observed  in  the  pembro  combo  compared  to  the  control  arm.  Approximately  33%  of  patients  were enrolled in EU region. Overall, 70% of patients had metastatic disease and 30% recurrent. Baseline tumor size  appeared slightly  higher  in  the  pembro  combo  compared  to  control  (median  67.3  vs  58.7  mm, tumor≥ITT median 52% vs 44.6%). A shorter time from the latest platinum therapy/prior systemic therapy in the pembro combo compared to control is also observed. Overall, approximately half of the subjects in both arms had received a prior systemic therapy for primary/locally advanced/with curative intent. When analysing PDL1 expression, 23% of patients overall had TPS≥50% (stratification factor). The distribution according to CPS appeared also quite well balanced for CPS≥1 (~85% i n both arms), while there was 5% more patients of CPS≥20 tumors in the pembro combo compared to the control arm (44.8% vs 39.6%). For comparison, a similar rate of TPS≥50% (25%) and CPS≥1 (80%) tumors was seen in the 2L study KEYNOTE-040.

The distribution of patients with CPS scores (≥1 and ≥20) were overall balanced between the treatment arms.  However,  when  considering  the  CPS≥1  and  CPS≥20  populations,  some  imbalances  (&gt;5% difference) in baseline characteristics among the two treatment arms are noted (e.g. in both populations: more female,  more  metastatic  disease,  higher  disease  tumour  burden  and  shorter  time  from  latest platinum/prior systemic therapy in pembro combo vs control; in CPS≥1 population: more current smoker in pembro combo vs control; in CPS≥20 population: older and more ECOG 1 subjects in pembro combo vs control). Overall, additional analyses to explore the potential impact of factors with relevant imbalance between treatment arms in the two populations CPS≥1 and CPS≥20 show that the imbalances observed have not had a relevant impact on the treatment HR estimates.

Overall, at the IA2, an OS event occurred in about 76% of the overall population. In the comparison pembro combo vs control, OS reached statistical significance in the ITT population only (HR 0.77, 95%CI 0.63, 0.93, p=0.00335), although this result was of borderline statistical significance (p-value boundary 0.0041). Gain in median OS was 2.3 months in the ITT population. The OS result in the higher PD-L1 expression population of CPS≥20 resulted to be not statistically significant, although the HR estimate (HR 0.69, 95%CI 0.51, 0.94) as well as the appearance of the KM curve seems to suggest a clinical benefit in this population. As per the multiplicity analysis strategy, because the OS hypothesis for CPS≥20 was not statistically significant, the CPS≥1 hypothesis could not be tested (OS HR was 0.71 (95%CI 0.57, 0.88) p=0.00072 in CPS≥1). At visual inspection, in all three populations analysed (ITT, CPS≥1 and CPS≥20) the  survival  KM  curves  of  the  two  arms  appear  to  overlap  up  to  month  8,  then  divide  and  remain separated in favour of pembro combo, with a difference in OS rate at 15 months of ≥10%. Extensive censoring in the OS curves is seen from month 16 onward.

<div style=\"page-break-after: always\"></div>

Compared to the IA2, OS at the final analysis resulted to be statistically significant superior for pembro combo compared to control in the CPS≥1 and CPS≥20, while at the IA2 statistical significance superiority was demonstrated in the ITT only. OS HRs point estimates tend to improve from the IA2 to the FA in the ITT as well as in all subpopulation according to PD-L1 expression (with the exception of worsening result in CPS&lt;1, see below).

The RMST sensitivity analyses showed that the benefit of pembrolizumab over standard treatment seems to increase over time in term of OS, according which, based on the confidence intervals, there is an indication of a difference in terms of RMST based on 24 months of follow up in the ITT and CPS≥1 populations in pembrolizumab plus chemotherapy vs standard treatment comparison.

No PFS advantage with the experimental treatment is observed (not statistically significant in the ITT and in  the  CPS≥20,  while not tested in the CPS≥1 per m ultiplicity  strategy).  PFS  curves  are  mostly overlapping, although a separation in the PFS curve is seen after month 6, particularly in the CPS ≥ 20 subgroup.

There was no observed ORR advantage for pembro combo over the EXTREME regimen. ORR (according to BICR per RECIST 1.1, with confirmation) was around 35% in each treatment arm, although in pembro combo a higher rate of complete responses is seen (3% in chemotherapy vs 6% in pembro combo, rising to 9% in CPS≥20). On the contrary, there was about 5% more PD as best response in the pembro combo arm. While ORR and median time to response were similar, median DOR was longer (6.7 vs 4.3 months) in the pembro combo arm, with a higher rate of responses that last ≥6 months (53% vs 37%). The advantage in duration of response does not appear however remarkable, and lower than what observed when pembrolizumab is used a single agent (see below). This lower duration of response in pembro in association with chemotherapy compared to pembro monotherapy has also been observed in indirect comparison in the NSCLC setting (see Keytruda II/60), likely due to some responses with pembro combo being (solely) attributable to the chemotherapy component.

The MAH was requested to provide exploratory statistics in the populations according to PD-L1 expression CPS&lt;1, CPS 1-19 and CPS&lt;20. Based on the data provided, the main concern pertains to the negative PD-L1 subgroup (i.e. CPS&lt;1), representing 15% of the ITT population (39 vs 43 pts in pembro combo vs control, respectively). In this subgroup, no advantage in OS is seen (HR=1.07) with KM curves totally overlapping;  PFS  appears  clearly  negative  (HR=1.49).  Response  rate  is  lower  with  pembro  combo compared to standard treatment (ORR 30.8% vs 39.5%) and no advantage in duration of response is evident either (median DOR 5.7 vs 4.3 months, responses ≥6 months duration 47% vs 49%). At the final analysis the longer follow-up indicated a trend for worse OS results in the CPS&lt;1 population [HR=1.21 (95% CI 0.76, 1.94)], which is of concern. As pointed out by the MAH, some patients with CPS&lt;1 disease could benefit from the use of immunotherapy in combination with chemo upfront, such as ECOG 0 or HPV positive patients. However, on the other hand, the standard treatment could be a better option in subjects with ECOG 1 or HPV negative. Numbers are however too limited to draw conclusion in this regard. It is acknowledged that the CPS&lt;1 is a small and exploratory subgroup for which the study was not powered for, and that OS was statistically significant superior in the CPS ≥ 1 subgroup and in the ITT population. However, it is considered that the lack of biological plausibility in using pembrolizumab in CPS&lt;1 disease, together  with  the  overall  similar/slightly  inferior  results  in  CPS&lt;1  population  for  pembrolizumab combination over EXTREME,  do  not  satisfactorily support the substitution of cetuximab  with pembrolizumab in combination with platinum/5-FU chemotherapy, which represents a potentially less active combination, with no clear advantage in terms of tolerability for patients with PD-L1 CPS&lt;1. Thus, the indication of pembrolizumab combination is restricted to patients whose disease expresses PD-L1 with CPS score ≥ 1.

Baseline  global  health  status/QoL  scores  were  similar  between  the  pembrolizumab  and  standard treatment groups in the PRO FAS population. Over 15 weeks of follow-up, participants showed overall

<div style=\"page-break-after: always\"></div>

stable global health status/QoL in both arms. The K-M curves of time to deterioration for global health status and pain indicate a detrimental effect of the pembrolizumab combination compared to the standard treatment.  K-M  curves  for  swallowing  are  instead  overlapping.  The  open-label  design  hampers  the interpretation of data. No proposal for inclusion of PRO data in the SmPC has been made, which is agreed.

Relevant differences in efficacy according to age (&lt;65, 65-74, 75-84 years) are not seen in the ITT or in the CPS≥1 and CPS≥20 populations. However, results in the older age subgroup (75 -84 years) should be interpreted with caution because of the small sample size (14 and 26 in the pembro combo and control arm, respectively). The limited amount of data available in over 75 subjects has been reflected in the SmPC.

Subgroup analyses according to disease status suggest an apparent very limited benefit of pembro combo over standard treatment in recurrent disease in the ITT population as well as in the CPS≥1 subjects (but n ot in the CPS≥20 population).

In the HPV positive subgroup a pembro combo benefit is observed in OS, PFS and ORR. For the HPV negative subgroup the median OS was only slightly higher, PFS results were similar and ORR was slightly less compared to the control arm.

## 2) PEMBRO MONO vs CONTROL

For  the  comparison  pembro  mono  vs  control,  the  ITT  population  included  301  and  300  patients randomized  to  pembrolizumab  and  to  chemotherapy  arm,  respectively.  89.3%  vs  96.5%  had discontinued trial medications in the two arms at the cut-off date, main reason being radiological disease progression (62% vs 64.8%). Clinical progressions were however more common in the pembrolizumab arm: so, when considering discontinuation due to radiological and clinical progression and death, this is slightly  higher  in  the  pembro  arm  (216/301=72%, 204/300=68%). Discontinuations due to adverse events were more commonly observed in the chemotherapy arm (11% vs 15.3%) as expected. Overall, patient disposition appears similar in the CPS≥1 and CPS ≥20 populations.

Baseline characteristics in the ITT population appeared overall well balanced. In the pembro monotherapy arm, a shorter median time from the latest platinum therapy/prior systemic therapy compared to the control arm is observed, similarly to pembro combo. Overall, approximately half of the subjects in both arms had received a prior systemic therapy for primary/locally advanced/with curative intent. When analysing PDL1 expression, 22% of patients overall had TPS≥50% (stratification factor). The distribution according to CPS appeared also quite well balanced for CPS≥1 (~85% in both arms). CPS≥20 subjects were 44.2% and 40.7% in the pembro mono and the control arm, respectively.

However, when considering the CPS≥1 and CPS≥20 populations, some imbalances (&gt;5% difference) in baseline  characteristics  among  the  two  treatment  arms  are  noted,  particularly  in  the  higher  PD-L1 expression  subgroup  (in  CPS≥1  population:  less  EU  subjects,  shorter  time  from  latest  platinum therapy/prior systemic therapy in pembro mono vs control; in CPS≥20 population more female, higher median age, more HPV negative, shorter time from prior systemic therapy in  the  pembro  mono  vs control). Overall, additional analyses to explore the potential impact of factors with relevant imbalance between treatment arms in the two populations CPS≥1 and CPS≥20 show that the imbalances observed have not had a relevant impact on the treatment HR estimates.

Overall, at the IA2 approximately 75% of the total population has experienced an OS event. In the ITT population,  OS  in  the  pembrolizumab  monotherapy  arm  resulted  non-inferior,  but  not  statistically significantly superior, compared to the control arm (OS HR=0.85, 95% CI 0.71, 1.03, median OS 11.6 vs 10.7 months). Statistically significant OS superiority was instead demonstrated in both positive PD-L1 subgroups (CPS≥1: HR 0.78 [0.64, 0.96], p = 0.00855, gain in median OS of 2 months; CPS≥20 : HR 0.61 [0.45, 0.83], p=0.00074, gain in median OS of 4.2 months). While the H7 hypothesis (i.e. OS in CPS≥20) is most compelling from a statistical perspective, the H8 hypothesis (CPS≥1 superiority in mono vs. SOC

<div style=\"page-break-after: always\"></div>

comparison) resulted to be statistically significant due to the α -shift from H14 hypothesis (OS combo) to H7 hypothesis (OS mono). At the final analysis, OS superiority for mono vs SOC in the ITT population was again not demonstrated.

As  repeatedly  observed  with  anti-PD1/PDL1  agents,  a  worse  early  performance  of  pembro  mono compared to the standard treatment is seen, with KM curves crossing around month 8. While this crossing is evident in the ITT and in the CPS≥1 populations, this appears less definite in the CPS≥20 group. After the crossing of the KM curves, the pembrolizumab monotherapy curve lies above the control arm one, with long-term advantage for some patients more pronounced the higher PD-L1 expression is (difference in OS rate at 12 months: 5% in the ITT, 7% in CPS≥1, 12% in CPS≥20). I nstantaneous hazard rates between 0 and 6 months generally favour the chemotherapy arm in the CPS≥1 and CPS≥20 populations . This issue is of particular concern for CPS≥1 patients . Indeed patients who died over the first 6 months were 73 in pembro mono arm and 54 in EXTREME arm; of those, 52 vs 27 died due to PD (i.e. 20% vs 10% of the overall population in each arm). In the 1 ≤ CPS&lt;20 population, subjects dying due to PD during the first 6 month of treatment have more than doubled in pembro mono vs standard treatment (29 vs 13). The  data  provided  confirmed  an  early  detrimental  effect  with  pembro  mono  vs  chemotherapy. Considering  the  results  obtained  from  specific  analyses  performed  to  explore  the  issue  of  the  early detrimental effect of immunotherapy compared with chemotherapy, it is believed that at the moment no specific  recommendation  can  be  included  in  the  SmPC,  since  consistency  of  results  obtained  from different studies is needed to make the results strong and convincing.

The OS RMST sensitivity analyses underline that the benefit of pembrolizumab over standard treatment increases over time and based on the confidence intervals, for the pembro mono comparison, there is an indication of a difference in terms of RMST based on 24 months of follow up in the CPS≥20 population only.

PFS did not show statistically significant improvement (HR 1.34, 95%IC 1.13, 1.59). It is observed that the KM curves of PFS2 in the ITT population are crossing as well, with a very late separation after month 10.

Although  slightly  improving  with  higher  PD-L1  expression,  the  ORR  to  pembrolizumab  monotherapy remains steadily below the response rate achieved with chemotherapy (ORR in the ITT population: 17% vs 36%). Rate of stable disease is lower for pembro mono than for standard treatment as well. Few more complete responses are however observed with pembrolizumab monotherapy compared to chemo. On the  contrary,  as  known  with  immunotherapy,  the  median  DOR  was  substantially  longer  (21  vs  4.5 months), and patients who achieve tumour response with pembro mono have high chance to respond for a long time (response duration ≥6 months 75% vs 39% in the ITT population). Median time to response was similar in both arms (2.1 months).

Exploratory analyses of the complementary PDL1 populations CPS&lt;1, 1≤CPS&lt;20 and CPS&lt;20 have been provided, showing no benefit from the use of pembrolizumab over standard treatment in all the subgroups, and clearly negative results for pembrolizumab monotherapy in the CPS&lt;1 population.

Therefore, the demonstration of a non-inferiority (and lack of superiority) in the ITT population is not considered supporting the clinical benefit of pembro mono in this 1L HNSCC setting (moreover based on NI margin which has not been justified), in light also of a (not so early) crossing of OS curve (at month 8). This is further corroborated by negative PFS and ORR data. An indication in the overall population was therefore not agreed by the CHMP. The MAH subsequently decided to restrict the sought indication for pembrolizumab monotherapy to CPS≥1 population only.

For the 1≤CPS&lt;20 population, representing about 40% of the overall population, the OS HR for pembro mono is 0.86 (95% CI 0.66, 1.12), OS KM curves cross at about 8 months, then overlap and clearly separate only at around month 15 in favour of pembrolizumab; the separation of the curves is rather

<div style=\"page-break-after: always\"></div>

small; however a small proportion of patients appear to derive a long-term benefit compared to SOC also in this subgroup. The early inferior OS of pembrolizumab is also reflected by a 10% lower OS rate at month 6 (68% vs. 78%). In the 1≤CPS&lt;20 population, an indication for pembrolizumab monotherapy could be acceptable as a treatment alternative, if taking the considerable better safety profile compared to the SOC into account.

Quality  of  life  evaluation  showed  similar  baseline  global  health  status/QoL  scores  between  the pembrolizumab and standard treatment groups in the PRO FAS population, with overall stable global health status/QoL over 15 weeks of follow-up. The K-M curves of time to deterioration for global health status and pain indicate a detrimental effect of the pembrolizumab combination compared to the standard treatment. An opposite tendency is seen for swallowing.

The apparent trend towards decreasing effect of pembrolizumab monotherapy compared to standard treatment is observed with increasing age in the ITT and in the CPS≥1 populations (not evident in the CPS≥20 subgroup, where however 75 -84 years patients are only 12 overall). Data in patients over 75 are limited, based on a small sample size.

According to subgroup analysis, there is no clear benefit of pembro mono over standard treatment in the recurrent setting in CPS≥1 population.

The OS result appears less convincing in female patients compared to male in subgroup analyses, however definitive conclusions are hampered by the small sample size of female subjects, which is by the way expected based on the epidemiology of the disease. Among subjects who died within the first 6 months from randomization a higher rate of female is seen in pembro mono compared to control in CPS ≥ 1 and ≥ 20 populations.

A small benefit in median OS in favour of pembro mono is observed in HPV negative patients. KM curves cross around month 9 indicating an early favourable effect for standard treatment. For HPV positive patients the KM curves are similar between the treatment arms. No PFS advantage is observed compared to standard treatment regardless of HPV status. Higher response rates were observed in the standard arm compared to Pembro Mono. The ORR difference between the treatment arms is smaller in the HPV positive subgroup.

KEYNOTE-048 study was not statistically powered to compare the two pembrolizumab-containing arms. This is acknowledged. However, the MAH was requested to provide a descriptive comparison between pembrolizumab monotherapy and pembrolizumab plus chemotherapy. OS in pembro mono and pembro combo arms appear overall quite similar. However, while KM OS curve of the pembro mono lies slightly below the one of pembro combo in the ITT population, curves appear closer in CPS ≥ 1 up to completely overlapping in the CPS ≥ 20 subgroup. Across all 3 populations (ITT, CPS ≥ 1, CPS ≥ 20), PFS and ORR were clearly in favour of the pembro combo. Conversely, mDOR and the number of durable (i.e. ≥ 6 months) responses were higher in the pembrolizumab monotherapy group. Median time to response was similar.

When taking the data for the pembro combo into account in the 1≤CPS&lt;20 population, a higher risk of early death is observed with pembro mono vs SOC but not with pembro combo vs SOC, reflected by similar 6 months OS rates for both treatment arms; the OS HR improves to 0.71 and the curves separate earlier and slightly more pronounced in the later parts compared to observations for monotherapy. Thus lastly, the considerably improved safety profile of the monotherapy has to be weighed against the better efficacy outcome for the pembro combination therapy. Regarding long-term efficacy, the difference is not so prominent anymore (OS rates at 18 months 34.5% vs. 31.8% and OS rates at 24 months 25.9% vs. 22% for pembro combo vs. pembro mono, respectively). From a regulatory point of view, it is acceptable to allow individual treatment decisions based on patients preferences if a clear presentation of efficacy data  in  the  SmPC  in  a  comparative  way  is  included  in  section  5.1  of  the  SmPC  for  the  subgroups 1&lt;CPS&lt;20 and CPS≥20.

<div style=\"page-break-after: always\"></div>

In patients with CPS≥20, the relevance for the addition of chemotherapy to pembrolizumab monotherapy appears questionable in view of the added toxicity of the chemotherapy. However, individual patients might benefit from combination therapy especially when a response with tumour shrinkage is needed, due to the higher ORR of pembro combo. Information regarding the B/R evaluation being dependent on CPS status has been included in section 4.4, as well as efficacy data for the CPS ≥20 subgroup in section 5.1 of the SmPC.

## 2.4.4. Conclusions on the clinical efficacy

Pembrolizumab  combination  demonstrated  statistically  significant  superiority  compared  to  EXTREME regimen in all the 3 pre-specified populations (ITT, CPS ≥ 1 and CPS ≥ 20). As opposed to the ITT and the other biomarker subpopulations, the longer follow-up indicated a trend for worse OS results in the CPS&lt;1 population, together with inferior results for PFS and ORR, and the lack of DOR benefit. Acknowledging that the CPS&lt;1 is a small and exploratory subgroup for which the study was not powered, the lack of biological plausibility in using pembrolizumab in CPS&lt;1 disease, together with the overall similar/slightly inferior results in CPS&lt;1 population for pembrolizumab combination over EXTREME, do not satisfactorily support  the  substitution  of  cetuximab  with  pembrolizumab  in  combination  with  platinum/5-FU chemotherapy. Thus, the indication of pembrolizumab combination is restricted to patients whose disease expresses PD-L1 with CPS ≥ 1 score.

For  pembrolizumab  monotherapy,  an  indication  restricted  to  the  CPS≥ 1  population  is  considered acceptable.

## 2.5. Clinical safety

## Introduction

The overall safety profile of pembrolizumab, evaluated across clinical studies in patients with different solid tumours, is mainly associated with immune-related adverse reactions, and characterised by general (fatigue, decreased appetite), gastrointestinal (nausea, diarrhoea, constipation), respiratory (cough, dyspnoea), and skin (pruritus and rash) disorders.

The safety profile to support the claimed indications for use of pembrolizumab in combination with chemotherapy based on platinum (cisplatin or carboplatin) and 5-FU, and as monotherapy for 1L treatment of patients with R/M HNSCC is based on the second interim analysis (IA2) in all subjects as treated (ASaT) of the KEYNOTE-048 study.

The IA2 was a time-driven analysis with data cut-off date 13-JUN-2018 (database lock date 29-JUN-2018), when all the participants had the opportunity to be followed for at least 17 months. Out of the 882 randomized subjects, 863 participants were included in all safety comparisons (the ASaT population).

Supportive data is provided by the pooled safety databases of HNSCC Safety DS for pembrolizumab and Pembrolizumab monotherapy RSD.

The pooled HNSCC Safety DS for pembrolizumab is used to reflect existing safety information of pembrolizumab monotherapy for HNSCC in the 2L+ treatment setting (N=609).

The pooled safety data from the Pembrolizumab monotherapy RSD enable comparison of safety of Pembrolizumab + Chemotherapy and of Pembrolizumab monotherapy for HNSCC with the established safety profile of pembrolizumab monotherapy across all the other indications (N=3830).

The table below summarizes the 5 datasets upon which safety results are based:

<div style=\"page-break-after: always\"></div>

Table 62: Safety datasets

<!-- image -->

| Dataset                                                                                                                                                                                                                                                                                    | Population                                                                                                                                                                                                                                                                                                                                                                                               | Nomenclature in Tables                                                                                                                                                                                                                                                                     | Nomenclature in Text                                                                                                                                                                                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| KEYNOTE-048 pembrolizumab plus chemotherapy                                                                                                                                                                                                                                                | (N=276): Safety data from participants with R/M HNSCC who received pembrolizumab in combination with chemotherapy in KEYNOTE-048                                                                                                                                                                                                                                                                         | KN048 Data for MK-3475 + Chemotherapy                                                                                                                                                                                                                                                      | Pembrolizumab plus chemotherapy*                                                                                                                                                                                                                                                           |
| KEYNOTE-048 pembrolizumab                                                                                                                                                                                                                                                                  | (N=300): Safety data from participants with R/M HNSCC who received pembrolizumab as monotherapy in KEYNOTE-048                                                                                                                                                                                                                                                                                           | KN048 Data for MK-3475                                                                                                                                                                                                                                                                     | Pembrolizumab monotherapy*                                                                                                                                                                                                                                                                 |
| KEYNOTE-048 standard treatment                                                                                                                                                                                                                                                             | (N=287): Safety data from participants with R/M HNSCC who received cetuximab in combination with chemotherapy in KEYNOTE-048                                                                                                                                                                                                                                                                             | KN048 Data for SOC                                                                                                                                                                                                                                                                         | Standard treatment*                                                                                                                                                                                                                                                                        |
| HNSCC pembrolizumab safety                                                                                                                                                                                                                                                                 | (N=609): Pooled safety data from participants with R/M HNSCC who received pembrolizumab as monotherapy in KEYNOTE-040, KEYNOTE-012, and KEYNOTE-055                                                                                                                                                                                                                                                      | HNSCC Safety Dataset for MK-3475                                                                                                                                                                                                                                                           | HNSCC pembrolizumab monotherapy                                                                                                                                                                                                                                                            |
| Pembrolizumab monotherapy reference safety                                                                                                                                                                                                                                                 | (N=3830): Pooled safety data from participants who received at least 1 dose of pembrolizumab in KEYNOTE-001Part B1 B2,B3,D,C,F1,F2,F3(NSCLC melanoma), KEYNOTE-002 (original phase, melanoma), KEYNOTE-006 (melanoma), KEYNOTE-010 (NSCLC), KEYNOTE-013 Cohort3 (Hodgkin's lymphoma),KEYNOTE-024 (NSCLC), KEYNOTE-045andKEYNOTE-052 (urothelial cancer), and KEYNOTE-087 (classical Hodgkin's lymphoma). | Reference Safety Dataset for MK-3475                                                                                                                                                                                                                                                       | Pembrolizumab monotherapy RSD                                                                                                                                                                                                                                                              |
| Abbreviations: HNSCC=head and neck squamous cell carcinoma; N=number, NSCLC=nonsmall cell lung cancer; R/M=recurrent/metastatic; RSD=reference safety dataset. * For the 3 KEYNOTE-048 study datasets, the term \"dataset\" and \"group\" may be used interchangeably throughout the document. | Abbreviations: HNSCC=head and neck squamous cell carcinoma; N=number, NSCLC=nonsmall cell lung cancer; R/M=recurrent/metastatic; RSD=reference safety dataset. * For the 3 KEYNOTE-048 study datasets, the term \"dataset\" and \"group\" may be used interchangeably throughout the document.                                                                                                               | Abbreviations: HNSCC=head and neck squamous cell carcinoma; N=number, NSCLC=nonsmall cell lung cancer; R/M=recurrent/metastatic; RSD=reference safety dataset. * For the 3 KEYNOTE-048 study datasets, the term \"dataset\" and \"group\" may be used interchangeably throughout the document. | Abbreviations: HNSCC=head and neck squamous cell carcinoma; N=number, NSCLC=nonsmall cell lung cancer; R/M=recurrent/metastatic; RSD=reference safety dataset. * For the 3 KEYNOTE-048 study datasets, the term \"dataset\" and \"group\" may be used interchangeably throughout the document. |

Note: The MAH and the Rapporteurs had agreed in advance not to include a 'Pembrolizumab Monotherapy Cumulative running Dataset' in the submission of this type II variation.

<div style=\"page-break-after: always\"></div>

## Patient exposure

Table 63: Summary of drug exposure (ASaT population)

|                                | KN048 Data for MK- 3475 (N=300)   | KN048 Data for MK- 3475 + Chemotherapy (N=276)   | KN048 Data for SOC (N=287)   | HNSCC Safety Dataset for MK34751 (N=609)   | Reference Safety Dataset for MK-3475! (N=3830)   |
|--------------------------------|-----------------------------------|--------------------------------------------------|------------------------------|--------------------------------------------|--------------------------------------------------|
| Study Days On-Therapy (Months) |                                   |                                                  |                              |                                            |                                                  |
| Mean                           | 6.4 3.50 7.04                     | 7.4 5.78 6.64                                    | 6.1 4.86 5.84                | 4.9 2.83 5.42 0.03 to 25.56                | 6.7 4.71 6.05 0.03 to 30.39                      |
| Median                         |                                   |                                                  |                              |                                            |                                                  |
| SD                             |                                   |                                                  |                              |                                            |                                                  |
| Range                          | 0.03 to 47.90                     | 0.10 to 28.72                                    | 0.03 to 35.25                |                                            |                                                  |
| Number of Administrations      |                                   |                                                  |                              |                                            |                                                  |
| Mean                           | 9.7                               | 10.7                                             | 8.7                          | 8.1                                        |                                                  |
| Median                         | 6.00                              | 8.00                                             | 7.00                         | 5.00                                       | 8.00                                             |
| SD                             | 9.39                              | 9.11                                             | 8.10                         | 8.50                                       | 9.56                                             |
| Range                          | 1.00 to 40.00                     | 1.00 to 35.00                                    | 1.00 to 48.00                | 1.00 to 52.00                              | 1.00 to 59.00                                    |

Each subject is couted once on each applicable duation category row.

Duration of Exposure is calculated as last dose date - first dose date + 1.

Includes allsubjects wh received atleast one dose ofM-3475 in KN001 PatBl,B2,B3, D, C, F1,F2, F3; KN002 (oriinalphase), KN006, and KN10, NO13-Cohort3,KN024, KN05. KN052 and KN087.

Includes allsubjects who received at least one dose of MK-3475 in KN012 Cohornts B and B2, KN040 and KN055.

MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015.KN006: 03MAR2015.KN054: 020CT2017)

MK-3475 Database CutoffDate for Lumg (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015,KN024: 10JULY2017)

MK-3475 Database CutoffDate for HNSCC (KN012-HNSCC: 26APR2016,KN040: 15MAY2017.KN048: 13JUN2018,KN055: 22APR2016)

MK-3475 Database Cutoff Date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

MK-3475 Database Cutoff Date for Bladder (KN045: 18IAN2017, KN052: 09MAR2017)

Source: [ISS: adam-adsl; adexsum]

Table 64: Clinical trial exposure to drug by duration (ASaT population)

|                        | KN048Data for MK-3475 (N=300)   | KN048Data for MK-3475 (N=300)   | KN048Data for MK-3475 (N=300)   | KN048Data for MK-3475 + Chemotherapy (N=276)   | KN048Data for MK-3475 + Chemotherapy (N=276)   | KN048Data for MK-3475 + Chemotherapy (N=276)   | KN048Data for SOC (N=287)   | KN048Data for SOC (N=287)   | KN048Data for SOC (N=287)   | HNSCC Safety Dalaset for MK3475l (N=609)   | HNSCC Safety Dalaset for MK3475l (N=609)   | HNSCC Safety Dalaset for MK3475l (N=609)   |
|------------------------|---------------------------------|---------------------------------|---------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|                        | n                               | (6)                             | Person-years                    | n                                              | (6)                                            | Person-years                                   | I                           | ()                          | Person-years                |                                            | (6)                                        | Person-years                               |
| Duuration of Exposiure |                                 |                                 |                                 |                                                |                                                |                                                |                             |                             |                             |                                            |                                            |                                            |
|                        | 300                             | (100.0)                         | (158.9)                         | 276                                            | (100.0)                                        | (171.2)                                        | 287                         | (100.0)                     | (145.0)                     | 609                                        | (100.0)                                    | (249.4)                                    |
| =1 m                   | 256                             | (85.3)                          | (157.2)                         | 239                                            | (86.6)                                         | (170.2)                                        | 260                         | (90.0)                      | (144.2)                     | 478                                        | (78.5)                                     | (245.4)                                    |
| =m                     | 165                             | (55.0)                          | (141.7)                         | 198                                            | (71.7)                                         | (163.0)                                        | 207                         | (72.1)                      | (135.3)                     | 294                                        | (48.3)                                     | (215.6)                                    |
| =6m                    | 105                             | (35.0)                          | (120.5)                         | 129                                            | (46.7)                                         | (136.5)                                        | 106                         | (36.9)                      | (97.7)                      | 176                                        | (28.9)                                     | (173.1)                                    |
| =12m                   | 52                              | (17.3)                          | (86.0)                          | 52                                             | (18.8)                                         | (83.2)                                         | 23                          | (8.0)                       | (43.1)                      | 66                                         | (10.8)                                     | (97.8)                                     |

<div style=\"page-break-after: always\"></div>

## Adverse events

AEs were coded using MedDRA (Version 21.0). All safety analyses were conducted using data from the ASaT population (i.e. all randomized participants who received at least 1 dose of study treatment) for each study or cohort as of the data cut-off dates.

The analysis of safety results followed a tiered approach. No Tier 1 safety parameters were pre-specified in the protocol.

Table 65: Safety analyses

<!-- image -->

| Safety Tier   | Safety Endpoint                     | p-Value   | 95% CI for Treatment Comparison   | Descriptive Statisties   |
|---------------|-------------------------------------|-----------|-----------------------------------|--------------------------|
| Tier 2        | Any AE                              |           | X                                 |                          |
| Tier 2        | Any Grade 3-5 AE                    |           | X                                 | X                        |
| Tier 2        | Any Serious AE                      |           | X                                 | X                        |
| Tier 2        | Any Drug-Related AE                 |           | X                                 | X                        |
| Tier 2        | Any Serious and Dnug-Related AE     |           | X                                 | X                        |
| Tier 2        | Any Grade3-5 and Drug-Related AE    |           | X                                 |                          |
| Tier 2        | Dose Modification due to AE         |           | X                                 | X                        |
| Tier 2        | Discontinuation due to AE           |           | X                                 | X                        |
| Tier 2        | Death                               |           | X                                 | X                        |
| Tier 3        | Specific AEs, SOCs                  |           |                                   | X                        |
| Tier 3        | Change from Baseline Results (Labs) |           |                                   | X                        |

## KEYNOTE-048 updated safety data - final analysis (cut-off date 25 Feb 2019)

A summary of AE at the updated cut-off date of the Final Analysis (25 Feb 2019) for KEYNOTE-048 study submitted during the procedure is presented below for the two comparisons.

<div style=\"page-break-after: always\"></div>

Table 66: Adverse event summary, Pembro combo vs Control (ASaT population)

|                                                                   | Pembrolizmmab + Chemotherapy   | Pembrolizmmab + Chemotherapy   | Cetximab + Chermotherapy   | Cetximab + Chermotherapy   | Tota1   | Tota1   |
|-------------------------------------------------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|---------|---------|
|                                                                   | r                              | (%)                            | n                          | (%)                        | r       | (%)     |
| Sub je cts ini popuktiort                                         | 276                            |                                | 287                        |                            | 695     |         |
| witl ore or more advers e everts                                  | 271                            | (98.2)                         | 286                        | (99.7)                     | 557     | (98 9)  |
| witlt ro adverse everit                                           | 5                              | (1.8)                          | 1                          | (03)                       | 6       | (1.1)   |
| with dnug-relate dl adverse everts                                |                                | (95.7)                         | 278                        | (96 9)                     | 5       | (96 3)  |
| witl toxicity grade 3 -5 adverse everts                           | 235                            | (85.1)                         | 239                        | ( E8)                      |         | ( 8)    |
| vwith toxicity grade 3 -5 dnug-related adverse everts             | 198                            | (71.7)                         | 199                        | (69 3)                     | 397     | (70 5)  |
| vwitht serious adverse evrerts                                    | 165                            | (59.8)                         | 141                        | (49 .1)                    | 905     | (5)     |
| witl serious dnug-related adverse everts                          | 103                            | (37.3)                         | 72                         | (25.1)                     | 175     | (31.1)  |
| witlt ary do se modif ir atior? due to art advers e everit        |                                | (84.4)                         | 240                        | (9 8)                      |         | (0 8)   |
| Perbrolizumab/Cetuximab dose modificatior                         | 159                            | (57.6)                         | 190                        | (66 2)                     |         | (62 .0) |
| Arty Chemotherapy dose rmodific atior                             | 220                            | (79.7)                         | 206                        | (71.8)                     |         | (75.7)  |
| All componerts dose rmodficatior                                  | 123                            | (9+)                           | 105                        | (9 9)                      | 228     | (5 0)   |
| vwho die d                                                        |                                | (11.6)                         | 28                         | (9.8)                      | 09      | (10.7)  |
| wlho die d due to a drug-related adverse evert                    | 11                             | (0)                            | 8                          | (2.8)                      | 19      | (3.4)   |
| discortirued ary dmug due to ar adverse evert                     | 90                             | (32.6)                         | 79                         | (27 5)                     | 169     | (00)    |
| discortiroue d Pembro linmab/Cetximab                             | 47                             | (17.0)                         | 51                         | (17 8)                     | 98      | (17 .4) |
| discortiroue d Ary Chermotherapy                                  | 74                             | (26.8)                         | 09                         | (20 9)                     | 134     | (23 8)  |
| discortiroe d All c omporerts                                     | 23                             | (8.3)                          | 26                         | (9.1)                      | 49      | (8 .7)  |
| discortiroued ary drug due to a drug-related adverse everit       | 69                             | (25.0)                         | 59                         | (20.6)                     | 128     | (22.7)  |
| discortiroue d Pembro linmmab/Cetuximab                           | 25                             | (9.1)                          | OE                         | (10 5)                     | 55      | (9.8)   |
| discortiroe d Arry Chermotherapy                                  | 61                             | (22.1)                         |                            | (15 3)                     | 10 5    | (18.7)  |
| discortiroe d All c omporterits                                   | 12                             | ()                             | 11                         | (3.8)                      |         | (4.1)   |
| discortinued ary dmug due to a serious adverse evrerit            | 58                             | (21.0)                         | 48                         | (16.7)                     | 106     | (18 8)  |
| discortiroe d Pembro linmmab/Cetuximsb                            | 39                             | (14.1)                         | 9E                         | (12 5)                     | 75      | (13 3)  |
| discortiroue d Ary Chermotherapy                                  |                                | (15.6)                         | 85                         | (13 2)                     | 81      | (14 .4) |
| discortiroe d All c ormporerts                                    | 20                             | (7.2)                          | 21                         | (73)                       | 41      | (7 3)   |
| discortirued ary dmug due to a serious dnug-related adverse evert | 35                             | (12.7)                         | 28                         | (9.8)                      | 9       | (11 2)  |
| discortiroue d Pembro lirmmab/Cetximab                            | 18                             | (6.5)                          | 16                         | (5.6)                      |         | (0 9)   |
| discortirue d Ary Chemother apy                                   | 29                             | (10.5)                         | 22                         | (7.7)                      | 51      | (9.1)   |
| discortiroe d All c omporerds                                     | 9                              | (3.3)                          | 7                          | (2.4)                      | 16      | (2.8)   |

I D etermired by the inrwrestigator to be re late d to the dmug.

↑ D efine d as an actior takern of dose re duc e d, dmug itermupte d or dnugwithudrawr.

ALL : all study drug(s) ort re spe ctivre treatmerit anm

For subjects vwko re c eivre d sec ord cours e tre atmert, adverse everts which o ccumre d irt se cor d c ourse phase are exc hude d.

Grades are b ase d or NCI C TCAE versior 4.03.

Nori- serious adverse evrerits up to 30 days of last dose ard serious adverse everts up to 90 days of last dose are iichude d. MedD RA pref erre dtemms 'Neoplasm progressior\", \"Maligrartrteop k sm pro gre ssion\" arud \"Dise ase progre ssion\" ruot re late d to fhte drug are exchude d.

D iscortirouatior/dose modificatior ir sbudy dnugs liste d inthte re ste d sub-rows are rot rmobually exc lusive. A subje ct car be conmite d in differertrows as applic ab k . Eut a subje ct can be coumnte d in each row ad cohmmr orly onice .

CHEMO THERAPY : Cip lation/Carboplatin +5-FTI. A subje ct willb e coumited in the chemotherapy group if ore or more of the c omporerits are disc ortiroied/do se modif ie d due to sarn adverse evert.

D atabase Cutoff Date: 25FEB20 19.

<div style=\"page-break-after: always\"></div>

Table 67: Adverse event summary, Pembro mono vs Control (ASaT population)

|                                                                        | Pembroliznnab   | Pembroliznnab   | Cebuximab + Chemotherapy   | Cebuximab + Chemotherapy   | Total   | Total   |
|------------------------------------------------------------------------|-----------------|-----------------|----------------------------|----------------------------|---------|---------|
|                                                                        | r               | (%)             | rt                         | (%)                        | r       | (%)     |
| Subje cts nip opulation                                                | 00E             |                 | 287                        |                            | 587     |         |
| wifh orte or rmore adverse everds                                      | 290             | (96.7)          | 286                        | (99.7)                     | 576     | (98.1)  |
| wift ro adverse evert                                                  | 10              | (33)            | 1                          | (0.3)                      | 11      | (1.9)   |
| wifh drug-re kte dl adverse everts                                     | 17 5            | (583)           | 278                        | (96.9)                     | 5       | (77.2)  |
| wifh tovic ity grade 3- 5 adverse everts                               | 16 4            | (54.7)          | 239                        | (83.3)                     | 0       | (68.7)  |
| vwifh tovic ity grade 3- 5 dnug-re late d advrerse everits             | 51              | (17.0)          | 199                        | (69.3)                     | 250     | (42.6)  |
| wifh serious adverse everts                                            | 123             | (4 1.0)         | 141                        | (49.1)                     |         | (45.0)  |
| wifh serious drug-re late d adverse everts                             | 28              | (93)            | 72                         | (25.1)                     | 100     | (17.0)  |
| wifht do se modif i ation? due to art adverse evrert                   | 116             | (38.7)          | 0                          | (9≤8)                      | 95 E    | (60.6)  |
| who died                                                               | 25              | (83)            | 87                         | (9.8)                      | 53      | (9.0)   |
| who died due to a drug-relate d adverse evert                          | E               | (1.0)           | 8                          | (2.8)                      | 11      | (1.9)   |
| disc oritiroe d dmug due to art adverse evrert                         | 95              | (12.0)          | 79                         | (27.5)                     | 115     | (19.6)  |
| disc ortiroe d dmug due to a dnug-related adverse evenit               | 15              | (5.0)           | 59                         | (20.6)                     |         | (12.6)  |
| disc ordiroue d dmug due to a serious advrerse evrert                  | 29              | (9.7)           | 8                          | (16.7)                     | 77      | (13.1)  |
| disc ortiroue d dmug due to a serious dmug- Ie late d advr erse evert. | 9               | (3.0)           | 28                         | (9.8)                      | 37      | (6.3)   |

Detenmine d by fhe irivre stigator to be related to the drug.

↑ Defied as ani action taken of dose Ie duce d, dnug nitemmupted or dnug vwithdravmri.

For subje cts vwho rece ived se cord course treatmernt, advrerse everts wkick oc cunre d ii sec ord c oumse plase are exc hude d.

Grades are base d on N CI C TCAE vrersior 4.03 .

Nor-serious adverse everts up to 30 days of last do se ad serious adverse everts up to 90 days of last dose are rchuded.

le dDRA prefenred tenms \"Ne oplasm progre ssion.\", \"Maligrart ne oplasm progression.\" ard \"T isease progression \" rotrelated to the dnug are e xchuded.

Database Cutoff D ate : 25FEB2019 .

<div style=\"page-break-after: always\"></div>

## Overall and exposure-adjusted Adverse Events

Table 68: Exposure-adjusted adverse event summary (including multiple occurrence of events (ASaT population)) - cut-off date 13-JUN-2018

|                                                                                       | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)   |
|---------------------------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                                                                                       | KN048 Data for MK- 3475                          | KN048 Data for MK- 3475 + Chemotherapy           | KN048 Data for SOC                               | HNSCC Safety Dataset for MK34751I                | Reference Safety Dataset forMK-34751             |
| Number of subjects exposed                                                            | 300                                              | 276                                              | 287                                              | 609                                              | 3830                                             |
| Total exposure in person-years                                                        | 180.61                                           | 190.63                                           | 167.83                                           | 295.92                                           | 2385.46                                          |
| Total events (rate)                                                                   |                                                  |                                                  |                                                  |                                                  |                                                  |
| adverse events                                                                        | 2619 (1450.11) 667 (369.31)                      | 5002 (2623.92) 2795 (1466.18)                    | 6111 (3641.08) 3691 (2199.19)                    | 5801 (1960.31) 1290 (435.92)                     | 41960 (1758.99) 13236 (554.86)                   |
| drug-related adverse events                                                           |                                                  |                                                  |                                                  |                                                  |                                                  |
| toxicity grade 3-5 adverse events                                                     | 365 (202.10)                                     | 884 (463.72)                                     | 859 (511.81)                                     | 861 (290.95)                                     | 3912 (163.99)                                    |
| toxicity grade 3-5 dnug-related adverse events                                        | 73 (40.42)                                       | 568 (297.96)                                     | 566 (337.24)                                     | 126 (42.58)                                      | 853 (35.76)                                      |
| serious adverse events                                                                | 224 (124.03)                                     | 342 (179.40)                                     | 266 (158.49)                                     | 536 (181.13)                                     | 2624 (110.00)                                    |
| serious dnug-related adverse events                                                   | 37 (20.49)                                       | 165 (86.55)                                      | 117 (69.71)                                      | 76 (25.68)                                       | 548 (22.97)                                      |
| adverse events resulting in dose modification!                                        | 214 (118.49)                                     | 697 (365.63)                                     | 716 (426.61)                                     | 356 (120.30)                                     | 2099 (87.99)                                     |
| adverse events leading to death                                                       | 25 (13.84)                                       | 32 (16.79)                                       | 28 (16.68)                                       | 56 (18.92)                                       | 162 (6.79)                                       |
| drug-related adverse events leading to death                                          | 3 (1.66)                                         | 10 (5.25)                                        | 8 (4.77)                                         | 5 (1.69)                                         | 17 (0.71)                                        |
| adverse events resulting in drug discontinuation                                      | 37 (20.49)                                       | 105 (55.08)                                      | 111 (66.14)                                      | 91 (30.75)                                       | 490 (20.54)                                      |
| drug-related adverse events resulting in dnug discontinuation                         | 15 (8.31)                                        | 80 (41.97)                                       | 85 (50.65)                                       | 41 (13.85)                                       | 239 (10.02)                                      |
| serious adverse events resulting in dnug                                              | 29 (16.06)                                       | 61 (32.00)                                       | 55 (32.77)                                       | 69 (23.32)                                       | 361 (15.13)                                      |
| discontinuation senious dnug-related adverse events resulting in drug discontinuation | 9 (4.98)                                         | 37 (19.41)                                       | 34 (20.26)                                       | 24 (8.11)                                        | 157 (6.58)                                       |

For subjects who received second course treatment, adverse events which occured in second course phnse are excluded.

IDefined as an action taken of dose reduced, drug intemupted or drug withdrawn.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA prefened terms * Neoplasm progression\", \"Maligmant neoplasm progression\" and *Disease progression\" not related to the drug are exchuded.

Includes allsubjects who received at least one dose ofMK-3475 in KN001 Part Bl, B2, B3, D, C, F1, F2, F3; KN002 (oniginal phase). KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087.

IIncludes allsubjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055.

MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 020CT2017)

MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017)

MK-3475 Database Cutoff Date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 13JUN2018, KN055: 22APR2016)

MK-3475 Database Cutoff Date for cHL (KN013-Cohort 3: 27SEP2016.KN087:25SEP2016)

MK-3475 Database Cutoff Date for Blhadder (KN045: 18JAN2017, KN052: 09MA R2017)

Sowrce: [ISS: adam-adsl; adhe]

<div style=\"page-break-after: always\"></div>

## All Adverse Events (AEs)

Table 69 : Subjects with adverse events (incidence ≥10% in one or more treatment groups) by decreasing frequency of preferred term from KN048 combo (ASaT population) - cut-off date 13-JUN-2018

<!-- image -->

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | KN048 Data for MK-3475                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | KN048 Data for MK-3475                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | KN048 Data for MK-3475 +                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | KN048 Data for MK-3475 +                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | KN048 Data for SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | KN048 Data for SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | HNSCC Safety Dataset for MK3475                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | HNSCC Safety Dataset for MK3475                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Reference Safety Dataset for MK-347511                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Reference Safety Dataset for MK-347511                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | n ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | n ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Chemotherapy (6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Chemotherapy (6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | n ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | n ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Subjects in population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 300                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 276                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Ⅱ 287                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 609                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3,830                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| with one or more adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 290                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (96.7) (3.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 271 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | (98.2) (1.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 286                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (99.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 592                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (97.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 3.720                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | (97.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| with no adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (2.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 110                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (2.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Annemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 63                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (21.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 159                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (57.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 132                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (46.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 142 102                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | (23.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 508 884                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | (13.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Nausea Constipation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 50 59                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | (16.7) (19.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 140 102                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | (50.7) (37.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 147 95                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (51.2) (33.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 118                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (16.7) (19.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 695                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (23.1) (18.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Fatigue                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 83                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (27.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 95                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (34.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 102                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (35.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 198                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (32.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 1,320                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | (34.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Neutropenia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (2.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 93                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (33.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 95                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (33.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (0.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 33                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (11.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 89                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 80                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (27.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 63                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (10.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 533                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (13.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Mucosal inflammation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (4.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 85                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (32.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 81                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (28.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (4.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (1.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Decreased appetite                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (14.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 80                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (30.8) (29.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 85                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (29.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 105                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (17.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 822                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (21.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Thrombocytopenia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (2.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 79                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (28.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (25.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (1.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dianhoea                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 46                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (15.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 77                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (27.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 66                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (34.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 87                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (14.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 838                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (21.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Stomatitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | (26.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 80                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (27.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (3.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 90                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (2.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Platelet count decreased                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (3.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (20.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 49                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (17.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (1.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (1.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Cough                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 40                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (1.0) (13.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 56 51                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | (18.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 37                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (12.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 105                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (17.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 804                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (21.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Neutrophil count decreased                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 51                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (18.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 57                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (6'61)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (0.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Asthenia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (5.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (17.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (15.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (7.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 470                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (12.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Pyrexia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 38                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (12.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 45                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (16.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 35                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (12.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (11.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 531                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (13.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (14.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (15.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 60                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (20.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 84                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (13.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 308                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (8.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Weight decreased                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (4.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (15.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 116                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (40.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 35                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (5.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 98                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (2.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Hypomagnesaemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 54                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (18.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (6.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 92                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (15.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 346                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (9.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Hypothyroidism Blood creatinine increased                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (4.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 39                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (15.2) (14.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (8.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (2.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 192                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (5.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Hyponataemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (8.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 39                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (14.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 9E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (12.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 66                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (10.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 219                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (5.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Leukopenia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (1.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 37                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (13.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (14.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (0.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| White blood cell count decreased                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (1.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (13.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (16.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (1.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 35                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (0.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dysphagia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (8.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (11.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (9.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 67                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (11.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 69                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (1.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Headache                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (12.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 31                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (11.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (8.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 59                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (9.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 468                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (12.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hypokalaemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (7.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (10.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (18.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 55                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (9.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 166                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (4.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dizziness                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (10.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 37                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (12.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (6.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 320                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (8.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Insomnia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (4.7) (7.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (10.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (8.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 51                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (8.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 295                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (7.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Rash                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (10.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (9.8) (8.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 111 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (38.7) (10.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 69 53                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | (11.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 642 764                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | (16.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 33                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (11.0) (13.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 23 21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | (7.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (7.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 98                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (8.7) (16.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 688                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (661) (18.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dyspnoea                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 39 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | (4.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (6.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (5.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 33                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (5.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 401                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (10.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Oedema peripheral                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (5.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (2.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 60                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 628                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (16.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Arthralgia Back pain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (7.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (5.4) (4.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (3.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (9.9) (8.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 477                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (12.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Abdominal pain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (1.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (3.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (7.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (4.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 382                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (10.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dry skin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (4.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | (3.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 37                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (12.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (3.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | (5.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Skin fisswres                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.01                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 9 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | r0.71                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 38                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (13.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.31                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 225                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (0.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dermatitis acneifonm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (2.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | E8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (28.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (1.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 5 42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (1.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Paronychia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (12.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| (0.3) Every subject is counteda single time for each applicable row and column. A system organ class or specific adverse event appears on this report only ifits incidence in one or more ofthe columns meets the incidence criterion in the report tile, after rounding. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\". \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the dnug are excluded. HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055. eauo) coN 'e1 'ta 'te 'o 'a '68 't8 '181ed toon 41 stte-wgo asop auo 1sea[1e panjaoan oqm spalqns 1e sapnpulm phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087. MK-3475 Database CutoffDate forMelanoma(KN001-Melanoma:18APR2014.KN002: 28FEB2015,KN006: 03MAR2015. KN054: 020CT2017) MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017) | (0.3) Every subject is counteda single time for each applicable row and column. A system organ class or specific adverse event appears on this report only ifits incidence in one or more ofthe columns meets the incidence criterion in the report tile, after rounding. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\". \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the dnug are excluded. HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055. eauo) coN 'e1 'ta 'te 'o 'a '68 't8 '181ed toon 41 stte-wgo asop auo 1sea[1e panjaoan oqm spalqns 1e sapnpulm phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087. MK-3475 Database CutoffDate forMelanoma(KN001-Melanoma:18APR2014.KN002: 28FEB2015,KN006: 03MAR2015. KN054: 020CT2017) MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017) | (0.3) Every subject is counteda single time for each applicable row and column. A system organ class or specific adverse event appears on this report only ifits incidence in one or more ofthe columns meets the incidence criterion in the report tile, after rounding. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\". \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the dnug are excluded. HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055. eauo) coN 'e1 'ta 'te 'o 'a '68 't8 '181ed toon 41 stte-wgo asop auo 1sea[1e panjaoan oqm spalqns 1e sapnpulm phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087. MK-3475 Database CutoffDate forMelanoma(KN001-Melanoma:18APR2014.KN002: 28FEB2015,KN006: 03MAR2015. KN054: 020CT2017) MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017) | (0.3) Every subject is counteda single time for each applicable row and column. A system organ class or specific adverse event appears on this report only ifits incidence in one or more ofthe columns meets the incidence criterion in the report tile, after rounding. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\". \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the dnug are excluded. HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055. eauo) coN 'e1 'ta 'te 'o 'a '68 't8 '181ed toon 41 stte-wgo asop auo 1sea[1e panjaoan oqm spalqns 1e sapnpulm phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087. MK-3475 Database CutoffDate forMelanoma(KN001-Melanoma:18APR2014.KN002: 28FEB2015,KN006: 03MAR2015. KN054: 020CT2017) MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017) | (0.3) Every subject is counteda single time for each applicable row and column. A system organ class or specific adverse event appears on this report only ifits incidence in one or more ofthe columns meets the incidence criterion in the report tile, after rounding. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\". \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the dnug are excluded. HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055. eauo) coN 'e1 'ta 'te 'o 'a '68 't8 '181ed toon 41 stte-wgo asop auo 1sea[1e panjaoan oqm spalqns 1e sapnpulm phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087. MK-3475 Database CutoffDate forMelanoma(KN001-Melanoma:18APR2014.KN002: 28FEB2015,KN006: 03MAR2015. KN054: 020CT2017) MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017) | (0.3) Every subject is counteda single time for each applicable row and column. A system organ class or specific adverse event appears on this report only ifits incidence in one or more ofthe columns meets the incidence criterion in the report tile, after rounding. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\". \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the dnug are excluded. HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055. eauo) coN 'e1 'ta 'te 'o 'a '68 't8 '181ed toon 41 stte-wgo asop auo 1sea[1e panjaoan oqm spalqns 1e sapnpulm phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087. MK-3475 Database CutoffDate forMelanoma(KN001-Melanoma:18APR2014.KN002: 28FEB2015,KN006: 03MAR2015. KN054: 020CT2017) MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017) | (0.3) Every subject is counteda single time for each applicable row and column. A system organ class or specific adverse event appears on this report only ifits incidence in one or more ofthe columns meets the incidence criterion in the report tile, after rounding. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\". \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the dnug are excluded. HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055. eauo) coN 'e1 'ta 'te 'o 'a '68 't8 '181ed toon 41 stte-wgo asop auo 1sea[1e panjaoan oqm spalqns 1e sapnpulm phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087. MK-3475 Database CutoffDate forMelanoma(KN001-Melanoma:18APR2014.KN002: 28FEB2015,KN006: 03MAR2015. KN054: 020CT2017) MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017) | (0.3) Every subject is counteda single time for each applicable row and column. A system organ class or specific adverse event appears on this report only ifits incidence in one or more ofthe columns meets the incidence criterion in the report tile, after rounding. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\". \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the dnug are excluded. HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055. eauo) coN 'e1 'ta 'te 'o 'a '68 't8 '181ed toon 41 stte-wgo asop auo 1sea[1e panjaoan oqm spalqns 1e sapnpulm phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087. MK-3475 Database CutoffDate forMelanoma(KN001-Melanoma:18APR2014.KN002: 28FEB2015,KN006: 03MAR2015. KN054: 020CT2017) MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017) | (0.3) Every subject is counteda single time for each applicable row and column. A system organ class or specific adverse event appears on this report only ifits incidence in one or more ofthe columns meets the incidence criterion in the report tile, after rounding. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\". \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the dnug are excluded. HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055. eauo) coN 'e1 'ta 'te 'o 'a '68 't8 '181ed toon 41 stte-wgo asop auo 1sea[1e panjaoan oqm spalqns 1e sapnpulm phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087. MK-3475 Database CutoffDate forMelanoma(KN001-Melanoma:18APR2014.KN002: 28FEB2015,KN006: 03MAR2015. KN054: 020CT2017) MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017) | (0.3) Every subject is counteda single time for each applicable row and column. A system organ class or specific adverse event appears on this report only ifits incidence in one or more ofthe columns meets the incidence criterion in the report tile, after rounding. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\". \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the dnug are excluded. HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055. eauo) coN 'e1 'ta 'te 'o 'a '68 't8 '181ed toon 41 stte-wgo asop auo 1sea[1e panjaoan oqm spalqns 1e sapnpulm phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087. MK-3475 Database CutoffDate forMelanoma(KN001-Melanoma:18APR2014.KN002: 28FEB2015,KN006: 03MAR2015. KN054: 020CT2017) MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017) | (0.3) Every subject is counteda single time for each applicable row and column. A system organ class or specific adverse event appears on this report only ifits incidence in one or more ofthe columns meets the incidence criterion in the report tile, after rounding. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\". \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the dnug are excluded. HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055. eauo) coN 'e1 'ta 'te 'o 'a '68 't8 '181ed toon 41 stte-wgo asop auo 1sea[1e panjaoan oqm spalqns 1e sapnpulm phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087. MK-3475 Database CutoffDate forMelanoma(KN001-Melanoma:18APR2014.KN002: 28FEB2015,KN006: 03MAR2015. KN054: 020CT2017) MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017) |

Sowrce: [IsS: adam-adsl: adhe]

Between-treatment comparisons in AEs for selected AE ( ≥ 10% incidence rate) proportions are shown below:

<div style=\"page-break-after: always\"></div>

<!-- image -->

DatabaseCutoff Date:13JUN2018.

Source: [P048V01MK3475: analysis-adsl; adae]

Figure 36: Between-treatment comparison in adverse events -selected  AEs  (≥10% incidence) and  sorted by risk difference  (ASaT)  population)  -  Pembro  +  Chemotherapy (N=276) vs. Cetuximab + Chemotherapy (N=287)

Database Cutoff Date:13JUN2018.

Sowce: [P048V01MK3475: analysis-adsl; adae]

Figure 37: Between-treatment comparison in adverse events selected AEs (≥10% incidence) and sorted by risk difference (ASaT) population) - Pembro mono (N=300) vs. Cetuximab + Chemotherapy (N=287)

Table 70: Subjects with Adverse Events by Maximum Toxicity Grade (Excerpt)

|                             | KN048Data for MK-3475   | KN048Data for MK-3475   | KN048Data for MK-3475 + Chemotherapy   | KN048Data for MK-3475 + Chemotherapy   | KN048Datafor SOC   | KN048Datafor SOC   | HNSCC Safety Dataset for MK34751   | HNSCC Safety Dataset for MK34751   | Reference SafetyDataset forMK-3475   | Reference SafetyDataset forMK-3475   |
|-----------------------------|-------------------------|-------------------------|----------------------------------------|----------------------------------------|--------------------|--------------------|------------------------------------|------------------------------------|--------------------------------------|--------------------------------------|
|                             | n                       | (%)                     | n                                      | (%)                                    | n                  | (%)                | n                                  | (%)                                | n                                    | (%)                                  |
| Subjects inpopulation       | 300                     |                         | 276                                    |                                        | 287                |                    | 609                                |                                    | 3,830                                |                                      |
| withoneormore adverseevents | 290                     | (96.7)                  | 271                                    | (98.2)                                 | 286                | (99.7)             | 592                                | (97.2)                             | 3,720                                | (97.1)                               |
| Grade 1                     | 30                      | (10.0)                  | 4                                      | (1.4)                                  | 1                  | (0.3)              | 59                                 | (9.7)                              | 546                                  | (14.3)                               |
| Grade 2                     | 98                      | (32.7)                  | 33                                     | (12.0)                                 | 45                 | (15.7)             | 185                                | (30.4)                             | 1,372                                | (35.8)                               |
| Grade 3                     | 111                     | (37.0)                  | 136                                    | (49.3)                                 | 146                | (50.9)             | 240                                | (39.4)                             | 1,439                                | (37.6)                               |
| Grade 4                     | 26                      | (8.7)                   | 66                                     | (23.9)                                 | 67                 | (23.3)             | 55                                 | (9.0)                              | 206                                  | (5.4)                                |
| Grade 5                     | 25                      | (8.3)                   | 32                                     | (11.6)                                 | 27                 | (9.4)              | 53                                 | (8.7)                              | 157                                  | (4.1)                                |
| withnoadverseevents         | 10                      | (3.3)                   | 5                                      | (1.8)                                  | 1                  | (0.3)              | 17                                 | (2.8)                              | 110                                  | (2.9)                                |

<div style=\"page-break-after: always\"></div>

## Grade 3 to 5 AEs

Table 71: Subjects with Grade 3-5 adverse events (incidence ≥ 1% in one or more treatment groups) by decreasing frequency of preferred term from KN048 combo (ASaT population) - cut-off date 13-JUN-2018

|                                  |            | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for SOC   | KN048 Data for SOC   | HNSCC Safety Dataset for MK347511   | HNSCC Safety Dataset for MK347511   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   |
|----------------------------------|------------|-----------------------------------------|-----------------------------------------|----------------------|----------------------|-------------------------------------|-------------------------------------|-------------------------------------------|-------------------------------------------|
|                                  |            | ()                                      | ()                                      | (76)                 | (76)                 | (6)                                 | (6)                                 | (6)                                       | (6)                                       |
| Subjects in population           | (6) 300    | 276                                     |                                         | n 287                |                      | n 609                               |                                     | DES'E                                     |                                           |
| with one or more adverse events  | 162 (54.0) | 234                                     | (84.8)                                  | 240                  | (83.6)               | 348                                 | (57.1)                              | 1.,802                                    | (47.0)                                    |
| with no adverse events           | 138 (46.0) | 42                                      | (15.2)                                  | 47                   | (16.4)               | 261                                 | (42.9)                              | 2,028                                     | (53.0)                                    |
| Anaemia                          | 14 (4.7)   | 89                                      | (24.6)                                  | 47                   | (16.4)               | 44                                  | (7.2)                               | 159                                       | (4.2)                                     |
| Neutropenia                      | 1 (0.3)    | 50                                      | (18.1)                                  | 62                   | (21.6)               | 2                                   | (0.3)                               | 11                                        | (0.3)                                     |
| Neutrophil count decreased       | 0 (0.0)    | 31                                      | (11.2)                                  | 37                   | (12.9)               | 1                                   | (0.2)                               |                                           | (0.1)                                     |
| Mucosal inflammation             | 4 (1.3)    | 27                                      | (9.8)                                   | 15                   | (5.2)                | 2                                   | (0.3)                               | 2                                         | (0.1)                                     |
| Thrombocytopenia                 | 1 (0.3)    | 25                                      | (9.1)                                   | 26                   | (9.1)                | 0                                   | (0.0)                               | 15                                        | (0.4)                                     |
| Febrile neutropenia              | D (0.0)    | 23                                      | (8.3)                                   | 15                   | (5.2)                | 0                                   | (0.0)                               | 4                                         | (0.1)                                     |
| Stomatitis                       | 0 (0.0)    | 23                                      | (8.3)                                   | 10                   | (3.5)                | 2                                   | (0.3)                               | 5                                         | (0.1)                                     |
| Hypomatraemia                    | 17 (5.7)   | 21                                      | (8.0)                                   | 18                   | (6.3)                | 26                                  | (4.3)                               | 91                                        | (2.4)                                     |
| Fatigue                          | 6 (3.0)    | 20                                      | (7.2)                                   | 14                   | (4.9)                | 15                                  | (2.5)                               | 103                                       | (2.7)                                     |
| Hypokalaemia                     | 6 (2.0)    | 17                                      | (6.2)                                   | 17                   | (5.9)                | 16                                  | (2.6)                               | 33                                        | (0.9)                                     |
| Nausea                           | 0 (0.0)    | 16                                      | (5.8)                                   | 17                   | (5.9)                | 5                                   | (0.8)                               | 40                                        | (1.0)                                     |
| Platelet count decreased         | 0 (0.0)    | 15                                      | (5.4)                                   | 10                   | (3.5)                | 0                                   | (0.0)                               | 6                                         | (0.2)                                     |
| White blood cell count decreased | 0 (0.0)    | 15                                      | (5.4)                                   | 26                   | (9.1)                | 0                                   | (0.0)                               | 3                                         | (0.1)                                     |
| Pneumonia                        | 16 (5.3)   | 14                                      | (5.1)                                   | 19                   | (6.6)                | 43                                  | (7.1)                               | 102                                       | (2.7)                                     |
| Decreased appetite               | 3 (1.0)    | 13                                      | (4.7)                                   | 10                   | (3.5)                | 12                                  | (2.0)                               | 45                                        | (1.2)                                     |
| Lymphocyte coumt decreased       | 2 (0.7)    | 11                                      | (4.0)                                   | 9                    | (3.1)                | 11                                  | (1.8)                               | 16                                        | (0.4)                                     |
| Asthenia                         | (1.0)      | 10                                      | (3.6)                                   | 6                    | (3.1)                | 1                                   | (0.2)                               | 45                                        | (1.2)                                     |
| Hypercalcaemia                   | (2.0)      | 10                                      | (3.6)                                   | 2                    | (0.7)                | 21                                  | (3.4)                               | 19                                        | (0.5)                                     |
| Vomiting                         | 1 (0.3)    | 10                                      | (3.6)                                   | 8                    | (2.8)                | 5                                   | (0.8)                               | 33                                        | (0.9)                                     |
| Leukopenia                       | 0 (0.0)    | 9                                       | (3.3)                                   | 16                   | (5.6)                | 0                                   | (0.0)                               | 7                                         | (0.2)                                     |
| Pneumonia aspiration             | 5 (1.7)    | 9                                       | (3.3)                                   | 3                    | (1.0)                | 21                                  | (3.4)                               | 4                                         | (0.1)                                     |
| Dysphagia                        | 7 (2.3)    | 8                                       | (2.9)                                   | 6                    | (2.1)                | 16                                  | (2.6)                               | 7                                         | (0.2)                                     |
| Lung infection                   | 3 (1.0)    | 8                                       | (2.9)                                   | 1                    | (0.3)                | E                                   | (0.5)                               | 15                                        | (0.4)                                     |
| Weight decreased                 | 6 (2.0)    | 8                                       | (2.9)                                   | 4                    | (1.4)                | 5                                   | (0.8)                               | 12                                        | (0.3)                                     |
| Dehydration                      | 2 (0.7)    |                                         | (2.5)                                   | 8                    | (2.8)                | 15                                  | (2.5)                               | 42                                        | (1.1)                                     |
| Dianhoea                         | 2 (0.7)    | 7                                       | (2.5)                                   | 8                    | (2.8)                | 10                                  | (1.6)                               | 55                                        | (1.4)                                     |
| Hyperglycaemia                   | 4 (1.3)    |                                         | (2.5)                                   |                      | (1.0)                | 7                                   | (1.1)                               | 45                                        | (1.2)                                     |
| Hypertension                     | 4 (1.3)    | 7                                       | (2.5)                                   | 4                    | (1.4)                | 5                                   | (0.8)                               | 50                                        | (1.3)                                     |
| Dyspnoea                         | 6 (2.0)    | 6                                       | (2.2)                                   | 3                    | (1.0)                | 15                                  | (2.5)                               | 95                                        | (2.5)                                     |
| Hypomagnesaemia                  | 0 (0.0)    | 6                                       | (2.2)                                   | 14                   | (4.9)                | 0                                   | (0.0)                               | 0                                         | (0.0)                                     |
| Hypotension                      | (1.7)      | 6                                       | (2.2)                                   | 6                    | (2.1)                | 9                                   | (1.5)                               | 15                                        | (0.4)                                     |
| Pulmonary embolism               | 4 (1.3)    | 6                                       | (2.2)                                   | 8                    | (2.8)                | 8                                   | (1.3)                               | 58                                        | (1.5)                                     |
| Septic shock                     | 1 (0.3)    | 6                                       | (2.2)                                   | 2                    | (0.7)                | 1                                   | (0.2)                               | 8                                         | (0.2)                                     |
| Syncope                          | 2 (0.7)    | 6                                       | (2.2)                                   | 10                   | (3.5)                | 9                                   | (1.5)                               | 19                                        | (0.5)                                     |
| Acute kidney injuy               | 4 (1.3)    | 5                                       | (1.8)                                   | 2                    | (0.7)                | 1                                   | (0.2)                               | 41                                        | (1.1)                                     |

<div style=\"page-break-after: always\"></div>

| Sepsis                                | 6       | (2.0)   | 5             | (1.8) E   | (1.0)   | 10   | (1.6)   | 21   | (0.5)   |
|---------------------------------------|---------|---------|---------------|-----------|---------|------|---------|------|---------|
| Tumow haemomhage                      | 9       | (3.0)   | 5             | 5         | (1.7)   | 11   | (1.8)   | 2    | (0.1)   |
| Alanine aminotransferse increased     | 1 (0.3) |         | (1.8) 4 (1.4) | 4         | (1.4)   | 3    | (0.5)   | 38   | (1.0)   |
| Hypocalcaemia                         | 0 (0.0) | 4       | (1.4)         | 4         | (1.4)   | 3    | (0.5)   | 4    | (0.1)   |
| Aspartate aminotransferase increased  | 2 (0.7) | 3       | (1.1)         | 5         | (1.7)   | 11   | (1.8)   | 41   | (1.1)   |
| Bronchitis                            | 2 (0.7) | 3       | (1.1)         | 1         | (0.3)   | 2    | (0.3)   | 12   | (0.3)   |
| Cellulitis                            | 2       | (0.7)   | 3 (1.1)       | 2         | (0.7)   | 8    | (1.3)   | 17   | (0.4)   |
| Hypophosphataemia                     | 0 (0.0) | 3       | (1.1)         | 6         | (3.1)   | 15   | (2.5)   | 19   | (0.5)   |
| Larymgeal oedema                      | 1       | (0.3)   | 3 (1.1)       | 0         | (0.0)   | 2    | (0.3)   | 1    | (0.0)   |
| Lymphopenia                           | 1       | (0.3)   | 3 (1.1)       | 5         | (1.7)   | 3    | (0.5)   | 6    | (0.2)   |
| Myocardial infarction                 |         | (1.0)   | (1.1)         | m         | (1.0)   | 4    | (0.7)   | 7    | (0.2)   |
| Neck pain                             | 2       | (0.7)   | 3 (1.1)       | 2         | (0.7)   | 2    | (0.3)   | 3    | (0.1)   |
| Oral pain                             | 0 (0.0) |         | 3 (1.1)       |           | (1.0)   | 0    | (0.0)   | 2    | (0.1)   |
| Peripheral sensory neuwropathy        | 0       | (0.0)   | 3 (1.1)       | 2         | (0.7)   | 0    | (0.0)   | 0    | (0.0)   |
| Pleural effusion                      | 0       | (0.0)   | 3 (1.1)       | D         | (0.0)   | 6    | (1.0)   | 48   | (1.3)   |
| Respiratory tract infection           |         | (0.3)   | 3 (1.1)       | 2         | (0.7)   | 1    | (0.2)   | 12   | (0.3)   |
| Urinary tract infection               | 0       | (0.0)   | (1.1)         | m         | (1.0)   | 2    | (0.3)   | 67   | (1.7)   |
| Abdominal pain                        | 1       | (0.3)   | 2 (0.7)       | 5         | (1.7)   | 6    | (o1)    | 35   | (0.9)   |
| Cancer pain                           | 3       | (1.0)   | 2 (0.7)       | 1         | (0.3)   | 3    | (0.5)   | 20   | (0.5)   |
| Death                                 | 2       | (0.7)   | 2 (0.7)       | 2         | (0.7)   | 11   | (1.8)   | 19   | (0.5)   |
| Gamma-ghutamyltransferase increased   | 4       | (ED)    | 2 (0.7)       |           | (0.3)   |      | (0.2)   | 23   | (0.6)   |
| Pancytopenia                          | 0       | (0.0)   | 2 (0.7)       | 3         | (1.0)   | 0    | (0.0)   | 1    | (0.0)   |
| Pneumonitis                           | 4       | (1.3)   | 2 (0.7)       | 2         | (0.7)   | 7    | (1.1)   | 49   | (1.3)   |
| Respiratory fhilue                    | 1       | (0.3)   | 2 (0.7)       | 1         | (0.3)   | 9    | (1.5)   | 18   | (0.5)   |
| Blood akaline phosphatase increased   | 2       | (0.7)   | 1 (0.4)       | 0         | (0.0)   | 8    | (1.3)   | 30   | (0.8)   |
| Colitis                               | 0       | (0.0)   | (0.4)         | 2         | (0.7)   | 1    | (0.2)   | 47   | (1.2)   |
| Device related infection              | 4       | (1.3)   | (0.4)         | 4         | (1.4)   | 2    | (0.3)   | 5    | (0.1)   |
| Hyperkalaemia                         | 1       | (0.3)   | 1 (0.4)       | 3         | (1.0)   | 2    | (0.3)   | 17   | (0.4)   |
| Hypoxia                               | 2       | (0.7)   | (0.4)         | 1         | (0.3)   | 6    | (1.0)   | 17   | (0.4)   |
| Infected neoplasm                     | 3       | (1.0)   | 1 (0.4)       | 1         | (0.3)   | 3    | (0.5)   | 2    | (0.1)   |
| Infusion related reaction             | 0       | (0.0)   | 1 (0.4)       | 3         | (1.0)   | 0    | (0.0)   | 0    | (0.0)   |
| Mouth haemonhage                      | 0       | (0.0)   | 1 (0.4)       | 0         | (0.0)   |      | (1.1)   | 0    | (0.0)   |
| Rash                                  |         | (0.7)   | 1 (0.4)       | 17        | (5.9)   |      | (0.3)   | 16   | (0.4)   |
| Aphthous ulcer                        | 0       | (0.0)   | 0 (0.0)       | E         | (1.0)   | 0    | (0.0)   | 0    | (0.0)   |
| Back pain                             | 3       | (1.0)   | 0 (0.0)       | 1         | (0.3)   | 6    | (1.0)   | 53   | (1.4)   |
| Constipation                          | 1       | (0.3)   | 0 (0.0)       | 4         | (1.4)   | 2    | (0.3)   | 20   | (0.5)   |
| Dermatitis acneifom                   | 0       | (0.0)   | 0 (0.0)       | 6         | (2.1)   | 0    | (0.0)   | 0    | (0.0)   |
| Face oedemn                           | 1       | (0.3)   | 0 (0.0)       | 0         | (0.0)   | 6    | (1.0)   | 0    | (0.0)   |
| General physical health deterioration | 0       | (0.0)   | 0 (0.0)       | 3         | (1.0)   | 2    | (0.3)   | 29   | (0.8)   |
| Malnutrition                          | 4       | (1.3)   | 0 (0.0)       | 0         | (0.0)   | 1    | (0.2)   | 2    | (0.1)   |
| Osteomyelitis                         | 0       | (0.0)   | 0 (0.0)       | 4         | (1.4)   |      | (0.2)   | 3    | (0.1)   |
| Soft tissue infection                 | 3       | (1.0)   | 0 (0.0)       | 1         | (0.3)   | 1    | (0.2)   | 2    | (0.1)   |
| Tumowr pain                           | 1       | (0.3)   | 0 (0.0)       | 4         | (1.4)   | 8    | (1.3)   | 21   | (0.5)   |
| Upper gastrointestinal haemorhage     |         | (0.3)   | 0 (0.0)       | 3         | (1.0)   | 0    | (0.0)   | E    | (0.1)   |

Every subject is counted a single time for each applicable row and column

- A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report tile, affter rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of lhast dose are included.

MedDRA preferred terms *Neoplasm Progression\". \"Maligmant Neoplasm Progression\" and \"Disease Progression not related to the dug are ewcluded.

H Includes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055.

phnse). KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087.

MK-3475 Database Cutoff Date for Melanomn (KN001-Melamoma:18APR2014,KN002:28FEB2015.KN006: 03MAR2015. KN054: 020CT2017)

MK-3475 Database Cutoff Date for Lung (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017)

MK-3475 Database CutoffDate for HNSCC (KN012-HNSCC: 26APR2016,KN040: 15MAY2017.KN048: 13IUN2018,KN055: 22APR2016)

MK-3475 Database Cutoff Date for cHL (KIN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

MK-3475 Database Cutoff Date for Blhdder (KN045: 18IAN2017, KN052: 09MAR2017)

Source: TIsS: adam-adsl: adael

In the next figures, rainfall plots show between-treatment comparisons of Pembrolizumab+Chemotherapy and Pembrolizumab monotherapy each versus Standard Treatment:

<div style=\"page-break-after: always\"></div>

<!-- image -->

Database Cutoff Date: 13JUN2018.

Source: [P048V01MK3475: analysis-adsl; adae]

Figure 38: Between-treatment comparison in Grade 3-5 AEs selected AEs (≥ 5% incidence) and sorted by risk difference (ASaT population) - Pembro combo (N=276) vs. Control (N=287)

Table 72: Exposure-adjusted Grade 3-5 AEs (including multiple occurrence of events) incidence ≥5% in one or more treatment groups - Pembro combo vs. control (ASaT population) - cut-off date 13-JUN-2018

|                             | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)   |
|-----------------------------|--------------------------------------------------|--------------------------------------------------|
|                             | Pembrolizumab + Chemotherapy                     | Cetuximab + Chemotherapy                         |
| Number of subjects exposed  | 276                                              | 287                                              |
| Total exposure person-years | 190.63                                           | 167.83                                           |
| Total events (rate)         | 453 (237.64)                                     | 485 (288.98)                                     |

<!-- image -->

Database Cutoff Date: 13JUN2018.

Figure 39: Between-treatment comparison in Grade 3-5 AEs selected AEs (≥ 5% incidence) and sorted by risk difference (ASaT population) - Pembro mono (N=300) vs. Cetuximab + Chemotherapy (N=287)

<div style=\"page-break-after: always\"></div>

Table 73: Exposure-adjusted Grade 3-5 AEs (including multiple occurrence of events) incidence ≥5% in one or more treatment groups - Pembro mono vs. control (ASaT population) - cut-off date 13-JUN-2018

|                             | Event Count and Rate (Events/100 person-years   | Event Count and Rate (Events/100 person-years   |
|-----------------------------|-------------------------------------------------|-------------------------------------------------|
|                             | Pembrolizumab                                   | Cehuximab+ Chemotherapy                         |
| Number of subjects exposed  | 300                                             | 287                                             |
| Total exposure*person-years | 180.60                                          | 167.83                                          |
| Total events (rate)         | 62 (34.33)                                      | 446 (265.74)                                    |

<div style=\"page-break-after: always\"></div>

## Drug-related Adverse Events

Table 74: Subjects with drug-related adverse events (incidence ≥ 5% in one or more treatment groups) by  decreasing  frequency  of  preferred  term  from  KN048  combo  (ASaT  population)  -  cut-off  date 13-JUN-2018

|                                                        | KN048 Data for MK-3475   | KN048 Data for MK-3475   | KN048 Data for MK-3475 + Chemothernapy   | KN048 Data for MK-3475 + Chemothernapy   | KN048 Data for SOC   | KN048 Data for SOC   | HNSCC Safety Dataset for MK34751   | HNSCC Safety Dataset for MK34751   | Reference Safety Dataset for Mk-347511   | Reference Safety Dataset for Mk-347511   |
|--------------------------------------------------------|--------------------------|--------------------------|------------------------------------------|------------------------------------------|----------------------|----------------------|------------------------------------|------------------------------------|------------------------------------------|------------------------------------------|
|                                                        | n (4)                    | n (4)                    | ()                                       | ()                                       | n ()                 | n ()                 | (6)                                | (6)                                | n (-)                                    | n (-)                                    |
| Subjects in population                                 | 300                      |                          | 276                                      |                                          | 287                  |                      | 609                                |                                    | 3,830                                    |                                          |
| withoneormore adverse events                           | 175                      | (58.3)                   | 263                                      | (95.3)                                   | 278                  | (96.9)               | 387                                | (63.5)                             | 2.751                                    | (71.8)                                   |
| with no adverse events                                 | 125                      | (41.7)                   | 13                                       | (4.7)                                    | 9                    | (3.1)                | 222                                | (36.5)                             | 1,079                                    | (28.2)                                   |
| Anaemia                                                | 12                       | (4.0)                    | 133                                      | (48.2)                                   | 118                  | (41.1)               | 31                                 | (5.1)                              | 122                                      | (3.2)                                    |
| Nausea                                                 | 12                       | (4.0)                    | 124                                      | (44.9)                                   | 131                  | (45.6)               | 34                                 | (5.6)                              | 395                                      | (10.3)                                   |
| Neutropenia                                            | 3                        | (1.0)                    | 91                                       | (33.0)                                   | 90                   | (31.4)               | 0                                  | (0.0)                              | 20                                       | (0.5)                                    |
| Fatigue                                                | 43                       | (14.3)                   | 84                                       | (30.4)                                   | E8                   | (28.9)               | 103                                | (16.9)                             | 826                                      | (21.6)                                   |
| Mucosal inflammation                                   | 8                        | (2.7)                    | 77                                       | (27.9)                                   | 76                   | (26.5)               | 11                                 | (1.8)                              | 28                                       | (0.7)                                    |
| Thrombocytopenia                                       | 4                        | (1.3)                    | 75                                       | (27.2)                                   | 63                   | (22.0)               | 1                                  | (0.2)                              | 29                                       | (0.8)                                    |
| Vomiting                                               | 7                        | (2.3)                    | 75                                       | (27.2)                                   | 64                   | (22.3)               | 11                                 | (1.8)                              | 146                                      | (3.8)                                    |
| Stomatitis                                             | 2                        | (0.7)                    | 67                                       | (24.3)                                   | 69                   | (24.0)               | 10                                 | (1.6)                              | 48                                       | (1.3)                                    |
| Decreased appetite                                     | 16                       | (5.3)                    | 62                                       | (22.5)                                   | 62                   | (21.6)               | 39                                 | (6.4)                              | 337                                      | (8.8)                                    |
| Platelet count decreased                               | 1                        | (0.3)                    | 51                                       | (18.5)                                   | 46                   | (16.0)               | 4                                  | (0.7)                              | 23                                       | (0.6)                                    |
| Dianhoea                                               | 16                       | (5.3)                    | 49                                       | (17.8)                                   | 75                   | (26.1)               | 35                                 | (5.7)                              | 445                                      | (11.6)                                   |
| Neutrophil count decreased                             | 1                        | (0.3)                    | 46                                       | (16.7)                                   | 54                   | (18.8)               | 4                                  | (0.7)                              | 17                                       | (0.4)                                    |
| White blood cell count decreased                       | 2                        | (0.7)                    | 36                                       | (13.0)                                   | 43                   | (15.0)               | 4                                  | (0.7)                              | 19                                       | (0.5)                                    |
| Hypothyroidism                                         | 39                       | (13.0)                   | 35                                       | (12.7)                                   | 1                    | (0.3)                | 68                                 | (11.2)                             | 309                                      | (8.1)                                    |
| Leukopenia                                             | 2                        | (0.7)                    | 34                                       | (12.3)                                   | BE                   | (13.2)               | 1                                  | (0.2)                              | 17                                       | (0.4)                                    |
| Asthenia                                               | 7                        | (2.3)                    | 33                                       | (12.0)                                   | OE                   | (10.5)               | 19                                 | (3.1)                              | 260                                      | (6.8)                                    |
| Blood creatinine increased                             | 2                        | (0.7)                    | 30                                       | (10.9)                                   | 15                   | (5.2)                | 1                                  | (0.2)                              | 51                                       | (1.3)                                    |
| Hypoma gesaemia                                        |                          | (1.0)                    | 29                                       | (10.5)                                   | 95                   | (33.1)               | 3                                  | (0.5)                              | 23                                       | (0.6)                                    |
| Constipation                                           | 6                        | (3.0)                    | 28                                       | (10.1)                                   | 31                   | (10.8)               | 6                                  | (1.0)                              | 121                                      | (3.2)                                    |
| Hyponataemia                                           | 9                        | (3.0)                    | 23                                       | (8.3)                                    | 20                   | (7.0)                | 9                                  | (1.5)                              | 32                                       | (0.8)                                    |
| Rash                                                   | 25                       | (8.3)                    | 22                                       | (8.0)                                    | 101                  | (35.2)               | 46                                 | (7.6)                              | 485                                      | (12.7)                                   |
| Febrile neutropenia                                    | 0                        | (0.0)                    | 21                                       | (7.6)                                    | 12                   | (4.2)                | 0                                  | (0.0)                              | 0                                        | (0.0)                                    |
| Weight decreased                                       | 9                        | (3.0)                    | 21                                       | (7.6)                                    | 30                   | (10.5)               | 16                                 | (2.6)                              | 84                                       | (2.2)                                    |
| Malaise                                                | 4                        | (1.3)                    | 18                                       | (6.5)                                    | 9                    | (3.1)                | 3                                  | (0.5)                              | 33                                       | (0.9)                                    |
| Dysgeusia                                              | 6                        | (2.0)                    | 16                                       | (5.8)                                    | 15                   | (5.2)                | 4                                  | (0.7)                              | 62                                       | (1.6)                                    |
| Pyrexia                                                | 10                       | (3.3)                    | 16                                       | (5.8)                                    | 12                   | (4.2)                | 19                                 | (3.1)                              | 197                                      | (5.1)                                    |
| Acute kidney injury                                    | 4                        | (1.3)                    | 15                                       | (5.4)                                    | 6                    | (2.1)                | 1                                  | (0.2)                              | 11                                       | (0.3)                                    |
| Hypokalaemia                                           | 4                        | (1.3)                    | 15                                       | (5.4)                                    | 36                   | (12.5)               | 6                                  | (1.0)                              | 23                                       | (0.6)                                    |
| Periphernal sensory neuropathy                         | 1                        | (0.3)                    | 15                                       | (5.4)                                    | 6                    | (2.1)                | E                                  | (0.5)                              | 17                                       | (0.4)                                    |
| Tinnihus                                               | 0                        | (0.0)                    | 15                                       | (5.4)                                    | 16                   | (5.6)                | 1                                  | (0.2)                              | 2                                        | (0.1)                                    |
| Pruitus                                                | 21                       | (7.0)                    | 14                                       | (5.1)                                    | 24                   | (8.4)                | 36                                 | (5.9)                              | 608                                      | (15.9)                                   |
| Alanine aminotransferase increased                     | 7                        | (2.3)                    | 10                                       | (3.6)                                    | 15                   | (5.2)                | 17                                 | (2.8)                              | 132                                      | (3.4)                                    |
| Arthralgia                                             | 6                        | (2.0)                    | 9                                        | (3.3)                                    | 3                    | (1.0)                | 24                                 | (3.9)                              | 324                                      | (8.5)                                    |
| Hypophosphataemia                                      | 1                        | (0.3)                    | 6                                        | (2.2)                                    | 19                   | (6.6)                | 4                                  | (0.7)                              | 27                                       | (0.7)                                    |
| Dry skin Palmar-plantar                                | 6                        | (2.0) (0.3)              | 5 4                                      | (1.8) (1.4)                              | 37                   | (9.4) (7.0)          | 13 0                               | (2.1) (0.0)                        | 119 10                                   | (3.1) (0.3)                              |
|                                                        |                          |                          |                                          |                                          |                      |                      |                                    |                                    | 1                                        |                                          |
| erythrodysaesthesia syndrome Infusion related reaction |                          | (0.3)                    | 2                                        | (0.7)                                    | 16                   | (5.6)                | 4                                  | (0.7)                              | 41                                       | (1.1)                                    |
| Skin fisswres Dermatitis acneifom                      | 0 6                      | (0.0) (2.0)              | 2 1                                      | (0.7) (0.4)                              | 36 82                | (12.5) (28.6)        | 1 4                                | (0.2) (0.7)                        | 36                                       | (0.0) (0.9)                              |
| Paronychia                                             |                          | (0.0)                    |                                          | (0.0)                                    | EE                   |                      | 0                                  |                                    | 0                                        |                                          |
|                                                        | 0                        |                          | 0                                        |                                          |                      | (11.5)               |                                    | (0.0)                              |                                          | (0.0)                                    |

Every subject is counted a single time for each applicable row and columm.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after roumding.

HIncludes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are inchuded.

Includes all subjects who received atleast one dose of MK-3475 in KN00l Part Bl. B2. B3. D. C. Fl. F2. F3: KN002 (original phnse). KN006, and KN010, KN013-Cohort 3. KN024. KN045, KN052 and KN087.

MK-3475 Database Cutoff Date for Melanoma (KN001-Melamoma:18APR2014.KN002:28FEB2015.KN006: 03MAR2015. KN054: 020CT2017)

MK-3475 Datbase CutoffDate forLumg (KN001-NSCLC: 23JAN2015.KN010:30SEP2015.KN024: 10JULY2017)

MK-3475 Database Cutoff Date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 13JUN2018, KN055: 22APR2016)

MK-3475 Database Cutoff Date for cHL (KN013-Cohort 3: 27SEP2016,KN087: 25SEP2016)

MK-3475 Database Cutoff Date for Blhdder (KN045: 18IAN2017, KN052: 09MAR2017)

Sowce:HisS: adam-adsl:adael

<div style=\"page-break-after: always\"></div>

Table 75: Subjects with drug-related AEs by maximum toxicity Grade (Incidence&gt;0% in one or more treatment groups) - Excerpt

<!-- image -->

|                            | KN048Data for MK-3475   | KN048Data for MK-3475   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for MK-3475 + Chemotherapy   | KN048Data for SOC   | KN048Data for SOC   | HNSCC Safety Dataset for MK347511   | HNSCC Safety Dataset for MK347511   | Reference Safety Dataset for MK-347511   | Reference Safety Dataset for MK-347511   |
|----------------------------|-------------------------|-------------------------|-----------------------------------------|-----------------------------------------|---------------------|---------------------|-------------------------------------|-------------------------------------|------------------------------------------|------------------------------------------|
|                            | I                       | (9.)                    | ()                                      | ()                                      |                     | (%.)                |                                     | (90)                                | n                                        | ()                                       |
| Subjects in population     | 300                     |                         | 276                                     |                                         | 287                 |                     | 609                                 |                                     | 3.830                                    |                                          |
| withoneormoreadverseevents | 175                     | (58.3)                  | 263                                     | (95.3)                                  | 278                 | (96.9)              | 387                                 | (63.5)                              | 2.751                                    | (71.8)                                   |
| Grade 1                    | 9                       | (21.3)                  | 13                                      | (4.7)                                   | 11                  | (3.8)               | 139                                 | (22.8)                              | 1,069                                    | (27.9)                                   |
| Grade 2                    | 61                      | (20.3)                  | 54                                      | (19.6)                                  | 69                  | (24.0)              | 165                                 | (27.1)                              | 1,105                                    | (28.9)                                   |
| Grade 3                    | 42                      | (14.0)                  | 133                                     | (48.2)                                  | 135                 | (47.0)              | 67                                  | (11.0)                              | 500                                      | (13.1)                                   |
| Grade 4                    |                         | (1.7)                   | 53                                      | (19.2)                                  | 55                  | (19.2)              | 11                                  | (1.8)                               | 60                                       | (1.6)                                    |
| Grade 5                    | 3                       | (1.0)                   | 10                                      | (3.6)                                   | 8                   | (2.8)               | 5                                   | (0.8)                               | 17                                       | (0.4)                                    |
| with no adverse events     | 125                     | (41.7)                  | 13                                      | (4.7)                                   | 9                   | (3.1)               | 222                                 | (36.5)                              | 1.079                                    | (28.2)                                   |

## Grade 3-5 Drug-related AEs

Table 76: Subjects with Grade 3-5 drug-related adverse events (incidence ≥ 1% in one or more treatment groups) by decreasing frequency of preferred term from KN048 combo (ASaT population) - cut-off date 13-JUN-2018

|                                                        |            | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for SOC   | KN048 Data for SOC   | HNSCC Safety Dataset for MK34751   | HNSCC Safety Dataset for MK34751   | Reference Safety Dataset for MK-347511   | Reference Safety Dataset for MK-347511   |
|--------------------------------------------------------|------------|-----------------------------------------|-----------------------------------------|----------------------|----------------------|------------------------------------|------------------------------------|------------------------------------------|------------------------------------------|
|                                                        |            | (96)                                    | (96)                                    | (96)                 | (96)                 | (96)                               | (96)                               | (96)                                     | (96)                                     |
| Subjects in population with one or more adverse events | (96) 300   | 276                                     |                                         | 287                  |                      | 609                                |                                    | 3,830                                    |                                          |
|                                                        | 50 (16.7)  | 196                                     | (71.0)                                  | 198                  | (69.0)               | 83                                 | (13.6)                             | 577                                      | (15.1)                                   |
| with no adverse events                                 | 250 (83.3) | 80                                      | (29.0)                                  | 89                   | (31.0)               | 526                                | (86.4)                             | 3,253                                    | (84.9)                                   |
| Anaemia                                                | 2 (0.7)    | 52                                      | (18.8)                                  | 42                   | (14.6)               | 5                                  | (0.8)                              | 18                                       | (0.5)                                    |
| Neutopenia                                             | 0 (0.0)    | 50                                      | (18.1)                                  | 59                   | (20.6)               | 0                                  | (0.0)                              | 8                                        | (0.2)                                    |
| Neutrophil coumt decreased                             | 0 (0.0)    | 28                                      | (10.1)                                  | 35                   | (12.2)               | 1                                  | (0.2)                              | E                                        | (0.1)                                    |
| Mucosal inflammation                                   | 2 (0.7)    | 26                                      | (9.4)                                   | 14                   | (4.9)                | 1                                  | (0.2)                              | 2                                        | (0.1)                                    |
| Thrombocytopenia                                       | 1 (0.3)    | 24                                      | (8.7)                                   | 24                   | (8.4)                | 0                                  | (0.0)                              | 4                                        | (0.1)                                    |
| Stomatitis                                             | 0 (00)     | 22                                      | (8.0)                                   | 10                   | (3.5)                | 2                                  | (0.3)                              | 3                                        | (0.1)                                    |
| Febrile neutropenia                                    | 0 (0.0)    | 21                                      | (7.6)                                   | 12                   | (4.2)                | 0                                  | (0.0)                              | 0                                        | (0.0)                                    |
| Fatigue                                                | 3 (1.0)    | 19                                      | (6.9)                                   | 11                   | (3.8)                | 7                                  | (1.1)                              | 45                                       | (1.2)                                    |
| Nausea                                                 | 0 (0.0)    | 15                                      | (5.4)                                   | 16                   | (5.6)                | 1                                  | (0.2)                              | 12                                       | (0.3)                                    |
| White blood cell couwt decreased                       | 0 (0.0)    | 15                                      | (5.4)                                   | 22                   | (7.7)                | 0                                  | (0.0)                              | 1                                        | (0.0)                                    |
| Platelet coumt decreased                               | 0 (0.0)    | 14                                      | (5.1)                                   | 9                    | (3.1)                | 0                                  | (0.0)                              | 2                                        | (0.1)                                    |
| Decreased appetite                                     | 1 (0.3)    | 12                                      | (4.3)                                   | 8                    | (2.8)                | 3                                  | (0.5)                              | 11                                       | (0.3)                                    |
| Hyponatraemia                                          | 6 (2.0)    | 10                                      | (3.6)                                   | 9                    | (3.1)                | E                                  | (0.5)                              | 16                                       | (0.4)                                    |
| Lymphocyte count decreased                             | 1 (0.3)    | 9                                       | (3.3)                                   | 6                    | (2.1)                | 1                                  | (0.2)                              | 5                                        | (0.1)                                    |
| Asthenia                                               | (0.3)      | 8                                       | (2.9)                                   | 6                    | (2.1)                | 1                                  | (0.2)                              | 17                                       | (0.4)                                    |
| Hypokalaemia                                           | (0.3)      | 8                                       | (2.9)                                   | 11                   | (3.8)                | 1                                  | (0.2)                              | 7                                        | (0.2)                                    |
| Leukopenia                                             | 0 (0.0)    | 8                                       | (2.9)                                   | 16                   | (5.6)                | 0                                  | (0.0)                              | 3                                        | (0.1)                                    |
| Vomiting                                               | 0 (0.0)    | 7                                       | (2.5)                                   | 5                    | (1.7)                | 0                                  | (0.0)                              | 10                                       | (0.3)                                    |
| Septic shock                                           | 0 (0.0)    | 6                                       | (2.2)                                   | 0                    | (0.0)                | 0                                  | (0.0)                              | 0                                        | (0.0)                                    |
| Pueumonia                                              | 1 (0.3)    | 5                                       | (1.8)                                   | 6                    | (2.1)                | 1                                  | (0.2)                              | 9                                        | (0.2)                                    |
| Acute kidney injuy                                     | (0.3)      | 4                                       | (1.4)                                   | 1                    | (0.3)                | 1                                  | (0.2)                              | 4                                        | (0.1)                                    |
| Hypomaguesaemia                                        | 0 (0.0)    | 4                                       | (1.4)                                   | 11                   | (3.8)                | 0                                  | (0.0)                              | 0                                        | (0.0)                                    |
| Syucope                                                | 0 (0.0)    | 4                                       | (1.4)                                   | 2                    | (0.7)                | 1                                  | (0.2)                              | 0                                        | (0.0)                                    |
| Dianhoea                                               | (0.3)      | E                                       | (1.1)                                   | 5                    | (1.7)                | 5                                  | (0.8)                              | 40                                       | (1.0)                                    |
| Hyperglycaemia                                         | 2 (0.7)    | E                                       | (1.1)                                   | 0                    | (0.0)                | 1                                  | (0.2)                              | 9                                        | (0.2)                                    |
| Hypotension                                            | 0 (0.0)    | E                                       | (1.1)                                   | 0                    | (0.0)                | 0                                  | (0.0)                              | 1                                        | (0.0)                                    |
| Lumg infection                                         | 0 (0.0)    | 3                                       | (1.1)                                   | 0                    | (0.0)                | 0                                  | (0.0)                              | 1                                        | (0.0)                                    |
| Peripheral sensory neuropathy                          | 0 (0.0)    | 3                                       | (1.1)                                   | 2                    | (0.7)                | 0                                  | (0.0)                              | 0                                        | (0.0)                                    |
| Aspartate aminotransferase increased                   | 1 (0.3)    | 2                                       | (0.7)                                   | 3                    | (1.0)                | 8                                  | (1.3)                              | 21                                       | (0.5)                                    |
| Hypophosphataemia                                      | 0 (0.0)    | 2                                       | (0.7)                                   | 5                    | (1.7)                | 1                                  | (0.2)                              | 8                                        | (0.2)                                    |
| Pancytopenia                                           | 0 (0.0)    | 2                                       | (0.7)                                   | 3                    | (1.0)                | 0                                  | (0.0)                              | 1                                        | (0.0)                                    |
| Puemonitis                                             | 4 (1.3)    | 2                                       | (0.7)                                   | 1                    | (0.3)                | 6                                  | (1.0)                              | 45                                       | (1.2)                                    |
| Abdominal pain                                         | 0 (0.0)    | 1                                       | (0.4)                                   | 4                    | (1.4)                | 1                                  | (0.2)                              | 1                                        | (0.0)                                    |
| Colitis                                                | 0 (0.0)    |                                         | (0.4)                                   | 2                    | (0.7)                |                                    | (0.2)                              | 41                                       | (1.1)                                    |

<div style=\"page-break-after: always\"></div>

Rate umulative

| Dehydration               | 1 (0.3)   | 1 (0.4)   | 4 (1.4)   | 1 (0.2)   | 6 (0.2)   |
|---------------------------|-----------|-----------|-----------|-----------|-----------|
| Lymphopenia               | 1 (0.3)   | 1 (0.4)   | 4 (1.4)   | (0.2)     | 2 (0.1)   |
| Rash                      | 2 (0.7)   | 1 (0.4)   | 17 (5.9)  | 2 (0.3)   | 12 (0.3)  |
| Sepsis                    | 0 (010)   | 1 (0.4)   | 3 (01)    | 0 (0.0)   | 0 (0.0)   |
| Demmatitis acneifonm      | 0 (0.0)   | 0 (0.0)   | 6 (2.1)   | 0 (0.0)   | 0 (0.0)   |
| Hyperkalaemia             | 0 (010)   | 0 (0.0)   | 3 (01)    | 0 (0.0)   | 1 (0.0)   |
| Imfusion related reaction | 0 (0.0)   | 0 (0.0)   | 3 (1.0)   | 0 (0.0)   | 0 (0.0)   |

- Every subject is coumted a single time for each applicable row and cohum.
- A system orgam class or specific adverse event appears on this report only ifits incidence in one or more of the columms meets the incidence criterion in the report title, after roumding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

ncludes allsubjects who received at least one dose ofMK-3475 in KN001 Pant B1, B2, B3, D, C, F1, F2, F3; KN002 (origimal phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087.

H Includes all subjects who received atleast one dose ofMK-3475 in KN012 Cohorts B and B2, KN040 and KN055.

MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MIAR2015, KN054: 020C T2017)

MK-3475 Database Cutof Date for Lumg (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JULY2017)

MK-3475 Database Cutoff Date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 13IUN2018, KN055: 22APR2016)

MK-3475 Database CutoffDate forcHL(KN013-Cohort3:27SEP2016,KN087:25SEP2010)

MK-3475 Database Cutoff Date for Bladder (KIN045: 18IAN2017,KN052: 09MAR2017)

Souurce:[ISS: adam-adsl; adae]

<!-- image -->

Event

AtRisk

Pembro+Chemo

At Risk

<!-- image -->

0

2

27610064

33

287 10560

25

17

19

11

14

7

10

6

9

5

8.

5

8

4

2

0

2

0

1

O

Figure 40: Kaplan-Meier estimates of time to first drug-related  Grade  3-5  AE  (ASaT  population)  -  Pembro combo vs control

## Adverse drug reactions (ADRs)

For pembrolizumab monotherapy, the following studies have been included in the pooled dataset: KEYNOTE-048, KEYNOTE-001 Part B1, B2, B3, D, C, F1, F2, F3; KEYNOTE-002 (original phase), KEYNOTE-006, KEYNOTE-010, KEYNOTE-012 HNSCC, KEYNOTE-013 Cohort 3, KEYNOTE-024, KEYNOTE-040, KEYNOTE-042, KEYNOTE-045, KEYNOTE-052, KEYNOTE-054, KEYNOTE-055, and KEYNOTE-087.

Table 77: Adverse Reactions in Patients Treated with Pembrolizumab Monotherapy

|                                      |                                      | Monotherapy (N=5884)   | Monotherapy (N=5884)   |
|--------------------------------------|--------------------------------------|------------------------|------------------------|
|                                      |                                      | All% (n)               | Gr 3-5 n               |
| Infections and infestations          | Infections and infestations          |                        |                        |
| Common                               | pneumonia                            | 5.8% (343)             | 209                    |
| Blood and lymphatic system disorders | Blood and lymphatic system disorders |                        |                        |
| Very common                          | anaemia                              | 13.9% (819)            | 234                    |
| Common                               | thrombocytopenia                     | 1.5% (89)              | 17                     |
| Common                               | lymphopenia                          | 1.1% (65)              | 16                     |
| Uncommon                             | neutropenia                          | 0.8% (48)              | 15                     |
| Uncommon                             | leukopenia                           | 0.8% (45)              | 7                      |
| Uncommon                             | eosinophilia                         | 0.7% (39)              | 0                      |
| Rare                                 | immune thrombocytopenic purpura      | 0.05% (3)              | 3                      |
| Rare                                 | haemolytic anaemia                   | 0.02% (1)              | 1                      |

Pembro

300235

287105

134

60

95

33

67

17

45

11

43

7

39

6

30

5

21

5

16

4

2

0

2

2

1

0

O

Figure 41: Kaplan-Meier estimates of time to first drug-related Grade 3-5 AE (ASaT population) - Pembro mono vs control

<div style=\"page-break-after: always\"></div>

| Rare                                             | pure red cell aplasia #                          | (0)                 | 0   |
|--------------------------------------------------|--------------------------------------------------|---------------------|-----|
| Immune system disorders                          | Immune system disorders                          |                     |     |
| Common                                           | infusion reactions a                             | 2.3% (134)          | 13  |
| Uncommon                                         | sarcoidosis                                      | 0.2% (10)           | 0   |
| Not known                                        | solid organ transplant rejection*                | (0)                 | 0   |
| Endocrine disorders                              | Endocrine disorders                              |                     |     |
| Very common                                      | hypothyroidism b                                 | 11.0% (645)         | 8   |
| Common                                           | hyperthyroidism c                                | 4.1% (244)          | 7   |
| Uncommon                                         | hypophysitis                                     | 0.6% (36)           | 20  |
| Uncommon                                         | thyroiditis d                                    | 0.95% (56)          |     |
|                                                  |                                                  |                     | 1   |
| Uncommon adrenal insufficiency                   | Uncommon adrenal insufficiency                   | 0.7% (41)           | 18  |
| Metabolism and nutrition Very common             | disorders decreased appetite                     | 19.0% (1117)        | 72  |
| Common                                           | hyponatraemia                                    | 5.8% (339)          | 151 |
| Common                                           | hypokalaemia                                     | 4.6% (271)          | 59  |
| Common                                           | hypocalcaemia                                    | 1.9% (112)          | 10  |
| Uncommon                                         | type 1 diabetes mellitus e                       | 0.3% (20)           | 19  |
| Psychiatric disorders                            | Psychiatric disorders                            |                     |     |
| Common insomnia                                  | Common insomnia                                  | 7.1% (417)          | 7   |
| Nervous system disorders                         | Nervous system disorders                         |                     |     |
| Very common                                      | headache                                         | 11.9% (703)         | 18  |
| Common                                           | dizziness                                        | 7.2% (424)          | 11  |
| Common                                           | neuropathy peripheral                            | 1.9% (112)          | 2   |
| Common                                           | lethargy                                         | 1.2% (71)           | 2   |
| Common                                           | dysgeusia                                        | 2.5% (149)          | 1   |
| Uncommon                                         | epilepsy                                         |                     | 7   |
| Rare                                             | guillain-barre f                                 | 0.2% (11)           | 2   |
| Rare                                             | syndrome myasthenic syndrome g                   | 0.07% (4) 0.05% (3) | 1   |
| Rare                                             | meningitis (aseptic) h                           | 0.05% (3)           | 3   |
| Rare                                             | encephalitis                                     | 0.03% (2)           | 2   |
| Eye disorders                                    | Eye disorders                                    |                     |     |
| Common                                           | dry eye                                          | 1.6% (94)           | 0   |
| Uncommon                                         | uveitis i                                        | 0.3% (20)           | 2   |
| Rare                                             | Vogt-Koyanagi-Harada syndrome                    | (0)                 | 0   |
| Cardiac disorders                                | Cardiac disorders                                |                     |     |
| Uncommon                                         | pericardial effusion                             | 0.9% (51)           | 25  |
| Uncommon                                         | pericarditis                                     | 0.1% (8)            | 4   |
| Rare                                             | myocarditis j                                    | 0.08% (5)           | 5   |
| Vascular disorders                               | Vascular disorders                               |                     |     |
| Common                                           | hypertension                                     | 4.9% (288)          | 99  |
| Respiratory, thoracic and mediastinal disorders  | Respiratory, thoracic and mediastinal disorders  |                     |     |
| Very common                                      | dyspnoea                                         | 16.6% (976)         | 130 |
| Very common                                      | cough                                            | 19.0% (1118)        | 9   |
| Common                                           | pneumonitis k                                    | 4.3% (253)          | 91  |
| disorders                                        | disorders                                        |                     |     |
| Gastrointestinal Very common                     | diarrhoea                                        | 20.2% (1186)        | 78  |
| Very common                                      | abdominal pain l                                 | 12.3% (726)         | 55  |
| Very common                                      | nausea                                           | 20.4% (1198)        | 49  |
| Very common                                      | vomiting                                         | 12.3% (721)         | 42  |
| Very common                                      | constipation                                     | 16.7% (983)         | 24  |
| Common                                           | colitism                                         | 1.8% (107)          | 65  |
| Common                                           | dry mouth                                        | 4.8% (280)          | 1   |
| Uncommon                                         | pancreatitis n                                   | 0.3% (16)           | 9   |
| Rare                                             | small intestinal perforation                     | 0.03% (2)           | 1   |
| Hepatobiliary disorders                          | Hepatobiliary disorders                          |                     |     |
| Uncommon                                         | o                                                | 0.8% (50)           | 39  |
| hepatitis Skin and subcutaneous tissue disorders | hepatitis Skin and subcutaneous tissue disorders |                     |     |
| Very common                                      | rash p                                           | 19.5% (1149)        | 2   |
| Very common                                      | pruritus q                                       | 18.3% (1075)        | 1   |
| Common                                           | severe skin reactions r                          | 1.5% (89)           | 66  |
| Common                                           | erythema                                         | 2.8% (165)          | 2   |
| Common                                           | dry skin                                         | 5.1% (299)          | 1   |
| Common                                           | vitiligos                                        | 4.2% (245)          | 0   |
| Common                                           | eczema                                           | 1.5% (91)           | 0   |
| Common                                           | alopecia                                         | 1.4% (84)           | 0   |
| Common                                           | dermatitis acneiform keratosis t                 | 1.2% (72)           | 0   |
| Uncommon                                         | lichenoid                                        | 0.4% (25)           | 9   |
| Uncommon                                         | psoriasis                                        | 0.6% (34) 0.9% (55) | 4 1 |
| Uncommon Uncommon                                | dermatitis papule                                | 0.5% (27)           | 1   |

<div style=\"page-break-after: always\"></div>

| Uncommon                                             | hair colour changes                                  | 0.3% (20)                                            | 0                                                    |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Rare                                                 | stevens-johnson syndrome                             | 0.05% (3)                                            | 2                                                    |
| Rare                                                 | erythema nodosum                                     | 0.05% (3)                                            | 0                                                    |
|                                                      | toxic epidermal necrolysis                           |                                                      | 0                                                    |
| Rare                                                 | #                                                    | (0)                                                  |                                                      |
| Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      |
| Very common                                          | musculoskeletal pain u                               | 18.7% (1102)                                         | 96                                                   |
| Very common                                          | arthralgia                                           | 14.3% (839)                                          | 38                                                   |
| Common                                               | pain in extremity                                    | 6.6% (386)                                           | 18                                                   |
| Common                                               | myositis v                                           | 7.5% (443)                                           | 16                                                   |
| Common                                               | arthritis w                                          | 2.2% (132)                                           | 9                                                    |
| Uncommon                                             | tenosynovitis x                                      | 0.5% (30)                                            | 1                                                    |
| Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          |
| Uncommon                                             | nephritis y                                          | 0.4% (22)                                            | 15                                                   |
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions |
| Very common                                          | fatigue                                              | 31.8% (1870)                                         | 143                                                  |
| Very common                                          | asthenia                                             | 11.2% (657)                                          | 58                                                   |
| Very common                                          | oedema z                                             | 11.5% (678)                                          | 42                                                   |
| Very common                                          | pyrexia                                              | 12.4% (729)                                          | 28                                                   |
| Common                                               | influenza like illness                               | 3.7% (219)                                           | 1                                                    |
| Common                                               | chills                                               | 4.1% (244)                                           | 0                                                    |
| Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       |
| Common                                               | aspartate aminotransferase increased                 | 6.5% (380)                                           | 64                                                   |
| Common                                               | alanine aminotransferase increased                   | 6.5% (384)                                           | 59                                                   |
| Common                                               | hypercalcaemia                                       | 3.1% (184)                                           | 52                                                   |
| Common                                               | blood alkaline phosphatase increased                 | 4.0% (237)                                           | 47                                                   |
| Common                                               | blood bilirubin increased                            | 2.1% (126)                                           | 23                                                   |
| Common                                               | blood creatinine increased                           | 4.2% (250)                                           | 11                                                   |
| Uncommon                                             | amylase increased                                    | 0.3% (17)                                            | 8                                                    |

- #  The 'rule of 3' has been applied in calculation.
- a. infusion reactions (anaphylactic reaction, anaphylactoid reaction, cytokine release syndrome, drug hypersensitivity, hypersensitivity, infusion related reaction)
- b. hypothyroidism (hypothyroidism, myxoedema, primary hypothyroidism)
- c. hypophysitis (hypophysitis, hypopituitarism)
- d. thyroiditis (autoimmune thyroiditis, thyroid disorder, thyroiditis)
- e. type 1 diabetes mellitus (diabetic ketoacidosis, type 1 diabetes mellitus)
- f. guillain-barre syndrome (axonal neuropathy, demyelinating polyneuropathy, guillain-barre syndrome)
- g. myasthenic syndrome (myasthenia gravis, myasthenic syndrome)
- h. meningitis (aseptic) (meningitis, meningitis noninfective)
- i. uveitis (iridocyclitis, iritis, uveitis)
- j. myocarditis (autoimmune myocarditis, myocarditis)
- k. pneumonitis (interstitial lung disease, organising pneumonia, pneumonitis)
- l. abdominal pain (abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper)
- m. colitis (autoimmune colitis, colitis, colitis microscopic, enterocolitis)
- n. pancreatitis (autoimmune pancreatitis, pancreatitis, pancreatitis acute)
- o. hepatitis (autoimmune hepatitis, drug-induced liver injury, hepatitis, hepatitis acute, immune-mediated hepatitis)
- p. rash (genital rash, rash, rash erythematous, rash follicular, rash generalised, rash macular, rash maculo-papular, rash papular, rash pruritic, rash vesicular)

q. pruritus (pruritus, pruritus generalised, pruritus genital, urticaria, urticaria papular)

- r. severe skin reactions (dermatitis bullous, dermatitis exfoliative, dermatitis exfoliative generalised, erythema multiforme, exfoliative rash, pemphigoid, pemphigus, pruritus, pruritus generalised, pruritus genital, rash, rash erythematous, rash generalised, rash maculo-papular, rash pruritic, rash pustular, skin necrosis, stevens-johnson syndrome, toxic skin eruption)
- s. vitiligo (hypopigmentation of eyelid, skin depigmentation, skin hypopigmentation, vitiligo)
- t. lichenoid keratosis (lichen planus, lichen sclerosus, lichenoid keratosis)
- u. musculoskeletal pain (back pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, musculoskeletal stiffness, torticollis)
- v. myositis (myalgia, myopathy, myositis, polymyalgia rheumatica, rhabdomyolysis)
- w. arthritis (arthritis, joint effusion, joint swelling, polyarthritis)
- x. tenosynovitis (synovitis, tendon pain, tendonitis, tenosynovitis)
- y. nephritis (acute kidney injury, autoimmune nephritis, glomerulonephritis membranous, nephritis, nephrotic syndrome, renal failure, tubulointerstitial nephritis)
- z. oedema (eyelid oedema, face oedema, fluid overload, fluid retention, generalised oedema, lip oedema, localised oedema, oedema, oedema peripheral, periorbital oedema)

For pembrolizumab + chemotherapy, the following studies have been included in the pooled dataset: KEYNOTE-048, KEYNOTE-189, KEYNOTE-021 (Cohorts A, C and G) and KEYNOTE-407.

Table 78: Adverse Reactions in Patients Treated with Pembrolizumab combination therapy

|                             | Combotherapy (N=1067)   | Combotherapy (N=1067)   |
|-----------------------------|-------------------------|-------------------------|
|                             | All %(n)                | Gr 3-5 n                |
| Infections and infestations |                         |                         |

<div style=\"page-break-after: always\"></div>

| Common                                          | pneumonia                                       | 9.1% (97)               | 64                      |
|-------------------------------------------------|-------------------------------------------------|-------------------------|-------------------------|
| Blood and lymphatic system disorders            | Blood and lymphatic system disorders            |                         |                         |
| Very common                                     | anaemia                                         | 50.2% (536)             | 192                     |
| Very common                                     | neutropenia                                     | 29.9% (319)             | 181                     |
| Very common                                     | thrombocytopenia                                | 23.0% (245)             | 78                      |
| Common                                          | febrile neutropenia                             | 6.6% (70)               | 68                      |
| Common                                          | leukopenia                                      | 8.2% (88)               | 32                      |
| Common                                          | lymphopenia                                     | 1.9% (20)               | 5                       |
| Rare                                            | eosinophilia                                    | 0.09% (1)               | 1                       |
| Immune system disorders                         | Immune system disorders                         |                         |                         |
| Common infusion reactions a                     | Common infusion reactions a                     | 2.6% (28)               | 8                       |
| Endocrine disorders                             | Endocrine disorders                             |                         |                         |
| Common                                          | hypothyroidism b                                | 9.8% (105)              | 3                       |
| Common                                          | hyperthyroidism                                 | 5.1% (54)               | 1                       |
| Uncommon                                        | hypophysitis c                                  | 0.7% (7)                | 3                       |
| Uncommon                                        | thyroiditis d                                   | 0.5% (5)                | 1                       |
| Uncommon                                        | adrenal insufficiency                           | 0.2% (2)                | 1                       |
| Metabolism and nutrition disorders              | Metabolism and nutrition disorders              |                         |                         |
| Very common                                     | hypokalaemia                                    | 10.0% (107)             | 35                      |
| Very common                                     | decreased appetite                              | 28.5% (304)             | 27                      |
| Common                                          | hyponatraemia                                   | 7.0% (75)               | 42                      |
| Common                                          | hypocalcaemia                                   | 4.3% (46)               | 10                      |
| Rare                                            | type 1 diabetes mellitus                        | 0.09% (1)               | 1                       |
| Psychiatric disorders                           | Psychiatric disorders                           | Psychiatric disorders   | Psychiatric disorders   |
| Common insomnia                                 | Common insomnia                                 | 9.3% (99)               | 1                       |
| Nervous system disorders                        | Nervous system disorders                        |                         |                         |
| Very common                                     | dizziness                                       | 11.2% (120)             | 4                       |
| Very common                                     | headache                                        | 11.9% (127)             | 3                       |
| Very common                                     | neuropathy                                      | 10.5% (112)             | 3                       |
| Very common                                     | peripheral dysgeusia                            | 10.3% (110)             | 1                       |
| Common                                          | lethargy                                        | 1.9% (20)               | 0                       |
| Uncommon                                        | epilepsy                                        |                         | 1                       |
|                                                 |                                                 | 0.2% (2)                |                         |
| Eye disorders                                   | Eye disorders                                   | Eye disorders           | Eye disorders           |
| Common dry eye                                  | Common dry eye                                  | 3.3% (35)               | 0                       |
| Cardiac disorders                               | Cardiac disorders                               |                         |                         |
| Uncommon                                        | pericardial effusion                            | 0.3% (3)                | 2                       |
| Rare                                            | myocarditis j                                   | 0.09% (1)               | 1                       |
| Rare                                            | pericarditis                                    | 0.09% (1)               | 1                       |
| Vascular disorders                              | Vascular disorders                              | Vascular disorders      | Vascular disorders      |
| Common hypertension                             | Common hypertension                             | 5.8% (62)               | 24                      |
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders |                         |                         |
| Very common                                     | dyspnoea                                        | 16.8% (179)             | 31                      |
| Very common                                     | cough                                           | 19.7% (210)             | 2                       |
| Common                                          | pneumonitis k                                   | 5.2% (56)               | 23                      |
| Gastrointestinal disorders                      | Gastrointestinal disorders                      |                         |                         |
| Very common diarrhoea                           | Very common diarrhoea                           | 30.5% (325)             | 41                      |
| Very common                                     | nausea                                          | 49.8% (531)             | 35                      |
| Very common                                     | vomiting                                        | 24.7% (264)             | 28                      |
| Very common                                     | constipation                                    | 34.6% (369)             | 6                       |
| Very common                                     | abdominal pain l                                | 12.1% (129)             | 6                       |
| Common                                          | colitism                                        | 2.8% (30)               | 13                      |
| Common Uncommon                                 | dry mouth pancreatitis n                        | 4.4% (47) 0.4% (4)      | 1 3                     |
| Hepatobiliary disorders                         | Hepatobiliary disorders                         | Hepatobiliary disorders | Hepatobiliary disorders |
| Uncommon hepatitis o                            | Uncommon hepatitis o                            | 0.9% (10)               | 9                       |
| Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          |                         |                         |
| Very common                                     | rash p                                          | 21.5% (229)             | 2                       |
| Very common                                     | alopecia                                        | 18.0% (192)             | 1                       |
| Very common                                     | pruritus q                                      | 13.3% (142)             | 1                       |
| Common                                          | severe skin reactions r                         | 1.6% (17)               | 15                      |
| Common                                          | erythema                                        | 3.7% (39)               |                         |
|                                                 |                                                 |                         | 1                       |
| Common                                          | dry skin                                        | 4.6% (49)               | 0                       |
| Uncommon Uncommon                               | psoriasis dermatitis acneiform                  | 0.6% (6) 0.8% (9)       | 3 0                     |
| Uncommon                                        | dermatitis vitiligos                            | 0.7% (8) 0.7% (7)       | 0                       |
| Uncommon                                        |                                                 |                         | 0                       |
| Uncommon                                        | eczema hair colour changes                      | 0.5% (5) 0.09% (1)      | 0 0                     |
| Rare                                            | lichenoid keratosis t                           | 0.09% (1)               | 0                       |
| Rare Rare                                       | papule                                          | 0.09% (1)               | 0                       |

<div style=\"page-break-after: always\"></div>

| Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      | Musculoskeletal and connective tissue disorders      |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Very common                                          | musculoskeletal pain u                               | 17.8% (190)                                          | 9                                                    |
| Very common                                          | arthralgia v                                         | 12.9% (138)                                          | 8                                                    |
| Common                                               | myositis                                             | 6.5% (69)                                            | 4                                                    |
| Common                                               | pain in extremity                                    | 7.7% (82)                                            | 2                                                    |
| Common                                               | arthritis w                                          | 2.2% (24)                                            | 0                                                    |
| Uncommon                                             | tenosynovitis x                                      | 0.4% (4)                                             | 1                                                    |
| Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          |
| Common                                               | nephritis y                                          | 1.0% (11)                                            | 8                                                    |
| Common                                               | acute kidney injury                                  | 5.6% (60)                                            | 23                                                   |
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions |
| Very common                                          | fatigue                                              | 37.4% (399)                                          | 58                                                   |
| Very common                                          | asthenia                                             | 18.1% (193)                                          | 42                                                   |
| Very common                                          | pyrexia                                              | 16.1% (172)                                          | 7                                                    |
| Very common                                          | oedema z                                             | 17.3% (185)                                          | 6                                                    |
| Common                                               | chills                                               | 2.3% (25)                                            | 0                                                    |
| Common                                               | influenza like illness                               | 2.3% (25)                                            | 0                                                    |
| Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       |
| Very common                                          | blood creatinine increased                           | 12.0% (128)                                          | 5                                                    |
| Common                                               | hypercalcaemia                                       | 3.1% (33)                                            | 12                                                   |
| Common                                               | alanine aminotransferase increased                   | 9.5% (101)                                           | 11                                                   |
| Common                                               | aspartate aminotransferase increased                 | 9.0% (96)                                            | 9                                                    |
| Common                                               | blood alkaline phosphatase increased                 | 3.5% (37)                                            | 2                                                    |
| Uncommon                                             | blood bilirubin increased                            | 0.8% (9)                                             | 1                                                    |
| Uncommon                                             | amylase increased                                    | 0.3% (3)                                             | 1                                                    |

- Every subject is counted a single time for each applicable row.
- a. infusion reactions (anaphylactic reaction, anaphylactoid reaction, cytokine release syndrome, drug hypersensitivity, hypersensitivity, infusion related reaction)
- b. hypothyroidism (hypothyroidism, myxoedema, primary hypothyroidism)
- c. hypophysitis (hypophysitis, hypopituitarism)
- d. thyroiditis (autoimmune thyroiditis, thyroid disorder, thyroiditis)
- e. type 1 diabetes mellitus (diabetic ketoacidosis, type 1 diabetes mellitus)
- j. myocarditis (autoimmune myocarditis, myocarditis)
- k. pneumonitis (interstitial lung disease, organising pneumonia, pneumonitis)
- l. abdominal pain (abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper)

m. colitis (autoimmune colitis, colitis, colitis microscopic, enterocolitis)

- n. pancreatitis (autoimmune pancreatitis, pancreatitis, pancreatitis acute)
- o. hepatitis (autoimmune hepatitis, drug-induced liver injury, hepatitis, hepatitis acute, immune-mediated hepatitis)
- p. rash (genital rash, rash, rash erythematous, rash follicular, rash generalised, rash macular, rash maculo-papular, rash papular, rash pruritic, rash vesicular)
- q. pruritus (pruritus, pruritus generalised, pruritus genital, urticaria, urticaria papular)
- r. severe skin reactions (dermatitis bullous, dermatitis exfoliative, dermatitis exfoliative generalised, erythema multiforme, exfoliative rash, pemphigoid, pemphigus, pruritus, pruritus generalised, pruritus genital, rash, rash erythematous, rash generalised, rash maculo-papular, rash pruritic, rash pustular, skin necrosis, stevens-johnson syndrome, toxic skin eruption)
- s. vitiligo (hypopigmentation of eyelid, skin depigmentation, skin hypopigmentation, vitiligo)
- t. lichenoid keratosis (lichen planus, lichen sclerosus, lichenoid keratosis)
- u. musculoskeletal pain (back pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, musculoskeletal stiffness, torticollis)
- v. myositis (myalgia, myopathy, myositis, polymyalgia rheumatica, rhabdomyolysis)
- w. arthritis (arthritis, joint effusion, joint swelling, polyarthritis)
- x. tenosynovitis (synovitis, tendon pain, tendonitis, tenosynovitis)
- y. nephritis (acute kidney injury, autoimmune nephritis, glomerulonephritis membranous, nephritis, nephrotic syndrome, renal failure, tubulointerstitial nephritis)
- z. oedema (eyelid oedema, face oedema, fluid overload, fluid retention, generalised oedema, lip oedema, localised oedema, oedema, oedema peripheral, periorbital oedema)

## Serious adverse event/deaths/other significant events

## Serious Adverse Events

<div style=\"page-break-after: always\"></div>

Table 79 : Subjects with serious adverse events up to 90 days of last dose (incidence ≥1% in or more treatment groups) by decreasing frequency of preferred term from KN048 combo (ASaT population)

<!-- image -->

|                                                                                                                                                                                                                                                                                                                                                                                                                                                          | KN048 Data for MK-3475   | KN048 Data for MK-3475   | KN048 Data for MK-3475 +   | KN048 Data for MK-3475 +   | KON048 Data for SOC   | KON048 Data for SOC   | HNSCC Safety Datset for   | HNSCC Safety Datset for   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   | Reference Safety Dataset for Mk-3475111   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|----------------------------|----------------------------|-----------------------|-----------------------|---------------------------|---------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Subjects in population                                                                                                                                                                                                                                                                                                                                                                                                                                   | OOE                      | (24)                     | n 276                      | Chemotherapy               | 287                   | (2)                   | 609                       | (2-)                      | Ⅱ 3,830                                   | ()                                        | ()                                        | ()                                        | ()                                        | ()                                        | ()                                        | ()                                        | ()                                        | ()                                        | ()                                        | ()                                        | ()                                        |
| with one or more adverse events                                                                                                                                                                                                                                                                                                                                                                                                                          | 121                      | (40.3)                   | 162                        | (58.7)                     | 141                   | (49.1)                | 281                       | (46.1)                    | 1,450                                     | (37.9)                                    | (37.9)                                    | (37.9)                                    | (37.9)                                    | (37.9)                                    | (37.9)                                    | (37.9)                                    | (37.9)                                    | (37.9)                                    | (37.9)                                    | (37.9)                                    | (37.9)                                    |
| with no adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                   | 179                      | (59.7)                   | 114                        | (41.3)                     | 146                   | (50.9)                | 328                       | (53.9)                    | 2.380                                     | (62.1)                                    | (62.1)                                    | (62.1)                                    | (62.1)                                    | (62.1)                                    | (62.1)                                    | (62.1)                                    | (62.1)                                    | (62.1)                                    | (62.1)                                    | (62.1)                                    | (62.1)                                    |
| Febrile neutropenia                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0                        | (0.0)                    | 16                         | (5.8)                      | 14                    | (4.9)                 | 0                         | (00)                      | 2                                         | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     |
| Pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                | 17                       | (5.7)                    | 15                         | (5.4)                      | 18                    | (6.3)                 | 38                        | (6.2)                     | 114                                       | (3.0)                                     | (3.0)                                     | (3.0)                                     | (3.0)                                     | (3.0)                                     | (3.0)                                     | (3.0)                                     | (3.0)                                     | (3.0)                                     | (3.0)                                     | (3.0)                                     | (3.0)                                     |
| Anaemia                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                          | (0.3)                    | 14                         | (5.1)                      | 9                     | (3.1)                 | 8                         | (1.3)                     | 48                                        | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     |
| Lung infection                                                                                                                                                                                                                                                                                                                                                                                                                                           | 3                        | (1.0)                    | 9                          | (3.3)                      | 2                     | (0.7)                 | 4                         | (0.7)                     | 13                                        | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     |
| Pneumonia aspiration                                                                                                                                                                                                                                                                                                                                                                                                                                     | 5                        | (1.7)                    | 8                          | (2.9)                      | 3                     | (1.0)                 | 15                        | (2.5)                     | 4                                         | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     |
| Stomatitis                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0                        | (0.0)                    | 8                          | (2.9)                      | 4                     | (1.4)                 | 2                         | (0.3)                     | 1                                         | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     |
| Hyponatraemia                                                                                                                                                                                                                                                                                                                                                                                                                                            |                          | (0.3)                    | 7                          | (2.5)                      | 3                     | (1.0)                 | 6                         | (1.0)                     | 28                                        | (0.7)                                     | (0.7)                                     | (0.7)                                     | (0.7)                                     | (0.7)                                     | (0.7)                                     | (0.7)                                     | (0.7)                                     | (0.7)                                     | (0.7)                                     | (0.7)                                     | (0.7)                                     |
| Neutropenia                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0                        | (0.0)                    | 7                          | (2.5)                      | 5                     | (1.7)                 | 2                         | (0.3)                     | 1                                         | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     |
| Pyreria                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 2                        | (0.7)                    | 7                          | (2.5)                      | 1                     | (0.3)                 | 5                         | (0.8)                     | 51                                        | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     | (1.3)                                     |
| Dehydration                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1                        | (0.3)                    | 6                          | (2.2)                      | 4                     | (1.4)                 | 8                         | (1.3)                     | 31                                        | (0.8)                                     | (0.8)                                     | (0.8)                                     | (0.8)                                     | (0.8)                                     | (0.8)                                     | (0.8)                                     | (0.8)                                     | (0.8)                                     | (0.8)                                     | (0.8)                                     | (0.8)                                     |
| Mucosal inflammation                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1                        | (0.3)                    | 6                          | (2.2)                      | 1                     | (0.3)                 | 0                         | (00)                      |                                           | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     |
| Nausea                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0                        | (0.0)                    | 6                          | (2.2)                      | 8                     | (2.8)                 | 4                         | (0.7)                     | 20                                        | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     |
| Septic shock                                                                                                                                                                                                                                                                                                                                                                                                                                             | 1                        | (0.3)                    | 6                          | (2.2)                      | 2                     | (0.7)                 | 1                         | (0.2)                     | 6                                         | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     |
| Thrombocytopenia                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0                        | (0.0)                    | 6                          | (2.2)                      |                       | (0.0)                 | 0                         | (0.0)                     | 6                                         | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     |
| Tumouurhaemomhage                                                                                                                                                                                                                                                                                                                                                                                                                                        | 9                        | (3.0)                    | 6                          | (2.2)                      | 5                     | (1.7)                 | 12                        | (2.0)                     | 4                                         | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     |
| Acute kidney injury                                                                                                                                                                                                                                                                                                                                                                                                                                      | 5                        | (1.7)                    | 5                          | (1.8)                      | 1                     | (0.3)                 | 1                         | (0.2)                     | 41                                        | (1.1)                                     | (1.1)                                     | (1.1)                                     | (1.1)                                     | (1.1)                                     | (1.1)                                     | (1.1)                                     | (1.1)                                     | (1.1)                                     | (1.1)                                     | (1.1)                                     | (1.1)                                     |
| Decreased appetite                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1                        | (0.3)                    | 5                          | (1.8)                      | 4                     | (1.4)                 | 6                         | (0D)                      | 5                                         | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     |
| Sepsis                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 6                        | (2.0)                    | 5                          | (1.8)                      | 3                     | (1.0)                 | 8                         | (1.3)                     | 21                                        | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     |
| Vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0                        | (0.0)                    | 5                          | (1.8)                      | 5                     | (1.7)                 | 5                         | (0.8)                     | 20                                        | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     | (0.5)                                     |
| Hypokalaemia                                                                                                                                                                                                                                                                                                                                                                                                                                             | 1                        | (0.3)                    | 4                          | (1.4)                      | 1                     | (0.3)                 | 1 3                       | (0.2)                     | 6                                         | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     |
| Hypotension                                                                                                                                                                                                                                                                                                                                                                                                                                              | 2                        | (0.7)                    | 4                          | (1.4)                      | 5                     | (1.7)                 | 6                         | (0.5)                     | 7                                         | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     | (0.2)                                     |
| Pulmonary embolism Respiratory tact infection.                                                                                                                                                                                                                                                                                                                                                                                                           | 2 1                      | (0.7) (0.3)              | 4 4                        | (1.4) (1.4)                | 6 1                   | (2.1) (0.3)           | 0                         | (00)                      | 48 12                                     | (1.3) (0.3)                               | (1.3) (0.3)                               | (1.3) (0.3)                               | (1.3) (0.3)                               | (1.3) (0.3)                               | (1.3) (0.3)                               | (1.3) (0.3)                               | (1.3) (0.3)                               | (1.3) (0.3)                               | (1.3) (0.3)                               | (1.3) (0.3)                               | (1.3) (0.3)                               |
| Blood creatinine increased                                                                                                                                                                                                                                                                                                                                                                                                                               | 0                        | (0.0)                    | 3                          | (1.1)                      | 0                     | (0.0)                 | 1                         | (0.2)                     |                                           | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     |
| Bronchitis                                                                                                                                                                                                                                                                                                                                                                                                                                               | 2                        | (0.7)                    | 3                          | (1.1)                      | 2                     | (0.7)                 | 2                         | (0.3)                     | 3 13                                      | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     | (0.3)                                     |
| Dyspnoea                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 6                        | (2.0)                    | 3                          | (1.1)                      | 2                     | (0.7)                 | 13                        | (2.1)                     | 57                                        | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 5                        | (1.7)                    | 3                          | (1.1)                      | 2                     | (0.7)                 | 14                        | (2.3)                     | 16                                        | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     |
| Hypercalcaemia Interstitial hmg disease                                                                                                                                                                                                                                                                                                                                                                                                                  | 1                        |                          | 3                          | (1.1)                      | 1                     | (0.3)                 |                           | (0.2)                     | 5                                         | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     |
| Larymgeal oedema                                                                                                                                                                                                                                                                                                                                                                                                                                         | 1                        | (0.3) (0.3)              | 3                          | (1.1)                      | 1                     | (0.3)                 |                           | (0.2)                     | 1                                         | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     |
| Myocardial infarction Platelet coumt decreased                                                                                                                                                                                                                                                                                                                                                                                                           | 3 0                      | (1.0)                    | 3                          | (1.1)                      | 3                     | (1.0) (0.3)           | 4 0                       | (0.7) (0.0)               | 8 0                                       | (0.2) (0.0)                               | (0.2) (0.0)                               | (0.2) (0.0)                               | (0.2) (0.0)                               | (0.2) (0.0)                               | (0.2) (0.0)                               | (0.2) (0.0)                               | (0.2) (0.0)                               | (0.2) (0.0)                               | (0.2) (0.0)                               | (0.2) (0.0)                               | (0.2) (0.0)                               |
| Plewal effusion                                                                                                                                                                                                                                                                                                                                                                                                                                          | 2                        | (0.0) (0.7)              | 3 3                        | (1.1) (1.1)                | 1                     | (0.0)                 | 10                        | (1.0)                     | 56                                        | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     | (1.5)                                     |
| Renal failure                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0                        | (0.0) (0.7)              | 3                          | (1.1)                      | 2                     | (0.7)                 | 0 8                       | (0.0) (1.3)               |                                           | (0.6)                                     | (0.6)                                     | (0.6)                                     | (0.6)                                     | (0.6)                                     | (0.6)                                     | (0.6)                                     | (0.6)                                     | (0.6)                                     | (0.6)                                     | (0.6)                                     | (0.6)                                     |
| Cellhulitis                                                                                                                                                                                                                                                                                                                                                                                                                                              | 2                        |                          |                            |                            |                       |                       |                           |                           | 22 17                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     |
| Death                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2                        | (0.7)                    | 2                          | (0.7)                      | 1 2                   | (0.3) (0.7)           | 11                        |                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |
| Dysphagia                                                                                                                                                                                                                                                                                                                                                                                                                                                | 4                        | (1.3)                    | 2 2                        | (0.7) (0.7)                | 1                     | (0.3)                 | 7                         | (1.8) (1.1)               | 19 5                                      | (0.5) (0.1)                               | (0.5) (0.1)                               | (0.5) (0.1)                               | (0.5) (0.1)                               | (0.5) (0.1)                               | (0.5) (0.1)                               | (0.5) (0.1)                               | (0.5) (0.1)                               | (0.5) (0.1)                               | (0.5) (0.1)                               | (0.5) (0.1)                               | (0.5) (0.1)                               |
| Pneumonitis                                                                                                                                                                                                                                                                                                                                                                                                                                              |                          |                          | 2                          | (0.7)                      | 1                     | (0.3)                 | 11                        | (1.8)                     | 69                                        | (1D)                                      | (1D)                                      | (1D)                                      | (1D)                                      | (1D)                                      | (1D)                                      | (1D)                                      | (1D)                                      | (1D)                                      | (1D)                                      | (1D)                                      | (1D)                                      |
| Symcope Colitis                                                                                                                                                                                                                                                                                                                                                                                                                                          | 3 0                      | (o1) (0.0)               | 2 1                        | (0.7) (0.4)                | 5 2                   | (1.7) (0.7)           | 8 4                       | (1.3) (0.7) (0.2)         | 11 41                                     | (0.3) (1.1)                               | (0.3) (1.1)                               | (0.3) (1.1)                               | (0.3) (1.1)                               | (0.3) (1.1)                               | (0.3) (1.1)                               | (0.3) (1.1)                               | (0.3) (1.1)                               | (0.3) (1.1)                               | (0.3) (1.1)                               | (0.3) (1.1)                               | (0.3) (1.1)                               |
| Device related infection                                                                                                                                                                                                                                                                                                                                                                                                                                 | 4                        | (0.0) (1.3)              | 1                          | (0.4)                      | 3                     | (1.0)                 | 1 9                       | (D                        | 4 37                                      | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     |
| Diamhoea                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2 3                      | (o.7)                    |                            | (0.4)                      | 4                     | (1.4)                 | 1                         | (0.2)                     |                                           | (D                                        | (D                                        | (D                                        | (D                                        | (D                                        | (D                                        | (D                                        | (D                                        | (D                                        | (D                                        | (D                                        | (D                                        |
| Fatigue                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                          | (1.0)                    | 1 1                        | (0.4)                      | 4                     | (1.4)                 |                           |                           | 17 1                                      | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     |
| Infected neoplasm                                                                                                                                                                                                                                                                                                                                                                                                                                        | 3                        | (1.0) (o.0)              | 1                          | (0.4) (0.4)                | 2 3                   | (0.7) (1.0)           | 3 0 6                     | (0.5) (0.0)               | 2                                         | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     |
| Infiusion related reaction Mouth haemonhage                                                                                                                                                                                                                                                                                                                                                                                                              | 0 0                      | (0.0)                    | 1                          |                            | 0                     |                       |                           | (1.0)                     | 0                                         | (0.1) (0.0)                               | (0.1) (0.0)                               | (0.1) (0.0)                               | (0.1) (0.0)                               | (0.1) (0.0)                               | (0.1) (0.0)                               | (0.1) (0.0)                               | (0.1) (0.0)                               | (0.1) (0.0)                               | (0.1) (0.0)                               | (0.1) (0.0)                               | (0.1) (0.0)                               |
| Respiratory faihure                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1                        |                          |                            | (0.4)                      |                       | (0.0) (0.3)           | 8                         |                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |
| Urinary tact infection Confisional state                                                                                                                                                                                                                                                                                                                                                                                                                 | 0                        | (0.3) (0.0)              | 1                          | (0.4) (0.4)                | 1 3                   | (1.0)                 | 3                         | (1.3) (0.5)               | 16 53                                     | (0.4) (1.4)                               | (0.4) (1.4)                               | (0.4) (1.4)                               | (0.4) (1.4)                               | (0.4) (1.4)                               | (0.4) (1.4)                               | (0.4) (1.4)                               | (0.4) (1.4)                               | (0.4) (1.4)                               | (0.4) (1.4)                               | (0.4) (1.4)                               | (0.4) (1.4)                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                          | (0.0)                    |                            |                            | 0                     | (0.0)                 | 6                         | (1.0)                     | 15                                        |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                          | (0.0)                    | 0 0                        | (0.0) (0.0)                | 3                     | (1.0)                 | 0 1                       | (0.0)                     | 1                                         | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     | (0.4)                                     |
| Neutrophil coumt decreased Soft tissue infection                                                                                                                                                                                                                                                                                                                                                                                                         | 3                        | (1.0)                    | 0                          |                            | 1                     | (0.3)                 |                           | (0.2)                     | 2                                         | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     | (0.0)                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 1                        | (0.3)                    | 0                          | (0.0)                      | 3                     |                       | 1                         |                           |                                           | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     |
| Upper gastrointestinal                                                                                                                                                                                                                                                                                                                                                                                                                                   |                          |                          |                            |                            |                       | (1.0)                 |                           | (0.2)                     | 2                                         |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |
| haemonhage                                                                                                                                                                                                                                                                                                                                                                                                                                               |                          |                          |                            |                            |                       |                       |                           |                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                          |                          |                            | (0.0)                      |                       |                       |                           |                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                          |                          |                            |                            |                       |                       |                           |                           |                                           | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     | (0.1)                                     |
| Every subject is coumted a single tiwe for each applicable row and cohumm.                                                                                                                                                                                                                                                                                                                                                                               |                          |                          |                            |                            |                       |                       |                           |                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |
| Al system organ clhss or specifc adverse event appears on this report only ifits incidence in one or more of the coluwns meets the incidence criterion in the report title, after rounding. MedDRA prefemred tenms \"Neoplasm Progression\". *Maligmant Neoplasm Progression\" and\"Disease Progression not related to the drug are evchuded.  Inchudes all subjects who received at least one dose of MK-3475 in KIN012 Cohorts B and B2, KIN040 and KN055. |                          |                          |                            |                            |                       |                       |                           |                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |
| phase]. KN006, nd KN010, KON013-Cohort 3, KN024, KN045, KN052 amd KON087. MK-3475 Database Cutoff Date for Melhanowa (KN001-Melanoma: 18APR2014, KN002: 28FEB2015,KN006: 03MAR2015. KN054: 02OCT2017) MK-3475 Database CutoffDate forLumg (KON001-NSCLC: 23JAN2015,KN010:30SEP2015,KN024: 10JULY2017) MK-3475 Database Cutoff Date forHNSCC (KIN012-HNSOC: 26APR2016. KN040: 15MAY2017. KIN048: 13JUN2018. KN055:                                        |                          |                          |                            |                            |                       |                       |                           |                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |
| 22APR2016) M-3475 Database Cutoff Date for cHL (KON013-Cohort 3: 27SEP2016, KN087: 25SEP2016)                                                                                                                                                                                                                                                                                                                                                            |                          |                          |                            |                            |                       |                       |                           |                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |
| MK-3475 Database Cutoff Date for Bladder (KIN045: 18JAN2017. KIN052: 09MAR2017)                                                                                                                                                                                                                                                                                                                                                                          |                          |                          |                            |                            |                       |                       |                           |                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |

Source:[ISS: adam-adsl; adae]

Table 80: Exposure-Adjusted Serious Adverse Events by Observation Period (Including Multiple Occurrences of Events) (Incidence &gt; 0% in One or More Treatment Groups) (Pembro Combo vs Control)

|                                   | Event Coumt and Rate (Events/100 person-yeas)   | Event Coumt and Rate (Events/100 person-yeas)   | Event Coumt and Rate (Events/100 person-yeas)   | Event Coumt and Rate (Events/100 person-yeas)   | Event Coumt and Rate (Events/100 person-yeas)   | Event Coumt and Rate (Events/100 person-yeas)   | Event Coumt and Rate (Events/100 person-yeas)   | Event Coumt and Rate (Events/100 person-yeas)   |
|-----------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                   | Pembrolizmab+ Chemotherapy                      | Pembrolizmab+ Chemotherapy                      | Pembrolizmab+ Chemotherapy                      | Pembrolizmab+ Chemotherapy                      | Cetuximnb+Chemothenpy                           | Cetuximnb+Chemothenpy                           | Cetuximnb+Chemothenpy                           | Cetuximnb+Chemothenpy                           |
| Observationperiodof drugexposuwre | 0-3months                                       | 3-6months                                       | 6-12 months                                     | Beyond 12 months                                | 0-3months                                       | 3-6months                                       | 6-12 months                                     | Beyond 12 months                                |
| Number of Subjects exposed        | 276                                             | 219                                             | 158                                             | 60                                              | 287                                             | 230                                             | 139                                             | 27                                              |
| Totalexposureperson-years         | 62.33                                           | 46.72                                           | 47.85                                           | 33.73                                           | 66.47                                           | 46.49                                           | 33.06                                           | 21.81                                           |
| Total events (rate)               | 210 (336.93)                                    | 75 (160.53)                                     | 47 (98.23)                                      | 10 (29.65)                                      | 174 (261.77)                                    | 64 (137.65)                                     | 27 (81.67)                                      | 1 (4.59)                                        |

<div style=\"page-break-after: always\"></div>

## Drug-related Serious Adverse Events

Table  81:  Subjects  with  drug-related  SAEs up  to  90  days  of  last  dose  (incidence  ≥1%  in  or  more treatment groups) by decreasing frequency of preferred term from KN048 combo (ASaT population)

|                                                                               | KN048 Data for MK-3475   | KN048 Data for MK-3475 + Chemotherapy   | SOC                       | KN048 Data for   | HNSOC Safety Dataset for MK347511   | HNSOC Safety Dataset for MK347511   | Reference Safety Dataset for MK-34751   | Reference Safety Dataset for MK-34751   |
|-------------------------------------------------------------------------------|--------------------------|-----------------------------------------|---------------------------|------------------|-------------------------------------|-------------------------------------|-----------------------------------------|-----------------------------------------|
|                                                                               |                          | ()                                      | n ()                      | n                | (/)                                 | ()                                  |                                         | (/)                                     |
| Subjects in population with one or more adverse events with no adverse events | 300 27 ELC               | (9.0) (91.0)                            | 276 102 (37.0) 174 (63.0) | 287 73 214       | (25.4) (74.6)                       | 609 60 (9.9) 549 (90.1)             | 3,830 403 3.427                         | (10.5) (89.5)                           |
| Febrile neutropenia                                                           | 0                        | (0.0) 14                                | (5.1)                     | 10               | (3.5)                               | 0                                   | 0                                       | (0.0)                                   |
| Anaemia                                                                       | 1                        | (0.3) 11                                | (4.0)                     | 8                | (2.8)                               | (0.0) 0 (o0)                        | 4                                       | (0.1)                                   |
| Stomatitis                                                                    | 0                        | (0.0) 8                                 | (2.9)                     | 4                | (1.4)                               | (0.3)                               | 1                                       | (0.0)                                   |
| Neutropenia                                                                   | 0                        | (0.0) 7                                 | (2.5)                     | 5                | (1.7)                               | 0 (0.0)                             | 1                                       | (0.0)                                   |
| Mucosal inflamwation                                                          | 1                        | (0.3)                                   | 6 (2.2)                   | 1                | (0.3)                               | 0 (0.0)                             | 0                                       | (0.0)                                   |
| Nausea                                                                        | 0                        | (0.0)                                   | 6 (2.2)                   | 7                | (2.4)                               | 1 (0.2)                             | 6                                       | (0.2)                                   |
| Septic shock                                                                  | 0                        | (0.0)                                   | 6 (2.2)                   | 0                | (0.0)                               | 0 (0.0)                             | 0                                       | (0.0)                                   |
| Thrombocytopenia                                                              | 0                        | (0.0)                                   | 6 (2.2)                   | 0                | (0.0)                               | 0 (0.0)                             |                                         | (0.1)                                   |
| Acute kidney injuy                                                            |                          | (0.7)                                   | 5 (1.8)                   | 1                | (0.3)                               | 1 (0.2)                             | 6                                       | (0.2)                                   |
| Decreased appetite                                                            | 0                        | (0.0)                                   | 5 (1.8)                   | 2                | (0.7)                               | 1 (0.2)                             | 1                                       | (0.0)                                   |
| Pneumonia                                                                     |                          | (0.3)                                   | 5 (1.8)                   | 7                | (2.4)                               | 1 (0.2)                             | 10                                      | (0.3)                                   |
| Hyponatraemia                                                                 | 1                        | (0.3)                                   | 4 (1.4)                   | 1                | (0.3)                               | 0 (0.0)                             | 8                                       | (0.2)                                   |
| Interstitial hung disease                                                     | 1                        | (0.3)                                   | 3 (1.1)                   | 1                | (0.3)                               | 1 (0.2)                             |                                         | (0.1)                                   |
| Lung infection                                                                | 0                        | (0.0)                                   | 3 (1.1)                   | 0                | (0.0)                               | 0 (0.0)                             |                                         | (0.0)                                   |
| Platelet coumt decreased                                                      | 0                        | (0.0)                                   | rn (1.1)                  | 1                | (0.3)                               | 0 (0.0)                             | 0                                       | (0.0)                                   |
| Vomiting                                                                      | 0                        | (0.0)                                   | 3 (1.1)                   | 3                | (1.0)                               | 2 (0.3)                             | 6                                       | (0.2)                                   |
| Pneumonitis                                                                   | 3                        | (1.0)                                   | 2 (0.7)                   | 1                | (0.3)                               | 9 (1.5)                             | 65                                      | (1.7)                                   |
| Dehydration                                                                   | 0                        | (0.0)                                   | 一 (0.4)                   |                  | (1.0)                               | 0 (0.0)                             | 4                                       | (0.1)                                   |
| Fatigue                                                                       | 1                        | (0.3)                                   | 1 (0.4)                   | 4                | (1.4)                               | 0 (o0)                              | 5                                       | (0.1)                                   |
| Sepsis                                                                        | 0                        | (0.0)                                   | 1 (0.4)                   | 3                | (1.0)                               | 0 (0.0)                             | 0                                       | (0.0)                                   |
| Diarhoea                                                                      | 1                        | (0.3)                                   | 0 (0.0)                   | 4                | (1.4)                               | 6 (1.0)                             | 24                                      | (0.6)                                   |
| Infision related reaction                                                     | 0                        | (0.0)                                   | 0 (0.0)                   | 3                | (1.0)                               | 0 (0.0)                             | 2                                       | (0.1)                                   |
| Neutrophilcoumt decreased                                                     | 0                        | (0.0)                                   | (0.0)                     | 3 (1.0)          |                                     | 0 (0.0)                             | 0                                       | (0.0)                                   |

Source: [IsS: adam-adsl; adae]

<!-- image -->

## Deaths due to Adverse Events

## All deaths

The number of deaths in the ITT population as per study status is displayed in tables below:

Table 82: Disposition of Subjects (Pembro Combo versus Control)

|                        | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   | Total   | Total   |
|------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|---------|---------|
|                        | 1n1                            | (%)                            | n1                         | (%)                        |         | (%)     |
| Subjects in population | 281                            |                                | 278                        |                            | 559     |         |
| Status for Trial       |                                |                                |                            |                            |         |         |
| Discontinued           | 200                            | (71.2)                         | 228                        | (82.0)                     | 428     | (76.6)  |
| Death                  | 188                            | (66.9)                         | 212                        | (76.3)                     | 400     | (71.6)  |
| Lost To Follow-Up      | 1                              | (0.4)                          | 1                          | (0.4)                      | 2       | (0.4)   |
| Withdrawal By Subject  | 11                             | (3.9)                          | 15                         | (5.4)                      | 26      | (4.7)   |
| Subjects Ongoing       | 81                             | (28.8)                         | 50                         | (18.0)                     | 131     | (23.4)  |

<div style=\"page-break-after: always\"></div>

Table 83: Disposition of Subjects (Pembro Mono versus Control)

|                        | Pembrolizumab   | Pembrolizumab   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   | Total   | Total   |
|------------------------|-----------------|-----------------|----------------------------|----------------------------|---------|---------|
|                        | n1              | (%)             | n1                         | (%)                        | 11      | (%)     |
| Subjects in population | 301             |                 | 300                        |                            | 601     |         |
| StatusforTrial         |                 |                 |                            |                            |         |         |
| Discontinued           | 216             | (71.8)          | 245                        | (81.7)                     | 461     | (76.7)  |
| Death                  | 203             | (67.4)          | 227                        | (75.7)                     | 430     | (71.5)  |
| Lost To Follow-Up      | 1               | (0.3)           | 1                          | (0.3)                      | 2       | (0.3)   |
| Withdrawal By Subject  | 12              | (4.0)           | 17                         | (5.7)                      | 29      | (4.8)   |
| Subjects Ongoing       | 85              | (28.2)          | 55                         | (18.3)                     | 140     | (23.3)  |

Total numbers (%) of Overall Survival events in the ITT population are higher than the numbers of death given in the Tables 'Disposition of Subjects' above:

- 197 of 281 (70.1%) in the pembrolizumab plus chemotherapy group versus
- 223 of 278 (80.2%) in the standard treatment group, and
- 213 of 301 (70.8%) in the pembrolizumab monotherapy group versus
- 240 of 300 (80.0%) in the standard treatment group (see respective Tables in section 4.4.2 above)

If withdrawal by subject occurs first and death thereafter, the subject is included with 'Withdrawal By Subject' as reason for discontinuation in the Table Disposition of Subjects.

## Table 84: Subjects with AEs resulting in death up to 90 days of last dose (incidence ≥ 0% in or more treatment groups) by decreasing frequency of preferred term from KN048 combo (ASaT population)

|                                 | KN048Data for MK-3475   | KN048Data for MK-3475   | KN048Datafor MK-3475+ Chemotherapy   | KN048Datafor MK-3475+ Chemotherapy   | KN048Data for OOS   | KN048Data for OOS   | HNSCC Safery Dataset for MK347511   | HNSCC Safery Dataset for MK347511   | Rleference Safety Dataset for MK-34751   | Rleference Safety Dataset for MK-34751   |
|---------------------------------|-------------------------|-------------------------|--------------------------------------|--------------------------------------|---------------------|---------------------|-------------------------------------|-------------------------------------|------------------------------------------|------------------------------------------|
|                                 | I1                      |                         |                                      |                                      |                     |                     |                                     |                                     | I                                        |                                          |
| Subjects in population          | 300                     |                         | 276                                  |                                      | 287                 |                     | 609                                 |                                     | 3.830                                    |                                          |
| with one or more adverse events | 25                      | (8.3)                   | 32                                   | (11.6)                               | 27                  | (6)                 | 54                                  | (8.9)                               | 157                                      | (4.1)                                    |
| with no adverse events          | 275                     | (91.7)                  | 244                                  | (88)                                 | 260                 | (90.6)              | 555                                 | (91.1)                              | 3.673                                    | (95.9)                                   |

When adjusted for exposure, event rates were slightly lower in the pembrolizumab monotherapy dataset compared to the pembrolizumab plus chemotherapy and standard treatment datasets (13.84 versus 16.79 and 16.68 events per 100 person-years).

Table 85: Summary of Death Reasons (All Randomized Subjects)

|                                 | Pembrolizumab (N=301) n (%)     | Pembrolizumab + Chemotherapy (N=281) n (%)   | Cetuximab + Chemotherapy (N=300) n (%)   | Total (N=882) n (%)             |
|---------------------------------|---------------------------------|----------------------------------------------|------------------------------------------|---------------------------------|
| Subjects who died               | 213 (70.8)                      | 197 (70.1)                                   | 240 (80.0)                               | 650 (73.7)                      |
| Progressive Disease             | 154 (51.2)                      | 152 (54.1)                                   | 173 (57.7)                               | 479 (54.3)                      |
| Adverse Event                   | 34 (11.3)                       | 33 (11.7)                                    | 42 (14.0)                                | 109 (12.4)                      |
| Not Related                     | 21 (7.0)                        | 16 (5.7)                                     | 18 (6.0)                                 | 55 (6.2)                        |
| Related                         | 13 (4.3)                        | 17 (6.0)                                     | 24 (8.0)                                 | 54 (6.1)                        |
| Unknown                         | 25 (8.3)                        | 12 (4.3)                                     | 25 (8.3)                                 | 62 (7.0)                        |
| Withdrawal by Subject           | 3 (1.0)                         | 2 (0.7)                                      | 8 (2.7)                                  | 13 (1.5)                        |
| Other                           | 22 (7.3)                        | 10 (3.6)                                     | 17 (5.7)                                 | 49 (5.6)                        |
| Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018 | Database Cutoff Date: 13JUN2018              | Database Cutoff Date: 13JUN2018          | Database Cutoff Date: 13JUN2018 |

650 (73.7)

55 (6.2)

54 (6.1)

13 (1.5)

49 (5.6)

<div style=\"page-break-after: always\"></div>

Table 86: Subjects with AEs resulting in death up to 90 days of last dose (incidence ≥ 0% in or more treatment groups) Pembro combo vs control (ASaT population)

|                                                                     | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   |
|---------------------------------------------------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|
|                                                                     |                                | (%6)                           |                            | (96)                       |
| Subjects in population                                              | 276                            |                                | 287                        |                            |
| with one or more adverse events resulting in death                  | 32                             | (11.6)                         | 27                         | (9.4)                      |
| with no adverse events resulting in death                           | 244                            | (88.4)                         | 260                        | (90.6)                     |
| Cardiac disorders                                                   | 4                              | (1.4)                          | 3                          | (1.0)                      |
| Cardiac arrest                                                      | 2                              | (0.7)                          | 0                          | (0.0)                      |
| Myocardial infarction                                               | 2                              | (0.7)                          | 2                          | (0.7)                      |
| Acute myocardial infarction                                         | 0                              | (0.0)                          | 1                          | (0.3)                      |
| General disorders and administration site conditions                | 5                              | (1.8)                          | 2                          | (0.7)                      |
| Death                                                               | 2                              | (0.7)                          | 2                          | (0.7)                      |
| Multiple organ dysfunction syndrome                                 | 2                              | (0.7)                          | 0                          | (0.0)                      |
| Sudden death                                                        | 1                              | (0.4)                          | 0                          | (0.0)                      |
| Infections and infestations                                         | 12                             | (4.3)                          | 13                         | (4.5)                      |
| Septic shock                                                        | 5                              | (1.8)                          | 2                          | (0.7)                      |
| Pueuwmonia                                                          | 2                              | (0.7)                          | 6                          | (2.1)                      |
| Sepsis                                                              | 2                              | (0.7)                          | 2                          | (0.7)                      |
| Bronchitis                                                          | 1                              | (0.4)                          | 0                          | (0.0)                      |
| Infection                                                           | 1                              | (0.4)                          | 0                          | (0.0)                      |
| Nosocomial infection                                                | 1                              | (0.4)                          | 0                          | (0.0)                      |
| Lung infection pseudomonal                                          | 0                              | (0.0)                          | 1                          | (0.3)                      |
| Osteomyelitis                                                       | 0                              | (0.0)                          | 1                          | (0.3)                      |
| Stoma site infection                                                | 0                              | (0.0)                          | 1                          | (0.3)                      |
| Urinary tract infection                                             | 0                              | (0.0)                          | 1                          | (0.3)                      |
| Neoplasms benign, maliguant and unspecified (incl cysts and polyps) | 1                              | (0.4)                          | 3                          | (1.0)                      |
| Tumow haemorhage                                                    | 1                              | (0.4)                          | 3                          | (1.0)                      |
| Nervous system disorders                                            | 3                              | (1.1)                          | 0                          | (0.0)                      |
| Carotid artery perforation                                          | 1                              | (0.4)                          | 0                          | (0.0)                      |
| Cerebral ischaemia                                                  | 1                              | (0.4)                          | 0                          | (0.0)                      |
| Embolic stroke                                                      | 1                              | (0.4)                          | 0                          | (0.0)                      |
| Respiratory, thoracic and mediastinal disorders                     | 6                              | (2.2)                          | 6                          | (2.1)                      |
| Puewmonia aspiration                                                | 2                              | (0.7)                          | 0                          | (0.0)                      |
| Dyspnoea                                                            | 1                              | (0.4)                          | 0                          | (0.0)                      |
| Haemoptysis                                                         | 1                              | (0.4)                          | 0                          | (0.0)                      |
| Interstitial lung disease                                           | 1                              | (0.4)                          | 0                          | (0.0)                      |
| Pulmonary embolism                                                  | 1                              | (0.4)                          | 2                          | (0.7)                      |
| Hypoxia                                                             | 0                              | (0.0)                          | 1                          | (0.3)                      |
| Pulmouary artery thrombosis                                         | 0                              | (0.0)                          | 1                          | (0.3)                      |
| Respiratory failure                                                 | 0                              | (0.0)                          | 1                          | (0.3)                      |
| Respiratory tract haemonhage                                        | 0                              | (0.0)                          | 1                          | (0.3)                      |
| Vascular disorders                                                  | 1                              | (0.4)                          | 0                          | (0.0)                      |
| Haemorrhage                                                         |                                | (0.4)                          | 0                          | (0.0)                      |

Every subject is counted a single time for each applicable row and columm.

A. system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

For subjects who received second couwrse reatment, adverse events which occurred in second course phase are excluded.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the dnug are excluded. Database Cutoff Date: 13JUN2018.

Source: [P048V01MK3475: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Table 87: Subjects with AEs resulting in death up to 90 days of last dose (incidence ≥ 0% in or more treatment groups) Pembro mono vs control (ASaT population)

<!-- image -->

|                                                                                                                                                                                             | Pembrolizmab                                                                                                                                                                                | Pembrolizmab                                                                                                                                                                                | Cetximab + Chemotherapy                                                                                                                                                                     | Cetximab + Chemotherapy                                                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                             |                                                                                                                                                                                             | (96)                                                                                                                                                                                        |                                                                                                                                                                                             | (%6)                                                                                                                                                                                        |
| Subjects in population                                                                                                                                                                      | 300                                                                                                                                                                                         |                                                                                                                                                                                             | 287                                                                                                                                                                                         |                                                                                                                                                                                             |
| with one or more adverse events resulting in death                                                                                                                                          | 25                                                                                                                                                                                          | (8.3)                                                                                                                                                                                       | 27                                                                                                                                                                                          | (9.4)                                                                                                                                                                                       |
| with no adverse events resulting in death                                                                                                                                                   | 275                                                                                                                                                                                         | (91.7)                                                                                                                                                                                      | 260                                                                                                                                                                                         | (90.6)                                                                                                                                                                                      |
| Blood and lymphatic system disorders                                                                                                                                                        | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Disseminated intravascular coagulation                                                                                                                                                      | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Cardiac disorders                                                                                                                                                                           | 3                                                                                                                                                                                           | (1.0)                                                                                                                                                                                       | 3                                                                                                                                                                                           | (1.0)                                                                                                                                                                                       |
| Myocardial infarction                                                                                                                                                                       | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       |
| Cardiac failure acute                                                                                                                                                                       | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Acute myocardial infarction                                                                                                                                                                 | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       |
| Gastrointestinal disorders                                                                                                                                                                  | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Gastic haemonhage                                                                                                                                                                           | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| General disordersand administrationsiteconditions                                                                                                                                           | 4                                                                                                                                                                                           | (1.3)                                                                                                                                                                                       | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       |
| Death                                                                                                                                                                                       | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       |
| Multiple organ dysfimction syudrome                                                                                                                                                         | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Immune system disorders                                                                                                                                                                     | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Autoinflammatory disease                                                                                                                                                                    | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Infections and infestations                                                                                                                                                                 | 9                                                                                                                                                                                           | (3.0)                                                                                                                                                                                       | 13                                                                                                                                                                                          | (4.5)                                                                                                                                                                                       |
| Sepsis                                                                                                                                                                                      | 3                                                                                                                                                                                           | (1.0)                                                                                                                                                                                       | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       |
| Pueumonia                                                                                                                                                                                   | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       | 6                                                                                                                                                                                           | (2.1)                                                                                                                                                                                       |
| Pseudomonal sepsis                                                                                                                                                                          | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Pulmonary sepsis                                                                                                                                                                            | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Septic shock                                                                                                                                                                                | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       |
| Soft tissue infection                                                                                                                                                                       | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Lumg infection pseudomonal                                                                                                                                                                  | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       |
| Osteomyelitis                                                                                                                                                                               | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       |
| Stoma site infection                                                                                                                                                                        | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       |
| Urinarv tract infection                                                                                                                                                                     | 0                                                                                                                                                                                           | (0.01                                                                                                                                                                                       | 1                                                                                                                                                                                           | (0.31                                                                                                                                                                                       |
| Neoplasms benign, maliguant and unspecified (incl cysts and polyps)                                                                                                                         | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       | 3                                                                                                                                                                                           | (1.0)                                                                                                                                                                                       |
| Tumour haemomhage                                                                                                                                                                           | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       | 3                                                                                                                                                                                           | (1.0)                                                                                                                                                                                       |
| Respiratory, thoracic and mediastinal disorders                                                                                                                                             | 4                                                                                                                                                                                           | (1.3)                                                                                                                                                                                       | 6                                                                                                                                                                                           | (2.1)                                                                                                                                                                                       |
| Aspiration                                                                                                                                                                                  | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Pneumonia aspiration                                                                                                                                                                        | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Pneumonitis                                                                                                                                                                                 | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       |
| Pulmonary embolism                                                                                                                                                                          | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       | 2                                                                                                                                                                                           | (0.7)                                                                                                                                                                                       |
| Hypoxia                                                                                                                                                                                     | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       |
| Pulmonary artery thrombosis                                                                                                                                                                 | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       |
| Respiratory failure                                                                                                                                                                         | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       |
| Respiratory tact haemorhage                                                                                                                                                                 | 0                                                                                                                                                                                           | (0.0)                                                                                                                                                                                       | 1                                                                                                                                                                                           | (0.3)                                                                                                                                                                                       |
| Every subject is coumted a single time for each applicable row and colum. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the | Every subject is coumted a single time for each applicable row and colum. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the | Every subject is coumted a single time for each applicable row and colum. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the | Every subject is coumted a single time for each applicable row and colum. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the | Every subject is coumted a single time for each applicable row and colum. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the |

Source: [P048V01MK3475: adam-adsl; adae]

Narratives were provided for all the 57 deaths occurring in the two pembrolizumab-treated arms of KEYNOTE-048 (i.e. 25 in the pembro mono arm and 32 in the pembro combo arm).

Based on the listing provided (data not shown), the AEs leading to death considered as drug-related by investigator in each arm were:

-  in  the  pembro  mono  arm  (n=3):  pneumonitis,  disseminated  intravascular  coagulation  (DIC), autoinflammatory disease (1 patient each)

<div style=\"page-break-after: always\"></div>

- in the pembro combo arm (n=10): septic shock (5 patients), sepsis, interstitial lung disease, tumour hemorrhage, hemorrhage, cerebral ischemia (1 patient each).

At the final analysis cut-off date (25 February 2019), there was one additional patient in the pembro combo arm who died due to a AE (bronchitis) which was classified as treatment related. However, the investigator considered bronchitis (Grade 5) related to carboplatin, but not related to pembrolizumab, or 5-FU.)

-  in  the  control arm (n=8): pneumonia (3 patients), sepsis (2 patients), hypoxia, osteomyelitis, and pulmonary artery thrombosis (1 patient each).

## AEOSIs

A prespecified list of PTs was developed to consistently characterize the nature and frequency of each AEOSI across the clinical program, regardless of causality as reported by investigators. These PTs are considered to be medically equivalent to the immune-mediated events and infusion-related reactions.

<div style=\"page-break-after: always\"></div>

## Table 88: List of AEOSI Preferred Terms, Version 14 (09 May 2018) - based on MedDRA Version 21.0

<!-- image -->

| AEOSI                                                                                                   | Preferred Terms                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Immune-mediated (yes/no)   |
|---------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| Pneumonitis                                                                                             | Acute interstitial pneumonitis, Autoimmune lung disease, Interstitial lung disease, Pneumonitis, Idiopathic pneumomia syudrome, Organising pneumonia                                                                                                                                                                                                                                                                                                                                 |                            |
| Colitis                                                                                                 | Colitis, Colitis microscopic, Enterocolitis, Enterocolitis haemorrhagic, Necrotising colitis, Colitis erosive, Autoimmune colitis                                                                                                                                                                                                                                                                                                                                                    | 531                        |
| Hepatitis                                                                                               | Hepatitis, Immune-mediated hepatitis, Autoimmune hepatitis, Hepatitis acute, Hepatitis fulminant, Dnug- induced liver injury                                                                                                                                                                                                                                                                                                                                                         |                            |
| Nephritis                                                                                               | Nephritis, Autoimmune nephritis, Chronic autoimmune glomenulonephritis, Fibrillary glomenlonephritis, Focal segmental glomerulosclerosis, Glomerulonephritis, Glomenulonephritis acute, Glomerulonephritis membranoproliferative, Glomerulonephritis membranous, Glomenulonephritis minimal lesion, Glomenlonephritis proliferative, Glomerlonephritis rapidly progressive, Mesangioproliferative glomerulonephritis, Nephritis haemorhagic, Tubulointerstitial nephritis, Nephrotic |                            |
| Adrenal Insufficiency                                                                                   | Adrenal insufficiency, Adrenocortical insufficiency acute, Secondary adrenocortical insufficiency                                                                                                                                                                                                                                                                                                                                                                                    |                            |
| Hypophysitis                                                                                            | Hypophysitis,Hypopituitarism,Lymphocytic hypophysitis                                                                                                                                                                                                                                                                                                                                                                                                                                |                            |
| Hyperthyroidism                                                                                         | Hyperthyroidism, Basedow's disease, Thyrotoxic crisis                                                                                                                                                                                                                                                                                                                                                                                                                                |                            |
| Hypothyroidism                                                                                          | Hypothyroidism, Hypothyroidic goitre, Myxoedema, Myxoedema coma, Primary hypothyroidism                                                                                                                                                                                                                                                                                                                                                                                              |                            |
| Thyroiditis                                                                                             | Thyroid disorder, Thyroiditis, Autoimmune thyroiditis, Thyroiditis acute, Silent thyroiditis, Autoimmume thyroid disorder                                                                                                                                                                                                                                                                                                                                                            |                            |
| Type l Diabetes Mellitus                                                                                | Diabetic ketoacidosis, Diabetic ketoacidotic Latent autoimmune diabetes in adults, Type 1 diabetes mellitus,Euglycaemic diabetic ketoacidosis,Diabetic ketosis, Ketosis-prone diabetes mellihus                                                                                                                                                                                                                                                                                      |                            |
| Severe Skin Reactions Including Stevens- Johnson Syndrome (SJS)and Toxic Epidermal Necrolysis (IEN): or | Dermatitis bullous, Dermatitis exfoliative, Dermatitis exfoliativegeneralised,Epidenmalnecrosis,Erythema multiforme, Exfoliative rash, Pemphigoid, Pemphigus, Skin necrosis, Stevens-Johnson syndrome, Toxic epidenmal necrolysis, Toxic skin eruption;                                                                                                                                                                                                                              |                            |
| Severe Skin (continued): If Grade 3 or higher:                                                          | Rash, Rash erythematous, Rash generalised, Rash maculo- papular, Rash pruritic, Rash pustular, Prwitus, Pruitus generalised, Pruritus genital                                                                                                                                                                                                                                                                                                                                        |                            |
| Uveitis                                                                                                 | Initis, Uveitis, Cyclitis, Autoimmune uveitis, Iridocyclitis                                                                                                                                                                                                                                                                                                                                                                                                                         |                            |
| Pancreatitis                                                                                            | Pancreatitis, Autoimmune pancreatitis, Pancreatitis acute, Paucreatitis haemonhagic, Pancreatitis necrotising                                                                                                                                                                                                                                                                                                                                                                        | 5a1                        |
| Myositis                                                                                                | Myositis, Necrotising myositis, Polymyositis, Immume-- mediated necrotising myopathy, Rhabdomyolysis, Myopathy, Dermatomyositis                                                                                                                                                                                                                                                                                                                                                      |                            |
| Guillain-Barre Syndrome                                                                                 | Demyelinating polyneuropathy, Guillain-Barre syndrome, Axonal neuropathy, Multifocal motor neuropathy, syudrome                                                                                                                                                                                                                                                                                                                                                                      |                            |
| Myocarditis                                                                                             | Myocarditis, Autoimmune myocarditis, Hypersensitivity myocarditis                                                                                                                                                                                                                                                                                                                                                                                                                    |                            |
| Encephalitis                                                                                            | Encephalitis, Encephalitis autoimmune, Limbic encephalitis, Noninfective encephalitis                                                                                                                                                                                                                                                                                                                                                                                                |                            |
| Sarcoidosis                                                                                             | Sarcoidosis, Cutaneous sarcoidosis, Ocular sarcoidosis, Pulmonary sarcoidosis                                                                                                                                                                                                                                                                                                                                                                                                        |                            |
| Infusion Reactions                                                                                      | Hypersensitivity, Drug hypersensitivity, Anaphylactic reaction, Anaphylactoid reaction, Cytokine release syudrome, Senum sickness, Serum sickness-like reaction, Infusion related reaction                                                                                                                                                                                                                                                                                           | No                         |
| Myasthenic Syndrome                                                                                     | Myasthenic syndrome, Myasthenia gravis, Myasthenia gravis crisis, Ocular myasthenia                                                                                                                                                                                                                                                                                                                                                                                                  |                            |

<div style=\"page-break-after: always\"></div>

Table 89: Adverse event summary AEOSI (ASaT population)

|                                                               | KN048 Data for MK-3475   | KN048 Data for MK-3475   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for SOC   | KN048 Data for SOC   | HNSCC Safety Dataset for MK34751   | HNSCC Safety Dataset for MK34751   | Reference Safety Dataset for MK-347511   | Reference Safety Dataset for MK-347511   |
|---------------------------------------------------------------|--------------------------|--------------------------|-----------------------------------------|-----------------------------------------|----------------------|----------------------|------------------------------------|------------------------------------|------------------------------------------|------------------------------------------|
|                                                               | n                        | (96)                     | (%)                                     | (%)                                     | (%)                  | (%)                  | (96)                               | (96)                               |                                          | (9%)                                     |
| Subjects in population                                        | 300                      |                          | 276                                     |                                         | 287                  |                      | 609                                |                                    | 3,830                                    |                                          |
| with oue or more adverse events                               | 91                       | (30.3)                   | 71                                      | (25.7)                                  | 89                   | (23.7)               | 148                                | (24.3)                             | 856                                      | (22.3)                                   |
| with no adverse event                                         | 209                      | (69.7)                   | 205                                     | (74.3)                                  | 219                  | (76.3)               | 461                                | (75.7)                             | 2,974                                    | (77.7)                                   |
| with dnug-related' adverse events                             | 70                       | (23.3)                   | 61                                      | (22.1)                                  | 48                   | (16.7)               | 114                                | (18.7)                             | 743                                      | (19.4)                                   |
| with toxicity gade 3-5 adverse events                         | 20                       | (6.7)                    | 13                                      | (4.7)                                   | 30                   | (10.5)               | 27                                 | (4.4)                              | 228                                      | (6.0)                                    |
| with toxicity grade 3-5 dnug- related adverse events          | 17                       | (5.7)                    | 11                                      | (4.0)                                   | 28                   | (9.8)                | 22                                 | (3.6)                              | 195                                      | (5.1)                                    |
| with serious adverse events                                   | 17                       | (5.7)                    | 12                                      | (4.3)                                   | 12                   | (4.2)                | 28                                 | (4.6)                              | 227                                      | (5.9)                                    |
| with serious dnug-related adverse events                      | 14                       | (4.7)                    | 10                                      | (3.6)                                   | 11                   | (3.8)                | 23                                 | (3.8)                              | 199                                      | (5.2)                                    |
| with dose modification' dhue to an adverse event              | 26                       | (8.7)                    | 21                                      | (7.6)                                   | 43                   | (15.0)               | 35                                 | (5.7)                              | 311                                      | (8.1)                                    |
| who died                                                      | 1                        | (0.3)                    | 1                                       | (0.4)                                   | 0                    | (0.0)                | 2                                  | (0.3)                              | 7                                        | (0.2)                                    |
| who died due to a dnug-related adverse event                  | 1                        | (0.3)                    | 1                                       | (0.4)                                   | 0                    | (0.0)                | 2                                  | (0.3)                              | 7                                        | (0.2)                                    |
| discontinued dnug dhie to an adverse event                    | 7                        | (2.3)                    | 8                                       | (2.9)                                   | 19                   | (6.6)                | 15                                 | (2.5)                              | 128                                      | (3.3)                                    |
| discontinued dnug due to a dnug- related adverse event        | 7                        | (2.3)                    | 8                                       | (2.9)                                   | 19                   | (6.6)                | 15                                 | (2.5)                              | 126                                      | (3.3)                                    |
| discontinued dnug due to a serious adverse event              | 6                        | (2.0)                    | 6                                       | (2.2)                                   | 9                    | (3.1)                | 11                                 | (1.8)                              | 99                                       | (2.6)                                    |
| discontinued dnug due to a serious drug-related adverse event |                          | 6 (2.0)                  | 6                                       | (2.2)                                   | 9                    | (3.1)                | 11                                 | (1.8)                              | 97                                       | (2.5)                                    |

I Defined as an action taken of dose reduced, dnug intemupted or drug withdrawn.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

I Includes all subjects who received at least one dose of MK-3475 in KN012 Coborts B and B2, KN040 and KN055.

phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045, KN052 and KN087.

MK-3475 Database Cutoff Date for Melanoma (KN001-Melamoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 020CT2017)

MK-3475 Database Cutoff Date for Lumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JULY2017)

MK-3475 Database Cutoff Date for HNSCC (KN012-HNSCC: 26APR2016,KN040: 15MAY2017, KN048: 13JUN2018,KN055: 22APR2016)

MK-3475 Database Cutoff Date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

MK-3475 Database Cutoff Date for Bladder (KN045: 18JAN2017, KN052: 09MAR2017)

Souce: [ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Table 90: (modified) Subjects With Adverse Events of Special Interest (AEOSI) by Maximum Toxicity Grade (Incidence &gt; 0% in One or More Treatment Groups)

|                                | KN048 Data for MK-3475   | KN048 Data for MK-3475   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for SOC   | KN048 Data for SOC   | HNSCC Safety Dataset for MK347511   | HNSCC Safety Dataset for MK347511   | Reference Safety Dataset forMK-3475*   | Reference Safety Dataset forMK-3475*   |
|--------------------------------|--------------------------|--------------------------|-----------------------------------------|-----------------------------------------|----------------------|----------------------|-------------------------------------|-------------------------------------|----------------------------------------|----------------------------------------|
|                                | n                        | (%)                      | n                                       | (%)                                     | n                    | (%)                  | n                                   | (%)                                 | n                                      | (%)                                    |
| Subjects inpopulation          | 300                      |                          | 276                                     |                                         | 287                  |                      | 609                                 |                                     | 3,830                                  |                                        |
| with one ormore adverse events | 91                       | (30.3)                   | 71                                      | (25.7)                                  | 68                   | (23.7)               | 148                                 | (24.3)                              | 856                                    | (22.3)                                 |
| Grade 1                        | 30                       | (10.0)                   | 25                                      | (9.1)                                   | 11                   | (3.8)                | 41                                  | (6.7)                               | 215                                    | (5.6)                                  |
| Grade 2                        | 41                       | (13.7)                   | 33                                      | (12.0)                                  | 27                   | (9.4)                | 80                                  | (13.1)                              | 413                                    | (10.8)                                 |
| Grade 3                        | 15                       | (5.0)                    | 9                                       | (3.3)                                   | 27                   | (9.4)                | 21                                  | (3.4)                               | 198                                    | (5.2)                                  |
| Grade 4                        | 4                        | (1.3)                    | 3                                       | (1.1)                                   | 3                    | (1.0)                | 4                                   | (0.7)                               | 23                                     | (0.6)                                  |
| Grade 5                        | 1                        | (0.3)                    | 1                                       | (0.4)                                   | 0                    | (0.0)                | 2                                   | (0.3)                               | 7                                      | (0.2)                                  |
| with no adverse events         | 209                      | (69.7)                   | 205                                     | (74.3)                                  | 219                  | (76.3)               | 461                                 | (75.7)                              | 2.974                                  | (77.7)                                 |
| Adrenal Insufficiency          | 1                        | (0.3)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 4                                   | (0.7)                               | 30                                     | (0.8)                                  |
| Colitis                        |                          | (1.0)                    | 7                                       | (2.5)                                   | 2                    | (0.7)                | 4                                   | (0.7)                               | 74                                     | (1.9)                                  |
| Encephalitis                   | 1                        | (0.3)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 0                                   | (0.0)                               | 1                                      | (0.0)                                  |
| Guillain-Barre Syndrome        | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 2                                   | (0.3)                               | 2                                      | (0.1)                                  |
| Hepatitis                      | 2                        | (0.7)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 6                                   | (1.0)                               | 24                                     | (0.6)                                  |
| Hyperthyroidism                | 8                        | (2.7)                    | 13                                      | (4.7)                                   | 3                    | (1.0)                | 10                                  | (1.6)                               | 134                                    | (3.5)                                  |
| Hypophysitis                   | 1                        | (0.3)                    | 1                                       | (0.4)                                   | 0                    | (0.0)                | 0                                   | (0.0)                               | 21                                     | (0.5)                                  |
| Hypothyroidism                 | 54                       | (18.0)                   | 42                                      | (15.2)                                  | 18                   | (6.3)                | 92                                  | (15.1)                              | 347                                    | (9.1)                                  |
| Infusion Reactions             | 4                        | (1.3)                    | 6                                       | (2.2)                                   | 27                   | (9.4)                | 11                                  | (1.8)                               | 101                                    | (2.6)                                  |
| Myasthenic Syndrome            | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 0                                   | (0.0)                               | 2                                      | (0.1)                                  |
| Myocarditis                    | 0                        | (0.0)                    | 1                                       | (0.4)                                   | 0                    | (0.0)                | 0                                   | (0.0)                               | 3                                      | (0.1)                                  |
| Myositis                       | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 1                    | (0.3)                | 1                                   | (0.2)                               | 17                                     | (0.4)                                  |
| Nephritis                      | 2                        | (0.7)                    | 2                                       | (0.7)                                   | 1                    | (0.3)                | 0                                   | (0.0)                               | 15                                     | (0.4)                                  |
| Pancreatitis                   | 2                        | (0.7)                    | 1                                       | (0.4)                                   | 0                    | (0.0)                | 1                                   | (0.2)                               | 10                                     | (0.3)                                  |
| Pneumonitis                    | 18                       | (6.0)                    | 15                                      | (5.4)                                   | 3                    | (1.0)                | 23                                  | (3.8)                               | 142                                    | (3.7)                                  |
| Sarcoidosis                    | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 0                                   | (0.0)                               | 3                                      | (0.1)                                  |
| Severe Skin Reactions          | 8                        | (2.7)                    | 2                                       | (0.7)                                   | 20                   | (7.0)                | 9                                   | (1.5)                               | 54                                     | (1.4)                                  |
| Thyroiditis                    | 0                        | (0.0)                    | 1                                       | (0.4)                                   | 0                    | (0.0)                | 3                                   | (0.5)                               | 27                                     | (0.7)                                  |
| Type l Diabetes Mellitus       | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 3                                   | (0.5)                               | 12                                     | (0.3)                                  |
| Uveitis                        | 1                        | (0.3)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 0                                   | (0.0)                               | 17                                     | (0.4)                                  |

Average time to onset of first AEOSI, number of events, and duration of episode are summarized for KEYNOTE-048 treatment arms in the next two tables:

Table 91: Time to onset and duration of AEOSI (pembro combo vs Control) - AsaT population

|                                              | Pembrolizumab+Chemotherapy   | Cetuximab+Chemotherapy   |
|----------------------------------------------|------------------------------|--------------------------|
| Subjects inpopulation                        | 276                          | 287                      |
| Subjects with AEOSI(%)                       | 71 (25.7)                    | 68 (23.7)                |
| Time to Onset ofFirstAEOSI(days)             |                              |                          |
| Mean (SD)                                    | 110.8 (113.7)                | 55.6 (73.3)              |
| Median                                       | 70.0                         | 25.5                     |
| Range                                        | 1 to 677                     | 1 to 331                 |
| Total number of episodesof AEOSI             | 100                          | 89                       |
| Average number ofepisodes of AEOSIpersubject | 1.4                          | 1.3                      |
| Episode Durations (days)t                    |                              |                          |
| Median                                       | 137.0                        | 25.0                     |
| Range                                        | 1 to 890+                    | 1 to 912+                |

<div style=\"page-break-after: always\"></div>

Table 92: Time to onset and duration of AEOSI (pembro mono vs Control) - AsaT population

<!-- image -->

|                                               | Pembrolizumab   | Cetuximab+Chemotherapy   |
|-----------------------------------------------|-----------------|--------------------------|
| Subjects in population                        | 300             | 287                      |
| Subjects with AEOSI (%)                       | 91 (30.3)       | 68 (23.7)                |
| Time to Onset of First AEOSI (days)           |                 |                          |
| Mean (SD)                                     | 123.6 (114.2)   | 55.6 (73.3)              |
| Median                                        | 85.0            | 25.5                     |
| Range                                         | 1 to 652        | 1 to 331                 |
| TotalnumberofepisodesofAEOSI                  | 112             | 89                       |
| Averagenumber ofepisodes of AEOSI per subject | 1.2             | 1.3                      |
| Episode Durations (days)t                     |                 |                          |
| Median                                        | 232.0           | 25.0                     |
| Range                                         | 2 to 909+       | 1 to 912+                |

Table 93: (modified) Summary of Outcome for Subjects With AEOSI (Incidence &gt; 0% in One or More Treatment Groups)

|                       | Outcome     | KN048DataforMK 3475 n (%)   | KN048DataforMK 3475+Chemotherapy n (%)   | KN048DataforSOC n (%)   | HNSCCSafetyDataset forMK3475 n (%)   | Referenca Safety DatasetforMK-3475 n (%)   |            |
|-----------------------|-------------|-----------------------------|------------------------------------------|-------------------------|--------------------------------------|--------------------------------------------|------------|
| Subjects inpopulation |             | 300                         |                                          | 276 287                 |                                      | 609                                        | 3830       |
| IWithoneormoreAEOSI   | Overall     | 91 (30.3)                   | 71                                       | (25.7) 68               | (23.7)                               | 148 (24.3)                                 | 856 (22.3) |
|                       | Fatal       | 1 (1.1)                     | 1                                        | (1.4) 0                 | (0.0) 2                              | (1.4) 7                                    | (0.8)      |
|                       | NotResolved | 36 (39.6)                   | 32                                       | (45.1) 13               | (19.1)                               | 82 (55.4)                                  | 387 (45.2) |
|                       | Resolving   | 18 (19.8)                   | 10                                       | (14.1) 9                | (13.2)                               | 16 (10.8)                                  | 39 (4.6)   |
|                       | Unlmown     | 1 (1.1)                     | 0                                        | (0.0) 1                 | (SD)                                 | 7 (4.7)                                    | 18 (2.1)   |
|                       | Sequelae    | 4 (4.4)                     | 2                                        | (2.8) 0                 | (0.0) 2                              | (1.4)                                      | 13 (S1)    |
|                       | Resolved    | 31 (34.1)                   | 26                                       | (36.6) 45               | (66.2)                               | 39 (26.4)                                  | 392 (45.8) |

<div style=\"page-break-after: always\"></div>

## - Treatment-emergent hypothyroidism

Table 94: Adverse event summary AEOSI - Hypothyroidism (ASaT population)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | KN048 Data for MK-3475                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | KN048 Data for MK-3475                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | KN048 Data for MK-3475 + Chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | KN048 Data for MK-3475 + Chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | KN048 Data for SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | KN048 Data for SOC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | HNSOC Safety Dataset for MK347511 n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | HNSOC Safety Dataset for MK347511 n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Reference Safety Dataset for MK-347511 n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Reference Safety Dataset for MK-347511 n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | n ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | n ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (2-)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (2-)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | ()                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Subjects in population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 300                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 276                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 287                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 609                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 3,830                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| with one or more adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 54                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (18.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (15.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (6.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 92                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (15.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 347                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (9.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| with no adverse event                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 246                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (82.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 234                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (84.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 269                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (93.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 517                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (84.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 3.483                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | (90.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| with drug-related' adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 39                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (13.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 35                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (12.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 68                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (11.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 310                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (8.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| with toxicity grade 3-5 adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| with toxicity gade 3-5 dnug- related adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0'0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| with serious adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0°0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| With serious drug-related adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| with dose modification* due to an adverse event                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (1.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | (0.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| who died                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| who died due to a dng-related adverse event                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| discontinued drug due to an adverse event                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| discontinued drug due to a drug- related adverse event                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| discontinued dnug due to a serious adverse event                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| discontinued drug due to a serious drug-related adverse event                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| t Determined by the investigator to be related to the dnug. I Defined as an action taken of dose reduced, drug intemupted or dnug withdrawn. Non-serious adverse events up to 30 days of lhast dose and serious adverse events up to 90 days of last dose are included. HInchudes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055. (emauo) c00n1 e1 'ta '1a'5 'a 's8 't8 Ta 1ed to0NI 4 stte-0n fo ssop amo 1stel1e paniaoan oqn soalqns me sapnpu.m phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087. MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015. KN006: 03MAR2015. | t Determined by the investigator to be related to the dnug. I Defined as an action taken of dose reduced, drug intemupted or dnug withdrawn. Non-serious adverse events up to 30 days of lhast dose and serious adverse events up to 90 days of last dose are included. HInchudes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055. (emauo) c00n1 e1 'ta '1a'5 'a 's8 't8 Ta 1ed to0NI 4 stte-0n fo ssop amo 1stel1e paniaoan oqn soalqns me sapnpu.m phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087. MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015. KN006: 03MAR2015. | t Determined by the investigator to be related to the dnug. I Defined as an action taken of dose reduced, drug intemupted or dnug withdrawn. Non-serious adverse events up to 30 days of lhast dose and serious adverse events up to 90 days of last dose are included. HInchudes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055. (emauo) c00n1 e1 'ta '1a'5 'a 's8 't8 Ta 1ed to0NI 4 stte-0n fo ssop amo 1stel1e paniaoan oqn soalqns me sapnpu.m phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087. MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015. KN006: 03MAR2015. | t Determined by the investigator to be related to the dnug. I Defined as an action taken of dose reduced, drug intemupted or dnug withdrawn. Non-serious adverse events up to 30 days of lhast dose and serious adverse events up to 90 days of last dose are included. HInchudes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055. (emauo) c00n1 e1 'ta '1a'5 'a 's8 't8 Ta 1ed to0NI 4 stte-0n fo ssop amo 1stel1e paniaoan oqn soalqns me sapnpu.m phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087. MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015. KN006: 03MAR2015. | t Determined by the investigator to be related to the dnug. I Defined as an action taken of dose reduced, drug intemupted or dnug withdrawn. Non-serious adverse events up to 30 days of lhast dose and serious adverse events up to 90 days of last dose are included. HInchudes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055. (emauo) c00n1 e1 'ta '1a'5 'a 's8 't8 Ta 1ed to0NI 4 stte-0n fo ssop amo 1stel1e paniaoan oqn soalqns me sapnpu.m phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087. MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015. KN006: 03MAR2015. | t Determined by the investigator to be related to the dnug. I Defined as an action taken of dose reduced, drug intemupted or dnug withdrawn. Non-serious adverse events up to 30 days of lhast dose and serious adverse events up to 90 days of last dose are included. HInchudes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055. (emauo) c00n1 e1 'ta '1a'5 'a 's8 't8 Ta 1ed to0NI 4 stte-0n fo ssop amo 1stel1e paniaoan oqn soalqns me sapnpu.m phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087. MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015. KN006: 03MAR2015. | t Determined by the investigator to be related to the dnug. I Defined as an action taken of dose reduced, drug intemupted or dnug withdrawn. Non-serious adverse events up to 30 days of lhast dose and serious adverse events up to 90 days of last dose are included. HInchudes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055. (emauo) c00n1 e1 'ta '1a'5 'a 's8 't8 Ta 1ed to0NI 4 stte-0n fo ssop amo 1stel1e paniaoan oqn soalqns me sapnpu.m phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087. MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015. KN006: 03MAR2015. | t Determined by the investigator to be related to the dnug. I Defined as an action taken of dose reduced, drug intemupted or dnug withdrawn. Non-serious adverse events up to 30 days of lhast dose and serious adverse events up to 90 days of last dose are included. HInchudes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055. (emauo) c00n1 e1 'ta '1a'5 'a 's8 't8 Ta 1ed to0NI 4 stte-0n fo ssop amo 1stel1e paniaoan oqn soalqns me sapnpu.m phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087. MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015. KN006: 03MAR2015. | t Determined by the investigator to be related to the dnug. I Defined as an action taken of dose reduced, drug intemupted or dnug withdrawn. Non-serious adverse events up to 30 days of lhast dose and serious adverse events up to 90 days of last dose are included. HInchudes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055. (emauo) c00n1 e1 'ta '1a'5 'a 's8 't8 Ta 1ed to0NI 4 stte-0n fo ssop amo 1stel1e paniaoan oqn soalqns me sapnpu.m phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087. MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015. KN006: 03MAR2015. | t Determined by the investigator to be related to the dnug. I Defined as an action taken of dose reduced, drug intemupted or dnug withdrawn. Non-serious adverse events up to 30 days of lhast dose and serious adverse events up to 90 days of last dose are included. HInchudes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055. (emauo) c00n1 e1 'ta '1a'5 'a 's8 't8 Ta 1ed to0NI 4 stte-0n fo ssop amo 1stel1e paniaoan oqn soalqns me sapnpu.m phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087. MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015. KN006: 03MAR2015. | t Determined by the investigator to be related to the dnug. I Defined as an action taken of dose reduced, drug intemupted or dnug withdrawn. Non-serious adverse events up to 30 days of lhast dose and serious adverse events up to 90 days of last dose are included. HInchudes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2. KN040 and KN055. (emauo) c00n1 e1 'ta '1a'5 'a 's8 't8 Ta 1ed to0NI 4 stte-0n fo ssop amo 1stel1e paniaoan oqn soalqns me sapnpu.m phase), KN006, and KN010, KN013-Cohort 3, KN024, KN045. KN052 and KN087. MK-3475 Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015. KN006: 03MAR2015. |

Source: [ISS: adam-adsl; adhe]

Among  the participants with treatment-emergent hypothyroidism in the pembrolizumab plus chemotherapy and the Pembrolizumab monotherapy datasets, a higher proportion was male and with prior radiation therapy. Median time to onset of hypothyroidism was 83 days in the Pembrolizumab plus chemotherapy dataset and 104 days in the Pembrolizumab monotherapy dataset (it was 106 days in HNSCC pembrolizumab dataset). Three subjects receiving pembrolizumab monotherapy required dose interruption. Hypothyroidism requires long-term thyroid replacement therapy and therefore the median duration has not been reached in any of the safety datasets.

## Oedema

The following preferred terms were selected: auricular swelling, ear swelling, eye oedema, eye swelling, orbital oedema, eyelid oedema, periorbital oedema, face oedema, swelling face, laryngeal oedema, laryngotracheal oedema, tracheal oedema, lip oedema, lip swelling, mouth swelling, oedema mouth, circumoral oedema, oedema mucosal, gingival oedema, gingival swelling, oropharyngeal swelling, pharyngeal oedema, epiglottic oedema, palatal oedema, palatal swelling, nasal oedema, swollen tongue, tongue oedema, localized oedema, local swelling, and oropharyngeal oedema.

<div style=\"page-break-after: always\"></div>

Table 95: Adverse Event Summary Oedema (Pembro Combo vs Control, Pembro Mono) (ASaT Population)

|                                                         | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   | Pembrolizmab   | Pembrolizmab   |
|---------------------------------------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|----------------|----------------|
|                                                         |                                | (%)                            | n                          | (%)                        | n              | (%)            |
| ubjectsinpopulation                                     | 276                            |                                | 287                        |                            | 300            |                |
| with one or more adverse events                         | 20                             | (7.2)                          | 20                         | (7.0)                      | 27             | (9.0)          |
| with no adverse event                                   | 256                            | (92.8)                         | 267                        | (93.0)                     | 273            | (91.0)         |
| with drug-related adverse events                        | 9                              | (3.3)                          | 6                          | (2.1)                      |                | (1.7)          |
| with toxicity grade 3-5 adverse events                  | 7                              | (2.5)                          | 1                          | (0.3)                      | 3              | (1.0)          |
| with toxicity grade 3-5 drug-related adverse events     | 4                              | (1.4)                          | 0                          | (0.0)                      | 1              | (0.3)          |
| with serious adverse events                             | 5                              | (1.8)                          | 1                          | (0.3)                      | 2              | (0.7)          |
| with serious drug-related adverse events                | 3                              | (1.1)                          | 0                          | (0.0)                      | 0              | (0.0)          |
| with dose modification+ due to an adverse event         | 5                              | (1.8)                          | 3                          | (1.0)                      | 1              | (0.3)          |
| who died                                                | 0                              | (0.0)                          | 0                          | (0.0)                      | 0              | (0.0)          |
| who died due to a drug-related adverse event            | 0                              | (0.0)                          | 0                          | (0.0)                      | 0              | (0.0)          |
| discontinued drug due to an adverse event               | 0                              | (0.0)                          | 1                          | (0.3)                      | 0              | (0.0)          |
| discontinued drug due to a drug-related adverse event   | 0                              | (0.0)                          | 0                          | (0.0)                      | 0              | (0.0)          |
| discontinued drug due to a serious adverse event        | 0                              | (0.0)                          | 0                          | (0.0)                      | 0              | (0.0)          |
| liscontinueddrugduetoaserious drug-relatedadverse event | 0                              | (0.0)                          | 0                          | (0.0)                      | 0              | (0.0)          |

Table 96: (modified)* 5 most common adverse events of oedema regardless of causality (ASaT population)

|                  | KN048 Data for MK-3475 N=300   | KN048 Data for MK-3475 + chemotherapy N=276   | KN048 Data for SOC N=287   | HNSCC Safety dataset for MK-3475 N=609   | Reference Safety Dataset for MK-3475 N=3,830   |
|------------------|--------------------------------|-----------------------------------------------|----------------------------|------------------------------------------|------------------------------------------------|
|                  | N (%)                          | N (%)                                         | N (%)                      | N (%)                                    | N (%)                                          |
| Face oedema      | 12 (4.0)                       | 7 (2.5)                                       | 6 (2.1)                    | 27 (4.4)                                 | 16 (0.4)                                       |
| Swelling face    | 8 (2.7)                        | 3 (1.1)                                       | 3 (1.0)                    | 18 (3.0)                                 | 7 (0.2)                                        |
| Laryngeal oedema | 2 (0.7)                        | 3 (1.1)                                       | 2 (0.7)                    | 3 (0.5)                                  | 1 (0.0)                                        |
| Swollen tongue   | 0 (0.0)                        | 3 (1.1)                                       | 0 (0.0)                    | 7 (1.1)                                  | 1 (0.0)                                        |
| Localised oedema | 4 (1.3)                        | 2 (0.7)                                       | 3 (1.0)                    | 13 (2.1)                                 | 13 (0.3)                                       |

*Source: Compiled from Supplemental Statistical Report / CSS

<div style=\"page-break-after: always\"></div>

## Bleeding From the Tumour Site

## Table 97: Subjects with AEs of bleeding from the tumour site by maximum toxicity grade (Incidence &gt;0% in one or more groups) - AsaT population

|                                 | KN048 Data for MK-3475   | KN048 Data for MK-3475   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for SOC   | KN048 Data for SOC   | HNSCC Safety Dataset for MK34751   | HNSCC Safety Dataset for MK34751   |
|---------------------------------|--------------------------|--------------------------|-----------------------------------------|-----------------------------------------|----------------------|----------------------|------------------------------------|------------------------------------|
|                                 | n                        | ()                       |                                         | (6)                                     |                      | (7.)                 |                                    | ()                                 |
| Subjects in population          | 300                      |                          | 276                                     |                                         | 287                  |                      | 609                                |                                    |
| with one or more adverse events | 19                       | (6.3)                    | 24                                      | (8.7)                                   | 16                   | (5.6)                | 45                                 | (7.4)                              |
| Gnade 1                         | 7                        | (2.3)                    | 8                                       | (2.9)                                   | 7                    | (2.4)                | 15                                 | (2.5)                              |
| Gnde 2                          | 2                        | (0.7)                    | 8                                       | (2.9)                                   | 3                    | (1.0)                | 8                                  | (1.3)                              |
| Gnade 3                         | 6                        | (2.0)                    | 4                                       | (1.4)                                   | 2                    | (0.7)                | 13                                 | (2.1)                              |
| Grade 4                         | 2                        | (0.7)                    | 2                                       | (0.7)                                   | 1                    | (0.3)                | 6                                  | (1.0)                              |
| Grade 5                         | 2                        | (0.7)                    | 2                                       | (0.7)                                   | 3                    | (1.0)                | 3                                  | (0.5)                              |
| with no adverse events          | 281                      | (93.7)                   | 252                                     | (91.3)                                  | 271                  | (94.4)               | 564                                | (92.6)                             |
| Arterial haemorhage             |                          | (0.3)                    | 0                                       | (0.0)                                   | 1                    | (0.3)                | 0                                  | (0.0)                              |
| Gnade 4                         | 1                        | (0.3)                    | 0                                       | (0.0)                                   | 1                    | (0.3)                |                                    | (0.0)                              |
| Carotid artery perforation      | 0                        | (0.0)                    |                                         | (0.4)                                   | 0                    | (0.0)                | 0                                  | (0.0)                              |
| Grade 5                         | 0                        | (0.0)                    |                                         | (0.4)                                   | 0                    | (0.0)                | 0                                  | (0.0)                              |
| Haemonhagic tumour necrosis     | 0                        | (0.0)                    | 1                                       | (0.4)                                   | 0                    | (0.0)                | 0                                  | (0.0)                              |
| Gnade 2                         | 0                        | (0.0)                    | 1                                       | (0.4)                                   | 0                    | (0.0)                |                                    | (0.0)                              |
| Laryngeal haemomhage            | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 3                                  | (0.5)                              |
| Grade 1                         | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 1                                  | (0.2)                              |
| Grade 2                         | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 1                                  | (0.2)                              |
| Grade 3                         | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 1                                  | (0.2)                              |
| Mouth huemorhage                | 5                        | (1.7)                    | 5                                       | (1.8)                                   | 6                    | (2.1)                | 15                                 | (2.5)                              |
| Grade 1                         | 5                        | (1.7)                    | 3                                       | (1.1)                                   | 5                    | (1.7)                | 6                                  | (1.0)                              |
| Gnade 2                         | 0                        | (0.0)                    | 1                                       | (0.4)                                   | 1                    | (0.3)                | 2                                  | (0.3)                              |
| Grade 3                         | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 3                                  | (0.5)                              |
| Grade 4                         | 0                        | (0.0)                    | 1                                       | (0.4)                                   | 0                    | (0.0)                | 4                                  | (0.7)                              |
| Pharyngeal haemonhage           | 1                        | (0.3)                    | 4                                       | (1.4)                                   | 0                    | (0.0)                | 1                                  | (0.2)                              |
| Grade 1                         | 0                        | (0.0)                    | 2                                       | (0.7)                                   | 0                    | (0.0)                | 0                                  | (0.0)                              |
| Grade 2                         |                          | (0.3)                    |                                         | (0.4)                                   | 0                    | (0.0)                |                                    | (0.2)                              |
| Gnde 3                          | 0                        | (0.0)                    | 1                                       | (0.4)                                   | 0                    | (0.0)                | 0                                  | (0.0)                              |
| Soft tissue haemorrhage         | 1                        | (0.3)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                |                                    | (0.2)                              |
| Grade 1                         | 1                        | (0.3)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 0                                  | (0.0)                              |
| Grade 3                         | 0 1                      | (0.0)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 1 0                                | (0.2) (0.0)                        |
| Tongue haemonhage Grade 1       |                          | (0.3) (0.3)              | 0 0                                     | (0.0)                                   | 0                    | (0.0) (0.0)          | 0                                  | (0.0)                              |
| Tracheal haemorhage             | 0                        | (0.0)                    | 3                                       | (0.0)                                   | 0                    | (0.0)                | 2                                  | (0.3)                              |
|                                 |                          | (0.0)                    | 1                                       | (1.1)                                   | 0 0                  | (0.0)                | 0                                  | (0.0)                              |
| Grade 1 Grade 2                 | 0 0                      | (0.0)                    |                                         | (0.4)                                   |                      |                      | 0                                  | (0.0)                              |
|                                 |                          |                          | 2                                       | (0.7)                                   | 0                    | (0.0)                |                                    |                                    |
| Gnde 3                          | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 2                                  | (0.3)                              |
| Tumour haemonhage               | 12                       | (4.0)                    | 13 4                                    | (4.7)                                   | 8                    | (2.8)                | 24 9                               | (3.9) (1.5)                        |
| Grade 2                         | 1                        | (0.3)                    | 4                                       | (1.4)                                   | 1                    | (0.3)                | 4                                  | (0.7)                              |
| Grade 1                         | 2                        | (0.7)                    |                                         | (1.4)                                   | 2                    | (0.7)                |                                    |                                    |
| Tumouwr haemonhage              | 12                       | (4.0)                    | 13 3                                    | (4.7) (1.1)                             | 8                    | (2.8)                | 24                                 | (3.9)                              |
| Gnade 3 Gnade 4                 | 6 1                      | (2.0) (0.3)              | 1                                       | (0.4)                                   | 0                    | (0.7) (0.0)          | 6 2                                | (1.0) (0.3)                        |
| Grade 5                         |                          | (0.7)                    | 1                                       | (0.4)                                   | m                    | (1.0)                | m                                  | (0.5)                              |
|                                 | 1                        | (0.3)                    | 0                                       | (0.0)                                   | 1                    | (0.3)                | 0                                  | (0.0)                              |
| Woumd haemorhage Gnde 1         | 1                        | (0.3)                    | 0                                       | (0.0)                                   | 0                    | (0.0)                | 0                                  | (0.0)                              |
| Grade 2                         | 0                        | (0.0)                    | 0                                       | (0.0)                                   | 1                    | (0.3)                | 0                                  | (0.0)                              |

Every subject is counted a single time for each applicable specific adverse event.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report tile, after rounding.

Only the highest reported grnde of a given adverse event is counted for the individual subject.

Grades are based on NCI CTCAE version 4.0.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MK-3475 Database Cutoff Date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 13JUN2018, KN055: 22APR2016)

I Includes allsubjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055.

Sowrce: [iSS: adhm-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Airway Obstruction with dyspnoea

## Table 98: Subjects with AEs of airway obstruction with dyspnoea by maximum toxicity grade (Incidence &gt;0% in one or more groups) - AsaT population

|                                 | KN048 Data for MK-3475   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for SOC   | HNSCC Safety Dataset for MK34751   |
|---------------------------------|--------------------------|-----------------------------------------|----------------------|------------------------------------|
|                                 | n (90)                   | n ()                                    | n (.)                | n ()                               |
| Subjects in population          | 300                      | 276                                     | 287                  | 609                                |
| with one or more adverse evenis | 3 (1.0)                  | 2 (0.7)                                 | 1 (0.3)              | 13 (2.1)                           |
| Gnde 1                          | 1 (0.3)                  | 1 (0.4)                                 | 1 (0.3)              | 4 (0.7)                            |
| Gnde 2                          | 2 (0.7)                  | 0 (0.0)                                 | 0 (0.0)              | E (0.5)                            |
| Grade 3                         | 0 (0.0)                  | 1 (0.4)                                 | 0 (0.0)              | (0.7)                              |
| Grade 4                         | 0 (0.0)                  | 0 (0.0)                                 | 0 (0.0)              | 2 (0.3)                            |
| with no adverse events          | 297 (99.0)               | 274 (99.3)                              | 286 (99.7)           | 596 (97.9)                         |
| Dyspnoea                        | 3 (1.0)                  | 2 (0.7)                                 | (0.3)                | 13 (2.1)                           |
| Gnade 1                         | 1 (0.3)                  | 1 (0.4)                                 | 1 (0.3)              | 6 (1.0)                            |
| Gnade 2                         | 2 (0.7)                  | 0 (0.0)                                 | 0 (0.0)              | 5 (0.8)                            |
| Gnde 3                          | 0 (0.0)                  | (0.4)                                   | 0 (0.0)              | 2 (0.3)                            |
| Epiglottic oedema               | 0 (0.0)                  | (0.4)                                   | 0 (0.0)              | 0 (0.0)                            |
| Gnde 3                          | 0 (0.0)                  | (0.4)                                   | 0 (0.0)              | 0 (0.0)                            |
| Laryngeal oedema                | 1 (0.3)                  | 0 (0.0)                                 | 0 (0.0)              | 1 (0.2)                            |
| Gnade 2                         | 1 (0.3)                  | 0 (0.0)                                 | 0 (0.0)              | 0 (0.0)                            |
| Grade 4                         | 0 (0.0)                  | 0 (0.0)                                 | 0 (0.0)              | 1 (0.2)                            |
| Laryngeal stenosis              | 0 (0.0)                  | 0 (0.0)                                 | 0 (0.0)              | (0.2)                              |
| Gnde 4                          | 0 (0.0)                  | 0 (0.0)                                 | 0 (0.0)              | 1 (0.2)                            |
| Stridor                         | 0 (0.0)                  | 0 (0.0)                                 | 0 (0.0)              | 3 (0.5)                            |
| Gnde 3                          | 0 (0.0)                  | 0 (0.0)                                 | 0 (0.0)              | E (0.5)                            |
| Swollen tongue                  | 0 (0.0)                  | 0 (0.0)                                 | 0 (0.0)              | (0.2)                              |
| Gnde 1                          | 0 (0.0)                  | 0 (0.0)                                 | 0 (0.0)              | (0.2)                              |
| Tongue oedema                   | 0 (0.0)                  | 0 (0.0)                                 | 0 (0.0)              | 2 (0.3)                            |
| Gnde 1                          | 0 (0.0)                  | 0 (0.0)                                 | 0 (0.0)              | 1 (0.2)                            |
| Gnade ?                         | 0 (0.0)                  | 0 (0.0)                                 | 0 (0.0)              | (0.2)                              |
| Wheezing                        | (0.7)                    | 1 (0.4)                                 | 1 (0.3)              | 5 (0.8)                            |
| Gnde 1                          | 1 m31                    | 1 10.41                                 | 1                    | 4 10.71                            |
| Wheezing                        | 2 (0.7)                  | (0.4)                                   | 1 (0.3)              | 5 (0.8)                            |
| Gnde ?                          | 1 (0.3)                  | 0 (0.0)                                 | 0 (0.0)              | (0.2)                              |

Every subjectis counted a single time for each applicable specific adverse event.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Grades are based on NCI CICAE version 4.0.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

H Includes all subjects who received at least one dose of MK-3475 in KN012 Cohorts B and B2, KN040 and KN055.

AEs were included if a subject reported both airway obstruction AEs and Dyspnoea AEs. Airway obstruction includes the prefered terms: Epiglottic oedema, Laryngeal obstruction, Lauryngeal oedema, Larymgeal stenosis, Larymgeal tracheal oedema,

Tracheal oedema, Wheezing.

Oropharymgeal swelling, Palatal oedema, Pharyngeal oedema, Stidor, Swollen tongue, Tongue oedema, Tongue swelling.

Dysponea includes the preferred terms: Dyspnoen, Dyspnoea with exertion

MK-3475 Databnse CutoffDate for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 13JUN2018.KN055: 22APR2016)

Souuce: [ISS: adam-adsl: adae]

<div style=\"page-break-after: always\"></div>

## Renal Toxicity events

Table 99: Adverse Event Summary (Pembro Combo vs Control) - ASaT Population (Renal Toxicity)

|                                                               | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   | Total   | Total   |
|---------------------------------------------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|---------|---------|
|                                                               | n                              | (%)                            | n                          | (%)                        | n       | (%)     |
| Subjects in population                                        | 276                            |                                | 287                        |                            | 563     |         |
| with one or more adverse events                               | 77                             | (27.9)                         | 56                         | (19.5)                     | 133     | (23.6)  |
| with no adverse event                                         | 199                            | (72.1)                         | 231                        | (80.5)                     | 430     | (76.4)  |
| with drug-related † adverse events                            | 55                             | (19.9)                         | 27                         | (9.4)                      | 82      | (14.6)  |
| with toxicity grade 3-5 adverse events                        | 12                             | (4.3)                          | 5                          | (1.7)                      | 17      | (3.0)   |
| with toxicity grade 3-5 drug-related adverse events           | 8                              | (2.9)                          | 3                          | (1.0)                      | 11      | (2.0)   |
| with serious adverse events                                   | 13                             | (4.7)                          | 3                          | (1.0)                      | 16      | (2.8)   |
| with serious drug-related adverse events                      | 10                             | (3.6)                          | 2                          | (0.7)                      | 12      | (2.1)   |
| with dose modification ‡ due to an adverse event              | 28                             | (10.1)                         | 10                         | (3.5)                      | 38      | (6.7)   |
| who died                                                      | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |
| who died due to a drug-related adverse event                  | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |
| discontinued drug due to an adverse event                     | 11                             | (4.0)                          | 7                          | (2.4)                      | 18      | (3.2)   |
| discontinued drug due to a drug-related adverse event         | 10                             | (3.6)                          | 6                          | (2.1)                      | 16      | (2.8)   |
| discontinued drug due to a serious adverse event              | 2                              | (0.7)                          | 2                          | (0.7)                      | 4       | (0.7)   |
| discontinued drug due to a serious drug-related adverse event | 2                              | (0.7)                          | 2                          | (0.7)                      | 4       | (0.7)   |

For subjects who received second course treatment, adverse events which occurred in second course phase are excluded.

Grades are based on NCI CTCAE version 4.03.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms 'Neoplasm progression', 'Malignant neoplasm progression' and 'Disease progression' not related to the drug are excluded.

Renal toxicity include preferred terms which are Acute renal failure SMQ or classified under renal and urinary disorders SOC.

Database Cutoff Date: 13JUN2018

(23.6)

(76.4)

(14.6)

(3.0)

(2.0)

(2.8)

(2.1)

(6.7)

(0.0)

(0.0)

(3.2)

(2.8)

(0.7)

(0.7)

<div style=\"page-break-after: always\"></div>

## Table 100: Summary of Baseline Renal Function (Pembro Combo vs Control) - ASaT Population - Subjects with Renal Toxicity

0.5 to 1.3

|                                                                                                               | Pembrolizumab + Chemotherapy                                                                                  | Cetuximab + Chemotherapy                                                                                      |
|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Subjects in population                                                                                        | 77                                                                                                            | 56                                                                                                            |
| Baseline Renal Function (mg/dL)                                                                               |                                                                                                               |                                                                                                               |
| Subjects with data                                                                                            | 77                                                                                                            | 55                                                                                                            |
| Mean                                                                                                          | 0.9                                                                                                           | 0.9                                                                                                           |
| SD                                                                                                            | 0.2                                                                                                           | 0.2                                                                                                           |
| Median                                                                                                        | 0.9                                                                                                           | 0.9                                                                                                           |
| Range                                                                                                         | 0.5 to 1.8                                                                                                    | 0.5 to 1.3                                                                                                    |
| Baseline Renal Function is defined as the blood creatinine level at baseline. Database Cutoff Date: 13JUN2018 | Baseline Renal Function is defined as the blood creatinine level at baseline. Database Cutoff Date: 13JUN2018 | Baseline Renal Function is defined as the blood creatinine level at baseline. Database Cutoff Date: 13JUN2018 |

## Table 101: Summary of Time to First Renal Toxicity Event (Pembro Combo vs Control) - ASaT Population

1.0 to 265.0

|                                                                                                                                                               | Pembrolizumab + Chemotherapy                                                                                                                                  | Cetuximab + Chemotherapy                                                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Subjects in population                                                                                                                                        | 276                                                                                                                                                           | 287                                                                                                                                                           |
| Time to onset (days)                                                                                                                                          |                                                                                                                                                               |                                                                                                                                                               |
| Subjects with data                                                                                                                                            | 77                                                                                                                                                            | 56                                                                                                                                                            |
| Mean                                                                                                                                                          | 67.5                                                                                                                                                          | 66.1                                                                                                                                                          |
| SD                                                                                                                                                            | 89.3                                                                                                                                                          | 72.3                                                                                                                                                          |
| Median                                                                                                                                                        | 43.0                                                                                                                                                          | 28.5                                                                                                                                                          |
| Range                                                                                                                                                         | 3.0 to 692.0                                                                                                                                                  | 1.0 to 265.0                                                                                                                                                  |
| Renal toxicity include preferred terms which are Acute renal failure SMQ or classified under renal and urinary disorders SOC. Database Cutoff Date: 13JUN2018 | Renal toxicity include preferred terms which are Acute renal failure SMQ or classified under renal and urinary disorders SOC. Database Cutoff Date: 13JUN2018 | Renal toxicity include preferred terms which are Acute renal failure SMQ or classified under renal and urinary disorders SOC. Database Cutoff Date: 13JUN2018 |

## Table 102: Summary of Outcome for Subjects With Renal Toxicity Events with incidence &gt; 0% (Pembro Combo vs Control) - ASaT Population

(0.0)

(16.1)

(8.9)

(0.0)

(0.0)

(75.0)

|                        |              | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   |
|------------------------|--------------|--------------------------------|--------------------------------|----------------------------|----------------------------|
|                        | Outcome      | n                              | (%)                            | n                          | (%)                        |
| Subjects in population |              | 276                            |                                | 287                        |                            |
| Renal Toxicity Events  | Overall      | 77                             | (27.9)                         | 56                         | (19.5)                     |
|                        | Fatal        | 0                              | (0.0)                          | 0                          | (0.0)                      |
|                        | Not Resolved | 21                             | (27.3)                         | 9                          | (16.1)                     |
|                        | Resolving    | 7                              | (9.1)                          | 5                          | (8.9)                      |
|                        | Unknown      | 1                              | (1.3)                          | 0                          | (0.0)                      |
|                        | Sequelae     | 2                              | (2.6)                          | 0                          | (0.0)                      |
|                        | Resolved     | 46                             | (59.7)                         | 42                         | (75.0)                     |

Every subject is counted once for each specific Renal Toxicity Events according to the worst outcome; the ordering of the outcomes is as follows: Fatal&gt;Not Resolved&gt;Resolving&gt;Unknown&gt;Sequelae&gt;Resolved.

'Subjects in population' is used for percentage calculation for the Overall row in each section. Within each section, the overall total is used for percentage calculation for each outcome.

Outcome: Resolved = RECOVERED/RESOLVED, Resolving = RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Not resolved = NOT RECOVERED/NOT RESOLVED.

Renal toxicity include preferred terms which are Acute renal failure SMQ or classified under renal and urinary disorders SOC. Database Cutoff Date: 13JUN2018

<div style=\"page-break-after: always\"></div>

Table 103: Adverse Event Summary (Pembro Combo vs Control) - ASaT Population-Carboplatin (Renal Toxicity)

|                                                               | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   | Total   | Total   |
|---------------------------------------------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|---------|---------|
|                                                               | n                              | (%)                            | n                          | (%)                        | n       | (%)     |
| Subjects in population                                        | 197                            |                                | 202                        |                            | 399     |         |
| with one or more adverse events                               | 30                             | (15.2)                         | 28                         | (13.9)                     | 58      | (14.5)  |
| with no adverse event                                         | 167                            | (84.8)                         | 174                        | (86.1)                     | 341     | (85.5)  |
| with drug-related † adverse events                            | 14                             | (7.1)                          | 8                          | (4.0)                      | 22      | (5.5)   |
| with toxicity grade 3-5 adverse events                        | 2                              | (1.0)                          | 1                          | (0.5)                      | 3       | (0.8)   |
| with toxicity grade 3-5 drug-related adverse events           | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |
| with serious adverse events                                   | 1                              | (0.5)                          | 0                          | (0.0)                      | 1       | (0.3)   |
| with serious drug-related adverse events                      | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |
| with dose modification ‡ due to an adverse event              | 3                              | (1.5)                          | 2                          | (1.0)                      | 5       | (1.3)   |
| who died                                                      | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |
| who died due to a drug-related adverse event                  | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |
| discontinued drug due to an adverse event                     | 0                              | (0.0)                          | 1                          | (0.5)                      | 1       | (0.3)   |
| discontinued drug due to a drug-related adverse event         | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |
| discontinued drug due to a serious adverse event              | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |
| discontinued drug due to a serious drug-related adverse event | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |

†  Determined by the investigator to be related to the drug.

‡  Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

For subjects who received second course treatment, adverse events which occurred in second course phase are excluded.

Grades are based on NCI CTCAE version 4.03.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms 'Neoplasm progression', 'Malignant neoplasm progression' and 'Disease progression' not related to the drug are excluded.

Renal toxicity include preferred terms which are Acute renal failure SMQ or classified under renal and urinary disorders SOC.

Patients who were treated with Carboplatin from first dose or who were initially treated with Cisplatin and later switched to Carboplatin are included.

For patients who switched to Carboplatin during treatment period, adverse events which occurred before first dose of Carboplatin are excluded; for patients who switched to Cisplatin, adverse events on or after the Cisplatin start date are excluded. Database Cutoff Date: 13JUN2018

Table  104:  Adverse  Event  Summary  (Pembro  Combo  vs  Control)  -  ASaT  Population-Cisplatin  (Renal Toxicity)

|                                                               | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Cetuximab + Chemotherapy   | Cetuximab + Chemotherapy   | Total   | Total   |
|---------------------------------------------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|---------|---------|
|                                                               | n                              | (%)                            | n                          | (%)                        | n       | (%)     |
| Subjects in population                                        | 119                            |                                | 120                        |                            | 239     |         |
| with one or more adverse events                               | 53                             | (44.5)                         | 35                         | (29.2)                     | 88      | (36.8)  |
| with no adverse event                                         | 66                             | (55.5)                         | 85                         | (70.8)                     | 151     | (63.2)  |
| with drug-related † adverse events                            | 43                             | (36.1)                         | 25                         | (20.8)                     | 68      | (28.5)  |
| with toxicity grade 3-5 adverse events                        | 10                             | (8.4)                          | 4                          | (3.3)                      | 14      | (5.9)   |
| with toxicity grade 3-5 drug-related adverse events           | 8                              | (6.7)                          | 3                          | (2.5)                      | 11      | (4.6)   |
| with serious adverse events                                   | 12                             | (10.1)                         | 3                          | (2.5)                      | 15      | (6.3)   |
| with serious drug-related adverse events                      | 10                             | (8.4)                          | 2                          | (1.7)                      | 12      | (5.0)   |
| with dose modification ‡ due to an adverse event              | 26                             | (21.8)                         | 8                          | (6.7)                      | 34      | (14.2)  |
| who died                                                      | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |
| who died due to a drug-related adverse event                  | 0                              | (0.0)                          | 0                          | (0.0)                      | 0       | (0.0)   |
| discontinued drug due to an adverse event                     | 11                             | (9.2)                          | 6                          | (5.0)                      | 17      | (7.1)   |
| discontinued drug due to a drug-related adverse event         | 10                             | (8.4)                          | 6                          | (5.0)                      | 16      | (6.7)   |
| discontinued drug due to a serious adverse event              | 2                              | (1.7)                          | 2                          | (1.7)                      | 4       | (1.7)   |
| discontinued drug due to a serious drug-related adverse event | 2                              | (1.7)                          | 2                          | (1.7)                      | 4       | (1.7)   |

†  Determined by the investigator to be related to the drug.

‡  Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

For subjects who received second course treatment, adverse events which occurred in second course phase are excluded.

Grades are based on NCI CTCAE version 4.03.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms 'Neoplasm progression', 'Malignant neoplasm progression' and 'Disease progression' not related to the drug are excluded.

<div style=\"page-break-after: always\"></div>

Renal toxicity include preferred terms which are Acute renal failure SMQ or classified under renal and urinary disorders SOC.

Patients who were treated with Cisplatin from first dose or who were initially treated with Carboplatin and later switched to Cisplatin are included. For patients who switched to Carboplatin during treatment period, adverse events which occurred on or after the Carboplatin start date are excluded; for the patient who switched to Cisplatin, adverse events before first dose of Cisplatin are excluded.

Database Cutoff Date: 13JUN2018

## Laboratory findings

## Pembrolizumab+Chemotherapy versus Standard Treatment

The proportion of most abnormal laboratory findings was comparable among the Pembrolizumab plus Chemotherapy  and  the Standard Treatment datasets: Glucose increased 54.9%  and  65.6%; Haemoglobin  decreased 89.4%  and  78.3%; Leucocytes  decreased 79.3%  and  84.8%; Neutrophils decreased 67.2% and 71.1%; Platelets decreased 73.2 and 76.3%. Creatinine increased was found more commonly in combination arm than in the standard of care (36% vs 27%).

## Pembrolizumab monotherapy versus Standard Treatment

The  proportion  of  participants  with  abnormal  laboratory  findings  was  either  lower  ( Haemoglobin decreased 51.7% vs 78.3%; Leukocyte decreased 11.2% vs 74.4%; Magnesium decreased 15.8% vs 75.5%; Neutrophils decreased 7.3% vs 71.1%; Platelets decreased 11.5% vs 76.3%) or comparable in the pembrolizumab monotherapy dataset compared to the Standard Treatment dataset. Incidence of Calc ium increased was 22.1% in Pembrolizumab monotherapy arm and 12.8% in Standard Treatment arm.

## Safety in special populations

## Intrinsic Factors

## Age

Table 105: AE summary by age category (ASaT population)

|                                                         | KN048 Data for MK-3475   | KN048 Data for MK-3475   | KN048 Data for MK-3475   | KN048 Data for MK-3475   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for MK-3475 + Chemotherapy   | KN048 Data for MK-3475 + Chemotherapy   |        |         |        | KN048 Data for SOC   | KN048 Data for SOC   | KN048 Data for SOC      | HNSCC Safety Dataset for MK347511   | HNSCC Safety Dataset for MK347511   | HNSCC Safety Dataset for MK347511   | ReferenceSafety Dataset for MK-34751   | ReferenceSafety Dataset for MK-34751   | ReferenceSafety Dataset for MK-34751   |
|---------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|--------|---------|--------|----------------------|----------------------|-------------------------|-------------------------------------|-------------------------------------|-------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
|                                                         | <65                      | <65                      | >=65                     | >=65                     | <65                                     | <65                                     | >=65                                    | >=65   | ≤65     | ≤65    | >=65                 | >=65                 | <65                     | <65                                 | >=65 <65                            | >=65 <65                            |                                        |                                        | =65                                    |
|                                                         | n                        | (%)                      | n                        | (%)                      | n                                       | (%)                                     | n                                       | (%)    | n       | (%)    | n                    | (%)                  | n                       | (%)                                 | n (%)                               | n                                   | (%)                                    | n                                      | (%)                                    |
| Subjects in population with one or more adverse events  | 189 181                  | (95.8)                   | 111 109                  | (98.2)                   | 176 173                                 | (98.3)                                  | 100 98                                  | (98.0) | 183 183 | (100.0 | 104 103              | (99.0)               | 397 385                 | 212 (97.0) 207                      | (97.6)                              | 2,056 1,997                         | (97.1)                                 | 1,774 1,723                            | (97.1)                                 |
| with no adverse event                                   | 8                        | (4.2)                    | 2                        | (1.8)                    | 3                                       | (1.7)                                   | 2                                       | (2.0)  | 0       | (0.0)  | 1                    | (1.0)                | 12                      | 5                                   | (2.4)                               | 59                                  | (2.9)                                  | 51                                     | (2.9)                                  |
| with drug-related' adverse events                       | 108                      | (57.1)                   | 67                       | (60.4)                   | 169                                     | (96.0)                                  | 94                                      | (94.0) | 180     | (98.4) | 98                   | (94.2)               | (3.0) 241 (60.7) (58.7) | 146                                 | (68.9)                              | 1,475                               | (71.7)                                 | 1,276                                  | (61D)                                  |
| with toxicity grade 3-5 adverse events                  | 97                       | (51.3)                   | 65                       | (58.0)                   | 151                                     | (85.8)                                  | 83                                      | (83.0) | 153     | (83.6) | 87                   | (83.7)               | 233 47                  | 115                                 | (54.2)                              | 880                                 | (42.8)                                 | 922                                    | (52.0)                                 |
| with toxicity grade 3-5 drug-related adverse events     | 30                       | (15.9)                   | 20                       | (18.0)                   | 124                                     | (70.5)                                  | 72                                      | (72.0) | 127     | (69.4) | 71                   | (68.3)               | (11.8)                  | 36                                  | (17.0)                              | 271                                 | (13.2)                                 | 306                                    | (17.2)                                 |
| with serious adverse events                             | 73                       | (38.6)                   | 48                       | (43.2)                   | 101                                     | (57.4)                                  | 61                                      | (61.0) | 87      | (47.5) |                      | (51.9)               | 181                     | (45.6) 100                          | (47.2)                              | 688                                 | (33.5)                                 | 762                                    | (43.0)                                 |
| with serious drug-related adverse events                | 17                       | (0:6)                    | 10                       | (9.0)                    | 62                                      | (35.2)                                  | 40                                      | (40.0) | 49      | (26.8) |                      | (23.1)               | 37                      | 23                                  | (10.8)                              | 191                                 | (9.3)                                  | 212                                    | (12.0)                                 |
| with dose modificationt due to an adverse event         | 67                       | (35.4)                   | 46                       | (41.4)                   | 145                                     | (82.4)                                  | 84                                      | (84.0) | 151     | (82.5) | 89                   | (85.6)               | 136                     | (9.3) (34.3) 81                     | (38.2)                              | 602                                 | (29.3)                                 | 654                                    | (36.9)                                 |
| who died                                                | 13                       | (6.9)                    | 12                       | (10.8)                   | 16                                      | (9.1)                                   | 16                                      | (16.0) | 15      | (8.2)  | 12                   | (11.5)               | 34                      | (8.6) 20                            | (9.4)                               | 61                                  | (3.0)                                  | 96                                     | (5.4)                                  |
| who died due to a drug-related adverse event            | 2                        | (11)                     | 1                        | (0.9)                    | 6                                       | (3.4)                                   | 4                                       | (4.0)  | 4       | (22)   | 4                    | (3.8)                | 4                       | (1.0)                               | 1 (0.5)                             | 7                                   | (0.3)                                  | 10                                     | (0.6)                                  |
| discontinued drug dne to an adverse event               | 19                       | (10.1)                   | 17                       | (15.3)                   | 47                                      | (26.7)                                  | 38                                      | (38.0) | 45      | (24.0) | 33                   | (31.7)               | 50                      | (12.0) 34                           | (16.0)                              | 205                                 | (10.0)                                 | 247                                    | (13.9)                                 |
| dliscontimued drug dhue to a drug-related adverse event | 8                        | (4.2)                    | 6                        | (5.4)                    | 37                                      | (21.0)                                  | 26                                      | (26.0) | 33      | (18.0) |                      | (23.1)               | 22                      | (5.5) 13                            | (6.1)                               | 92                                  | (4.5)                                  | 132                                    | (+L)                                   |
| discontinued drug due to a serious adverse event        | 14                       | (FD                      | 15                       | (13.5)                   | 27                                      | (15.3)                                  | 27                                      | (27.0) | 26      | (14.2) | 22                   | (21.2)               | 44                      | (11.1) 23                           | (10.8)                              | 154                                 | (SL)                                   | 184                                    | (10.4)                                 |
| discontinued drug dhue to a serious drug-               | 4                        | (2.1)                    | 5                        | (4.5)                    | 18                                      | (10.2)                                  | 13                                      | (13.0) | 15      | (8.2)  | 13                   | (12.5)               | 16 (4.0)                | 7                                   | (3.3)                               | 63                                  | (3.1)                                  | 86                                     | (8+)                                   |

Source: [ISS: adam-adSl; adhe]

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 106: Age-specific AE summary (Pembro combo vs control) - AsaT population

|                                 | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   |
|---------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                 | <65                          | <65                          | 65-74                        | 65-74                        | 75-84 =85                    | 75-84 =85                    |
|                                 |                              | (%)                          | n                            | (%)                          | n (%)                        | n (%)                        |
| Subjects inpopulation           | 176                          |                              | 85                           |                              | 14                           | 1                            |
| with one ormore adverse events  | 173                          | (98.3)                       | 83                           | (97.6)                       | 14 (100.0)                   | 1 (100.0)                    |
| who died                        | 16                           | (9.1)                        | 12                           | (14.1)                       | 3 (21.4)                     | (0'001)                      |
| with serious adverse events     | 101                          | (57.4)                       | 50                           | (58.8)                       | 10 (71.4)                    | (100.0)                      |
| discontinuedduetoanadverseevent | 47                           | (26.7)                       | 29                           | (34.1)                       | 8 (57.1)                     | 1 (100.0)                    |
| CNS(confusion/extrapyramidal)   | 13                           | (7.4)                        | 12                           | (14.1)                       | 2 (14.3)                     | 0 (0.0)                      |
| AErelatedtofalling              | 10                           | (5.7)                        | 9                            | (9'01)                       | 1 (7.1)                      | 0 (0.0)                      |
| CVevents                        | 47                           | (26.7)                       | 24                           | (28.2)                       | 4 (28.6)                     | 0 (0.0)                      |
| Cerebrovascularevents           | 5                            | (2.8)                        | 2                            | (2.4)                        | 1 (7.1)                      | 0 (0.0)                      |
| Infection                       | 95                           | (54.0)                       | 48                           | (56.5)                       | 9 (64.3)                     | (100.0)                      |

Table 107: Age-specific AE summary (Pembro mono vs control) - ASaT population

|                                  | Pembrolizumab   | Pembrolizumab   | Pembrolizumab   | Pembrolizumab   | Pembrolizumab   | Pembrolizumab   |
|----------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                  | 65              | 65              | 65-74           | 65-74           | 75-84 =85       | 75-84 =85       |
|                                  | n               | (%)             | n               | (%)             | n (%)           | n (%)           |
| Subjectsinpopulation             | 189             |                 | 95              |                 | 15              | 1               |
| with one ormore adverseevents    | 181             | (95.8)          | 93              | (97.9)          | 15 (100.0)      | 1 (100.0)       |
| who died                         | 13              | (6.9)           | 10              | (10.5)          | 2 (13.3)        | 0 (0.0)         |
| with serious adverse events      | 73              | (38.6)          | 40              | (42.1)          | (53.3)          | 0 (0.0)         |
| discontinuedduetoan adverseevent | 19              | (10.1)          | 12              | (12.6)          | (33.3)          | 0 (0.0)         |
| CNS(confusion/exhrapyramidal)    | 14              | (7.4)           | 6               | (6.3)           | 3 (20.0)        | 0 (0.0)         |
| AErelatedtofalling               | 16              | (8.5)           | 6               | (6.3)           | (13.3)          | 0 (0.0)         |
| CV events                        | 22              | (11.6)          | 16              | (16.8)          | (33.3)          | 1 (100.0)       |
| Cerebrovascularevents            | 3               | (1.6)           | 1               | (1.1)           | 0 (0.0)         | 0 (0.0)         |
| Infection                        | 78              | (41.3)          | 47              | (49.5)          | 7 (46.7)        | 0 (0.0)         |

Table 108: Age-specific AE summary (Pembro combo vs control) - ASaT population

|                                    | Cetuximab+ Chemotherapy   | Cetuximab+ Chemotherapy   | Cetuximab+ Chemotherapy   | Cetuximab+ Chemotherapy   | Cetuximab+ Chemotherapy   | Cetuximab+ Chemotherapy   |
|------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                                    | ≤65                       | ≤65                       | 65-74                     | 65-74                     | 75-84 =85                 | 75-84 =85                 |
|                                    | n                         | (%)                       | n                         | (%) n                     | (%)                       | n (%)                     |
| Subjects in population             | 183                       |                           | 77                        | 27                        |                           | 0                         |
| with one ormore adverseevents      | 183                       | (100.0)                   | 76                        | (98.7) 27                 | (100.0)                   | 0 (0.0)                   |
| who died                           | 15                        | (8.2)                     | 9                         | (11.7) 3                  | (11.1)                    | 0 (0.0)                   |
| with serious adverse events        | 87                        | (47.5)                    | 40                        | (51.9) 14                 | (51.9)                    | 0 (0.0)                   |
| discontinueddue to anadverse event | 45                        | (24.6)                    | 28                        | (36.4) 5                  | (18.5)                    | 0 (0.0)                   |
| CNS (confusion/extrapyramidal)     | 16                        | (8.7)                     | 7                         | (9.1) 3                   | (11.1)                    | 0 (0.0)                   |
| AE related to falling              | 14                        | (7.7)                     | 11                        | (14.3) 5                  | (18.5)                    | 0 (0.0)                   |
| CV events                          | 41                        | (22.4)                    | 22                        | (28.6) 9                  | (33.3)                    | 0 (0.0)                   |
| Cerebrovascularevents              | 5                         | (2.7)                     | 2                         | (2.6) 1                   | (3.7)                     | 0 (0.0)                   |
| Infection                          | 114                       | (62.3)                    | 48                        | (62.3) 15                 | (55.6)                    | 0 (0.0)                   |

Study medication withdrawn.

For subjects who received second course treatment, adverse events which occured in second course phase are excluded. Non-serious adverse events up to30days oflast dose and serious adverse events up to90 days of last dose are included. MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. DatabaseCutoffDate:13JUN2018.

Sowrce:[P048V01MK3475:adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Gender

## Table 109: AE summary by gender - AsaT population

<!-- image -->

|                                                        | KN048Data forMIK-3475   | KN048Data forMIK-3475   | KN048Data forMIK-3475   | KN048Data forMIK-3475   | KN048Data for MIK-3475 + Chemotherapy   | KN048Data for MIK-3475 + Chemotherapy   | KN048Data for MIK-3475 + Chemotherapy   | KN048 Data for SOC   | KN048 Data for SOC   | KN048 Data for SOC   | KN048 Data for SOC   | HNSCC Safety Dataset for MK34751   | HNSCC Safety Dataset for MK34751   | HNSCC Safety Dataset for MK34751   | HNSCC Safety Dataset for MK34751   | Reference Safety Dataset for MK-347511   | Reference Safety Dataset for MK-347511   | Reference Safety Dataset for MK-347511   | Reference Safety Dataset for MK-347511   |
|--------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|----------------------|----------------------|----------------------|----------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                                        |                         |                         | F                       | F                       |                                         |                                         |                                         | F                    | F                    | M                    | M                    | F                                  | F                                  | F                                  | F                                  |                                          |                                          | F                                        | F                                        |
|                                                        | n                       | (%)                     | n                       | (%)                     | n                                       | (%)                                     | n                                       | (%)                  | n                    | (%)                  | n                    | (%)                                | n (%)                              | n                                  | (%)                                | n                                        | (%)                                      | n                                        | (%)                                      |
| Subjects in population with one or more adverse events | 249 241                 | (96.8)                  | 51 49                   | (96.1)                  | 220 217                                 | (98.0)                                  | 56 54                                   | (96.4)               | 249 248              | (9'66)               | 38 38                | 503 (100.0 490                     | (97.4)                             | 106 102                            | (96.2)                             | 2,366 2,297                              | (97.1)                                   | 1,464 1,423                              | (97.2)                                   |
| with no adverse event                                  | 8                       | (3.2)                   | 2                       | (3.9)                   | 3                                       | (1.4)                                   | 2                                       | (3.6)                | 1                    | (0.4)                | 0                    | (0.0) 13                           | (2.0)                              | 4                                  | (3.8)                              | 69                                       | (2.9)                                    | 41                                       | (2.8)                                    |
| with drug-related' adverse events                      | 144                     | (57.8)                  | 31                      | (60.8)                  | 210                                     | (95.5)                                  | 53                                      | (94.6)               | 242                  | (97.2)               | 36                   | 316                                | (62.8)                             | 71                                 | (67.0)                             | 1,713                                    | (72.4)                                   | 1,038                                    | (70.9)                                   |
| with toxicity grade 3-5 adverse events                 | 135                     | (54.2)                  | 27                      | (52.9)                  | 185                                     | (84.1)                                  | 49                                      | (87.5)               | 204                  | (618)                | 36                   | (94.7) (94.7) 286                  | (56.9)                             | 62                                 | (58.5)                             | 1,124                                    | (47.5)                                   | 678                                      | (46.3)                                   |
| with toxicity grade 3-5 drug-related adverse events    | 44                      | (17.7)                  | 6                       | (81D)                   | 152                                     | (69.1)                                  | 44                                      | (78.6)               | 170                  | (68.3)               | 28                   | (73.7) 67                          | (13.3)                             | 16                                 | (15.1)                             | 379                                      | (16.0)                                   | 198                                      | (13.5)                                   |
| with serious adverse events                            | 102                     | (41.0)                  | 19                      | (37.3)                  | 123                                     | (55.9)                                  | 39                                      | (69.6)               | 120                  | (48.2)               | 21                   | (55.3) 230                         | (45.7)                             | 51                                 | (48.1)                             | 924                                      | (39.1)                                   | 526                                      | (35.9)                                   |
| with serious drug-related adverse events               | 22                      | (8.8)                   | 5                       | (9.8)                   | 78                                      | (35.5)                                  | 24                                      | (42.9)               | 19                   | (24.5)               | 12                   | (31.6) 47                          | (9.3)                              | 13                                 | (12.3)                             | 269                                      | (11.4)                                   | 134                                      | (9.2)                                    |
| with dose modificationt due to an adverse event        | 90                      | (36.1)                  | 23                      | (45.1)                  | 181                                     | (82.3)                                  | 48                                      | (85.7)               | 205                  | (82.3)               | 35                   | (92.1) 175                         | (34.8)                             | 42                                 | (39.6)                             | 776                                      | (32.8)                                   | 480                                      | (32.8)                                   |
| who died                                               | 19                      | (9D)                    | 6                       | (11.8)                  | 25                                      | (11.4)                                  | 7                                       | (12.5)               | 22                   | (8.8)                | 5                    | (13.2) 40                          | (8.0)                              | 14                                 | (13.2)                             | 106                                      | (4.5)                                    | 51                                       | (3.5)                                    |
| who died due to a drug-related adverse event           |                         | (0.4)                   |                         | (3.9)                   | 7                                       | (3.2)                                   | 3                                       | (5.4)                | 6                    | (2.4)                | 2                    | (5.3) 2                            | (0.4)                              | 3                                  | (2.8)                              | 13                                       | (0.5)                                    | 4                                        | (0.3)                                    |
| discontinued drug dhetoan adverse event                | 30                      | (12.0)                  | 6                       | (11.8)                  | 69                                      | (31.4)                                  | 16                                      | (28.6)               | 66                   | (26.5)               | 12                   | (31.6) 66                          | (13.1)                             | 18                                 | (17.0)                             | 284                                      | (12.0)                                   | 168                                      | (11.5)                                   |
| discontinued drug due to a drug-related adverse event  | 11                      | (4.4)                   | 3                       | (5.9)                   | 51                                      | (23.2)                                  | 12                                      | (21.4)               | 48                   | (E61)                | 9                    | (23.7) 24                          | (4.8)                              |                                    | (10.4)                             | 152                                      | (6.4)                                    | 72                                       | (4.9)                                    |
| discontinued drug dhe to a serious adverse event       | 23                      | (9.2)                   | 6                       | (11.8)                  | 42                                      | (19.1)                                  | 12                                      | (21.4)               | 39                   | (15.7)               | 9                    | (23.7) 53                          | (10.5)                             | 14                                 | (13.2)                             | 216                                      | (9.1)                                    | 122                                      | (8.3)                                    |

## ECOG Status

Table 110: AE summary by ECOG performance status - AsaT population

|                                                                | KN048 Data for MK-3475   | KN048 Data for MK-3475   | KN048 Data for MK-3475   | KN048 Data for MK-3475   | KN048 Data forMK-3475 + Chemotherapy   | KN048 Data forMK-3475 + Chemotherapy   | KN048 Data forMK-3475 + Chemotherapy   | KN048 Data for SOC   | KN048 Data for SOC   | KN048 Data for SOC   | KN048 Data for SOC   | HNSCC Safety Dataset for MK347511   | HNSCC Safety Dataset for MK347511   | HNSCC Safety Dataset for MK347511   | HNSCC Safety Dataset for MK347511   | Reference SafetyDataset for MK-347511   | Reference SafetyDataset for MK-347511   | Reference SafetyDataset for MK-347511   | Reference SafetyDataset for MK-347511   |
|----------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------|----------------------|----------------------|----------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                                                | 0                        | 0                        |                          |                          | 0                                      | 0                                      |                                        |                      |                      | 0                    | 0                    | 0                                   | 0                                   |                                     |                                     | 0                                       | 0                                       |                                         |                                         |
|                                                                | n                        | (%)                      | n                        | (%)                      | n                                      | (%)                                    | n                                      | (%)                  | n                    | ()                   | n                    | (%)                                 | n                                   | (%) n                               | (%)                                 | n                                       | (%)                                     | n                                       | (%)                                     |
| Subjects in population with one or more adverse events         | 118 111                  | (94.1)                   | 182 179                  | (98.4)                   | 109 108                                | (99.1)                                 | 167 163                                | (97.6)               | 113 113              | (100.0               | 174 173              | (99.4)                              | 176 172                             | 430 (97.7) 417                      | (97.0)                              | 1,811 1,770                             | (97.7)                                  | 1,851 1,789                             | (96.7)                                  |
| with no adverse event                                          | 7                        | (5.9)                    | 3                        | (1.6)                    | 1                                      | (60)                                   | 4                                      | (2.4)                | 0                    | (0.0)                | 1                    | (0.0)                               | 4 (2.3)                             | 13                                  | (3.0)                               | 41                                      | (2.3)                                   | 62                                      | (3.3)                                   |
| with drnug-relhted adverse events                              | 69                       | (58.5)                   | 106                      | (58.2)                   | 106                                    | (97.2)                                 | 157                                    | (94.0)               | 111                  | (98.2)               | 167                  | (96.0)                              | 118 (67.0)                          | 268                                 | (62.3)                              | 1,400                                   | (77.3)                                  | 1,261                                   | (68.1)                                  |
| with toxicity grade 3-5 adverse events                         | 51                       | (43.2)                   | 111                      | (61.0)                   | 16                                     | (83.5)                                 | 143                                    | (85.6)               | 16                   | (80.5)               | 149                  | (85.6)                              | 69 (39.2)                           | 276                                 | (64.2)                              | 743                                     | (41.0)                                  | 960                                     | (51.9)                                  |
| with toxicity gade 3-5 drug-related adverse events             | 18                       | (15.3)                   | 32                       | (17.6)                   | 83                                     | (76.1)                                 | 113                                    | (67.7)               | 79                   | (69.9)               | 119                  | (68.4)                              | 14 (8.0)                            | 68                                  | (15.8)                              | 263                                     | (14.5)                                  | 285                                     | (15.4)                                  |
| with serious adverse events                                    | 38                       | (32.2)                   | 83                       | (45.6)                   | 57                                     | (52.3)                                 | 105                                    | (62.9)               | 48                   | (42.5)               | 93                   | (53.4)                              | 46 (26.1)                           | 232                                 | (54.0)                              | 587                                     | (32.4)                                  | 780                                     | (42.1)                                  |
| with serious drug-related adverse events                       | 11                       | (9.3)                    | 16                       | (8.8)                    | 35                                     | (32.1)                                 | 67                                     | (40.1)               | 21                   | (18.6)               | 52                   | (29.9)                              | 8 (4.5) 45                          | 51                                  | (11.9)                              | 193                                     | (10.7)                                  | 192                                     | (10.4)                                  |
| with dose modificationt due to an adverse event                | 45                       | (38.1)                   | 68                       | (37.4)                   | 93                                     | (85.3)                                 | 136                                    | (81.4)               | 16                   | (80.5)               | 149                  | (85.6)                              | (25.6)                              | 171                                 | (39.8)                              | 537                                     | (29.7)                                  | 659                                     | (35.6)                                  |
| who died                                                       | 6                        | (5.1)                    | 19                       | (10.4)                   | 10                                     | (9.2)                                  | 22                                     | (13.2)               | 9                    | (8.0)                | 18                   | (10.3)                              | (2.8)                               | 48                                  | (11.2)                              | 50                                      | (2.8)                                   | 95                                      | (5.1)                                   |
| who died due to a drug-related adverse event                   | 1                        | (0.8)                    | 2                        | (1.1)                    | 4                                      | (3.7)                                  | 6                                      | (3.0)                | 2                    | (1.8)                | 6                    | (3.4)                               | 5 1 (0.6)                           | 4                                   | (0.9)                               | 7                                       | (+0)                                    | 10                                      | (0.5)                                   |
| discontinued drug due to an adverse event                      | 11                       | (9.3)                    | 25                       | (13.7)                   | 26                                     | (23.9)                                 | 59                                     | (35.3)               | 31                   | (27.4)               | 47                   | (27.0)                              | 10 (5.7)                            | 73                                  | (17.0)                              | 182                                     | (10.0)                                  | 244                                     | (13.2)                                  |
| discontinued drug due to a drug-related adverse event          | 4                        | (3.4)                    | 10                       | (5.5)                    | 21                                     | (19.3)                                 | 42                                     | (25.1)               | 25                   | (22.1)               | 32                   | (18.4)                              | 6 (3.4)                             | 29                                  | (6.7)                               | 105                                     | (5.8)                                   | 106                                     | (5.7)                                   |
| discontinued drug due to a serious adverse event               | 9                        | (9D)                     | 20                       | (11.0)                   | 14                                     | (12.8)                                 | 40                                     | (24.0)               | 14                   | (12.4)               |                      | (19.5)                              | 6 (3.4)                             | 60                                  | (14.0)                              | 128                                     | (7.1)                                   | 190                                     | (10.3)                                  |
| discontinued drug dhe to a serious drug- related adverse event | 3                        | (2.5)                    | 6                        | (3.3)                    | 8                                      | (7.3)                                  | 23                                     | (13.8)               | 7                    | (6.2)                | 21                   | (12.1)                              | 3 (1.7)                             | 20                                  | (4.7)                               | 66                                      | (3.0)                                   | 74                                      | (4.0)                                   |

Souce: [ISS: adam-adSl; adhe]

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Extrinsic Factors

## Region

Table 111: AE summary by region - AsaT population

<!-- image -->

|                                                                                                                                                                                                                                                                                                           | KN048Data forMK-3475        |           |                                                                                                     | KN048 Data for MK-3475 + Chemotherapy   |                | KN048Data forSOC   |               |                | HNSCC Safety Dataset for MK3475ll   |      |               | 3475111                          |       |               | ReferenceSafety Dataset forMK-   |             |                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------|-----------------------------------------------------------------------------------------------------|-----------------------------------------|----------------|--------------------|---------------|----------------|-------------------------------------|------|---------------|----------------------------------|-------|---------------|----------------------------------|-------------|-------------------|
|                                                                                                                                                                                                                                                                                                           | North America               |           | Europea nUnion                                                                                      | Rest of North the America               | European Union | Rest of the World  | North America | European Union | Rest of the World                   |      | North America | European Rest of the Union World | North | America       | European Union                   |             | Rest of the World |
|                                                                                                                                                                                                                                                                                                           | (%)                         |           | (%)                                                                                                 | n (%) n (%)                             | (%)            | n (%)              | n (%)         | (%)            |                                     | (%)  | (%)           | (%)                              | n     | (%) n (/6)    | (%)                              | n           | (%)               |
| Subjects in population                                                                                                                                                                                                                                                                                    | 75                          |           |                                                                                                     | 58                                      | n 88           |                    | 56            | 102            | 129                                 |      | 388           | 153                              | 68    | 1.72 7        | 1.38 +                           | 719         |                   |
| with one or more adverse events                                                                                                                                                                                                                                                                           | mom5寸 7 2 1                 | (96.0     | w  6                                                                                                | (97.1 57 8m                             | 87             | 27 (97.            | 56 (10 (00    | 102 (10 0.0)   | 128 97.                             |      | 378           | 147                              | 67    | (98 1,69 8. m | 1,33 956.                        | 693         |                   |
| with no adverse event                                                                                                                                                                                                                                                                                     | (4.0)                       |           |                                                                                                     | (2.9) 1                                 |                |                    |               | D (0.0         | 6 102                               | (0.8 | 0             | 1                                |       | 34            | 50                               | 26          |                   |
| with drug-related adverse events with toxicity grade 3-5 adverse events with toxicity gade 3-5 drug-related adverse events                                                                                                                                                                                | 寸寸 (58.7 8485mm (49.3 (14.7 |           | 406                                                                                                 | 56 2 (23.7 48                           | 8 60           | 24 0. 8            | 48 39         | 99 18 69       | 111 8 90 22                         |      |               | 6刀6g4 7                          |       | 249           | 213                              | 509 335 115 |                   |
| with serious adverse events with dose modificationt adverse events                                                                                                                                                                                                                                        | 286 (8.0) (33.3             | (37.3 m22 |                                                                                                     | (43.9 36 (13.7 9                        | 9              | 6                  | 22 49         |                | ,α2@ 64 70 108                      |      |               |                                  | EE    |               | 550                              |             |                   |
| with serious drug-relhted dhe to an adiverse event who died                                                                                                                                                                                                                                               | 605582 25 1 (1.3)           |           |                                                                                                     | 20 49                                   | 8              | 0６15               |               | 54 OE 8 9      |                                     |      |               |                                  |       | 625 149 549 4 | 8                                |             |                   |
| Who died due to a drug- discontimed drug dne to related adverse event an adverse event drug-related adverse event                                                                                                                                                                                         | (1.3)                       | mm6       |                                                                                                     | (1.4) 2 23                              | 22             | 8 3 22             | 1 20          | 3              |                                     |      |               | 18 ３2                            |       | 99            | 6                                |             | (5.7              |
|                                                                                                                                                                                                                                                                                                           | (4.0) 2                     |           |                                                                                                     |                                         |                |                    |               |                |                                     |      |               |                                  |       | 208           |                                  |             |                   |
| discontinued drug due to a                                                                                                                                                                                                                                                                                | 2                           |           |                                                                                                     | (7.2) (13.7                             |                |                    |               |                | 13                                  |      |               | 18                               | 2     |               |                                  | 41          |                   |
|                                                                                                                                                                                                                                                                                                           | (2.n) 10                    |           |                                                                                                     | 19                                      | 66             |                    | 16            |                |                                     |      | 22            | 11                               |       |               | 84                               |             |                   |
| discontinued drug due to a serious adverse event                                                                                                                                                                                                                                                          | 2 (2.7)                     |           |                                                                                                     |                                         |                | 2                  |               | 28             |                                     |      |               | (7.2                             |       | 142           |                                  |             |                   |
| discontinued drug dne to a senous dnug-related                                                                                                                                                                                                                                                            | 1                           |           |                                                                                                     | 13                                      | 18             |                    | 10            |                |                                     |      |               |                                  |       |               |                                  |             |                   |
| adverse event                                                                                                                                                                                                                                                                                             | (1.3)                       |           |                                                                                                     |                                         |                |                    |               |                | 8                                   |      |               |                                  |       |               | (8.2                             |             |                   |
|                                                                                                                                                                                                                                                                                                           |                             | 2         |                                                                                                     |                                         |                |                    |               | nn             | 2 15 10                             | 6n   | 手 13          | (9.8 8 2                         |       |               | 127 60                           | 69          |                   |
|                                                                                                                                                                                                                                                                                                           |                             |           |                                                                                                     |                                         |                |                    |               |                |                                     |      |               | (5.2                             |       | 1             |                                  | 30          | (4.2              |
|                                                                                                                                                                                                                                                                                                           |                             |           |                                                                                                     | (4.3)                                   |                | 14                 |               |                |                                     |      |               |                                  |       |               |                                  |             |                   |
| Includes allsubjects who received atleast one dose ofMK3475 inKN001 Pat Bl B2B3.D.C. Fl.F2.F3: KN002 (oniginl pase), KN006 and KN010, KN013-Cohort 3,KN024, KN045, KN052and K087. MK-3475Database CutoffDate forMelanoma (KN001-Melanoma: 18APR2014,KN002: 28FEB2015, KN006: 03MAR2015, KN054: 020CT2017) |                             |           | MK-3475 Database Cutoff Date for Lumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JULY2017) |                                         |                |                    |               |                |                                     |      |               |                                  |       |               |                                  |             |                   |
|                                                                                                                                                                                                                                                                                                           |                             |           |                                                                                                     |                                         |                |                    |               |                |                                     |      |               |                                  |       | 59            |                                  |             |                   |
| + Defined as an action taken of dose reduced, drug intemupted or drug withdrawn. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.                                                                                                |                             |           |                                                                                                     |                                         |                |                    |               |                |                                     |      |               |                                  |       |               |                                  |             |                   |
| #Inchudes all subjects whoreceived atleast one dose ofMK-3475 in KN012 Cohorts B and B2, KN040 and KN055.                                                                                                                                                                                                 |                             |           |                                                                                                     |                                         |                |                    |               |                |                                     |      |               |                                  |       |               |                                  |             |                   |

Source: [ISS: adam-adsl; adhe]

## Safety related to drug-drug interactions and other interactions

See clinical pharmacology section.

## Discontinuation due to adverse events

## All drug-related AEs leading to Treatment Discontinuation

The proportion of subjects with AEs leading to treatment discontinuation was 30.8%, 12%, and 27.2% in respectively the Pembrolizumab+Chemotherapy, Pembrolizumab monotherapy and the Standard Treatment arms.

<div style=\"page-break-after: always\"></div>

## Drug-related AEs Leading to Treatment Discontinuation

Table 112: Subjects with drug-related adverse events resulting in treatment discontinuation (incidence &gt;0% in one or more treatment groups) by decreasing frequency of preferred term from KN048 Combo (ASaT population)

|                                 | KN048Datafor MK-3475   | KN048Datafor MK-3475   | KN048Data for MK-3475 + Chemotherapy   | KN048Data for MK-3475 + Chemotherapy   | KN048 Data for   | KN048 Data for   | HNSCC Safety Dataset for MK34751   | HNSCC Safety Dataset for MK34751   | Reference Safety Dathaset for MK-347511   | Reference Safety Dathaset for MK-347511   |
|---------------------------------|------------------------|------------------------|----------------------------------------|----------------------------------------|------------------|------------------|------------------------------------|------------------------------------|-------------------------------------------|-------------------------------------------|
|                                 |                        | (%.)                   | n                                      | (6)                                    |                  | []               | I                                  | (6)                                |                                           | (6)                                       |
| Subjects in population          | 300                    |                        | 276                                    |                                        | 287              |                  | 609                                |                                    | 3.830                                     |                                           |
| with one or more adverse events | 14                     | (4.7)                  | 63                                     | (22.8)                                 | 57               | (660)            | 35                                 | (5.7)                              | 224                                       | (5.8)                                     |
| withno adverseevents            | 286                    | (95.3)                 | 213                                    | (77.2)                                 | 230              | (80.1)           | 574                                | (94.3)                             | 3.606                                     | (94.2)                                    |

In  the  Pembrolizumab  + Chemotherapy  arm,  the  most  frequently  reported  (≥1.0%  incidence) drug-related AEs leading to discontinuation of Pembrolizumab plus Chemotherapy were Blood creatinine increased (5 patients; 1.8%, vs 0.3% in control arm), Mucosal inflammation, Neutropenia, Septic shock, Pneumonia (4 patients each; 1.4%), Pneumonitis, Thrombocytopenia , Nausea, Tinnitus and peripheral sensory neuropathy (3 patients each; 1.1%). Rate of renal and urinary disorders SOC was similar in pembro combo and standard treatment arm (1.8% vs 2.1%).

In  the  Pembrolizumab  monotherapy  arm,  the  most  frequently  reported  drug-related  AEs  leading  to discontinuation of pembrolizumab included Pneumonitis and Autoimmune hepatitis reported in 0.7% (2 patients) each. Of the 2 Grade 4 autoimmune hepatitis events, 1 had resolved and 1 was resolving. Of the 2 pneumonitis events, 1 was not resolved and 1 was fatal.

The  most  common drug-related  AE  resulting  in  the  discontinuation  of  study  treatment  was  infusion related reaction and rash and anemia in the standard treatment group.

## All AEs leading to Treatment Interruption

While proportions of subjects with AEs resulting in interruption of study intervention were 64.1% and 63.4% in the Pembrolizumab+Chemotherapy and the Standard Treatment arms, it was 30.7% in the Pembrolizumab monotherapy arm.

## Drug-related Adverse Events Leading to Treatment Interruption

Table 113: Subjects with drug-related adverse events resulting in treatment interruption (incidence &gt;0% in one or more treatment groups) by decreasing frequency of preferred term from KN048 Combo (ASaT population)

<!-- image -->

|                                 | KN048Data for MK-3475   | KN048Data for MK-3475   | KN048Datafor MO-3475 + Chemotherapy   | KN048Datafor MO-3475 + Chemotherapy   | KN048Data for SOC   | KN048Data for SOC   | HNSCC Safety Dataset for MK3475!   | HNSCC Safety Dataset for MK3475!   | Reference Safety Dataset for MK-3475I   | Reference Safety Dataset for MK-3475I   |
|---------------------------------|-------------------------|-------------------------|---------------------------------------|---------------------------------------|---------------------|---------------------|------------------------------------|------------------------------------|-----------------------------------------|-----------------------------------------|
|                                 |                         | (6)                     | (96)                                  | (96)                                  | (0)                 | (0)                 | (96)                               | (96)                               | (96)                                    | (96)                                    |
| Subjectsinpopulation            | 300                     |                         | 276                                   |                                       | 287                 |                     | 609                                |                                    | 3,830                                   |                                         |
| with one or more adverse events | 53                      | (17.7)                  | 148                                   | (53.6)                                | 145                 | (50.5)              | 62                                 | (10.2)                             | 509                                     | (13.3)                                  |
| Withnosdverseevents             | 247                     | (82.3)                  | 128                                   | (46.4)                                | 142                 | (49.5)              | 547                                | (89.8)                             | 3.321                                   | (86.7)                                  |

The  most  common  drug-related  AEs  leading  to  interruption  of  study  intervention  were Neutropenia (15.9% and 15.3%) and Thrombocytopenia (11.6% and 6.6%) in both the Pembrolizumab+Chemotherapy and the Standard Treatment arms. Drug-related Anaemia (11.6% vs 4.5%), Platelet count decreased (7.6% vs 2.8%), Neutrophil count decreased (7.2% vs 5.9%) White blood cell count decreased (2.9% vs 1.0%), Blood creatinine increased (2.5% vs 0.0%) resulted more often cause of treatment interruption in the Pembrolizumab+Chemotherapy group compared with the Standard treatment group. A higher proportion of participants with drug-related Infusion-related reaction (3.5% vs 0.4%), Nausea (2.8% vs 0.4%), Rash (2.8% vs 0.4%), and Dermatitis acneiform (2.8% vs 0.0%) resulted  in  study  intervention  interruption  in  the  standard  treatment  versus  the  combination group.

<div style=\"page-break-after: always\"></div>

In the Pembrolizumab monotherapy arm compared to the Standard Treatment arm, Pneumonitis (2.3% vs 0.0%) was the only AE leading to treatment interruption in more than 2% of subjects.

## Post marketing experience

The safety profile of pembrolizumab was summarized in the Periodic Safety Update Report covering the period 4 March 2018 to 3 September 2018.

## 2.5.1. Discussion on clinical safety

## Pembrolizumab+Chemotherapy versus Standard Treatment

Proportions of subjects in the adverse event summary show consistent results in the Pembrolizumab+Chemotherapy and the Standard Treatment study arms for overall AEs (98.2% and 99.7%),  drug-related  AEs  (98.2%  and  99.7%),  Grade  3-5  AEs  (95.3%  and  96.9%),  Grade  3-5 drug-related  AEs  (84.8%  and  83.6%).  Differently,  the  rates  of  SAEs  (58.7%  vs  49.1%)  and  of drug-related SAEs (37% vs 25.4%), overall deaths (11.6% vs 9.4%), deaths due to drug-related AE (3.6%  vs  2.8%),  drug  discontinuation  due  to  AE  (30.8%  vs  27.2%),  drug  discontinuation  due  to drug-related  AE  (22.8%  vs  19.9%),  drug  discontinuation  due  to  SAE  (19.6%  vs  11%),  and  drug discontinuation due to drug-related SAE (11.2% vs 3.8%) were increased in subjects treated with the pembrolizumab  combination  treatment  than  in  those  receiving  standard  of  care.  After  adjusting  for exposure and including multiple occurrence of events, the higher incidence rates in SAEs (179 vs 158/100 person-years)  and  in  drug-related  SAEs  (86  vs  69/100  person-years)  among  subjects  receiving Pembrolizumab+Chemotherapy in respect to those treated with Standard Treatment were confirmed.

In the Pembrolizumab+Chemotherapy and the Standard Treatment arms, the pattern and frequency of most common AEs were similar and consistent with that expected for platinum-based chemotherapy. Pembrolizumab+Chemotherapy compared favourably to chemotherapy in skin-related AEs, Hypomagnesaemia, and Hypokalaemia. This is consistent with the known toxicity profile of cetuximab, used in the control arm. The standard treatment was of advantage for Anaemia, Hypothyroidism, and Blood creatinine increased. Other AEs with a higher incidence in the pembrolizumab chemotherapy group compared to the standard treatment group were acute kidney injury (6.5% versus 3.1%), peripheral neuropathy (5.8% versus 2.8%), peripheral sensory neuropathy (5.8% versus 2.4%) and paraesthesia (4.0% versus 2.8%).

The overall proportion of Grade 3-5 AEs (84.8% and 83.6%) as well as exposure-adjusted incidence rates (238 and 289/100 p-y) were comparable among the Pembrolizumab+Chemotherapy and the standard treatment datasets. When adjusted for exposure, rates of Grade 3 to 5 events, stomatitis and mucosal inflammation were higher (events/100 person-years) in subjects on pembrolizumab plus chemotherapy compared to subjects on standard treatment, 13.1 versus 6.6 and 15.7 versus 8.9, respectively.

The incidence of drug-related AEs was comparable in the two arms (95.3% vs 96.9%). Drug-related AEs more frequently reported in the pembrolizumab-combination arm when compared to Standard Treatment were: Anaemia (48.2% vs 41.1%), Thrombocytopenia (27.2% vs 22.0%), Hypothyroidism (12.7% vs 0.3%), Blood creatinine increased (10.9% vs 5.2%), Peripheral sensory neuropathy (5.4% vs 2.1%), Malaise (6.5% 3.1%), and Acute kidney injury (5.4% vs 2.1%). On the contrary, chemotherapy-treated subjects compared to those receiving pembro combo treatment displayed an increased frequency of various  skin  -related  PTs  (e.g. Rash 35.2%  vs  8.0%),  electrolyte  alterations,  and  infusion-related reactions.

Proportions of subjects with Grade 3-5 drug-related AEs and median time to first event were comparable in the Pembrolizumab+Chemotherapy and the Standard Treatment (71.0% and 69.0%) datasets. In the pembrolizumab combination arm, Acute kidney injury (4 patients, 1.4%) and Septic shock (6 patients,

<div style=\"page-break-after: always\"></div>

2.2%) were reported more often than in the standard treatment arm (0.3% and 0.0%, respectively).

Incidences  of  SAEs  and  exposure-adjusted  SAE  rates  were  higher  in  the  pembrolizumab  plus chemotherapy group than in the standard treatment group (58.7% and 179.40 events/100 person-years, respectively, versus 49.1% and 158.49 events/100person-years). Febrile neutropenia (5.8% vs 4.9%), Pneumonia (5.4% vs 6.3%), Anaemia (5.1% vs 3.1%), and Lung infection (3.3% vs 0.7%) were the most commonly observed SAEs in the pembrolizumab combination arm. Incidences of drug-related SAEs were higher  in  pembrolizumab-treated  subjects  (37.0%  versus  25.4%).  The  most  frequently  reported drugrelated  SAEs  (≥2.0%  incidence)  in  the  pembrolizumab  plus  chemotherapy  group  were  febrile Neutropenia (5.1%), Anaemia (4.0%), Stomatitis (2.9%), Neutropenia (2.5%), Mucosal inflammation, Nausea, Septic shock and Thrombocytopenia (2.2% each) in the pembrolizumab plus chemotherapy group.

There were few more deaths due to AEs in the Pembrolizumab+Chemotherapy arm than in the Standard Treatment arm [11.6% (32 patients) vs 9.4% (27 patients)]. When adjusted for exposure, event rates were similar (16.79 versus 16.68 events/100 person-years).

Drug-related AEs leading to treatment discontinuation (22.8% and 19.9%) or interruption (53.6% and 50.5%) were equally frequent among the Pembrolizumab+Chemotherapy and the Chemotherapy arms.

Based on the overall data provided, a concern was raised regarding the renal toxicity of pembrolizumab in  combination  with  chemotherapy,  in  particular  related  to  higher  frequencies  of  blood  creatinine increased, Acute kidney injury and Acute renal failure in the pembro combo arm compared to standard chemotherapy. Review of renal toxicity by SMQ showed in participants treated with pembrolizumab+chemotherapy compared to subjects receiving standard of care, higher proportions of overall Renal AEs (27.9% vs 19.5%, respectively) as well as of all related AE categories. When stratifying for type of platinum compound, differences between combination treatment and standard of care were larger in participants treated with cisplatin than in those with carboplatin. No baseline factor predictive of renal toxicity was identified, but average time to onset was longer for the pembrolizumab+chemotherapy arm  in  comparison  to  the  cetuximab+chemotherapy  arm,  leading  to  the  hypothesis  of  a  diverse etiopathogenesis (proximal tubule cell toxicity vs immune-mediated). In light of the above described findings,  the  MAH was requested to provide more detailed information for renal toxicity events with unfavourable outcome (not resolved or resolved with sequelae) [data not shown]. Overall, the proportion of subjects with renal toxicity were higher in patients treated with pembrolizumab+cisplatin (14/119; 11.8%)  or  with  pembrolizumab+carboplatin  (9/197;  4.5%)  when  compared  to  those  receiving cetuximab+carboplatin (6/202; 2.9%) or cetuximab+cisplatin (3/120; 2.5%). However, when looking at exposure-adjusted incidences the difference between treatment arms was small. Among subjects with unfavourable renal events, the vast majority reported non-immune-related events (none was treated with corticosteroids) and had events of mild to moderate grade in maximum toxicity. Further, a similar proportion  of  subjects  among  treatment  arms  received  subsequent  antineoplastic  treatment,  and generally the cause of death was not due to renal events. Thus, it is agreed with the MAH that evidences are insufficient to support changes to the SmPC.

Regarding  the  safety  profile  of  the  pembrolizumab  combination  treatment  in  relation  to  type  of chemotherapy  used  (cisplatin/carboplatin),  also  within  each  platinum  compound  strata  a  higher proportion of SAEs (Carboplatin: 51.3% vs 43.6%; Cisplatin: 61.3% vs 45.8%) and of drug-related SAEs (Carboplatin: 26.4% vs 15.8%; Cisplatin: 45.5% vs 35.0%) are found in the Pembrolizumab+Chemotherapy  in  respect  to  Standard  of  Care  group.  Furthermore,  regardless  of pembrolizumab use, almost all AEs frequencies were higher in subjects treated with pembrolizumab-cisplatin than in those receiving pembrolizumab-carboplatin. As these findings seem to reflect  known  tolerability  differences  between  platinum  agents  and  due  to  limitations  (a  priori investigator's  selection  of  chemotherapeutic  agent,  limited  sample  size,  and  post  hoc  analysis),  no

<div style=\"page-break-after: always\"></div>

definitive  conclusions  can  be  drawn  on  pembrolizumab's  safety  when  combined  with  different chemotherapeutic agent.

## Pembrolizumab m onotherapy versus Standard Treatment

In the adverse event summary, although the proportion of patients who experienced AEs was similar in pembro mono vs the control arm, the pembrolizumab monotherapy arm showed lower rates of almost all AE categories. Adverse Event rates adjusted for exposure confirmed the favourable safety profile of pembrolizumab monotherapy compared to chemotherapy.

In the pembrolizumab monotherapy arm, most common AEs with incidence &gt;20% were Fatigue (27.7% vs 35.5%) and Anaemia (21.0% vs 46.0%). A clear advantage of pembro mono over standard treatment is seen for most the AEs with exception of Hypothyroidism, as already expected for pembrolizumab.

The proportion of Grade 3-5 AEs was considerably lower in the Pembrolizumab monotherapy dataset compared with in the Standard Treatment (54.0% versus 83.6%, respectively). The most common Grade 3-5 AEs in the Pembrolizumab monotherapy dataset (&gt;5% incidence) were Hyponatremia (5.7%) and Pneumonia (5.3%), whereas Neutropenia, Anaemia, and Neutrophil count decreased were the most commonly reported events in the Standard Treatment dataset (&gt;10% incidence). Exposure-adjusted rates (34.33 and 265.74/100 p-y) confirmed the better safety profile of Pembrolizumab monotherapy compared to Standard Treatment.

Frequency of drug-related AEs (58.3% vs 96.9%) and Grade 3-5 drug-related AEs (16.7% vs 69%) was clearly  lower  for  Pembrolizumab  monotherapy  in  respect  to  standard  treatment.  The  most  common drug-related AEs recorded with pembrolizumab were Hyponatraemia (5.7%) and Pneumonia (5.3%). However, with the exception of Hypothyroidism (13% vs 0.3%), overall single drug-related AEs were more frequently observed with chemotherapy than with pembrolizumab; all hypothyroidism events were grade 1-2. Few more events of grade 3-5 drug-related pneumonitis were reported in pembrolizumab-treated patients [1.3% (4 cases) vs 0.3% (1 case)]. Median time to first Grade 3-5 drug-related  AE  was  considerably  longer  in  the  Pembrolizumab  monotherapy  arm  in  respect  to  the Standard Treatment arm (62.5 vs 22 days).

Both SAEs (40.3% vs 49.1%) and drug-related SAEs (9.0% versus 25.4%), were less common in the Pembrolizumab monotherapy arm when compared to the Standard Treatment arm. The most common drug-related SAEs in the pembrolizumab monotherapy arm were pneumonitis (1%, 3 patients) and acute kidney injury (0.7%, 2 patients). Both events occurred in only 1 patient each in the SOC arm (0.3%).

AEs resulting  in  death  were  less  frequently  observed  in  participants  assigned  to  the  Pembrolizumab monotherapy arm when compared to standard treatment [8.3% (25 patients) vs 9.4% (27 patients)]. The most common SOC was Infections (3.0% vs 4.5%), with Sepsis (1.0% vs 0.7%) as the most common PT in the pembro arm, and Pneumonia (1.7% vs 2.1%) the most common PT in the chemotherapy arm. Three fatal events were classified as due to pembrolizumab-related AEs by the investigator ( Pneumonitis, disseminated intravascular  coagulation  (DIC) and autoinflammatory disease ).  The  MAH  will  continue monitoring  of  DIC  cases  through  routine  pharmacovigilance  activities  in  clinical  studies  and  the post-marketing environment.

With  regard  to  the  event  'autoinflammatory  disease',  this  occurred  in  a  subject  after  1  cycle  of pembrolizumab. In this complex case, the subject experienced also a grade 3 encephalitis, considered a treatment  related  AEOSI  by  the  MAH  (already  included  as  ADR  in  Keytruda  SmPC),  and  a  possible diagnosis of Hemophagocytic lymphohistiocytosis (HLH). The risk of HLH has been added to the list of ADRs in section 4.8 of the SmPC with the frequency of 'rare' following the most recent PSUR procedure (EMEA/H/C/PSUSA/00010403/201809, CHMP opinion adopted on 28 March 2019).

Drug-related AEs leading to treatment discontinuation (4.7% versus 19.9%) were less frequent in the

<div style=\"page-break-after: always\"></div>

Pembrolizumab  monotherapy  arm  if  compared  to  standard  of  care  and  most  common  PTs  were Pneumonitis and Autoimmune hepatitis reported in 0.7% (2 patients) each. Both events are known ADR for  pembrolizumab.  Drug-related  AEs  leading  to  treatment  interruption  mirrored  the  same  finding: Pembrolizumab monotherapy 17.7% versus Standard Treatment 50.5%.

## AEOSIs

Frequency of overall AEOSIs, SAEs and deaths due to AEOSIs were not noticeably dissimilar among KEYNOTE-048 arms. Type and frequency of specific AEOSIs were consistent with known safety profiles, showing as most common events Hypothyroidism (15.2% and 18.0% in pembro combo and pembro mono, respectively), Pneumonitis (5.4% and 6.0%), and Hyperthyroidism (4.7% and 2.7%).

Drug-related  hypothyroidism  occurred  in  approximately  13%  of  pembrolizumab-treated  subjects regardless whether chemotherapy was given in association. Male gender and prior radiation therapy were more frequently observed in subjects experiencing this event. With the exception of a slightly shorter median time to onset of hypothyroidism in patients receiving pembro combo compared to pembro mono (83 and 104 days, respectively), overall the addition of chemotherapy to pembrolizumab did not change the  pattern  of  hypothyroidism  in  HNSCC.  As  seen  in  the  HNSCC  pembro  monotherapy  RSD,  in KEYNOTE-048 study the higher incidence of this AEOSI in the HNSCC setting compared to other disease site is confirmed and this has been reflected in section 4.8 of the SmPC.

Incidences of Pneumonitis were  higher  in  the  pembrolizumab  monotherapy and pembrolizumab plus chemotherapy groups (6.0% and 5.4%) compared to the standard treatment group (1.0%) in study KN048. These incidences were also higher when compared to the pembrolizumab monotherapy HNSCC and  RSD  datasets  (3.8%  and  3.7%,  respectively).  The  frequency  of  pneumonitis  was  higher  in  the pembrolizumab and the pembro combo arm in participants that had prior radiation (general). Numbers of participants  with  explicit  prior  radiation  to  the  lung  were  far  too  small,  8  of  863,  to  be  meaningful. Radiation of advanced HNSCC may involve intrathoracic radiation, which is associated with a risk of pneumonitis. Thus, the higher frequency of pneumonitis recorded in participants with prior radiation is considered to be in line with the observed increases of pneumonitis events after prior thoracic radiation across several other indications (also reflected in section 4.8. of the SmPC). Considering the overall data for KN048, a special wording with regard to the frequencies of pneumonitis in HNSCC is not warranted (updated frequency of pneumonitis in SmPC now 4.3%).

## Other events

Facial  oedema  (Face  oedema  and  Swelling  face)  occurred  with  higher  rates  in  the  Pembrolizumab monotherapy arm (pembro mono 6.0%, pembro combo 3.6%, standard treatment 3.1%), although comparable with the HNSCC pembrolizumab monotherapy dataset (7.2%). Severity was Grade 1-2 in most cases.

The  proportion  of  participants  with  events  of  Bleeding  from  the  tumour  site  was  higher  in  the Pembrolizumab+Chemotherapy (8.7%) and Pembrolizumab monotherapy (6.3%) datasets in comparison  with  Standard  treatment  (5.6%)  arm.  Monitoring  of  fatal  hemorrhages  through  routine pharmacovigilance activities in clinical studies and the post-marketing environment is recommended.

Airway obstruction events with dyspnea occurred rarely but were more common in pembrolizumab-based treatments [1% (3 patients) in Pembrolizumab monotherapy, 0.7% (2 patients) in Pembrolizumab+Chemotherapy]) than in Standard Treatment arm (0.3%, 1 patient). Longer time to onset than in standard of care and partial or complete treatment response at the time of event in most subjects are not suggestive of causal relationship with drug exposure.

## Laboratory findings

Incidence of most all-grades abnormal laboratory findings was comparable among

<div style=\"page-break-after: always\"></div>

Pembrolizumab+Chemotherapy and Standard Treatment arms. Notably however, Creatinine increased was more often reported for subjects receiving  pembrolizumab combination treatment in respect to standard of care (36% vs 27%, respectively).

When compared to Standard Treatment, while none of the abnormal laboratory findings, except for Calcium  increased ,  exceeded  in  the  pembrolizumab  monotherapy  arm,  abnormalities  related  to myelotoxicity were all strongly reduced ( Haemoglobin decreased 51.7% vs 78.3%; Leukocyte decreased 11.2% vs 74.4%; Neutrophils decreased 7.3% vs 71.1%; Platelets decreased 11.5% vs 76.3%).

## Safety in special populations

Comparison  of  safety  profiles  by  intrinsic  factors,  showed  enlarging  proportions  of  subjects  in  both pembrolizumab-containing  arms  who  discontinued  treatment,  experienced  SAEs,  and  who  died  with increasing  age  groups  (&lt;65,  65-74,  75-84).  Similar  observation  is  made  in  the  control  group  when considering patients &lt;65 years and between 65-74 years, while no relevant differences are seen between 65-74 and 75-84. This could be related to a more limited number of subjects in the 75-84 class.

Also  keeping  in  mind,  the  proportions  of  females  enrolled  in  KEYNOTE-048  study  arms  (56% pembrolizumab+Chemotherapy, 51% Pembrolizumab monotherapy, 38% Standard Treatment), analysis by Gender showed that female versus male participants of the Pembrolizumab+Chemotherapy arm had higher frequency of Grade 3 to 5 drug-related AEs (78.6% vs 69.1%), SAEs (69.6% vs 55.9%), and drug-related SAEs (42.9% vs 35.5%). The same trend was observed in the standard chemotherapy arm, and not in the Pembrolizumab monotherapy arm, suggesting a contribution of chemotherapy to the observation.

As expected, participants with an ECOG status of 1 displayed a higher proportion of subjects with SAEs and AEs leading to study intervention discontinuations. AEs summary by Region of enrolment did not document significant differences among KEYNOTE-048 study arms.

## Comparison of KEYNOTE-048 study with pooled datasets

Median duration of exposure was longest in the pembrolizumab plus chemotherapy group (5.78 months), whereas the median duration of exposure was shorter in the pembrolizumab monotherapy group (3.50 months) than in the Reference Safety Dataset (4.71 months), but longer than in the HNSCC Safety Dataset (2.83 months). This may reflect the progression of disease in subjects treated second-line for HNSCC, and the different indications in the RSD.

While frequency of overall AEs was comparable across datasets, proportions of all other AE categories in the Pembrolizumab+Chemotherapy arm, being comparable to those of the Chemotherapy arm, were higher than in pooled datasets. Drug-related AEs were 95.3% in Pembrolizumab+Chemotherapy and lower  in  the  Pembrolizumab  monotherapy  RSD  (71.8%)  and  HNSCC  pembrolizumab  monotherapy (63.5%) datasets. Incidence and pattern of common drug-related AEs reported for the Pembrolizumab+Chemotherapy arm differed from those found for pooled pembrolizumab datasets. Most common drug-related AEs observed in the KEYNOTE-048 Pembrolizumab monotherapy arm were similar to the Pembrolizumab monotherapy RSD, with the exception of a higher rate of Hypothyroidism events (13% vs 8.1%), which instead was consistent with the HNSCC pembrolizumab monotherapy dataset (11.2%).

Overall incidence of drug-related Grade 3 to 5 AEs (71%, 15.1%, and 13.6%) and of drug-related SAEs (37.0%,  10.5%,  and  9.9%)  was  higher  in  the  Pembrolizumab  plus  Chemotherapy  dataset  when compared  to  the  Pembrolizumab  monotherapy  RSD  and  HNSCC  pembrolizumab  datasets.  In  the Pembrolizumab  monotherapy  dataset,  incidences  of  drug-related  Grade  3  to  5  AEs  (16.7%)  and  of drug-related SAEs (9.0%) were similar.

In comparison to the Pembrolizumab monotherapy RSD  (4.1%) and  HNSCC  pembrolizumab

<div style=\"page-break-after: always\"></div>

monotherapy  (8.9%)  datasets,  the  overall  incidence  of  AEs  leading  to  death  was  higher  in  the Pembrolizumab  plus  Chemotherapy  dataset  (11.6%).  Event  frequency  was  in  the  Pembrolizumab monotherapy arm (8.3%) higher compared to the Pembrolizumab monotherapy RSD, but comparable to the HNSCC pembrolizumab monotherapy dataset.

Proportions of deaths were higher in the indication R/M HNSCC (KN048 pembrolizumab monotherapy group  [8.3%],  KN048  pembrolizumab  plus  chemotherapy  group  [11.6%]  and  in  the  HNSCC  Safety Dataset [8.9%]) when compared to the Reference Safety Dataset (4.1%).

## 2.5.2. Conclusions on clinical safety

In  the  1L  treatment  of  subjects  with  R/M  HNSCC,  Pembrolizumab+Chemotherapy  compared  to cetuximab-based chemotherapy showed an overall similar safety profile.  The  toxicity  pattern  of  the combination  pembrolizumab  +  platinum/5-FU  appears  consistent  with  the  known  safety  profile  of pembrolizumab monotherapy and the cytotoxic agents used. Of note is the higher incidence of SAEs recorded  with  pembrolizumab  plus  chemotherapy  compared  to  standard  treatment.  SAEs  which contributed to the higher overall incidence were distributed across several SOCs with no individual SAE raising special concern. Incidences of Grade 3 to 5 adverse events and of drug-related Grade 3 to 5 AEs were comparable. When adjusted for exposure, hypothyroidism, pyrexia, and blood creatinine increase were higher in the pembrolizumab plus chemotherapy than in the standard treatment group.

The safety profile of pembrolizumab monotherapy in 1L R/M HNSCC is consistent with the established safety profile of pembrolizumab monotherapy in 2L R/M HNSCC and other indications. Pembrolizumab monotherapy  for  the  treatment  of  1L  R/M  HNSCC  favourably  compared  to  standard  treatment,  as expected, taking also into account the known toxicity of the poly-chemotherapy regimen EXTREME used as control.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 27.0 is acceptable.

The CHMP endorsed this advice without changes.

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                        |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related adverse reactions (including immune related pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies)                                                                                                                                                                                      |
| Important potential risks    | For hematologic malignancies: increased risk of severe complications of allogeneic stem cell transplantation (SCT) in patients who have previously received pembrolizumab Graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic stem cell transplant (SCT) |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns   |
|------------------------------|------------------------------|
| Missing information          | Long term safety             |

## Pharmacovigilance plan

## On-going and planned additional pharmacovigilance activities

| Study Status                                                  | Study/activity Type, title and category                                                                                                                                                                                                             | Summary of Objectives                                                                                                                                                                                                                                                                                       | Safety concerns addressed                                                                                                                                                                                                | Milestones                                                    | Due dates                                                     |
|---------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                       | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                               | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                            | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| Started                                                       | Clinical trial A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer | To evaluate the overall survival (OS) and progression free survival (PFS) and to examine the safety and tolerability profile of pembrolizumab in subjects with PD-L1 positive 1L advanced/metastatic NSCLC, treated with pembrolizumab compared to standard of care (SOC) chemotherapies.                   | -Important identified risks (Immune-related adverse reactions) -Important potential risks (GVHD after pembrolizumab administration in patients with a history of allogeneic SCT) -Missing information (Long term safety) | Final Study Report                                            | Dec 2019                                                      |
| Planned                                                       | (KN042) Cumulative review of literature, clinical trial and post-marketing cases for the risk of GVHD after pembrolizumab administration in patients with a history of allogeneic SCT                                                               | To monitor, identify and evaluate reports of GVHD after pembrolizumab administration in patients with a history of allogeneic SCT.                                                                                                                                                                          | Important potential risk of GVHD after pembrolizumab administration in patients with a history of allogeneic SCT                                                                                                         | PSUR                                                          | 2019                                                          |
| Started                                                       | Clinical trial A Phase I/II Study of MK-3475 in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma (KN021)                                                                | To determine the recommended Phase II dose for MK-3475 in combination with chemotherapy or immunotherapy in subjects with unresectable or metastatic NSCLC.                                                                                                                                                 | -Important identified risks (Immune-related adverse reactions) -Important potential risk (GVHD after pembrolizumab administration in patients with a history of allogeneic SCT)                                          | Final Study Report                                            | Apr 2020                                                      |
| Started                                                       | Clinical Trial A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KN189)                           | To evaluate the antitumour activity of pembrolizumab in combination with chemotherapy compared with saline placebo in combination with chemotherapy and to evaluate the antitumour activity of pembrolizumab in combination with chemotherapy compared with saline placebo in combination with chemotherapy | -Important identified risks (Immune-related adverse reactions) -Important potential risk (GVHD after pembrolizumab administration in patients with a history of allogeneic SCT)                                          | Final Study Report                                            | Jun 2021                                                      |

<div style=\"page-break-after: always\"></div>

## On-going and planned additional pharmacovigilance activities

| Study Status   | Study/activity Type, title and category   | Summary of Objectives   | Safety concerns addressed   | Milestones   | Due dates   |
|----------------|-------------------------------------------|-------------------------|-----------------------------|--------------|-------------|
|                |                                           | using OS.               |                             |              |             |

## Risk minimisation measures

## Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                                                | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance Activities                                                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks: Immune-Related Adverse Reactions                                                                                  | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                                                                                                                                                                     | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                          |
| Immune-related adverse reactions (including immune-related pneumonitis, colitis, hepatitis, nephritis and endocrinopathies)                   | Routine risk minimisation measures: • The risk of the immune-related adverse reactions (including immune-related pneumonitis colitis, hepatitis, nephritis, and endocrinopathies) associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk.            | Routine pharmacovigilance activities Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire for spontaneous postmarketing reports of all adverse events |
|                                                                                                                                               | Additional risk minimisation measures: Patient educational materials                                                                                                                                                                                                                                                                                             | Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumour types                                                                    |
| Important Potential Risks                                                                                                                     | Important Potential Risks                                                                                                                                                                                                                                                                                                                                        | Important Potential Risks                                                                                                                                                                                             |
| For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab | Routine risk minimisation measures: • For Hematologic malignancies: the increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab is described in the SmPC, Section 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in the ongoing HL trials (KN087, KN204).                                                                             |
| GVHD after pembrolizumab                                                                                                                      | Routine risk minimisation measures:                                                                                                                                                                                                                                                                                                                              | Routine pharmacovigilance activities                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

## Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern administration in patients with a history of allogeneic SCT   | Risk minimisation Measures • GVHD after pembrolizumab administration in patients with a history of allogeneic SCT is described in the SmPC, Section 4.4 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted   | Pharmacovigilance Activities Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumour types • Cumulative review of literature, clinical trial and post-marketing cases of GVHD after pembrolizumab administration in patients with a history of allogeneic SCT with PSUR submission in 2019.   |
|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing Information                                                          | Missing Information                                                                                                                                                                                                                                                                     | Missing Information                                                                                                                                                                                                                                                                                                                                                                |
| Long term safety                                                             | No risk minimisation measures warranted                                                                                                                                                                                                                                                 | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in the ongoing MAH-sponsored clinical trial in NSCLC (KN042) for pembrolizumab                                                                                                                                                                                                    |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated. Particularly, a new warning with regard to the higher frequency of ADRs reported with pembrolizumab in combination with chemotherapy compared to pembrolizumab monotherapy or chemotherapy alone has been added to the product information together with a recommendation to consider available treatment options before initiating treatment. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The only change in the leaflet is the addition of one paragraph regarding the combination products in section 1 'What KEYTRUDA is and what it is used for'. There are no other proposed changes to the content of the package leaflet; in particular the key messages for the safe use of the medicinal product are not impacted. Furthermore the design, layout and format of the package leaflet will not be affected by the proposed revisions.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Head and neck cancers describe an anatomically heterogeneous group of cancers characterized by an aggressive behaviour and very high mortality rate, usually with squamous histology (i.e. HNSCC), and overall accounting for 6% of cancer cases. Median age of diagnosis is in the late 60s and 70s, prevalently

<div style=\"page-break-after: always\"></div>

in male. Tobacco, alcohol, male gender and older age are considered risk factors for HNSCC, together with HPV infection for cancers located in the oropharynx.

## 3.1.2. Available therapies and unmet medical need

In the first-line treatment of R/M HNSCC, combination therapy with cetuximab plus cisplatin/carboplatin plus 5-fluorouracil followed by maintenance cetuximab (the 'EXTREME' regimen) has shown the best results so far, with median survival of 10-14 months. In clinical practice, other combinations, such as a taxane or cisplatin plus cetuximab, are also sometimes used when patients are not fit enough for the EXTREME regimen. For patients who are asymptomatic, treatment is usually monotherapy to balance the side-effects recorded with combination regimens. Options for first-line single agent treatment include platinum-based chemotherapy, 5-FU, paclitaxel, docetaxel, methotrexate, cetuximab, gemcitabine and capecitabine.

In the EXTREME study, the addition of cetuximab to cisplatin/carboplatin plus 5 FU resulted in a significant increase in OS compared to cisplatin/carboplatin plus 5 FU (10.1 months versus 7.4 months, respectively, HR of 0.80, 95% CI: 0.64, 0.99; p=0.04). The cetuximab combination regimen was associated with a frequency  of  Grade  3  to  4  AEs  comparable  to  the  comparator  regimen  (82%  versus  76%,  p=0.19, respectively). The EXTREME regimen is the only Category 1 evidence-supported combination regimen recommended by NCCN as 1L treatment for subjects with R/M HNSCC. The EHNS-ESMO-ESTRO Clinical Practice Guidelines also recommend the 1L option of cetuximab with carboplatin or cisplatin plus 5-FU.

Although the EXTREME study resulted in an improved OS, it is still palliative, as the disease remains incurable, and newer therapeutic options are necessary to address the unmet medical needs of this incurable population of R/M HNSCC patients with poor prognosis.

## 3.1.3. Main clinical studies

The evidence submitted for the new indication is KEYNOTE-048, a randomized, multi-centre, open-label trial investigating pembrolizumab, or pembrolizumab plus platinum plus 5-FU chemotherapy versus platinum plus 5-FU plus cetuximab in subjects with first-line recurrent or metastatic HNSCC.

## 3.2. Favourable effects

## Pembrolizumab plus platinum/5FU :

Statistically significant OS superiority was demonstrated for pembro combo vs control in all the 3 pre-specified populations: ITT: HR 0.72 (0.60, 0.87); median OS 13.0 vs 10.7 months; CPS≥1: HR 0.65 (0.53, 0.80); median OS 13.6 vs 10.4 months and CPS≥20: HR 0.60 (0.45, 0.82 ); median OS 14.7 vs 11 months.

In the CPS&lt;20 and CPS≥1 to &lt;20 populations, OS results were slightly in favour of Pembro Combo with, respectively, a median OS of 11.8 months vs 10.2 months (HR 0.83 [95%CI: 0.65, 1.05]) and median OS 12.7 months vs 9.9 months (HR 0.71 [95%CI: 0.54, 0.94]).

For the CPS ≥ 1 population, median PFS was 5.1 vs 5.0 months in Pembro Combo vs standard arm (HR=0.84, 95% CI: 0.69, 1.02. In the ITT PFS rates at 6 months were similar in both arms, while PFS rates at 9 and 12 months were in favour of Pembro Combo. In the CPS ≥1 and CPS ≥20 populations PFS rates at 6, 9 and 12 months were in favour of Pembro Combo.

In the CPS ≥ 1 population, ORR was 36% in both arms. In the ITT, CPS ≥1 and CPS ≥20 populations, a higher CR rate was observed. Median DOR and higher proportion of responders ≥6 months observed in Pembro Combo arm in the ITT, CPS ≥1 and CPS ≥20 populations.

<div style=\"page-break-after: always\"></div>

## Pembrolizumab monotherapy:

OS was non-inferior for Pembro Mono compared to standard treatment in the ITT population (HR=0.83, 95% CI: 0.70, 0.99). OS rate at 12 months was 48.7% vs 44.4%.

In the CPS≥1 population, statistically significant OS benefit for the Pembro Mono was show n with median OS 12.3 months (95% CI: 10.8, 14.3) versus 10.3 months (95% CI: 9.0, 11.5). The HR was 0.74 (95% CI: 0.61, 0.90). OS rate at 12 months was 50.4% versus 43.6%. OS rate at 24 months was 28.9% versus 17.4%. Median response duration was longer in the Pembro Mono arm compared to standard treatment (22.6  vs  4.5  months)  in  the  ITT,  (23.4  vs  4.5  months) CPS≥1 and (22.6  vs  4.2  months) CPS≥20 populations, with higher proportion of long (≥6 months) re sponders (ITT: 77.8% vs 38.8% of those with a response).

## 3.3. Uncertainties and limitations about favourable effects

## Pembrolizumab plus platinum/5FU:

In the CPS&lt;1 population, no OS benefit was observed. Compared to the IA2, OS results seem to worsen with longer follow-up at the final analysis (median OS of 11.3 vs 10.7 months; at the final analysis OS HR=1.21, 95%CI: 0.76, 1.94; OS rate at 12 months 41.0% vs 46.5%, OS rate at 24 months 20.5% vs 25.6% in favour of the standard arm.

There was no statistically significant improvement in PFS in the ITT or CPS ≥20 populations, therefore, PFS in the CPS ≥1 population was not tested as per the multiplicity strategy. For the CPS&lt;1, CPS≥1 to &lt;20 and CPS&lt;20 populations, no PFS benefit was observed (HR 1.46, HR 0.93 and HR 1.05, respectively).

A slightly higher rate of PD was observed in the Pembro Combo for the ITT (17.1% vs 11.9%), CPS ≥ 1 (17.4% vs 12.3%) and CPS ≥ 20 (15.1% vs 8.2%) populations. In the CPS&lt;20, CPS≥1 to &lt;20, CPS&lt;1 populations, ORR was lower in the Pembro Combo arm compared to standard treatment. For the CPS&lt;1 population, the median duration of response was higher in the Pembro Combo arm, however  the estimated response duration ≥6 months was lower in the Pembro Combo compared to standard.

As a consequence of these results the indication was restricted to patients with CPS≥ 1.

## Pembrolizumab monotherapy:

Pembro mono did not show statistical superiority on OS in the ITT population, but was associated with a higher risk of early death compared to standard treatment as reflected in the KM curves crossing at month 8. Although OS was statistically significant in the PD-L1 expressing populations (CPS≥1 and CPS≥20 ), a higher risk of early death during the first 6 months after randomization was confirmed / also seen in this subset of pembro mono treated patients, compared to patients receiving EXTREME.

At the moment no specific recommendation can be included in the SmPC, since consistency of results obtained from different studies is needed to make the results strong and convincing. OS and all efficacy results were in favour of standard treatment in the CPS&lt;1 population. The pembro mono indication was therefore restricted to CPS≥1.

For all populations, PFS results were in favour of standard treatment. The ORR was lower in the Pembro Mono arm compared to standard treatment in the ITT, CPS&lt;1, CPS≥1 to &lt;20 and CPS&lt;20 populations. The median duration of response of pembro mono was shorter for the CPS&lt;1.

## Both pembrolizumab combo and mono:

<div style=\"page-break-after: always\"></div>

No direct comparison was performed between pembrolizumab when used as monotherapy or in combination with chemotherapy. Appropriate information to help physicians in the choice among the two alternative treatments has been included in sections 4.4 and 5.1 of the SmPC.

The availability of only limited data on patients over 75 years has been reflected in the SmPC.

## 3.4. Unfavourable effects

## Pembrolizumab plus platinum/5FU:

Pembrolizumab combination showed an overall comparable safety profile with the SOC, with higher incidence of SAE (both all causality and drug-related), AE (both all causality and drug related) leading to deaths and leading to drug discontinuation in the pembrolizumab combination arm compared to chemotherapy alone. Such trend was confirmed in the exposure-adjusted analysis for all SAEs and drug-related SAEs.

Most common AEs were Anaemia (58.3% vs 46.7%), Nausea (51.1% vs 51.2%), Constipation (37% vs 33.1%), Fatigue (34.4% vs 35.5%), Neutropenia (33.7% vs 32.8%), Vomiting (32.6% vs 27.9%), and Mucosal inflammation (30.8% vs 28.2%).

Higher incidence of hypothyroidism, anaemia and blood creatinine increase was seen in the pembro combo arm vs control. When adjusted for exposure, hypothyroidism, pyrexia, and blood creatinine increase were higher in the pembrolizumab plus chemotherapy than in the standard treatment group. On the contrary, increased frequency of skin-related AEs, electrolyte alterations, and infusion-related reactions was observed with standard treatment vs pembro combo, consistent with the known toxicities of cetuximab included in the control regimen.

## Pembrolizumab monotherapy:

A favourable safety profile of pembrolizumab monotherapy as compared to the EXTREME regime was demonstrated, with the exception of hypothyroidism (reflected in the SmPC).

## 3.5. Uncertainties and limitations about unfavourable effects

The interpretation of safety data in the age group ≥75 years is limited by the low number of elderly subjects included in the ASaT population (15 in pembro combo and 16 subjects in pembro mono group).

## 3.6. Effects Table

Table  114 : Effects  Table  for  Keytruda  in  1L  R/M  HNSCC  (KEYNOTE-048,  OS  from  Final  analysis  data cut-off: 25 Feb 2019)

| Effect                                                           | Short description                                                                                                               | unit                                                                                                                          | treatment control Uncertainties / Strength of evidence                                                                                                                                                                                                                                                                                                | Ref                                          |
|------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| Favourable Effects                                               | Favourable Effects                                                                                                              | Favourable Effects                                                                                                            | Favourable Effects                                                                                                                                                                                                                                                                                                                                    | Favourable Effects                           |
| Pembrolizumab + cisplatin/carboplatin + 5-FU                     | Pembrolizumab + cisplatin/carboplatin + 5-FU                                                                                    | Pembrolizumab + cisplatin/carboplatin + 5-FU                                                                                  | Pembrolizumab + cisplatin/carboplatin + 5-FU                                                                                                                                                                                                                                                                                                          | Pembrolizumab + cisplatin/carboplatin + 5-FU |
| OS (ITT) OS (CPS≥1) OS (CPS<1) PFS (ITT) PFS (CPS≥1) PFS (CPS<1) | Time from randomization to death due to any cause Time from randomization to first PD (based on BICR) or death due to any cause | HR=0.72 (0.60, 0.87) HR=0.65 (0.53, 0.80) HR=1.21 (0.76, 1.94) HR=0.93 (0.78, 1.11) HR=0.84 (0.69, 1.02) HR=1.46 (0.93, 2.30) | Dual primary endpoints. ITT, CPS≥1 and CPS≥20: Statistically significant superiority. Exploratory subgroup CPS<1 Dual primary endpoints. PFS not statistically significant in all populations; Similar PFS rate in ITT at 6 months, higher PFS rates at 9, 12 months, higher PFS rates at 6, 9 and 12 months in CPS ≥ 1 and CPS ≥ 20, but not inCPS<1 | CSR                                          |

<div style=\"page-break-after: always\"></div>

| Effect                         | Short description                                 | unit                                                           |                                                                | treatment control                                              | Uncertainties / Strength of evidence                                                                                                                                                           | Ref                  |
|--------------------------------|---------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| OS (ITT) OS (CPS≥1) OS (CPS<1) | Time from randomization to death due to any cause | HR=0.83 (0.70, 0.99) HR=0.74 (0.61, 0.90) HR=1.51 (0.96, 2.37) | HR=0.83 (0.70, 0.99) HR=0.74 (0.61, 0.90) HR=1.51 (0.96, 2.37) | HR=0.83 (0.70, 0.99) HR=0.74 (0.61, 0.90) HR=1.51 (0.96, 2.37) | OS in ITT non-inferior (but not statistically superior) Crossing KM survival curves at months 7-8 with early favourable OS effect for standard treatment OS in CPS≥1 statistically significant | CSR                  |
| Unfavourable Effects           | Unfavourable Effects                              | Unfavourable Effects                                           | Unfavourable Effects                                           | Unfavourable Effects                                           | Unfavourable Effects                                                                                                                                                                           | Unfavourable Effects |
|                                |                                                   | P+C                                                            | P                                                              | C                                                              |                                                                                                                                                                                                |                      |
| Drug-related anaemia           | %                                                 | 48.2                                                           | 4                                                              | 41.1                                                           | No new safety concerns with pembrolizumab treatment were identified in 1L R/M HNSCC                                                                                                            |                      |
| Drug-related nausea            |                                                   | 44.9                                                           | 4                                                              | 45.6                                                           | No new safety concerns with pembrolizumab treatment were identified in 1L R/M HNSCC                                                                                                            |                      |
| Drug-related neutropenia       |                                                   | 33                                                             | 1                                                              | 31.4                                                           | No new safety concerns with pembrolizumab treatment were identified in 1L R/M HNSCC                                                                                                            |                      |
| Drug-related hypothyroidism    |                                                   | 12.7                                                           | 13                                                             | 0.3                                                            | No new safety concerns with pembrolizumab treatment were identified in 1L R/M HNSCC                                                                                                            |                      |
| Drug-related G3-5 AEs          |                                                   | 71                                                             | 16.7                                                           | 69                                                             | No new safety concerns with pembrolizumab treatment were identified in 1L R/M HNSCC                                                                                                            |                      |
| Drug-related SAE               |                                                   | 37                                                             | 9                                                              | 25.4                                                           | No new safety concerns with pembrolizumab treatment were identified in 1L R/M HNSCC                                                                                                            |                      |
| Drug-related deaths            |                                                   | 3.6                                                            | 1                                                              | 2.8                                                            | No new safety concerns with pembrolizumab treatment were identified in 1L R/M HNSCC                                                                                                            |                      |

Abbreviations: OS: overall survival; PFS: progression free survival; ORR: objective response rate; CR: complete response; PR: partial response; DOR: duration of response; CPS: combined positive score; ITT: intention to treat; HNSCC: head and neck squamous cell carcinoma; R/M: recurrent/metastatic; CSR: clinical study report; AE: adverse event; P+C= pembrolizumab + chemotherapy; P= pembrolizumab; C=control

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

## Pembrolizumab plus platinum/5FU:

When cetuximab is replaced by pembrolizumab in the association with platinum/5FU for the 1L treatment of R/M HNSCC, a statistically significant advantage in overall survival is seen in the ITT population at the final analysis. KM OS curves are overlapping up to month 8, but reassuringly a crossing is not visually apparent. Lack of PFS and ORR advantages does not fully support the positive OS trend, but there is some advantage in duration of response for pembro combo vs standard treatment.

The benefit of the pembrolizumab combination over EXTREME regimen appear more pronounced the higher the PD-L1 expression by CPS score is (of the ITT population, about 85% of subjects had CPS≥1 score  and 42% were CPS≥20). In  both  populations,  a  statistically  significant  advantage in  OS  was reached.  Overall,  imbalances  observed  between  treatment  arms  in  the  two  populations  CPS≥1  and CPS≥20 had no relevant impact on the treatment HR estimates. However, although acknowledging the small sample size of an exploratory subgroup for which the study was not powered, concern is raised by the absence of an observable OS improvement / negative results in the exploratory CPS&lt;1 subgroup (15% of the ITT population). OS worsened in CPS&lt;1 population with longer follow-up from the IA2 to the FA. In addition, inferior PFS and ORR results, together with no DOR advantage were observed. The lack of biological plausibility of using pembrolizumab in PD-L1 negative patients and the negative results of pembrolizumab monotherapy and combination therapy in CPS&lt;1 subjects, do not satisfactorily support the substitution of cetuximab with pembrolizumab in combination with platinum/5-FU chemotherapy, representing a potentially less active combination, with no clear advantage in terms of tolerability.

Toxicity of both experimental and control arms appears substantial. The safety profile of pembro combo is overall consistent with the known toxic effects of each agent used in the combination. While lacking of

<div style=\"page-break-after: always\"></div>

the typical AEs associated with cetuximab, the pembro combo arm appears characterized by a higher incidence of hypothyroidism (known ADR of pembrolizumab), as well as pyrexia and renal toxicity.

## Pembrolizumab monotherapy:

Pembrolizumab monotherapy, although statistically non-inferior to the EXTREME regimen, demonstrated a detrimental effect during the first 8 months from randomization, and a small OS benefit afterwards. During the procedure, the MAH restricted the sought indication of pembrolizumab monotherapy from all patients to those whose tumour express PDL1 with CPS≥1 score. A statistically significant OS benefit was observed in the CPS≥1 and CPS≥20 populations. Nevertheless, crossing survival curves in the PD -L1 expressing patients (more pronounced in CPS≥1) display that OS is in favour of standard treatment during the first 7-8 months. Only in patients surviving longer than 7-8 months, OS rates favour Pembro Mono at months 12 and 18. The higher risk of death within 6 months from randomization in subjects treated with pembro mono vs standard treatment was confirmed. In the CPS &gt;1 to &lt;20 population, the number of subjects who died from PD in the first 6 months of treatment was double in pembro mono compared to control. However, at the moment no specific recommendation can be included in the SmPC, since consistency of results obtained from different studies is needed to make the results strong and convincing. PFS failed to show improvement, and ORR was lower in pembrolizumab-treated patients, although the patients who respond showed considerably higher chance to have durable response.

As expected, the safety profile of pembrolizumab monotherapy compares favourably with the toxicity of the EXTREME regimen.

## 3.7.2. Balance of benefits and risks

For the pembrolizumab combination, acknowledging the small sample size of the exploratory subgroup of PD-L1  CPS&lt;1,  for  which  the  study  was  not  powered,  the  lack  of  biological  plausibility  in  using pembrolizumab in negative PD-L1 disease, together with the overall similar/slightly inferior results in CPS&lt;1  population  for  pembrolizumab  combination  over  EXTREME,  do  not  satisfactorily  support  the substitution of cetuximab with pembrolizumab in combination with platinum/5-FU chemotherapy, which represent  a  potentially  less  active  combination,  with  no  clear  advantage  in  terms  of  tolerability.  In patients whose disease expresses PD-L1 with CPS score ≥ 1, the B/R of pembrolizumab when used in combination with platinum/5-FU chemotherapy is favourable since the survival benefits outweighed the risk in this population with dismal prognosis.

For pembrolizumab monotherapy, an indication restricted to CPS≥1 pat ients is considered acceptable.

## 3.8. Conclusions

The overall B/R of pembrolizumab as monotherapy and in combination with platinum/5-FU chemotherapy for the first line treatment of R/M HNSCC PD-L1 expressing CPS ≥ 1 is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                          | Type    | Annexes affected   |
|----------------------|-------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition | Type II | I and IIIB         |

<div style=\"page-break-after: always\"></div>

| of a new therapeutic indication or modification of an approved one   |
|----------------------------------------------------------------------|

Extension of indication to include, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose disease expresses PD-L1 with CPS score ≥ 1, based on the results from KEYNOTE-048, a randomized, multi-centre, open-label phase 3 study investigating pembrolizumab, or pembrolizumab plus platinum plus 5-FU chemotherapy versus platinum plus 5-FU plus cetuximab in subjects with first-line metastatic or unresectable recurrent HNSCC. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. An updated version of the RMP (Version 27.0) has also been agreed.

The variation leads to amendments to the Summary of Product Characteristics, Package Leaflet and to the Risk Management Plan (RMP).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of indication to include, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose disease expresses PD-L1 with CPS score ≥ 1, based on the results from KEYNOTE-048, a randomized, multi-centre, open-label phase 3 study investigating pembrolizumab, or pembrolizumab plus platinum plus 5-FU chemotherapy versus platinum plus 5-FU plus cetuximab in subjects with first-line metastatic or unresectable recurrent HNSCC. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. An updated version of the RMP (Version 27.0) has also been agreed.

## Summary

Please refer to the Scientific Discussion Keytruda-EMEA-H-C-3820-II-0065.